Anti-CD19 antibodies and uses in B cell disorders

ABSTRACT

The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/603,154 (filed Sep. 4, 2012), which is a continuation of U.S. patentapplication Ser. No. 12/885,341 (filed Sep. 17, 2010), which is acontinuation-in-part of U.S. patent application Ser. No. 12/401,310(filed Mar. 10, 2009), U.S. patent application Ser. No. 12/325,426(filed Dec. 1, 2008), and U.S. patent application Ser. No. 12/275,545(filed Nov. 21, 2008). U.S. patent application Ser. No. 12/401,310 is acontinuation of U.S. patent application Ser. No. 11/355,905 (filed Feb.15, 2006), which claims the benefit of U.S. Provisional Application Nos.60/653,587 (filed Feb. 15, 2005) and U.S. 60/702,063 (filed on Jul. 22,2005). U.S. patent application Ser. No. 12/325,426 is a continuation ofU.S. patent application Ser. No. 11/429,545 (filed May 5, 2006), whichclaims the benefit of U.S. Provisional Application No. 60/679,095 (filedMay 5, 2005). U.S. patent application Ser. No. 12/275,545 is acontinuation of U.S. patent application Ser. No. 11/450,931 (filed Jun.8, 2006), which claims the benefit of U.S. Provisional Application Nos.60/689,033 (filed Jun. 8, 2005) and 60/701,365 (filed Jul. 20, 2005).The entire teachings of the referenced applications are expresslyincorporated herein by reference.

This invention was made in part with government support under grantnumbers CA1776, CA105001, and CA96547 awarded by the National CancerInstitute of the National Institutes of Health and under grant numberAI56363 awarded by the National Institute of Allergy and InfectiousDisease of the National Institutes of Health. The United StatesGovernment has certain rights in the invention.

1. INTRODUCTION

The present invention is directed to methods for the treatment and/orprevention of diseases and disorders, using therapeutic antibodies thatbind to the human CD19 antigen. Diseases and disorders include B celldisorders or diseases in human subjects, including B cell malignancies,and autoimmune conditions. The present invention is also directed tomethods for treatment and prevention of graft versus host disease(GVHD), humoral rejection, and post-transplantation lymphoproliferativedisorder in human transplant recipients. In a preferred embodiment, thetherapeutic anti-CD19 antibodies of the compositions and methods of theinvention mediate human antibody-dependent-cell-mediated-cytotoxicity(ADCC). The present invention is further directed to compositionscomprising human, humanized, or chimeric anti-CD19 antibodies of theIgG1 and/or IgG3 human isotype. The present invention is furtherdirected to compositions comprising human, humanized, or chimericanti-CD19 antibodies of the IgG2 and/or IgG4 human isotype thatpreferably mediate human ADCC. The present invention also encompassesmonoclonal human, humanized, or chimeric anti-CD19 antibodies.

2. BACKGROUND OF THE INVENTION

B cell surface markers have been generally suggested as targets for thetreatment of B cell disorders or diseases, autoimmune disease, andtransplantation rejection. Examples of B cell surface markers includeCD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD53, CD72, CD74, CD75,CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85, and CD86leukocyte surface markers. Antibodies that specifically bind thesemarkers have been developed, and some have been tested for the treatmentof diseases and disorders.

For example, chimeric or radiolabeled monoclonal antibody (mAb)-basedtherapies directed against the CD20 cell surface molecule specific formature B cells and their malignant counterparts have been shown to be aneffective in vivo treatment for non-Hodgkin's lymphoma (Tedder et al.,Immunol. Today, 15:450-454 (1994); Press et al., Hematology, 221-240(2001); Kaminski et al., N. Engl. J. Med., 329:459-465 (1993); Weiner,Semin. Oncol., 26:43-51 (1999); Onrust et al., Drugs, 58:79-88 (1999);McLaughlin et al., Oncology, 12:1763-1769 (1998); Reff et al., Blood,83:435-445 (1994); Maloney et al., Blood, 90:2188-2195 (1997); Maloneyet al., J. Clin. Oncol., 15:3266-3274 (1997); Anderson et al., Biochem.Soc. Transac., 25:705-708 (1997)). Anti-CD20 monoclonal antibody therapyhas also been found to ameliorate the manifestations of rheumatoidarthritis, systemic lupus erythematosus, idiopathic thrombocytopenicpurpura and hemolytic anemia, as well as other immune-mediated diseases(Silverman et al., Arthritis Rheum., 48:1484-1492 (2002); Edwards etal., Rheumatology, 40:1-7 (2001); De Vita et al., Arthritis Rheumatism,46:2029-2033 (2002); Leandro et al., Ann. Rheum. Dis., 61:883-888(2002); Leandro et al., Arthritis Rheum., 46:2673-2677 (2001)). Theanti-CD22 monoclonal antibody LL-2 was shown to be effective in treatingaggressive and relapsed lymphoma patients undergoing chemotherapeutictreatment (Goldenberg U.S. Pat. Nos. 6,134,982 and 6,306,393). Theanti-CD20 (IgG1) antibody, RITUXAN™, has successfully been used in thetreatment of certain diseases such as adult immune thrombocytopenicpurpura, rheumatoid arthritis, and autoimmune hemolytic anemia (Cured etal., WO 00/67796). Despite the effectiveness of this therapy, most acutelymphoblastic leukemias (ALL) and many other B cell malignancies eitherdo not express CD20, express CD20 at low levels, or have lost CD20expression following CD20 immunotherapy (Smith et al., Oncogene,22:7359-7368 (2003)). Moreover, the expression of CD20 is not predictiveof response to anti-CD20 therapy as only half of non-Hodgkin's lymphomapatients respond to CD20-directed immunotherapy.

The human CD19 molecule is a structurally distinct cell surface receptorthat is expressed on the surface of human B cells, including, but notlimited to, pre-B cells, B cells in early development (i.e., immature Bcells), mature B cells through terminal differentiation into plasmacells, and malignant B cells. Unlike CD20, the CD19 antigen was thoughtto be expressed at higher levels and internalized by cells when bound byan anti-CD19 antibody. The CD19 antigen has been one of the manyproposed targets for immunotherapy. However, the perceivedunavailability as a target due to cellular internalization, was thoughtto have presented obstacles to the development of therapeutic protocolsthat could be successfully used in human subjects.

CD19 is expressed by most pre-B acute lymphoblastic leukemias (ALL),non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemias (CLL),pro-lymphocytic leukemias, hairy cell leukemias, common acutelymphocytic leukemias, and some Null-acute lymphoblastic leukemias(Nadler et al., J. Immunol., 131:244-250 (1983), Loken et al., Blood,70:1316-1324 (1987), Uckun et al., Blood, 71:13-29 (1988), Anderson etal., 1984. Blood, 63:1424-1433 (1984), Scheuermann, Leuk. Lymphoma,18:385-397 (1995)). The expression of CD19 on plasma cells furthersuggests it may be expressed on differentiated B cell tumors such asmultiple myeloma, plasmacytomas, Waldenstrom's tumors (Grossbard et al.,Br. J. Haematol., 102:509-15 (1998); Treon et al., Semin. Oncol.,30:248-52 (2003)). The CLB-CD19 antibody (anti-CD19 murine IgG2a mAb)was shown to inhibit growth of human tumors implanted in athymic mice(Hooijberg et al., Cancer Research, 55:840-846 (1995)). In anotherstudy, the monoclonal murine antibody FMC63 (IgG2a) was chimerized usinga human IgG1 Fc region. Administration of this chimeric antibody to SCIDmice bearing a human B cell lymphoma (xenotransplantation model) did notinduce complement-mediated cytotoxicity or ADCC, but resulted insignificant killing of the transplanted tumor cells (Geoffrey et al.,Cancer Immunol. Immunother., 41:53-60 (1995)) In addition to favorableinternalization and greater efficiency in depleting B cells, anti-CD19antibody therapy was not recognized for the depletion of serumimmunoglobulin levels.

The results obtained using xenotransplantation mouse models of tumorimplantation led to studies using murine anti-CD19 antibodies in humanpatients. The murine CLB-CD19 antibody was administered to six patientsdiagnosed with a progressive non-Hodgkin's lymphoma who had failedprevious conventional therapy (chemotherapy or radiotherapy). Thesepatients were given total antibody doses ranging from 225 to 1,000 mg(Hekman et al., Cancer Immunol. Immunotherapy, 32:364-372 (1991)).Although circulating tumor cells were temporarily reduced in twopatients after antibody infusion, only one patient achieved partialremission after two periods of antibody treatment. No conclusionsregarding therapeutic efficacy could be drawn from this small group ofrefractory patients.

Subsequently, these investigators showed that the anti-tumor effects ofunconjugated CD20 mAbs are far superior to those of CD19 mAbs intransplantation models (Hooijberg et al., Cancer Res., 55:840-846(1995); and Hooijberg et al., Cancer Res., 55:2627-2634 (1995)).Moreover, they did not observe additive or synergistic effects on tumorincidence when using CD19 and CD20 mAbs in combination (Hooijberg etal., Cancer Res., 55:840-846 (1995)). Although the xenotransplantationanimal models were recognized to be poor prognostic indicators forefficacy in human subjects, the negative results achieved in theseanimal studies discouraged interest in therapy with naked anti-CD19antibodies.

The use of anti-CD19 antibody-based immunotoxins produced equallydiscouraging results. In early clinical trials, the B4 anti-CD19antibody (murine IgG1 mAb) was conjugated to the plant toxin ricin andadministered to human patients having multiple myeloma who had failedprevious conventional therapy (Grossbard et al., British Journal ofHaematology, 102:509-515 (1998)), advanced non-Hodgkin's lymphoma(Grossbard et al., Clinical Cancer Research, 5:2392-2398 (1999)), andrefractory B cell malignancies (Grossbard et al., Blood, 79:576-585(1992)). These trials generally demonstrated the safety of administeringthe B4-ricin conjugate to humans; however, results were mixed andresponse rates were discouraging in comparison to clinical trials withRITUXAN™ (Grossbard et al., Clinical Cancer Research, 5:2392-2398(1999)). In addition, a significant portion of the patients developed ahuman anti-mouse antibody (HAMA) response or a human anti-ricin antibody(HARA) response.

In another trial, seven low-grade non-Hodgkin's lymphoma patientspreviously treated with conventional therapy were treated with themurine CLB-CD19 antibody in combination with continuous infusion oflow-dose interleukin-2 (Vlasveld et al., Cancer Immunol. Immunotherapy,40:37-47 (1995)). A partial remission occurred in one leukemic patient,and a greater than 50% reduction of circulating B cells was observed.Circulating B cell numbers were not changed in 4 of 5 remaining patientsassessed. Thus, the therapeutic evaluation of murine anti-CD19antibodies and anti-CD19 antibody-based immunotoxins in humans,generated anecdotal data that could not be evaluated for efficacy.

Due to the relatively recent appreciation of the role of humoralimmunity in acute and chronic graft rejection, current therapeuticagents and strategies for targeting humoral immunity are less welldeveloped than those for targeting cellular immunity.

Both cellular (T cell-mediated) and humoral (antibody, B cell-mediated)immunity are now known to play significant roles in graft rejection.While the importance of T cell-mediated immunity in graft rejection iswell established, the critical role of humoral immunity in acute andchronic rejection has only recently become evident. Consequently, mostof the advances in the treatment and prevention of graft rejection havedeveloped from therapeutic agents that target T cell activation. Thefirst therapeutic monoclonal antibody that was FDA approved for thetreatment of graft rejection was the murine monoclonal antibodyORTHOCLONE-OKT3™ (muromonab-CD3), directed against the CD3 receptor of Tcells. OKT3 has been joined by a number of other anti-lymphocytedirected antibodies, including the monoclonal anti-CD52 CAMPATH™antibodies, CAMPATH-1G, CAMPATH-1H (alemtuzumab), and CAMPATH-1M), andpolyclonal anti-thymocyte antibody preparations (referred to asanti-thymocyte globulin, or “ATG,” also called “thymoglobin” or“thymoglobulin”). Other T cell antibodies approved for the prevention oftransplant rejection include the chimeric monoclonal antibody SIMULECT™(basiliximab) and the humanized monoclonal antibody ZENAPAX™(daclizumab), both of which target the high-affinity IL-2 receptor ofactivated T cells.

The importance of humoral immunity in graft rejection was initiallythought to be limited to hyperacute rejection, in which the graftrecipient possesses anti-donor HLA antibodies prior to transplantation,resulting in rapid destruction of the graft in the absence of aneffective therapeutic regimen of antibody suppression. Recently, it hasbecome evident that humoral immunity is also an important factormediating both acute and chronic rejection. For example, clinicalobservations demonstrated that graft survival in patients capable ofdeveloping class I or class II anti-HLA alloantibodies (also referred toas “anti-MHC alloantibodies”) was reduced compared to graft survival inpatients that could not develop such antibodies. Clinical andexperimental data also indicate that other donor-specific alloantibodiesand autoantibodies are critical mediators of rejection. For a currentreview of the evidence supporting a role for donor-specific antibodiesin allograft rejection, see Rifle et al., Transplantation, 200579:S14-S18.

The available strategies for targeting humoral immunity include antibodydepletion regimens and anti-B lymphocyte directed antibodies. For arecent review of immunological strategies for targeting humoralimmunity, see Snanoudj et al., Transplantation, 2005 79:S33-35. Examplesof antibody depletion regimens include treatment of the recipient withintravenous immunoglobulin, the removal of donor-reactive antibodies byimmunoadsorption, and plasmapheresis. Most reports of anti-B lymphocytedirected antibodies have focused on anti-CD20 antibodies, andparticularly the chimeric mouse-human anti-CD20 monoclonal antibody,RITUXAN™ (rituximab), which is FDA approved for the treatment of some Bcell malignancies. More recently, rituximab has been evaluated for usein transplantation-related therapeutic regimens. For example, rituximabhas been reported for use in a pre-transplant conditioning regimen, in atreatment regimen for acute rejection, and to reduce the anti-ABOantibody titer for ABO-incompatible kidney transplantation, with mixedresults. Sinder et al. (Hum. Antibodies, 2004 13:55-62) reported asingle-dose, dose-escalation phase 1 trial using rituximab forconditioning of dialysis patients awaiting transplantation. The resultsindicated that rituximab, as a single agent, partially depleted asubpopulation of B cells and reduced panel reactive alloantibodies.However, Viera et al. (Transplantation, 2004 77:542) reported onlymodest reductions in panel reactive alloantibodies using a single-doseof rituximab in patients awaiting renal transplantation. Becker et al.(Am. J. Transplant, 2004 4:996) reported the use of rituximab to treatacute rejection which had previously failed to respond to steroidtreatment or to combination therapy with anti-thymocyte globulin andplasmapheresis. Rituximab conditioning in combination with otherstrategies such as immunoadsorption, plasmaphoresis, and intravenousimmunoglobulins, without the need for splenectomy, was also reported inconnection with ABO-incompatible kidney transplantations (see Tyden etal. Transplantation, 2003 76:730; Sonnenday Am. J. Transplant., 20044:1315).

Anti-CD19 antibodies may offer advantages over anti-CD20 antibodies inbeing able to target a wider repertoire of B cells, but their use intransplantation immunotherapy has been limited primarily to theidentification and monitoring of B cells. An additional use of anti-CD19directed antibodies in transplantation was reported by Barfield et al.,Cytotherapy, 2004 6:1-6. Barfield reported anti-CD3 antibodies andanti-CD19 antibodies conjugated to magnetic microbeads used as affinityreagents to capture T and B lymphocytes from donor peripheral stem cellgrafts, ex vivo, to reduce allogeneic lymphocytes in the graft prior totransplantation.

In addition to the treatment and prevention of graft rejection, B celldirected antibodies have been used to treat post-transplantlymphoproliferative disorder (PTLD) (see LeVasseur et al. Pediatr.Transplant., 2003 7:370-75). PTLD is characterized by hyperproliferativeB cells and is associated with Epstein-Barr virus infected B cells,either originating from the graft or latent in the recipient. Schaar etal. reported a five-step protocol for the treatment of PTLD in patientsat high risk following solid organ transplants of the pancreas-kidney,liver, heart, and kidney (Transplantation, 2001 71:47-52). The regimenincluded a murine anti-CD19 monoclonal antibody of isotype IgG2a incombination with a reduction in the amount of immunosuppressive agentsand the addition of anti-viral agents, interferon-alpha, andgamma-globulins.

3. SUMMARY OF THE INVENTION

The invention relates to immunotherapeutic compositions and methods forthe treatment of diseases, disorders, and other conditions of the immunesystem in human subjects, using therapeutic antibodies that bind to thehuman CD19 antigen and that preferably mediate human ADCC. In aparticular embodiment, the anti-CD19 antibodies of the present inventionmediate ADCC, complement dependent cellular cytotoxicity (CDC), orapoptosis of B cells. Diseases and disorders treatable with thecompositions and methods of the present application include but are notlimited to B cell diseases and disorders such as B cell malignanacies,and autoimmune diseases and disorders. The compositions and methods mayalso be used for the prophylaxis and treatment of GVHD, humoralrejection, and post-transplantation lymphoproliferative disorders inhuman subjects.

The present invention relates to pharmaceutical compositions comprisinghuman or humanized anti-CD19 antibodies of the IgG1 or IgG3 humanisotype. The present invention relates to pharmaceutical compositionscomprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4human isotype that preferably mediate human ADCC. The present inventionrelates to pharmaceutical compositions comprising chimerized anti-CD19antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate humanADCC. In preferred embodiments, the present invention relates topharmaceutical compositions comprising monoclonal human, humanized, orchimeric anti-CD19 antibodies.

The methods of the invention are demonstrated by way of example, using atransgenic mouse model for evaluating CD19-directed immunotherapies inhuman subjects.

In one embodiment, the invention provides for a pharmaceuticalcomposition comprising a monoclonal human or humanized anti-CD19antibody of the IgG1 or IgG3 human isotype in a pharmaceuticallyacceptable carrier. In another embodiment, the invention provides for apharmaceutical composition comprising a therapeutically effective amountof a monoclonal chimerized anti-CD19 antibody of the IgG1 or IgG3 humanisotype in a pharmaceutically acceptable carrier. In relatedembodiments, a therapeutically effective amount of a monoclonalchimerized anti-CD19 antibody of the IgG1 or IgG3 human isotype is lessthan 1 mg/kg of patient body weight. In other related embodiments, atherapeutically effective amount of a monoclonal chimerized anti-CD19antibody of the IgG1 or IgG3 human isotype is greater than 2 mg/kg ofpatient body weight.

According to one aspect, the invention provides for a pharmaceuticalcomposition comprising a therapeutically effective amount of monoclonalhuman or humanized anti-CD19 antibody that mediates humanantibody-dependent cellular cytotoxicity (ADCC), in a pharmaceuticallyacceptable carrier. According to another aspect, the invention providesfor a pharmaceutical composition comprising a monoclonal chimerizedanti-CD19 antibody that mediates human antibody-dependent cellularcytotoxicity (ADCC), and/or complement dependent cytotoxicty (CDC)and/or apoptotic activity in a pharmaceutically acceptable carrier.

In some embodiments, therapeutic formulations and regimens are describedfor treating human subjects diagnosed with B cell malignancies thatderive from B cells and their precursors, including but not limited to,acute lymphoblastic leukemias (ALL), Hodgkin's lymphomas, non-Hodgkin'slymphomas, B cell chronic lymphocytic leukemias (CLL), multiple myeloma,follicular lymphoma, mantle cell lymphoma, pro-lymphocytic leukemias,hairy cell leukemias, common acute lymphocytic leukemias and someNull-acute lymphoblastic leukemias.

In certain embodiments, the present invention concerns a method oftreating a B cell malignancy in a human comprising administering to ahuman in need thereof a monoclonal human or humanized anti-CD19 antibodyof the IgG1 or IgG3 human isotype in an amount sufficient to depletecirculating B cells. The present invention also concerns a method oftreating a B cell malignancy in a human comprising administering to ahuman in need thereof a monoclonal human or humanized anti-CD19 antibodythat mediates human antibody-dependent cellular cytotoxicity (ADCC) inan amount sufficient to deplete circulating B cells. ADCC The presentinvention also concerns a method of treating a B cell malignancy in ahuman patient comprising the administration of a therapeuticallyeffective regimen of a monoclonal human or humanized anti-CD19 antibodyof the IgG1 or IgG3 human isotype to a human patient in need of suchtreatment.

In one embodiment, the present invention provides a method of treating aB cell malignancy in a human patient comprising the administration of atherapeutically effective regimen of a monoclonal human or humanizedanti-CD19 antibody that mediates human antibody-dependent cellularcytotoxicity (ADCC), to a human patient in need of such treatment. Inanother embodiment, the present invention provides a method of treatingan early stage disease resulting from a B cell malignancy in a humanpatient comprising administration of a therapeutically effective regimenof a monoclonal anti-CD19 antibody that mediates humanantibody-dependent cellular cytotoxicity (ADCC), to a human in need ofsuch treatment. In a further embodiment, the present invention providesa method of treating a B cell malignancy in a human patient comprisingadministration of a therapeutically effective regimen of a monoclonalanti-CD19 antibody that mediates human antibody-dependent cellularcytotoxicity (ADCC), to a human subject in need thereof, wherein thehuman subject has not previously received treatment for the malignancy.Yet another embodiment of the present invention provides a method oftreating a B cell malignancy in a human patient comprisingadministration of a therapeutically effective regimen of a monoclonalanti-CD19 antibody that mediates human antibody-dependent cellularcytotoxicity (ADCC), to a human patient in need of such treatment,wherein the B cell malignancy is CD19 positive. In a further embodiment,the present invention provides a method of treating a B cell malignancyin a human patient comprising administration of a therapeuticallyeffective regimen of a monoclonal anti-CD19 antibody that mediates humanantibody-dependent cellular cytotoxicity (ADCC), to a human patient inneed of such treatment, wherein the human patient has a monocyte countof at least 1 per dL of circulating blood.

In other embodiments, therapeutic formulations and regimens aredescribed for treating human subjects diagnosed with or at risk fordevelopment of autoimmune diseases or disorders, including but notlimited to, rheumatoid arthritis, Systemic Lupus Erythematosis (SLE),Idiopathic/Autoimmune Thrombocytopenia Purpura (ITP), pemphigus-relateddisorders, diabetes, or scleroderma.

In certain embodiments, the present invention concerns a method oftreating an autoimmune disease or disorder in a human comprisingadministering to a human in need thereof a monoclonal human or humanizedanti-CD19 antibody of the IgG1 or IgG3 human isotype in an amountsufficient to deplete circulating B cells. The present invention alsoconcerns a method of treating an autoimmune disease or disorder in ahuman patient comprising the administration of a therapeuticallyeffective regimen of an anti-CD19 antibody that mediates human ADCC to ahuman patient in need of such treatment. The present invention alsoconcerns methods of treating autoimmune disorders comprising theadministration of a therapeutically effective regimen of a monoclonalhuman or humanized anti-CD19 antibody of the IgG1 or IgG3 human isotype.

In one embodiment, the present invention provides a method of treatingan autoimmune disorder in a human patient comprising the administrationof a therapeutically effective regimen of a monoclonal human orhumanized anti-CD19 antibody that mediates ADCC, to a human patient inneed of such treatment. In another embodiment, the present inventionprovides a method of treating an early stage autoimmune disordercomprising administration of a therapeutically effective regimen of amonoclonal anti-CD19 antibody that mediates ADCC, to a human in need ofsuch treatment. In a further embodiment, the present invention providesa method of treating an autoimmune disorder in a human patientcomprising administration of a therapeutically effective regimen of amonoclonal anti-CD19 antibody that mediates ADCC, to a human subject inneed thereof, wherein the human subject has not previously receivedtreatment for the disorder. Yet another embodiment of the presentinvention provides a method of treating an autoimmune disease ordisorder in a human patient comprising administration of atherapeutically effective regimen of a monoclonal anti-CD19 antibodythat mediates ADCC, to a human patient in need of such treatment,wherein the autoimmune disease or disorder is CD19 positive. In afurther embodiment, the present invention provides a method of treatingan autoimmune disease or disorder in a human patient comprisingadministration of a therapeutically effective regimen of a monoclonalanti-CD19 antibody that mediates human ADCC, to a human patient in needof such treatment, wherein the human patient has a monocyte count of atleast 1 per dL of circulating blood. The present invention providesmethods of treatment of an autoimmune disease or disorder, wherein theautoimmune disease or disorder is rheumatoid arthritis, systemic lupuserythematosis, idiopathic/autoimmune thrombocytopenia purpura, apemphigus-related disorder, diabetes, or scleroderma.

In certain embodiments, the present invention provides methods fortreating or preventing humoral rejection in a human transplant recipientin need thereof comprising administering to the recipient an anti-CD19antibody in an amount sufficient to deplete circulating B cells, orcirculating immunoglobulin, or both, wherein the anti-CD19 antibody isadministered alone or in combination with one or more other therapeuticagents. In one embodiment, the transplant recipient in need ofprophylaxis against humoral rejection is identified as a patient orpatient population who has detectable circulating anti-HLAalloantibodies prior to transplantation. In another embodiment, thepatient or patient population is identified as having panel reactivealloantibodies prior to transplantation. In another embodiment, thetransplant recipient in need of treatment for humoral rejection isidentified as a patient or patient population who has detectablecirculating anti-HLA alloantibodies post-transplantation. In anotherembodiment, the patient or patient population is identified as havingpanel reactive alloantibodies post-transplantation. In anotherembodiment, the patient or patient population is identified as in needof transplant from an ABO blood type incompatible donor.

In certain embodiments, the invention provides methods for preventinghumoral rejection in a human transplant recipient in need thereofcomprising administering to the recipient prior to transplantation ananti-CD19 antibody in an amount sufficient to deplete circulating Bcells, or circulating immunoglobulin, or both, wherein the anti-CD19antibody is administered alone or in combination with one or more othertherapeutic agents. In other embodiments, the invention provides methodsfor preventing graft rejection or graft versus host disease in a humantransplant recipient in need thereof comprising contacting a graft priorto transplantation with an amount of an anti-CD19 antibody sufficient todeplete B cells from the graft. In one embodiment, the graft iscontacted with the anti-CD19 antibody ex vivo. In another embodiment,the method further comprises contacting the graft with one or more of ananti-T lymphocyte antibody or anti-thymocyte globulin.

In certain embodiments, the invention provides methods for treatinghumoral rejection in a human transplant recipient in need thereofcomprising administering to the recipient an anti-CD19 antibody in anamount sufficient to deplete circulating B cells, or circulatingimmunoglobulin, or both, wherein the anti-CD19 antibody is administeredalone or in combination with one or more other therapeutic agents. Inone embodiment, the rejection is an acute or a chronic humoralrejection. In one embodiment, the transplant recipient in need oftreatment for humoral rejection is identified as a patient or patientpopulation in an early stage of rejection, such as a latent humoralresponse characterized by circulating anti-donor alloantibodies, asilent reaction characterized by circulating anti-donor alloantibodiesand C4d deposition, or a subclinical rejection characterized bycirculating anti-donor alloantibodies, C4d deposition, and tissuepathology. In another embodiment, the transplant recipient in need oftreatment for humoral rejection is identified as a patient or patientpopulation is in a stage of rejection characterized by circulatinganti-donor alloantibodies, C4d deposition, tissue pathology, and graftdysfunction.

In certain embodiments, the present invention also concerns methods fortreating or preventing humoral rejection in a human transplant recipientin need thereof comprising administering a therapeutically effectiveregimen of an anti-CD19 antibody to the recipient. In one embodiment,the regimen further comprises administering a compound that enhancesmonocyte or macrophage function. In one embodiment, the regimencomprises a single administration of the anti-CD19 antibody to therecipient. In another embodiment, the regimen comprises more than oneadministration of the anti-CD19 antibody to the recipient. In oneembodiment, the regimen comprises the administration of the antibody asa single therapeutic agent. In one embodiment, the regimen comprises theadministration of the antibody in combination with one or more othertherapeutic agents.

In certain embodiments, wherein the invention provides for theadministration of an anti-CD19 antibody in combination with one or moreother therapeutic agents, the therapeutic agents are selected from thegroup consisting of adriamycin, azathiopurine, busulfan,cyclophosphamide, cyclosporin A, cytoxin, fludarabine, 5-fluorouracil,methotrexate, mycophenolate mofetil, a nonsteroidal anti-inflammatory,rapamycin, sirolimus, and tacrolimus. In related embodiments, the one ormore other therapeutic agents is an antibody selected from the groupconsisting of OKT3™ (muromonab-CD3), CAMPATH™-1H (alemtuzumab),CAMPATH™-1G, CAMPATH™-1M, SIMULECT™ (basiliximab), ZENAPAX™(daclizumab), RITUXAN™ (rituximab), and anti-thymocyte globulin.

According to one aspect, the invention provides methods for thetreatment and prevention of GVHD and rejection in transplant recipientswho are characterized as being at risk for developing a humoral responseto an allograft. In a related embodiment, the recipient has detectablelevels of circulating anti-HLA alloantibodies.

In particular embodiments of the invention, the transplant recipient isa recipient of an allogeneic solid organ transplant selected from thegroup consisting of a heart transplant, a kidney-pancreas transplant, akidney transplant, a liver transplant, a lung transplant, and a pancreastransplant. In one embodiment, the recipient is a recipient of anallogeneic transplant of pancreatic islet cells. In another embodiment,the recipient is a recipient of a hematopoietic cell transplant, forexample, a bone marrow transplant and/or a transplant of peripheralblood stem cells.

The invention also provides for the administration of an anti-CD19antibody as part of a therapeutic regimen for the treatment orprevention of graft rejection. In one embodiment, the therapeuticregimen further comprises one or more immunosuppression therapy,anti-lymphocyte therapy, immunoadsorption, or plasmapheresis. Inparticular embodiments, the immunosuppression therapy comprisesadministering to the transplant recipient one or more compounds selectedfrom the group consisting of a steroid, an inhibitor of cytokinetranscription, an inhibitor of nucleotide synthesis, an inhibitor ofgrowth factor signal transduction, and an inhibitor of a T cellinterleukin 2 receptor. In particular embodiments, the anti-lymphocytetherapy comprises administering to the recipient one or more antibodiesselected from the group consisting of OKT3™ (muromonab-CD3), CAMPATH™-1H(alemtuzumab), CAMPATH™-1G, CAMPATH™-1M, SIMULECT™ (basiliximab),ZENAPAX™ (daclizumab), RITUXAN™ (rituximab), and anti-thymocyteglobulin.

In certain embodiments of the methods of the present invention, theanti-CD19 antibody is a monoclonal antibody selected from the groupconsisting of a human antibody, a humanized antibody, and a chimericantibody. Preferably, the anti-CD19 antibody mediates humanantibody-dependent cellular cytotoxicity (ADCC). In certain embodiments,the anti-CD19 antibody is an IgG1 or IgG3 human isotype antibody. Inother embodiments, the anti-CD19 antibody is an IgG2 or IgG4 humanisotype antibody. In one embodiment, the anti-CD19 antibody has ahalf-life that is at least 4 to 7 days.

In particular embodiments of the invention, the anti-CD19 antibody isadministered by a parenteral, intraperitoneal, or intramuscular route.In other embodiments, the anti-CD19 antibody is administered by anintravenous or subcutaneous route, preferably by a subcutaneous route ina dose of 37.5 mg/m² or less or in a dose of 1.5 mg/m² or less.

In a preferred embodiment of the methods provided by the invention, theanti-CD19 antibody is administered in an amount effective to reduce ordeplete circulating B cells, to reduce or deplete circulatingimmunoglobulin (Ig), or to reduce or deplete both circulating B cellsand circulating Ig in a transplant recipient. In one embodiment, theanti-CD19 antibody is administered in an amount effective to reduce ordeplete B cells, to reduce or deplete immunoglobulin (Ig), or to reduceor deplete both B cells and Ig in a graft prior to transplantation ofthe graft to a recipient. In one embodiment, the methods provided by theinvention achieve at least a 50% or at least a 75% depletion incirculating B cells. In related embodiments, the depletion incirculating B cells is observed for a period of at least 7 days, atleast 30 days, or at least 6 months. In another preferred embodiment,the methods of the invention are effective to reduce panel reactivealloantibodies in the transplant recipient by at least 50%, at least70%, at least 80%, at least 90%, or at least 95%.

The present invention also concerns methods for treating or preventing apost-transplant lymphoproliferative disorder in a human transplantrecipient in need thereof comprising administering to the transplantrecipient a human or humanized anti-CD19 antibody in an amountsufficient to deplete circulating B cells. In one embodiment, theinvention further provides for the administration of an anti-viral agentto the transplant recipient.

3.1 Definitions

As used herein, the terms “antibody” and “antibodies” (immunoglobulins)refer to monoclonal antibodies (including full-length monoclonalantibodies), polyclonal antibodies, multispecific antibodies (e.g.,bispecific antibodies) formed from at least two intact antibodies, humanantibodies, humanized antibodies, camelised antibodies, chimericantibodies, single-chain Fvs (scFv), single-chain antibodies, singledomain antibodies, domain antibodies, Fab fragments, F(ab′)₂ fragments,antibody fragments that exhibit the desired biological activity,disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies(including, e.g., anti-Id antibodies to antibodies of the invention),intrabodies, and epitope-binding fragments of any of the above. Inparticular, antibodies include immunoglobulin molecules andimmunologically active fragments of immunoglobulin molecules, i.e.,molecules that contain an antigen-binding site. Immunoglobulin moleculescan be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g.,IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

Native antibodies are usually heterotetrameric glycoproteins of about150,000 daltons, composed of two identical light (L) chains and twoidentical heavy (H) chains. Each light chain is linked to a heavy chainby one covalent disulfide bond, while the number of disulfide linkagesvaries between the heavy chains of different immunoglobulin isotypes.Each heavy and light chain also has regularly spaced intrachaindisulfide bridges. Each heavy chain has at one end a variable domain(V_(H)) followed by a number of constant domains. Each light chain has avariable domain at one end (V_(L)) and a constant domain at its otherend; the constant domain of the light chain is aligned with the firstconstant domain of the heavy chain, and the light chain variable domainis aligned with the variable domain of the heavy chain. Particular aminoacid residues are believed to form an interface between the light andheavy chain variable domains. Such antibodies may be derived from anymammal, including, but not limited to, humans, monkeys, pigs, horses,rabbits, dogs, cats, mice, etc.

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areresponsible for the binding specificity of each particular antibody forits particular antigen. However, the variability is not evenlydistributed through the variable domains of antibodies. It isconcentrated in segments called Complementarity Determining Regions(CDRs) both in the light chain and the heavy chain variable domains. Themore highly conserved portions of the variable domains are called theframework regions (FR). The variable domains of native heavy and lightchains each comprise four FR regions, largely adopting a β-sheetconfiguration, connected by three CDRs, which form loops connecting, andin some cases forming part of, the β-sheet structure. The CDRs in eachchain are held together in close proximity by the FR regions and, withthe CDRs from the other chain, contribute to the formation of theantigen-binding site of antibodies (see, Kabat et al., Sequences ofProteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991)). The constantdomains are generally not involved directly in antigen binding, but mayinfluence antigen binding affinity and may exhibit various effectorfunctions, such as participation of the antibody in ADCC.

The term “hypervariable region” when used herein refers to the aminoacid residues of an antibody which are responsible for binding to itsantigen. The hypervariable region comprises amino acid residues from a“complementarity determining region” or “CDR” (e.g., residues 24-34(L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variabledomain; Kabat et al., Sequences of Proteins of Immunological Interest,5th Ed. Public Health Service, National Institutes of Health, Bethesda,Md. (1991)) and/or those residues from a “hypervariable loop” (e.g.,residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chainvariable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavychain variable domain; Chothia and Lesk, J. Mol. Biol., 196:901-917(1987)). “Framework” or “FR” residues are those variable domain residuesother than the hypervariable region residues as herein defined, andinclude chimeric, humanized, human, domain antibodies, diabodies,vaccibodies, linear antibodies, and bispecific antibodies.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,i.e., the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations that may be present inminor amounts. Monoclonal antibodies are highly specific, being directedagainst a single antigenic site. Furthermore, in contrast toconventional (polyclonal) antibody preparations which typically includedifferent antibodies directed against different determinants (epitopes),each monoclonal antibody is directed against a single determinant on theantigen. In addition to their specificity, the monoclonal antibodies areadvantageous in that they are synthesized by the hybridoma cells,uncontaminated by other immunoglobulin producing cells. Alternatively,the monoclonal antibody may be produced by cells stably or transientlytransfected with the heavy and light chain genes encoding the monoclonalantibody.

The modifier “monoclonal” indicates the character of the antibody asbeing obtained from a substantially homogeneous population ofantibodies, and is not to be construed as requiring engineering of theantibody by any particular method. The term “monoclonal” is used hereinto refer to an antibody that is derived from a clonal population ofcells, including any eukaryotic, prokaryotic, or phage clone, and notthe method by which the antibody was engineered. For example, themonoclonal antibodies to be used in accordance with the presentinvention may be made by the hybridoma method first described by Kohleret al., Nature, 256:495 (1975), or may be made by any recombinant DNAmethod (see, e.g., U.S. Pat. No. 4,816,567), including isolation fromphage antibody libraries using the techniques described in Clackson etal., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol.,222:581-597 (1991), for example. These methods can be used to producemonoclonal mammalian, chimeric, humanized, human, domain antibodies,diabodies, vaccibodies, linear antibodies, and bispecific antibodies.

The term “chimeric” antibodies includes antibodies in which at least oneportion of the heavy and/or light chain is identical with or homologousto corresponding sequences in antibodies derived from a particularspecies or belonging to a particular antibody class or subclass, and atleast one other portion of the chain(s) is identical with or homologousto corresponding sequences in antibodies derived from another species orbelonging to another antibody class or subclass, as well as fragments ofsuch antibodies, so long as they exhibit the desired biological activity(U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA,81:6851-6855 (1984)). Chimeric antibodies of interest herein include“primatized” antibodies comprising variable domain antigen-bindingsequences derived from a nonhuman primate (e.g., Old World Monkey, suchas baboon, rhesus or cynomolgus monkey) and human constant regionsequences (U.S. Pat. No. 5,693,780).

“Humanized” forms of nonhuman (e.g., murine) antibodies are chimericantibodies that contain minimal sequence derived from nonhumanimmunoglobulin. For the most part, humanized antibodies are humanimmunoglobulins (recipient antibody) in which residues from ahypervariable region of the recipient are replaced by residues from ahypervariable region of a nonhuman species (donor antibody) such asmouse, rat, rabbit or nonhuman primate having the desired specificity,affinity, and capacity. In some instances, framework region (FR)residues of the human immunoglobulin are replaced by correspondingnonhuman residues. Furthermore, humanized antibodies may compriseresidues that are not found in the recipient antibody or in the donorantibody. These modifications are made to further refine antibodyperformance. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the hypervariable loops correspondto those of a nonhuman immunoglobulin and all or substantially all ofthe FRs are those of a human immunoglobulin sequence. In certainembodiments, the humanized antibody will comprise at least a portion ofan immunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details, see, Jones et al., Nature,321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); andPresta, Curr. Op. Struct. Biol., 2:593-596 (1992).

A “human antibody” can be an antibody derived from a human or anantibody obtained from a transgenic organism that has been “engineered”to produce specific human antibodies in response to antigenic challengeand can be produced by any method known in the art. According topreferred techniques, elements of the human heavy and light chain lociare introduced into strains of the organism derived from embryonic stemcell lines that contain targeted disruptions of the endogenous heavychain and light chain loci. The transgenic organism can synthesize humanantibodies specific for human antigens, and the organism can be used toproduce human antibody-secreting hybridomas. A human antibody can alsobe an antibody wherein the heavy and light chains are encoded by anucleotide sequence derived from one or more sources of human DNA. Afully human antibody also can be constructed by genetic or chromosomaltransfection methods, as well as phage display technology, or in vitroactivated B cells, all of which are known in the art.

The “CD19” antigen refers to an antigen of about 90 kDa identified, forexample, by the HD237 or B4 antibody (Kiesel et al., Leukemia ResearchII, 12:1119 (1987)). CD19 is found on cells throughout differentiationof B-lineage cells from the stem cell stage through terminaldifferentiation into plasma cells, including but not limited to, pre-Bcells, B cells (including naïve B cells, antigen-stimulated B cells,memory B cells, plasma cells, and B lymphocytes) and folliculardendritic cells. CD19 is also found on B cells in human fetal tissue. Inpreferred embodiments, the CD19 antigen targeted by the antibodies ofthe invention is the human CD19 antigen.

“Antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to acell-mediated reaction in which non-specific cytotoxic cells (e.g.,Natural Killer (NK) cells, neutrophils, and macrophages) recognize boundantibody on a target cell and subsequently cause lysis of the targetcell. In preferred embodiments, such cells are human cells. While notwishing to be limited to any particular mechanism of action, thesecytotoxic cells that mediate ADCC generally express Fc receptors (FcRs).The primary cells for mediating ADCC, NK cells, express FcγRIII, whereasmonocytes express FcγRI, FcγRII, FcγRIII and/or FcγRIV. FcR expressionon hematopoietic cells is summarized in Ravetch and Kinet, Annu. Rev.Immunol., 9:457-92 (1991). To assess ADCC activity of a molecule, an invitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or5,821,337 may be performed. Useful effector cells for such assaysinclude peripheral blood mononuclear cells (PBMC) and Natural Killer(NK) cells. Alternatively, or additionally, ADCC activity of themolecules of interest may be assessed in vivo, e.g., in an animal modelsuch as that disclosed in Clynes et al., PNAS (USA), 95:652-656 (1998).

“Complement dependent cytotoxicity” or “CDC” refers to the ability of amolecule to initiate complement activation and lyse a target in thepresence of complement. The complement activation pathway is initiatedby the binding of the first component of the complement system (C1q) toa molecule (e.g., an antibody) complexed with a cognate antigen. Toassess complement activation, a CDC assay, e.g., as described inGazzano-Santaro et al., J. Immunol. Methods, 202:163 (1996), may beperformed.

“Effector cells” are leukocytes which express one or more FcRs andperform effector functions. Preferably, the cells express at leastFcγRI, FcγRII, FcγRIII and/or FcγRIV and carry out ADCC effectorfunction. Examples of human leukocytes which mediate ADCC includeperipheral blood mononuclear cells (PBMC), natural killer (NK) cells,monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cellsbeing preferred. In preferred embodiments the effector cells are humancells.

The terms “Fc receptor” or “FcR” are used to describe a receptor thatbinds to the Fc region of an antibody. The preferred FcR is a nativesequence human FcR. Moreover, a preferred FcR is one which binds an IgGantibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII,FcγRIII, and FcγRIV subclasses, including allelic variants andalternatively spliced forms of these receptors. FcγRII receptors includeFcγRIIA (an “activating receptor”) and FcγRIIB (an “inhibitingreceptor”), which have similar amino acid sequences that differprimarily in the cytoplasmic domains thereof. Activating receptorFcγRIIA contains an immunoreceptor tyrosine-based activation motif(ITAM) in its cytoplasmic domain Inhibiting receptor FcγRIIB contains animmunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmicdomain. (See, Daëron, Annu. Rev. Immunol., 15:203-234 (1997)). FcRs arereviewed in Ravetech and Kinet, Annu. Rev. Immunol., 9:457-92 (1991);Capel et al., Immunomethods, 4:25-34 (1994); and de Haas et al., J. Lab.Clin. Med., 126:330-41 (1995). Other FcRs, including those to beidentified in the future, are encompassed by the term “FcR” herein. Theterm also includes the neonatal receptor, FcRn, which is responsible forthe transfer of maternal IgGs to the fetus (Guyer et al., Immunol.,117:587 (1976) and Kim et al., J. Immunol., 24:249 (1994)).

“Fv” is the minimum antibody fragment which contains a completeantigen-recognition and binding site. This region consists of a dimer ofone heavy and one light chain variable domain in tight, non-covalent orcovalent association. In the Fv configuration, the three CDRs of eachvariable domain interact to define an antigen-binding site on thesurface of the V_(H)-V_(L) dimer. Collectively, these six CDRs conferantigen-binding specificity to the Fv fragment. However, even a singlevariable domain (or half of a Fv comprising only three CDRs specific foran antigen) has the ability to recognize and bind antigen, although at alower affinity than the entire binding site.

“Affinity” of an antibody for an epitope to be used in the treatment(s)described herein is a term well understood in the art and means theextent, or strength, of binding of antibody to epitope. Affinity may bemeasured and/or expressed in a number of ways known in the art,including, but not limited to, equilibrium dissociation constant (KD orKd), apparent equilibrium dissociation constant (KD′ or Kd′), and IC50(amount needed to effect 50% inhibition in a competition assay). It isunderstood that, for purposes of this invention, an affinity is anaverage affinity for a given population of antibodies which bind to anepitope. Values of KD′ reported herein in terms of mg IgG per mL ormg/mL indicate mg Ig per mL of serum, although plasma can be used. Whenantibody affinity is used as a basis for administration of the treatmentmethods described herein, or selection for the treatment methodsdescribed herein, antibody affinity can be measured before and/or duringtreatment, and the values obtained can be used by a clinician inassessing whether a human patient is an appropriate candidate fortreatment.

An “epitope” is a term well understood in the art and means any chemicalmoiety that exhibits specific binding to an antibody. An “epitope” canalso comprise an antigen, which is a moiety or molecule that contains anepitope, and, as such, also specifically binds to antibody.

A “B cell surface marker” as used herein is an antigen expressed on thesurface of a B cell which can be targeted with an agent which bindsthereto. Exemplary B cell surface markers include the CD10, CD19, CD20,CD21, CD22, CD23, CD24, CD25, CD37, CD53, CD72, CD73, CD74, CD75, CD77,CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85, and CD86 leukocytesurface markers. The B cell surface marker of particular interest ispreferentially expressed on B cells compared to other non-B cell tissuesof a mammal and may be expressed on both precursor B cells and mature Bcells. In one embodiment, the preferred marker is CD19, which is foundon B cells throughout differentiation of the lineage from the pro/pre-Bcell stage through the terminally differentiated plasma cell stage.

The term “antibody half-life” as used herein means a pharmacokineticproperty of an antibody that is a measure of the mean survival time ofantibody molecules following their administration. Antibody half-lifecan be expressed as the time required to eliminate 50 percent of a knownquantity of immunoglobulin from the patient's body or a specificcompartment thereof, for example, as measured in serum, i.e.,circulating half-life, or in other tissues. Half-life may vary from oneimmunoglobulin or class of immunoglobulin to another. In general, anincrease in antibody half-life results in an increase in mean residencetime (MRT) in circulation for the antibody administered.

The term “isotype” refers to the classification of an antibody. Theconstant domains of antibodies are not involved in binding to antigen,but may exhibit various effector functions. Depending on the amino acidsequence of the heavy chain constant region, a given antibody orimmunoglobulin can be assigned to one of five major classes ofimmunoglobulins: IgA, IgD, IgE, IgG, and IgM. Several of these classesmay be further divided into subclasses (isotypes), e.g., IgG1 (gamma 1),IgG2 (gamma 2), IgG3 (gamma 3), and IgG4 (gamma 4), and IgA1 and IgA2.The heavy chain constant regions that correspond to the differentclasses of immunoglobulins are called α, δ, ε, γ, and μ, respectively.The structures and three-dimensional configurations of different classesof immunoglobulins are well-known. Of the various human immunoglobulinclasses, only human IgG1, IgG2, IgG3, IgG4, and IgM are known toactivate complement. Human IgG1 and IgG3 are known to mediate ADCC inhumans.

As used herein, the term “immunogenicity” means that a compound iscapable of provoking an immune response (stimulating production ofspecific antibodies and/or proliferation of specific T cells).

As used herein, the term “antigenicity” means that a compound isrecognized by an antibody or may bind to an antibody and induce animmune response.

As used herein, the term “avidity” is a measure of the overall bindingstrength (i.e., both antibody arms) with which an antibody binds anantigen. Antibody avidity can be determined by measuring thedissociation of the antigen-antibody bond in antigen excess using anymeans known in the art, such as, but not limited to, by the modificationof indirect fluorescent antibody as described by Gray et al., J. Virol.Meth., 44:11-24. (1993).

By the terms “treat,” “treating” or “treatment of” (or grammaticallyequivalent terms) it is meant that the severity of the subject'scondition is reduced or at least partially improved or amelioratedand/or that some alleviation, mitigation or decrease in at least oneclinical symptom is achieved and/or there is an inhibition or delay inthe progression of the condition and/or prevention or delay of the onsetof a disease or illness. The terms “treat,” “treating” or “treatment of”also means managing an autoimmune disease or disorder. Thus, the terms“treat,” “treating” or “treatment of” (or grammatically equivalentterms) refer to both prophylactic and therapeutic treatment regimes.

As used herein, a “sufficient amount” or “an amount sufficient to”achieve a particular result refers to an amount of an antibody orcomposition of the invention that is effective to produce a desiredeffect, which is optionally a therapeutic effect (i.e., byadministration of a therapeutically effective amount). For example, a“sufficient amount” or “an amount sufficient to” can be an amount thatis effective to deplete B cells.

A “therapeutically effective” amount as used herein is an amount thatprovides some improvement or benefit to the subject. Alternativelystated, a “therapeutically effective” amount is an amount that providessome alleviation, mitigation, and/or decrease in at least one clinicalsymptom. Clinical symptoms associated with the disorders that can betreated by the methods of the invention are well-known to those skilledin the art. Further, those skilled in the art will appreciate that thetherapeutic effects need not be complete or curative, as long as somebenefit is provided to the subject.

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1E illustrate CD19 expression by hCD19TG mouse lines. FIG. 1Ashows human and mouse CD19 expression by B cells from hCD19TG(TG-1^(+/−)) mice. FIG. 1B shows the relative mean densities of humanand mouse CD19 expression by CD19⁺ blood B cells from hCD19TG mice. FIG.1C shows the relative densities of hCD19 and mCD19 expression by CD19⁺ Bcells from TG-1^(+/−) mouse tissues. FIG. 1D shows CD19 antibody bindingdensity on mouse blood and spleen B220⁺ B cells from TG-1^(+/−) mice.FIG. 1E shows anti-CD19 antibody binding to hCD19 cDNA-transfected300.19 cells.

FIGS. 2A-2D show blood, spleen, and lymph node B cell depletion inhCD19TG mice. FIG. 2A demonstrates representative B cell depletion fromblood, spleen, and lymph node 7 days following anti-CD19 orisotype-matched control (CTL) antibody treatment of TG-1^(+/−) mice.FIG. 2B shows a time course of circulating B cell depletion by anti-CD19antibodies. FIG. 2C and FIG. 2D show spleen and lymph node B cellnumbers (±SEM), respectively, after treatment of TG-1^(+/−) mice withanti-CD19 (filled bars) or control (open bars) antibody at the indicateddoses.

FIGS. 3A-3F depict bone marrow B cell depletion following anti-CD19antibody treatment. FIG. 3A shows representative hCD19 and mCD19expression by TG-1^(+/−) bone marrow B cell subpopulations assessed byfour-color immunofluorescence staining with flow cytometry analysis.FIG. 3B shows depletion of hCD19⁺ cells in the bone marrow of hCD19TGmice seven days following FMC63 or isotype-matched control antibody (250μg) treatment assessed by two-color immunofluorescence staining withflow cytometry analysis. FIG. 3C shows representative B220⁺ B celldepletion in the bone marrow seven days following CD19 orisotype-matched control antibody (250 μg) treatment of TG-1^(+/−) mice.FIG. 3D shows representative B cell subset depletion seven daysfollowing FMC63 or isotype-matched control antibody (250 μg) treatmentof TG-1^(+/−) mice as assessed by three-color immunofluorescencestaining IgM⁻B220^(lo) pro-/pre-B cells were further subdivided based onCD43 expression (lower panels). FIG. 3E shows representative depletionof CD25⁺B220^(lo) pre-B cells seven days following FMC63 orisotype-matched control antibody (250 μg) treatment of hCD19TG mouselines as assessed by two-color immunofluorescence staining FIG. 3F showsbar graphs indicating numbers (±SEM) of pro-B, pre-B, immature, andmature B cells within bilateral femurs seven days following FMC63(closed bars) or control (open bars) antibody treatment of ≧3 littermatepairs.

FIGS. 4A-4C demonstrate that peritoneal cavity B cells are sensitive toanti-CD19 antibody treatment. FIG. 4A shows human and mouse CD19expression by peritoneal cavity CD5⁺B220⁺ B1a and CD5⁻B220^(hi) B2(conventional) B cells. FIG. 4B shows depletion of peritoneal cavityB220⁺ cells from TG-1^(+/−) mice treated with CD19 (HB12a, HB12b, andFMC63 at 250 μg; B4 and HD237 at 50 μg) antibodies or control antibody(250 μg). FIG. 4C shows representative depletion of CD5⁺B220⁺ B1a andCD5⁻B220^(hi) B2 B cells seven days following anti-CD19 or controlantibody treatment of hCD19TG mice.

FIG. 5A depicts the nucleotide (SEQ ID NO:1) and predicted amino acid(SEQ ID NO:2) sequences for heavy chain V_(H)-D-J_(H) junctionalsequences of the HB12a anti-CD19 antibody. FIG. 5B depicts thenucleotide (SEQ ID NO:3) and predicted amino acid (SEQ ID NO:4)sequences for heavy chain V_(H)-D-J_(H) junctional sequences of theHB12b anti-CD19 antibody.

FIG. 6A depicts the nucleotide (SEQ ID NO:15) and predicted amino acid(SEQ ID NO:16) sequences for light chain sequences of the HB12aanti-CD19 antibody. FIG. 6B depicts the nucleotide (SEQ ID NO:17) andpredicted amino acid (SEQ ID NO:18) sequences for light chain sequencesof the HB12b anti-CD19 antibody.

FIGS. 7A-7B depict the amino acid sequence alignment of published mouseanti-(human) CD19 antibodies. FIG. 7A shows a sequence alignment forheavy chain V_(H)-D-J_(H) junctional sequences including a consensussequence (SEQ ID NO:5), HB12a (SEQ ID NO:2), 4G7 (SEQ ID NO:6), HB12b(SEQ ID NO:4), HD37 (SEQ ID NO:7), B43 (SEQ ID NO:8), and FMC63 (SEQ IDNO:9). FIG. 7B shows light chain Vκ amino acid sequence analysis ofanti-CD19 antibodies. Consensus sequence (SEQ ID NO:10), HB12a (SEQ IDNO:16), HB12b (SEQ ID NO:18), HD37 (SEQ ID NO:11), B43 (SEQ ID NO:12),FMC63 (SEQ ID NO:13), and 4G7 (SEQ ID NO:14) are aligned.

FIGS. 8A-8C demonstrate that CD19 density influences the efficiency of Bcell depletion by anti-CD19 antibodies in vivo. Representative blood andspleen B cell depletion in hCD19TG mice are shown following HB12b (FIG.8A) or FMC63 (FIG. 8B) antibody treatment (seven days, 250 μg/mouse).FIG. 8C shows the relative anti-CD19 antibody-binding densities on bloodB220⁺ B cells from TG-1^(+/−) mice. FIG. 8D shows the relative anti-CD19antibody-binding densities on spleen B220⁺ B cells from hCD19TG-1^(+/−)mice.

FIGS. 9A-9D demonstrate B cell depletion following anti-CD19 antibodytreatment is FcRγ- and monocyte-dependent. FIG. 9A Representative bloodand spleen B cell depletion 7 days after CD19 or isotype-controlantibody treatment of hCD19 TG-1^(+/−) FcRγ^(+/−) or TG-1^(+/−)FcRγ^(−/−) littermates. FIG. 9B Blood and tissue B cell depletion sevendays after antibody treatment of FcRγ^(−/−) littermates on day zero.FIG. 9C Representative B cell numbers in monocyte-depletedhCD19TG-1^(+/−) mice. FIG. 9D Blood and tissue B cell depletion sevendays after antibody treatment.

FIGS. 10A-10D demonstrate duration and dose response of B cell depletionfollowing anti-CD19 antibody treatment. FIG. 10A shows numbers of bloodB220⁺ B cells and Thy-1⁺ T cells following FMC63 or isotype-controlantibody treatment of TG-1^(+/−) mice on day zero. FIGS. 10B-C showrepresentative tissue B cell depletion in mice shown in FIG. 10A at 11,16, and 30 weeks following antibody treatment. FIG. 10D shows anti-CD19antibody dose responses for blood, bone marrow, and spleen B celldepletion.

FIGS. 11A-11C demonstrate that CD19 is not internalized followingantibody binding in vivo. Cell surface CD19 expression and B cellclearance in TG-1^(+/−) mice treated with HB12a (FIG. 11A), HB12b (FIG.11B), FMC63 (FIG. 11C) or isotype-matched control antibody (250 μg) invivo.

FIGS. 12A-12C demonstrate CD19 saturation following anti-CD19 antibodybinding in vivo. FIG. 12A shows B cell clearance in TG-1^(+/−) micetreated with FMC63 or isotype-matched control antibody (250 μg) in vivo.FIG. 12B shows FMC63 antibody treatment (250 μg) saturatesantibody-binding sites on hCD19 within 1 hour of administration. FIG.12C shows HB12b anti-CD19 antibody treatment (250 μg) saturatesantibody-binding sites on hCD19 within 1 hour of administration asassessed in FIG. 12B.

FIGS. 13A-13B demonstrate anti-CD19 antibody treatment reduces serumimmunoglobulin and autoantibody levels in TG-1^(+/−) mice. FIG. 13Adepicts serum immunoglobulin levels and FIG. 13B anti-dsDNA, anti-ssDNAand anti-histone autoantibody levels after anti-CD19 antibody treatment.

FIGS. 14A-14B demonstrate anti-CD19 antibody treatment blocks humoralimmune responses in TG-1^(+/−) mice. Antibody-treated mice wereimmunized with FIG. 14A TNP-LPS, FIG. 14B DNP-Ficoll and FIGS. 14C-14DDNP-KLH. Littermates were treated with FMC63 (closed circles) or control(open circles) antibody (250 μg) either (A-C) 7 days before or (D) 14days after primary immunizations on day 0.

FIG. 15 demonstrates that simultaneous anti-CD19 and anti-CD20 antibodytreatments are additive.

FIG. 16 demonstrates that subcutaneous (s.c.), intraperitoneal (i.p.)and i.v. administration of anti-CD19 antibody effectively depletescirculating and tissue B cells in vivo.

FIG. 17A-17B. Anti-CD19 antibody treatment prevents hCD19⁺ lymphomagrowth in vivo (FIG. 17A) and increases survival rate (FIG. 17B).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to pharmaceutical compositions comprisinghuman, humanized, or chimeric anti-CD19 antibodies of the IgG1 or IgG3human isotype. The present invention also relates to pharmaceuticalcompositions comprising human or humanized anti-CD19 antibodies of theIgG2 or IgG4 human isotype that preferably mediate human ADCC. Incertain embodiments, the present invention also relates topharmaceutical compositions comprising monoclonal human, humanized, orchimerized anti-CD19 antibodies that can be produced by means known inthe art.

In certain embodiments, the invention relates to immunotherapeuticcompositions and methods for the treatment of B cell diseases anddisorders in human subjects, such as, but not limited to, B cellmalignancies, using therapeutic antibodies that bind to the CD19 antigenand preferably mediate human ADCC. Therapeutic formulations and regimensare described for treating human subjects diagnosed with B cellmalignancies that derive from B cells and their precursors, includingbut not limited to, acute lymphoblastic leukemias (ALL), Hodgkin'slymphomas, non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemias(CLL), multiple myeloma, follicular lymphoma, mantle cell lymphoma,pro-lymphocytic leukemias, hairy cell leukemias, common acutelymphocytic leukemias and some Null-acute lymphoblastic leukemias

In certain embodiments, the invention relates to immunotherapeuticcompositions and methods for the treatment of autoimmune diseases anddisorders in human subjects using therapeutic antibodies that bind tothe CD19 antigen and preferably mediate human ADCC. Therapeuticformulations and regimens are described for treating human subjectsdiagnosed with autoimmune diseases or disorders, including but notlimited to, rheumatoid arthritis, SLE, ITP, pemphigus-related disorders,diabetes, and scleroderma.

In certain embodiments, the invention relates to immunotherapeuticcompositions and methods for the treatment and prevention of GVHD, graftrejection, and post-transplant lymphocyte proliferative disorder inhuman transplant recipients using therapeutic antibodies that bind tothe CD19 antigen and preferably mediate human ADCC. In particularembodiments, the anti-CD19 antibodies of the invention mediate ADCC,complement dependent cellular cytotoxicity, or apoptosis. Thecompositions and methods of the invention have the advantage ofspecifically targeting B cells, leaving intact other functional elementsand cell types of the immune system. Accordingly, in one aspect theinvention provides compositions and methods for the treatment andprevention of GVHD, graft rejection, and post-transplantationlymphoproliferative disorder which are associated with fewer and/or lesssevere complications than less targeted therapeutic agents and regimens.In one embodiment, the compositions and methods of the invention areused in combination with lower doses of traditional therapeutic agentsthan would be possible in the absence of the methods and compositions ofthe invention. In another embodiment, the compositions and methods ofthe invention obviate the need for a more severe form of therapy, suchas radiation therapy, high-dose chemotherapy, or splenectomy.

The compositions and methods of the invention also have the advantage oftargeting a wider population of B cells than other B-cell directedimmunotherapies. For example, the anti-CD19 antibodies of the presentinvention are effective to target bone marrow B cells, circulating Bcells, and mature, antibody-secreting B cells. Accordingly, the methodsand compositions of the invention are effective to reduce or depletecirculating B cells as well as circulating immunoglobulin (see, forexample, FIGS. 13 and 14).

In certain embodiments, the anti-CD19 antibodies and compositions of theinvention may be administered to a transplant recipient prior to orfollowing transplantation, alone or in combination with othertherapeutic agents or regimens for the treatment or prevention of GVHDand graft rejection. For example, the anti-CD19 antibodies andcompositions of the invention may be used to deplete alloantibodies froma transplant recipient prior to or following transplantation of anallogeneic graft. The anti-CD19 antibodies and compositions of theinvention may also be used to deplete antibody producing cells from thegraft ex vivo, prior to transplantation, or in the donor, as prophylaxisagainst GVHD and graft rejection.

The transplant recipient in need of prophylaxis or treatment for humoralrejection is identified according to the knowledge and skill in the art.For example, a transplant recipient in need of prophylaxis against graftrejection may be identified as a patient or patient population havingdetectable circulating anti-HLA alloantibodies prior to transplantation.In another example, the patient or patient population is identified ashaving panel reactive alloantibodies prior to transplantation. Thepresence of detectable circulating anti-HLA alloantibodies in atransplant recipient post-transplantation can also be used to identifythe patient or patient population in need of treatment for humoralrejection according to the invention. The patient or patient populationin need of treatment for humoral rejection can also be identifiedaccording to other clinical criteria which indicate that a transplantrecipient is at risk for developing a humoral rejection or has alreadydeveloped a humoral rejection. For example, a transplant recipient inneed of treatment for humoral rejection may be identified as a patientor patient population in an early stage of humoral rejection, such as alatent humoral response characterized by circulating anti-donoralloantibodies. An early stage of humoral rejection may also be a silentreaction characterized by circulating anti-donor alloantibodies and C4ddeposition, or a subclinical rejection characterized by circulatinganti-donor alloantibodies, C4d deposition, and tissue pathology. Inlater stages, the recipient is identified as a patient or patientpopulation presenting with clinical indications of humoral rejectioncharacterized according to the knowledge and skill in the art, forexample, by circulating anti-donor alloantibodies, C4d deposition,tissue pathology, and graft dysfunction.

The present invention provides compositions and methods effective toreduce the incidence, severity, or duration of GVHD, a rejectionepisode, or post-transplant lymphoproliferative disorder. In certainembodiments, the compositions and methods of the invention are effectiveto attenuate the host response to ischemic reperfusion injury of a solidtissue or organ graft. In a preferred embodiment, the anti-CD19 antibodycompositions and methods of the invention are effective to prolongsurvival of a graft in a transplant recipient.

Therapeutic formulations and regimens are described for treating orpreventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder. The present invention encompasses graftsthat are autologous, allogeneic, or xenogeneic to the recipient. Thetypes of grafts encompassed by the invention include tissue and organgrafts, including, but not limited to, bone marrow grafts, peripheralblood stem cell grafts, skin grafts, arterial and venous grafts,pancreatic islet cell grafts, and transplants of the kidney, liver,pancreas, thyroid, and heart. The terms “graft” and “transplant” areused interchangeably herein. In one embodiment, the autologous graft isa bone marrow graft, an arterial graft, a venous graft, or a skin graft.In one embodiment, the allograft is a bone marrow graft, a cornealgraft, a kidney transplant, a heart transplant, a liver transplant, alung transplant, a pancreatic transplant, a pancreatic islet celltransplant, or a combined transplant of a kidney and pancreas. In oneembodiment, the graft is a xenograft, preferably wherein the donor is apig. The compositions and methods of the present invention may also beused to suppress a deleterious immune response to a non-biological graftor implant, including, but not limited to, an artificial joint, a stent,or a pacemaker device.

The anti-CD19 antibodies, compositions and methods of the invention canbe used to treat or prevent GVHD, humoral rejection, or post-transplantlymphoproliferative disorder without regard to the particularindications initially giving rise to the need for the transplant or tothe particular type of tissue transplanted. However, the indicationswhich gave rise to the need for a transplant and the type of tissuetransplanted may provide the basis for a comprehensive therapeuticregimen for the treatment or prevention of GVHD, graft rejection, andpost-transplant lymphoproliferative disorder, which comprehensiveregimen comprises the anti-CD19 antibody compositions and methods of theinvention. A more detailed description of diagnostic criteria andtherapeutic regimens is provided below.

5.1. Generation of Anti-CD19 Antibodies

5.1.1. Polyclonal Anti-CD19 Antibodies

Polyclonal antibodies are preferably raised in animals by multiplesubcutaneous (s.c.) or intraperitoneal (i.p.) injections of the relevantantigen and an adjuvant. It may be useful to conjugate the relevantantigen to a protein that is immunogenic in the species to be immunized,e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, orsoybean trypsin inhibitor using a bifunctional or derivatizing agent,for example, maleimidobertzoyl sulfosuccinimide ester (conjugationthrough cysteine residues), N-hydroxysuccinimide (through lysineresidues), glutaraldehyde, succunic anhydride, SOCl₂.

Animals are immunized against the antigen, immunogenic conjugates, orderivatives by combining, e.g., 100 μg or 5 μg of the protein orconjugate (for rabbits or mice, respectively) with 3 volumes of Freund'scomplete adjuvant and injecting the solution intradermally at multiplesites. One month later the animals are boosted with ⅕ to 1/10 theoriginal amount of peptide or conjugate in Freund's incomplete adjuvantby subcutaneous injection at multiple sites. Seven to 14 days later theanimals are bled and the serum is assayed for antibody titer. Animalsare boosted until the titer plateaus. Preferably, the animal is boostedwith the conjugate of the same antigen, but conjugated to a differentprotein and/or through a different cross-linking reagent. Conjugatesalso can be made in recombinant cell culture as protein fusions. Also,aggregating agents such as alum are suitably used to enhance the immuneresponse.

5.1.2. Monoclonal Anti-CD19 Antibodies

The monoclonal anti-CD19 antibodies of the invention exhibit bindingspecificity to human CD19 antigen and can preferably mediate human ADCC.These antibodies can be generated using a wide variety of techniquesknown in the art including the use of hybridoma, recombinant, and phagedisplay technologies, or a combination thereof. Antibodies are highlyspecific, being directed against a single antigenic site. Furthermore,in contrast to conventional (polyclonal) antibody preparations whichtypically include different antibodies directed against differentdeterminants (epitopes), each monoclonal antibody is directed against asingle determinant on the human CD19 antigen. For example, themonoclonal antibodies to be used in accordance with the presentinvention may be made by the hybridoma method first described by Kohleret al., Nature, 256:495 (1975), which can be used to generate murineantibodies (or antibodies derived from other nonhuman mammals, e.g.,rat, goat, sheep, cows, camels, etc.), or human antibodies derived fromtransgenic animals (see, U.S. Pat. Nos. 6,075,181, 6,114,598, 6,150,584,and 6,657,103). Alternatively, the monoclonal antibodies can be made byrecombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567) and includechimeric and humanized antibodies. The “monoclonal antibodies” may alsobe isolated from phage antibody libraries using the techniques describedin Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol.Biol., 222:581-597 (1991), for example.

An engineered anti-CD19 antibody can be produced by any means known inthe art, including, but not limited to, those techniques described belowand improvements to those techniques. Large-scale high-yield productiontypically involves culturing a host cell that produces the engineeredanti-CD19 antibody and recovering the anti-CD19 antibody from the hostcell culture.

5.1.3. Hybridoma Techniques

Monoclonal antibodies can be produced using hybridoma techniquesincluding those known in the art and taught, for example, in Harlow etal., Antibodies: A Laboratory Manual, (Cold Spring Harbor LaboratoryPress, 2nd ed. 1988); Hammerling et al., in Monoclonal Antibodies and TCell Hybridomas, 563-681 (Elsevier, NY, 1981) (said referencesincorporated by reference in their entireties). For example, in thehybridoma method, a mouse or other appropriate host animal, such as ahamster or macaque monkey, is immunized to elicit lymphocytes thatproduce or are capable of producing antibodies that will specificallybind to the protein used for immunization. Alternatively, lymphocytesmay be immunized in vitro. Lymphocytes then are fused with myeloma cellsusing a suitable fusing agent, such as polyethylene glycol, to form ahybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice,pp. 59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitableculture medium that preferably contains one or more substances thatinhibit the growth or survival of the unfused, parental myeloma cells.For example, if the parental myeloma cells lack the enzyme hypoxanthineguanine phosphoribosyl transferase (HGPRT or HPRT), the culture mediumfor the hybridomas typically will include hypoxanthine, aminopterin, andthymidine (HAT medium), which substances prevent the growth ofHGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stablehigh-level production of antibody by the selected antibody-producingcells, and are sensitive to a medium such as HAT medium. Among these,preferred myeloma cell lines are murine myeloma lines, such as thosederived from MOPC-21 and MPC-11 mouse tumors available from the SalkInstitute Cell Distribution Center, San Diego, Calif., USA, and SP-2 orX63-Ag8.653 cells available from the American Type Culture Collection,Rockville, Md., USA. Human myeloma and mouse-human heteromyeloma celllines also have been described for the production of human monoclonalantibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al.,Monoclonal Antibody Production Techniques and Applications, pp. 51-63(Marcel Dekker, Inc., NY, 1987)).

Culture medium in which hybridoma cells are growing is assayed forproduction of monoclonal antibodies directed against the human CD19antigen. Preferably, the binding specificity of monoclonal antibodiesproduced by hybridoma cells is determined by immunoprecipitation or byan in vitro binding assay, such as radioimmunoassay (RIA) orenzyme-linked immunoabsorbent assay (ELISA).

After hybridoma cells are identified that produce antibodies of thedesired specificity, affinity, and/or activity, the clones may besubcloned by limiting dilution procedures and grown by standard methods(Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103(Academic Press, 1986)). Suitable culture media for this purposeinclude, for example, D-MEM or RPMI 1640 medium. In addition, thehybridoma cells may be grown in vivo as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitablyseparated from the culture medium, ascites fluid, or serum byconventional immunoglobulin purification procedures such as, forexample, protein A-Sepharose, hydroxylapatite chromatography, gelelectrophoresis, dialysis, or affinity chromatography.

5.1.4. Recombinant DNA Techniques

DNA encoding the anti-CD19 antibodies of the invention is readilyisolated and sequenced using conventional procedures (e.g., by usingoligonucleotide probes that are capable of binding specifically to genesencoding the heavy and light chains of the anti-CD19 antibodies). Thehybridoma cells serve as a preferred source of such DNA. Once isolated,the DNA may be placed into expression vectors, which are thentransfected into host cells such as E. coli cells, simian COS cells,Chinese hamster ovary (CHO) cells, or myeloma cells that do nototherwise produce immunoglobulin protein, to obtain the synthesis ofanti-CD19 antibodies in the recombinant host cells.

In phage display methods, functional antibody domains are displayed onthe surface of phage particles which carry the polynucleotide sequencesencoding them. In particular, DNA sequences encoding V_(H) and V_(L)domains are amplified from animal cDNA libraries (e.g., human or murinecDNA libraries of affected tissues). The DNA encoding the V_(H) andV_(L) domains are recombined together with an scFv linker by PCR andcloned into a phagemid vector. The vector is electroporated in E. coliand the E. coli is infected with helper phage. Phage used in thesemethods are typically filamentous phage including fd and M13 and theV_(H) and V_(L) domains are usually recombinantly fused to either thephage gene III or gene VIII. Phage expressing an antigen-binding domainthat binds to a particular antigen can be selected or identified withantigen, e.g., using labeled antigen or antigen bound or captured to asolid surface or bead. Examples of phage display methods that can beused to make the antibodies of the present invention include thosedisclosed in Brinkman et al., 1995, J. Immunol. Methods, 182:41-50; Ameset al., 1995, J. Immunol. Methods, 184:177-186; Kettleborough et al.,1994, Eur. J. Immunol., 24:952-958; Persic et al., 1997, Gene, 187:9-18;Burton et al., 1994, Advances in Immunology, 57:191-280; InternationalApplication No. PCT/GB91/O1 134; International Publication Nos. WO90/02809, WO 91/10737, WO 92/01047, WO 92/18619, WO 93/11236, WO95/15982, WO 95/20401, and WO97/13844; and U.S. Pat. Nos. 5,698,426,5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047,5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727, 5,733,743, and5,969,108; each of which is incorporated herein by reference in itsentirety.

As described in the above references, after phage selection, theantibody coding regions from the phage can be isolated and used togenerate whole antibodies, including human antibodies, or any otherdesired antigen-binding fragment, and expressed in any desired host,including mammalian cells, insect cells, plant cells, yeast, andbacteria, e.g., as described below. Techniques to recombinantly produceFab, Fab′ and F(ab′)₂ fragments can also be employed using methods knownin the art such as those disclosed in PCT Publication No. WO 92/22324;Mullinax et al., 1992, BioTechniques, 12(6):864-869; Sawai et al., 1995,AJRI, 34:26-34; and Better et al., 1988, Science, 240:1041-1043 (saidreferences incorporated by reference in their entireties).

In a further embodiment, antibodies may be isolated from antibody phagelibraries generated using the techniques described in McCafferty et al.,Nature, 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991).Marks et al., J. Mol. Biol., 222:581-597 (1991) describe the isolationof murine and human antibodies, respectively, using phage libraries.Chain shuffling can be used in the production of high affinity (nMrange) human antibodies (Marks et al., Bio/Technology, 10:779-783(1992)), as well as combinatorial infection and in vivo recombination asa strategy for constructing very large phage libraries (Waterhouse etal., Nuc. Acids. Res., 21:2265-2266 (1993)). Thus, these techniques areviable alternatives to traditional monoclonal antibody hybridomatechniques for isolation of anti-CD19 antibodies.

To generate whole antibodies, PCR primers including V_(H) or V_(L)nucleotide sequences, a restriction site, and a flanking sequence toprotect the restriction site can be used to amplify the V_(H) or V_(L)sequences in scFv clones. Utilizing cloning techniques known to those ofskill in the art, the PCR amplified V_(H) domains can be cloned intovectors expressing a V_(H) constant region, e.g., the human gamma 4constant region, and the PCR amplified V_(L) domains can be cloned intovectors expressing a V_(L) constant region, e.g., human kappa or lambdaconstant regions. Preferably, the vectors for expressing the V_(H) orV_(L) domains comprise an EF-1α promoter, a secretion signal, a cloningsite for the variable domain, constant domains, and a selection markersuch as neomycin. The V_(H) and V_(L) domains may also be cloned intoone vector expressing the necessary constant regions. The heavy chainconversion vectors and light chain conversion vectors are thenco-transfected into cell lines to generate stable or transient celllines that express full-length antibodies, e.g., IgG, using techniquesknown to those of skill in the art.

The DNA also may be modified, for example, by substituting the codingsequence for human heavy and light chain constant domains in place ofthe homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison etal., Proc. Natl. Acad. Sci. USA, 81:6851 (1984)), or by covalentlyjoining to the immunoglobulin coding sequence all or part of the codingsequence for a non-immunoglobulin polypeptide.

5.1.5. Chimeric Antibodies

The anti-CD19 antibodies herein specifically include chimeric antibodies(immunoglobulins) in which a portion of the heavy and/or light chain isidentical with or homologous to corresponding sequences in antibodiesderived from a particular species or belonging to a particular antibodyclass or subclass, while another portion of the chain(s) is identicalwith or homologous to corresponding sequences in antibodies derived fromanother species or belonging to another antibody class or subclass, aswell as fragments of such antibodies, so long as they exhibit thedesired biological activity (U.S. Pat. No. 4,816,567; Morrison et al.,Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies ofinterest herein include “primatized” antibodies comprising variabledomain antigen-binding sequences derived from a nonhuman primate (e.g.,Old World Monkey, such as baboon, rhesus or cynomolgus monkey) and humanconstant region sequences (U.S. Pat. No. 5,693,780).

5.1.6. Humanized Antibodies

A humanized antibody can be produced using a variety of techniques knownin the art, including but not limited to, CDR-grafting (see, e.g.,European Patent No. EP 239,400; International Publication No. WO91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, eachof which is incorporated herein in its entirety by reference), veneeringor resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnickaet al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al.,1994, PNAS, 91:969-973, each of which is incorporated herein by itsentirety by reference), chain shuffling (see, e.g., U.S. Pat. No.5,565,332, which is incorporated herein in its entirety by reference),and techniques disclosed in, e.g., U.S. Patent Application PublicationNo. US2005/0042664, U.S. Patent Application Publication No.US2005/0048617, U.S. Pat. No. 6,407,213, U.S. Pat. No. 5,766,886,International Publication No. WO 9317105, Tan et al., J. Immunol.,169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000),Morea et al., Methods, 20(3):267-79 (2000), Baca et al., J. Biol. Chem.,272(16):10678-84 (1997), Roguska et al., Protein Eng., 9(10):895-904(1996), Couto et al., Cancer Res., 55 (23 Supp):5973s-5977s (1995),Couto et al., Cancer Res., 55(8):1717-22 (1995), Sandhu J S, Gene,150(2):409-10 (1994), and Pedersen et al., J. Mol. Biol., 235(3):959-73(1994), each of which is incorporated herein in its entirety byreference. Often, framework residues in the framework regions will besubstituted with the corresponding residue from the CDR donor antibodyto alter, preferably improve, antigen binding. These frameworksubstitutions are identified by methods well-known in the art, e.g., bymodeling of the interactions of the CDR and framework residues toidentify framework residues important for antigen binding and sequencecomparison to identify unusual framework residues at particularpositions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; andRiechmann et al., 1988, Nature, 332:323, which are incorporated hereinby reference in their entireties.)

A humanized anti-CD19 antibody has one or more amino acid residuesintroduced into it from a source which is nonhuman. These nonhuman aminoacid residues are often referred to as “import” residues, which aretypically taken from an “import” variable domain. Thus, humanizedantibodies comprise one or more CDRs from nonhuman immunoglobulinmolecules and framework regions from human. Humanization of antibodiesis well-known in the art and can essentially be performed following themethod of Winter and co-workers (Jones et al., Nature, 321:522-525(1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al.,Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDRsequences for the corresponding sequences of a human antibody, i.e.,CDR-grafting (EP 239,400; PCT Publication No. WO 91/09967; and U.S. Pat.Nos. 4,816,567; 6,331,415; 5,225,539; 5,530,101; 5,585,089; 6,548,640,the contents of which are incorporated herein by reference herein intheir entirety). In such humanized chimeric antibodies, substantiallyless than an intact human variable domain has been substituted by thecorresponding sequence from a nonhuman species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies. Humanization of anti-CD19 antibodies canalso be achieved by veneering or resurfacing (EP 592,106; EP 519,596;Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnicka et al.,Protein Engineering, 7(6):805-814 (1994); and Roguska et al., PNAS,91:969-973 (1994)) or chain shuffling (U.S. Pat. No. 5,565,332), thecontents of which are incorporated herein by reference herein in theirentirety.

The choice of human variable domains, both light and heavy, to be usedin making the humanized antibodies is to reduce antigenicity. Accordingto the so-called “best-fit” method, the sequence of the variable domainof a rodent antibody is screened against the entire library of knownhuman variable-domain sequences. The human sequence which is closest tothat of the rodent is then accepted as the human framework (FR) for thehumanized antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothiaet al., J. Mol. Biol., 196:901 (1987), the contents of which areincorporated herein by reference herein in their entirety). Anothermethod uses a particular framework derived from the consensus sequenceof all human antibodies of a particular subgroup of light or heavychains. The same framework may be used for several different humanizedanti-CD19 antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285(1992); Presta et al., J. Immunol., 151:2623 (1993), the contents ofwhich are incorporated herein by reference herein in their entirety).

Anti-CD19 antibodies can be humanized with retention of high affinityfor CD19 and other favorable biological properties. According to oneaspect of the invention, humanized antibodies are prepared by a processof analysis of the parental sequences and various conceptual humanizedproducts using three-dimensional models of the parental and humanizedsequences. Three-dimensional immunoglobulin models are commonlyavailable and are familiar to those skilled in the art. Computerprograms are available which illustrate and display probablethree-dimensional conformational structures of selected candidateimmunoglobulin sequences. Inspection of these displays permits analysisof the likely role of the residues in the functioning of the candidateimmunoglobulin sequence, i.e., the analysis of residues that influencethe ability of the candidate immunoglobulin to bind CD19. In this way,FR residues can be selected and combined from the recipient and importsequences so that the desired antibody characteristic, such as increasedaffinity for CD19, is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.

A “humanized” antibody retains a similar antigenic specificity as theoriginal antibody, i.e., in the present invention, the ability to bindhuman CD19 antigen. However, using certain methods of humanization, theaffinity and/or specificity of binding of the antibody for human CD19antigen may be increased using methods of “directed evolution,” asdescribed by Wu et al., J. Mol. Biol., 294:151 (1999), the contents ofwhich are incorporated herein by reference herein in their entirety.

5.1.7. Human Antibodies

For in vivo use of antibodies in humans, it may be preferable to usehuman antibodies. Completely human antibodies are particularly desirablefor therapeutic treatment of human subjects. Human antibodies can bemade by a variety of methods known in the art including phage displaymethods described above using antibody libraries derived from humanimmunoglobulin sequences, including improvements to these techniques.See, also, U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publicationsWO 98/46645, WO 98/50433, WO 98/24893, WO98/16654, WO 96/34096, WO96/33735, and WO 91/10741; each of which is incorporated herein byreference in its entirety. A human antibody can also be an antibodywherein the heavy and light chains are encoded by a nucleotide sequencederived from one or more sources of human DNA.

Human anti-CD19 antibodies can also be produced using transgenic micewhich are incapable of expressing functional endogenous immunoglobulins,but which can express human immunoglobulin genes. For example, the humanheavy and light chain immunoglobulin gene complexes may be introducedrandomly or by homologous recombination into mouse embryonic stem cells.Alternatively, the human variable region, constant region, and diversityregion may be introduced into mouse embryonic stem cells in addition tothe human heavy and light chain genes. The mouse heavy and light chainimmunoglobulin genes may be rendered non-functional separately orsimultaneously with the introduction of human immunoglobulin loci byhomologous recombination. For example, it has been described that thehomozygous deletion of the antibody heavy chain joining region (JH) genein chimeric and germ-line mutant mice results in complete inhibition ofendogenous antibody production. The modified embryonic stem cells areexpanded and microinjected into blastocysts to produce chimeric mice.The chimeric mice are then bred to produce homozygous offspring whichexpress human antibodies. The transgenic mice are immunized in thenormal fashion with a selected antigen, e.g., all or a portion of apolypeptide of the invention. Anti-CD19 antibodies directed against thehuman CD19 antigen can be obtained from the immunized, transgenic miceusing conventional hybridoma technology. The human immunoglobulintransgenes harbored by the transgenic mice rearrange during B celldifferentiation, and subsequently undergo class switching and somaticmutation. Thus, using such a technique, it is possible to producetherapeutically useful IgG, IgA, IgM and IgE antibodies, including, butnot limited to, IgG1 (gamma 1) and IgG3. For an overview of thistechnology for producing human antibodies, see, Lonberg and Huszar (Int.Rev. Immunol., 13:65-93 (1995)). For a detailed discussion of thistechnology for producing human antibodies and human monoclonalantibodies and protocols for producing such antibodies, see, e.g., PCTPublication Nos. WO 98/24893, WO 96/34096, and WO 96/33735; and U.S.Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016;5,545,806; 5,814,318; and 5,939,598, each of which is incorporated byreference herein in their entirety. In addition, companies such asAbgenix, Inc. (Freemont, Calif.) and Genpharm (San Jose, Calif.) can beengaged to provide human antibodies directed against a selected antigenusing technology similar to that described above. For a specificdiscussion of transfer of a human germ-line immunoglobulin gene array ingerm-line mutant mice that will result in the production of humanantibodies upon antigen challenge see, e.g., Jakobovits et al., Proc.Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature,362:255-258 (1993); Bruggermann et al., Year in Immunol., 7:33 (1993);and Duchosal et al., Nature, 355:258 (1992).

Human antibodies can also be derived from phage-display libraries(Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol.Biol., 222:581-597 (1991); Vaughan et al., Nature Biotech., 14:309(1996)). Phage display technology (McCafferty et al., Nature,348:552-553 (1990)) can be used to produce human antibodies and antibodyfragments in vitro, from immunoglobulin variable (V) domain generepertoires from unimmunized donors. According to this technique,antibody V domain genes are cloned in-frame into either a major or minorcoat protein gene of a filamentous bacteriophage, such as M13 or fd, anddisplayed as functional antibody fragments on the surface of the phageparticle. Because the filamentous particle contains a single-strandedDNA copy of the phage genome, selections based on the functionalproperties of the antibody also result in selection of the gene encodingthe antibody exhibiting those properties. Thus, the phage mimics some ofthe properties of the B cell. Phage display can be performed in avariety of formats; for their review see, e.g., Johnson, Kevin S, andChiswell, David J., Current Opinion in Structural Biology 3:564-571(1993). Several sources of V-gene segments can be used for phagedisplay. Clackson et al., Nature, 352:624-628 (1991) isolated a diversearray of anti-oxazolone antibodies from a small random combinatoriallibrary of V genes derived from the spleens of unimmunized mice. Arepertoire of V genes from unimmunized human donors can be constructedand antibodies to a diverse array of antigens (including self-antigens)can be isolated essentially following the techniques described by Markset al., J. Mol. Biol., 222:581-597 (1991), or Griffith et al., EMBO J.,12:725-734 (1993). See, also, U.S. Pat. Nos. 5,565,332 and 5,573,905,each of which is incorporated herein by reference in its entirety.

Human antibodies may also be generated by in vitro activated B cells(see, U.S. Pat. Nos. 5,567,610 and 5,229,275, each of which isincorporated herein by reference in its entirety). Human antibodies mayalso be generated in vitro using hybridoma techniques such as, but notlimited to, that described by Roder et al. (Methods Enzymol.,121:140-167 (1986)).

5.1.8. Altered/Mutant Antibodies

The anti-CD19 antibodies of the compositions and methods of theinvention can be mutant antibodies. As used herein, “antibody mutant” or“altered antibody” refers to an amino acid sequence variant of ananti-CD19 antibody wherein one or more of the amino acid residues of ananti-CD19 antibody have been modified. The modifications to the aminoacid sequence of the anti-CD19 antibody, include modifications to thesequence to improve affinity or avidity of the antibody for its antigen,and/or modifications to the Fc portion of the antibody to improveeffector function. The modifications may be made to any known anti-CD19antibodies or anti-CD19 antibodies identified as described herein. Suchaltered antibodies necessarily have less than 100% sequence identity orsimilarity with a known anti-CD19 antibody. In a preferred embodiment,the altered antibody will have an amino acid sequence having at least25%, 35%, 45%, 55%, 65%, or 75% amino acid sequence identity orsimilarity with the amino acid sequence of either the heavy or lightchain variable domain of an anti-CD19 antibody, more preferably at least80%, more preferably at least 85%, more preferably at least 90%, andmost preferably at least 95%. In a preferred embodiment, the alteredantibody will have an amino acid sequence having at least 25%, 35%, 45%,55%, 65%, or 75% amino acid sequence identity or similarity with theamino acid sequence of the heavy chain CDR1, CDR2, or CDR3 of ananti-CD19 antibody, more preferably at least 80%, more preferably atleast 85%, more preferably at least 90%, and most preferably at least95%. In a preferred embodiment, the altered antibody will maintain humanCD19 binding capability. In certain embodiments, the anti-CD19 antibodyof the invention comprises a heavy chain that is about 10%, 15%, 20%,25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,95% or more identical to an amino acid sequence of SEQ ID NO:2 (FIG. 5A)corresponding to the heavy chain of HB12a. In certain embodiments, theanti-CD19 antibody of the invention comprises a heavy chain that isabout 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, 95% or more identical to an amino acid sequence ofSEQ ID NO:4 (FIG. 5B) corresponding to the heavy chain of HB12b. Incertain embodiments, the anti-CD19 antibody of the invention comprises alight chain that is about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more identical to anamino acid sequence of SEQ ID NO:16 (FIG. 6A) corresponding to the lightchain of HB12a. In certain embodiments, the anti-CD19 antibody of theinvention comprises a light chain that is about 10%, 15%, 20%, 25%, 30%,35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or moreidentical to an amino acid sequence of SEQ ID NO:18 (FIG. 6B)corresponding to the light chain of HB12b. In a preferred embodiment,the altered antibody will have an amino acid sequence having at least25%, 35%, 45%, 55%, 65%, or 75% amino acid sequence identity orsimilarity with the amino acid sequence of light chain CDR1, CDR2, orCDR3 of an anti-CD19 antibody, more preferably at least 80%, morepreferably at least 85%, more preferably at least 90%, and mostpreferably at least 95%. Hybridomas producing HB12a and HB12b anti-CD19antibodies have been deposited under ATCC deposit nos. PTA-6580 andPTA-6581.

Identity or similarity with respect to this sequence is defined hereinas the percentage of amino acid residues in the candidate sequence thatare identical (i.e., same residue) or similar (i.e., amino acid residuefrom the same group based on common side-chain properties, see below)with anti-CD19 antibody residues, after aligning the sequences andintroducing gaps, if necessary, to achieve the maximum percent sequenceidentity. None of N-terminal, C-terminal, or internal extensions,deletions, or insertions into the antibody sequence outside of thevariable domain shall be construed as affecting sequence identity orsimilarity.

“% identity” as known in the art, is a measure of the relationshipbetween two polynucleotides or two polypeptides, as determined bycomparing their sequences. In general, the two sequences to be comparedare aligned to give a maximum correlation between the sequences. Thealignment of the two sequences is examined and the number of positionsgiving an exact amino acid or nucleotide correspondence between the twosequences determined, divided by the total length of the alignment andmultiplied by 100 to give a % identity figure. This % identity figuremay be determined over the whole length of the sequences to be compared,which is particularly suitable for sequences of the same or very similarlength and which are highly homologous, or over shorter defined lengths,which is more suitable for sequences of unequal length or which have alower level of homology.

For example, sequences can be aligned with the software clustalW underUnix which generates a file with an “.aln” extension, this file can thenbe imported into the Bioedit program (Hall, T. A. 1999, BioEdit: auser-friendly biological sequence alignment editor and analysis programfor Windows 95/98/NT. Nucl. Acids. Symp. Ser., 41:95-98) which opens the.aln file. In the Bioedit window, one can choose individual sequences(two at a time) and alignment them. This method allows for comparison ofthe entire sequence.

Methods for comparing the identity of two or more sequences arewell-known in the art.

Thus for instance, programs are available in the Wisconsin SequenceAnalysis Package, version 9.1 (Devereux J. et al., Nucleic Acids Res.,12:387-395, 1984, available from Genetics Computer Group, Madison, Wis.,USA). The determination of percent identity between two sequences can beaccomplished using a mathematical algorithm. For example, the programsBESTFIT and GAP, may be used to determine the % identity between twopolynucleotides and the % identity between two polypeptide sequences.BESTFIT uses the “local homology” algorithm of Smith and Waterman(Advances in Applied Mathematics, 2:482-489, 1981) and finds the bestsingle region of similarity between two sequences. BESTFIT is moresuited to comparing two polynucleotide or two polypeptide sequenceswhich are dissimilar in length, the program assuming that the shortersequence represents a portion of the longer. In comparison, GAP alignstwo sequences finding a “maximum similarity” according to the algorithmof Neddleman and Wunsch (J. Mol. Biol., 48:443-354, 1970). GAP is moresuited to comparing sequences which are approximately the same lengthand an alignment is expected over the entire length. Preferably theparameters “Gap Weight” and “Length Weight” used in each program are 50and 3 for polynucleotides and 12 and 4 for polypeptides, respectively.Preferably % identities and similarities are determined when the twosequences being compared are optimally aligned.

Other programs for determining identity and/or similarity betweensequences are also known in the art, for instance the BLAST family ofprograms (Karlin & Altschul, 1990, Proc. Natl. Acad. Sci. USA,87:2264-2268, modified as in Karlin & Altschul, 1993, Proc. Natl. Acad.Sci. USA, 90:5873-5877, available from the National Center forBiotechnology Information (NCB), Bethesda, Md., USA, and accessiblethrough the home page of the NCBI at www.ncbi.nlm.nih.gov). Theseprograms exemplify a preferred, non-limiting example of a mathematicalalgorithm utilized for the comparison of two sequences. Such analgorithm is incorporated into the NBLAST and XBLAST programs ofAltschul et al., 1990, J. Mol. Biol. 215:403-410. BLAST nucleotidesearches can be performed with the NBLAST program, score=100,wordlength=12 to obtain nucleotide sequences homologous to a nucleicacid molecule encoding all or a portion if an anti-CD19 antibody of theinvention. BLAST protein searches can be performed with the XBLASTprogram, score=50, wordlength=3 to obtain amino acid sequenceshomologous to a protein molecule of the invention. To obtain gappedalignments for comparison purposes, Gapped BLAST can be utilized asdescribed in Altschul et al., 1997, Nucleic Acids Res., 25:3389-3402.Alternatively, PSI-Blast can be used to perform an iterated search whichdetects distant relationships between molecules (Id.). When utilizingBLAST, Gapped BLAST, and PSI-Blast programs, the default parameters ofthe respective programs (e.g., XBLAST and NBLAST) can be used. See,http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example ofa mathematical algorithm utilized for the comparison of sequences is thealgorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithmis incorporated into the ALIGN program (version 2.0) which is part ofthe GCG sequence alignment software package. When utilizing the ALIGNprogram for comparing amino acid sequences, a PAM120 weight residuetable, a gap length penalty of 12, and a gap penalty of 4 can be used.

Another non-limiting example of a program for determining identityand/or similarity between sequences known in the art is FASTA (PearsonW. R. and Lipman D. J., Proc. Nat. Acad. Sci. USA, 85:2444-2448, 1988,available as part of the Wisconsin Sequence Analysis Package).Preferably the BLOSUM62 amino acid substitution matrix (Henikoff S, andHenikoff J. G., Proc. Nat. Acad. Sci. USA, 89:10915-10919, 1992) is usedin polypeptide sequence comparisons including where nucleotide sequencesare first translated into amino acid sequences before comparison.

Yet another non-limiting example of a program known in the art fordetermining identity and/or similarity between amino acid sequences isSeqWeb Software (a web-based interface to the GCG Wisconsin Package: Gapprogram) which is utilized with the default algorithm and parametersettings of the program: blosum62, gap weight 8, length weight 2.

The percent identity between two sequences can be determined usingtechniques similar to those described above, with or without allowinggaps. In calculating percent identity, typically exact matches arecounted.

Preferably the program BESTFIT is used to determine the % identity of aquery polynucleotide or a polypeptide sequence with respect to apolynucleotide or a polypeptide sequence of the present invention, thequery and the reference sequence being optimally aligned and theparameters of the program set at the default value.

To generate an altered antibody, one or more amino acid alterations(e.g., substitutions) are introduced in one or more of the hypervariableregions of the species-dependent antibody. Alternatively, or inaddition, one or more alterations (e.g., substitutions) of frameworkregion residues may be introduced in an anti-CD19 antibody where theseresult in an improvement in the binding affinity of the antibody mutantfor the antigen from the second mammalian species. Examples of frameworkregion residues to modify include those which non-covalently bindantigen directly (Amit et al., Science, 233:747-753 (1986)); interactwith/effect the conformation of a CDR (Chothia et al., J. Mol. Biol.,196:901-917 (1987)); and/or participate in the V_(L)-V_(H) interface (EP239 400B1). In certain embodiments, modification of one or more of suchframework region residues results in an enhancement of the bindingaffinity of the antibody for the antigen from the second mammalianspecies. For example, from about one to about five framework residuesmay be altered in this embodiment of the invention. Sometimes, this maybe sufficient to yield an antibody mutant suitable for use inpreclinical trials, even where none of the hypervariable region residueshave been altered. Normally, however, an altered antibody will compriseadditional hypervariable region alteration(s).

The hypervariable region residues which are altered may be changedrandomly, especially where the starting binding affinity of an anti-CD19antibody for the antigen from the second mammalian species is such thatsuch randomly produced altered antibody can be readily screened.

One useful procedure for generating such an altered antibody is called“alanine scanning mutagenesis” (Cunningham and Wells, Science,244:1081-1085 (1989)). Here, one or more of the hypervariable regionresidue(s) are replaced by alanine or polyalanine residue(s) to affectthe interaction of the amino acids with the antigen from the secondmammalian species. Those hypervariable region residue(s) demonstratingfunctional sensitivity to the substitutions then are refined byintroducing additional or other mutations at or for the sites ofsubstitution. Thus, while the site for introducing an amino acidsequence variation is predetermined, the nature of the mutation per seneed not be predetermined. The Ala-mutants produced this way arescreened for their biological activity as described herein.

Another procedure for generating such an altered antibody involvesaffinity maturation using phage display (Hawkins et al., J. Mol. Biol.,254:889-896 (1992) and Lowman et al., Biochemistry, 30(45):10832-10837(1991)). Briefly, several hypervariable region sites (e.g., 6-7 sites)are mutated to generate all possible amino acid substitutions at eachsite. The antibody mutants thus generated are displayed in a monovalentfashion from filamentous phage particles as fusions to the gene IIIproduct of M13 packaged within each particle. The phage-displayedmutants are then screened for their biological activity (e.g., bindingaffinity) as herein disclosed.

Mutations in antibody sequences may include substitutions, deletions,including internal deletions, additions, including additions yieldingfusion proteins, or conservative substitutions of amino acid residueswithin and/or adjacent to the amino acid sequence, but that result in a“silent” change, in that the change produces a functionally equivalentanti-CD19 antibody. Conservative amino acid substitutions may be made onthe basis of similarity in polarity, charge, solubility, hydrophobicity,hydrophilicity, and/or the amphipathic nature of the residues involved.For example, non-polar (hydrophobic) amino acids include alanine,leucine, isoleucine, valine, proline, phenylalanine, tryptophan, andmethionine; polar neutral amino acids include glycine, serine,threonine, cysteine, tyrosine, asparagine, and glutamine; positivelycharged (basic) amino acids include arginine, lysine, and histidine; andnegatively charged (acidic) amino acids include aspartic acid andglutamic acid. In addition, glycine and proline are residues that caninfluence chain orientation. Non-conservative substitutions will entailexchanging a member of one of these classes for another class.Furthermore, if desired, non-classical amino acids or chemical aminoacid analogs can be introduced as a substitution or addition into theantibody sequence. Non-classical amino acids include, but are notlimited to, the D-isomers of the common amino acids, α-amino isobutyricacid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ-Abu, ε-Ahx,6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionicacid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine,citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine,cyclohexylalanine, β-alanine, fluoro-amino acids, designer amino acidssuch as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl aminoacids, and amino acid analogs in general.

In another embodiment, the sites selected for modification are affinitymatured using phage display (see above).

Any technique for mutagenesis known in the art can be used to modifyindividual nucleotides in a DNA sequence, for purposes of making aminoacid substitution(s) in the antibody sequence, or for creating/deletingrestriction sites to facilitate further manipulations. Such techniquesinclude, but are not limited to, chemical mutagenesis, in vitrosite-directed mutagenesis (Kunkel, Proc. Natl. Acad. Sci. USA, 82:488(1985); Hutchinson, C. et al., J. Biol. Chem., 253:6551 (1978)),oligonucleotide-directed mutagenesis (Smith, Ann. Rev. Genet.,19:423-463 (1985); Hill et al., Methods Enzymol., 155:558-568 (1987)),PCR-based overlap extension (Ho et al., Gene, 77:51-59 (1989)),PCR-based megaprimer mutagenesis (Sarkar et al., Biotechniques,8:404-407 (1990)), etc. Modifications can be confirmed bydouble-stranded dideoxy DNA sequencing.

In certain embodiments of the invention the anti-CD19 antibodies can bemodified to produce fusion proteins; i.e., the antibody, or a fragmentfused to a heterologous protein, polypeptide or peptide. In certainembodiments, the protein fused to the portion of an anti-CD19 antibodyis an enzyme component of ADEPT. Examples of other proteins orpolypeptides that can be engineered as a fusion protein with ananti-CD19 antibody include, but are not limited to toxins such as ricin,abrin, ribonuclease, DNase I, Staphylococcal enterotoxin-A, pokeweedanti-viral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin, andPseudomonas endotoxin. See, for example, Pastan et al., Cell, 47:641(1986), and Goldenberg et al., Cancer Journal for Clinicians, 44:43(1994). Enzymatically active toxins and fragments thereof which can beused include diphtheria A chain, non-binding active fragments ofdiphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricinA chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordiiproteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII,and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonariaofficinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin,enomycin and the tricothecenes. See, for example, WO 93/21232 publishedOct. 28, 1993.

Additional fusion proteins may be generated through the techniques ofgene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling(collectively referred to as “DNA shuffling”). DNA shuffling may beemployed to alter the activities of SYNAGIS® antibodies or fragmentsthereof (e.g., an antibody or a fragment thereof with higher affinitiesand lower dissociation rates). See, generally, U.S. Pat. Nos. 5,605,793;5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., 1997,Curr. Opinion Biotechnol., 8:724-33; Harayama, 1998, Trends Biotechnol.,16(2):76-82; Hansson et al., 1999, J. Mol. Biol., 287:265-76; andLorenzo and Blasco, 1998, Biotechniques, 24(2):308-313 (each of thesepatents and publications are hereby incorporated by reference in itsentirety). The antibody can further be a binding-domain immunoglobulinfusion protein as described in U.S. Publication 20030118592, U.S.Publication 200330133939, and PCT Publication WO 02/056910, all toLedbetter et al., which are incorporated herein by reference in theirentireties.

In certain embodiments of the invention, the anti-CD19 antibodies can bemodified to alter their isoelectric point (pI). Antibodies like allpolypeptides have a pI, which is generally defined as the pH at which apolypeptide carries no net charge. It is known in the art that proteinsolubility is typically lowest when the pH of the solution is equal tothe isoelectric point (pI) of the protein. As used herein the pI valueis defined as the pI of the predominant charge form. The pI of a proteinmay be determined by a variety of methods including but not limited to,isoelectric focusing and various computer algorithms (see, e.g.,Bjellqvist et al., 1993, Electrophoresis, 14:1023). In addition, thethermal melting temperatures (Tm) of the Fab domain of an antibody, canbe a good indicator of the thermal stability of an antibody and mayfurther provide an indication of the shelf-life. A lower Tm indicatesmore aggregation/less stability, whereas a higher Tm indicates lessaggregation/more stability. Thus, in certain embodiments antibodieshaving higher Tm are preferable. Tm of a protein domain (e.g., a Fabdomain) can be measured using any standard method known in the art, forexample, by differential scanning calorimetry (see, e.g., Vermeer etal., 2000, Biophys. J. 78:394-404; Vermeer et al., 2000, Biophys. J. 79:2150-2154).

Accordingly, an additional nonexclusive embodiment of the presentinvention includes modified antibodies of the invention that havecertain preferred biochemical characteristics such as a particularisoelectric point (pI) or melting temperature (Tm).

More specifically, in one embodiment, the modified antibodies of thepresent invention have a pI ranging from 5.5 to 9.5. In still anotherspecific embodiment, the modified antibodies of the present inventionhave a pI that ranges from about 5.5 to about 6.0, or about 6.0 to about6.5, or about 6.5 to about 7.0, or about 7.0 to about 7.5, or about 7.5to about 8.0, or about 8.0 to about 8.5, or about 8.5 to about 9.0, orabout 9.0 to about 9.5. In other specific embodiments, the modifiedantibodies of the present invention have a pI that ranges from 5.5-6.0,or 6.0 to 6.5, or 6.5 to 7.0, or 7.0-7.5, or 7.5-8.0, or 8.0-8.5, or8.5-9.0, or 9.0-9.5. Even more specifically, the modified antibodies ofthe present invention have a pI of at least 5.5, or at least 6.0, or atleast 6.3, or at least 6.5, or at least 6.7, or at least 6.9, or atleast 7.1, or at least 7.3, or at least 7.5, or at least 7.7, or atleast 7.9, or at least 8.1, or at least 8.3, or at least 8.5, or atleast 8.7, or at least 8.9, or at least 9.1, or at least 9.3, or atleast 9.5. In other specific embodiments, the modified antibodies of thepresent invention have a pI of at least about 5.5, or at least about6.0, or at least about 6.3, or at least about 6.5, or at least about6.7, or at least about 6.9, or at least about 7.1, or at least about7.3, or at least about 7.5, or at least about 7.7, or at least about7.9, or at least about 8.1, or at least about 8.3, or at least about8.5, or at least about 8.7, or at least about 8.9, or at least about9.1, or at least about 9.3, or at least about 9.5.

It is possible to optimize solubility by altering the number andlocation of ionizable residues in the antibody to adjust the pI. Forexample the pI of a polypeptide can be manipulated by making theappropriate amino acid substitutions (e.g., by substituting a chargedamino acid such as a lysine, for an uncharged residue such as alanine).Without wishing to be bound by any particular theory, amino acidsubstitutions of an antibody that result in changes of the pI of saidantibody may improve solubility and/or the stability of the antibody.One skilled in the art would understand which amino acid substitutionswould be most appropriate for a particular antibody to achieve a desiredpI. In one embodiment, a substitution is generated in an antibody of theinvention to alter the pI. It is specifically contemplated that thesubstitution(s) of the Fc region that result in altered binding to FcγR(described supra) may also result in a change in the pI. In anotherembodiment, substitution(s) of the Fc region are specifically chosen toeffect both the desired alteration in FcγR binding and any desiredchange in pI.

In one embodiment, the modified antibodies of the present invention havea Tm ranging from 65° C. to 120° C. In specific embodiments, themodified antibodies of the present invention have a Tm ranging fromabout 75° C. to about 120° C., or about 75° C. to about 85° C., or about85° C. to about 95° C., or about 95° C. to about 105° C., or about 105°C. to about 115° C., or about 115° C. to about 120° C. In other specificembodiments, the modified antibodies of the present invention have a Tmranging from 75° C. to 120° C., or 75° C. to 85° C., or 85° C. to 95°C., or 95° C. to 105° C., or 105° C. to 115° C., or 115° C. to 120° C.In still other specific embodiments, the modified antibodies of thepresent invention have a Tm of at least about 65° C., or at least about70° C., or at least about 75° C., or at least about 80° C., or at leastabout 85° C., or at least about 90° C., or at least about 95° C., or atleast about 100° C., or at least about 105° C., or at least about 110°C., or at least about 115° C., or at least about 120° C. In yet otherspecific embodiments, the modified antibodies of the present inventionhave a Tm of at least 65° C., or at least 70° C., or at least 75° C., orat least 80° C., or at least 85° C., or at least 90° C., or at least 95°C., or at least 100° C., or at least 105° C., or at least 110° C., or atleast 115° C., or at least 120° C.

5.1.9. Domain Antibodies

The anti-CD19 antibodies of the compositions and methods of theinvention can be domain antibodies, e.g., antibodies containing thesmall functional binding units of antibodies, corresponding to thevariable regions of the heavy (V_(H)) or light (V_(L)) chains of humanantibodies. Examples of domain antibodies include, but are not limitedto, those available from Domantis Limited (Cambridge, UK) and DomantisInc. (Cambridge, Mass., USA) that are specific to therapeutic targets(see, for example, WO04/058821; WO04/003019; U.S. Pat. Nos. 6,291,158;6,582,915; 6,696,245; and 6,593,081). Commercially available librariesof domain antibodies can be used to identify anti-CD19 domainantibodies. In certain embodiments, the anti-CD19 antibodies of theinvention comprise a CD19 functional binding unit and a Fc gammareceptor functional binding unit.

5.1.10. Diabodies

The term “diabodies” refers to small antibody fragments with twoantigen-binding sites, which fragments comprise a heavy chain variabledomain (V_(H)) connected to a light chain variable domain (V_(L)) in thesame polypeptide chain (V_(H)-V_(L)). By using a linker that is tooshort to allow pairing between the two domains on the same chain, thedomains are forced to pair with the complementary domains of anotherchain and create two antigen-binding sites. Diabodies are described morefully in, for example, EP 404,097; WO 93/11161; and Hollinger et al.,Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

5.1.11. Vaccibodies

In certain embodiments of the invention, the anti-CD19 antibodies arevaccibodies. Vaccibodies are dimeric polypeptides. Each monomer of avaccibody consists of a scFv with specificity for a surface molecule onAPC connected through a hinge region and a Cγ3 domain to a second scFv.In other embodiments of the invention, vaccibodies containing as one ofthe scFv's an anti-CD19 antibody fragment may be used to juxtapose thoseB cells to be destroyed and an effector cell that mediates ADCC. Forexample, see, Bogen et al., U.S. Patent Application Publication No.20040253238.

5.1.12. Linear Antibodies

In certain embodiments of the invention, the anti-CD19 antibodies arelinear antibodies. Linear antibodies comprise a pair of tandem Fdsegments (V_(H)-C_(H1)-V_(H)-C_(H1)) which form a pair ofantigen-binding regions. Linear antibodies can be bispecific ormonospecific. See, Zapata et al., Protein Eng., 8(10):1057-1062 (1995).

5.1.13. Parent Antibody

In certain embodiments of the invention, the anti-CD19 antibody is aparent antibody. A “parent antibody” is an antibody comprising an aminoacid sequence which lacks, or is deficient in, one or more amino acidresidues in or adjacent to one or more hypervariable regions thereofcompared to an altered/mutant antibody as herein disclosed. Thus, theparent antibody has a shorter hypervariable region than thecorresponding hypervariable region of an antibody mutant as hereindisclosed. The parent polypeptide may comprise a native sequence (i.e.,a naturally occurring) antibody (including a naturally occurring allelicvariant) or an antibody with pre-existing amino acid sequencemodifications (such as other insertions, deletions and/or substitutions)of a naturally occurring sequence. Preferably the parent antibody is ahumanized antibody or a human antibody.

5.1.14. Antibody Fragments

“Antibody fragments” comprise a portion of a full-length antibody,generally the antigen binding or variable region thereof. Examples ofantibody fragments include Fab, Fab′, F(ab′)₂, and Fv fragments;diabodies; linear antibodies; single-chain antibody molecules; andmultispecific antibodies formed from antibody fragments.

Traditionally, these fragments were derived via proteolytic digestion ofintact antibodies (see, e.g., Morimoto et al., Journal of Biochemicaland Biophysical Methods, 24:107-117 (1992) and Brennan et al., Science,229:81 (1985)). However, these fragments can now be produced directly byrecombinant host cells. For example, the antibody fragments can beisolated from the antibody phage libraries discussed above.Alternatively, Fab′-SH fragments can be directly recovered from E. coliand chemically coupled to form F(ab′)₂ fragments (Carter et al.,Bio/Technology, 10:163-167 (1992)). According to another approach,F(ab′)₂ fragments can be isolated directly from recombinant host cellculture. Other techniques for the production of antibody fragments willbe apparent to the skilled practitioner. In other embodiments, theantibody of choice is a single-chain Fv fragment (scFv). See, forexample, WO 93/16185. In certain embodiments, the antibody is not a Fabfragment.

5.1.15. Bispecific Antibodies

Bispecific antibodies are antibodies that have binding specificities forat least two different epitopes. Exemplary bispecific antibodies maybind to two different epitopes of the B cell surface marker. Other suchantibodies may bind a first B cell marker and further bind a second Bcell surface marker. Alternatively, an anti-B cell marker binding armmay be combined with an arm which binds to a triggering molecule on aleukocyte such as a T cell receptor molecule (e.g., CD2 or CD3), or Fcreceptors for IgG (FcγR), so as to focus cellular defense mechanisms tothe B cell. Bispecific antibodies may also be used to localize cytotoxicagents to the B cell. These antibodies possess a B cell marker-bindingarm and an arm which binds the cytotoxic agent (e.g., saporin,anti-interferon-α, vinca alkaloid, ricin A chain, metholaexate orradioactive isotope hapten). Bispecific antibodies can be prepared asfull-length antibodies or antibody fragments (e.g., F(ab′), bispecificantibodies).

Methods for making bispecific antibodies are known in the art. (See, forexample, Millstein et al., Nature, 305:537-539 (1983); Traunecker etal., EMBO J., 10:3655-3659 (1991); Suresh et al., Methods in Enzymology,121:210 (1986); Kostelny et al., J. Immunol., 148(5):1547-1553 (1992);Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993);Gruber et al., J. Immunol., 152:5368 (1994); U.S. Pat. Nos. 4,474,893;4,714,681; 4,925,648; 5,573,920; 5,601,81; 95,731,168; 4,676,980; and4,676,980, WO 94/04690; WO 91/00360; WO 92/200373; WO 93/17715; WO92/08802; and EP 03089).

In certain embodiments of the invention, the compositions and methods donot comprise a bispecific murine antibody with specificity for humanCD19 and the CD3 epsilon chain of the T cell receptor such as thebispecific antibody described by Daniel et al., Blood, 92:4750-4757(1998). In preferred embodiments, where the anti-CD19 antibody of thecompositions and methods of the invention is bispecific, the anti-CD19antibody is human or humanized and has specificity for human CD19 and anepitope on a T cell or is capable of binding to a human effector cellsuch as, for example, a monocyte/macrophage and/or a natural killer cellto effect cell death.

5.1.16. Engineering Effector Function

It may be desirable to modify the anti-CD19 antibody of the inventionwith respect to effector function, so as to enhance the effectiveness ofthe antibody in treating B cell malignancies, an autoimmune disease ordisorder, or a GVHD or rejection, for example. For example, cysteineresidue(s) may be introduced in the Fc region, thereby allowinginterchain disulfide bond formation in this region. The homodimericantibody thus generated may have improved internalization capabilityand/or increased complement-mediated cell killing and/orantibody-dependent cellular cytotoxicity (ADCC). See, Caron et al., J.Exp Med., 176:1191-1195 (1992) and Shopes, B., J. Immunol.,148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumoractivity may also be prepared using heterobifunctional cross-linkers asdescribed in Wolff et al., Cancer Research, 53:2560-2565 (1993).Alternatively, an antibody can be engineered which has dual Fc regionsand may thereby have enhanced complement lysis and ADCC capabilities.See, Stevenson et al., Anti-Cancer Drug Design, 3:219-230 (1989).

Other methods of engineering Fc regions of antibodies so as to altereffector functions are known in the art (e.g., U.S. Patent PublicationNo. 20040185045 and PCT Publication No. WO 2004/016750, both to Koeniget al., which describe altering the Fc region to enhance the bindingaffinity for FcγRIIB as compared with the binding affinity for FCγRIIA;see, also, PCT Publication Nos. WO 99/58572 to Armour et al., WO99/51642 to Idusogie et al., and U.S. Pat. No. 6,395,272 to Deo et al.;the disclosures of which are incorporated herein in their entireties).Methods of modifying the Fc region to decrease binding affinity toFcγRIIB are also known in the art (e.g., U.S. Patent Publication No.20010036459 and PCT Publication No. WO 01/79299, both to Ravetch et al.,the disclosures of which are incorporated herein in their entireties).Modified antibodies having variant Fc regions with enhanced bindingaffinity for FcγRIIIA and/or FcγRIIA as compared with a wild type Fcregion have also been described (e.g., PCT Publication Nos. WO2004/063351, to Stavenhagen et al.; the disclosure of which isincorporated herein in its entirety).

In vitro assays known in the art can be used to determine whether theanti-CD19 antibodies used in the compositions and methods of theinvention are capable of mediating ADCC, such as those described herein.

5.1.17. Variant Fc Regions

The present invention provides formulation of proteins comprising avariant Fc region. That is, a non-naturally occurring Fc region, forexample an Fc region comprising one or more non-naturally occurringamino acid residues. Also encompassed by the variant Fc regions of thepresent invention are Fc regions which comprise amino acid deletions,additions and/or modifications.

It will be understood that Fc region as used herein includes thepolypeptides comprising the constant region of an antibody excluding thefirst constant region immunoglobulin domain. Thus Fc refers to the lasttwo constant region immunoglobulin domains of IgA, IgD, and IgG, and thelast three constant region immunoglobulin domains of IgE and IgM, andthe flexible hinge N-terminal to these domains. For IgA and IgM Fc mayinclude the J chain. For IgG, Fc comprises immunoglobulin domainsCgamma2 and Cgamma3 (Cγ2 and Cγγ3) and the hinge between Cgamma1 (Cγ1)and Cgamma2 (Cγ2). Although the boundaries of the Fc region may vary,the human IgG heavy chain Fc region is usually defined to compriseresidues C226 or P230 to its carboxyl-terminus, wherein the numbering isaccording to the EU index as in Kabat et al. (1991, NIH Publication91-3242, National Technical Information Service, Springfield, Va.). The“EU index as set forth in Kabat” refers to the residue numbering of thehuman IgG1 EU antibody as described in Kabat et al. supra. Fc may referto this region in isolation, or this region in the context of anantibody, antibody fragment, or Fc fusion protein. An Fc variant proteinmay be an antibody, Fc fusion, or any protein or protein domain thatcomprises an Fc region. Particularly preferred are proteins comprisingvariant Fc regions, which are non-naturally occurring variants of an Fc.Note: Polymorphisms have been observed at a number of Fc positions,including but not limited to Kabat 270, 272, 312, 315, 356, and 358, andthus slight differences between the presented sequence and sequences inthe prior art may exist.

The present invention encompasses Fc variant proteins which have alteredbinding properties for an Fc ligand (e.g., an Fc receptor, C1q) relativeto a comparable molecule (e.g., a protein having the same amino acidsequence except having a wild type Fc region). Examples of bindingproperties include but are not limited to, binding specificity,equilibrium dissociation constant (K_(D)), dissociation and associationrates (K_(off) and K_(on) respectively), binding affinity and/oravidity. It is generally understood that a binding molecule (e.g., a Fcvariant protein such as an antibody) with a low K_(D) is preferable to abinding molecule with a high K_(D). However, in some instances the valueof the K_(on) or K_(off) may be more relevant than the value of theK_(D). One skilled in the art can determine which kinetic parameter ismost important for a given antibody application.

The affinities and binding properties of an Fc domain for its ligand,may be determined by a variety of in vitro assay methods (biochemical orimmunological based assays) known in the art for determining Fc-FcγRinteractions, i.e., specific binding of an Fc region to an FcγRincluding but not limited to, equilibrium methods (e.g., enzyme-linkedimmunoabsorbent assay (ELISA), or radioimmunoassay (RIA)), or kinetics(e.g., BIACORE® analysis), and other methods such as indirect bindingassays, competitive inhibition assays, fluorescence resonance energytransfer (FRET), gel electrophoresis and chromatography (e.g., gelfiltration). These and other methods may utilize a label on one or moreof the components being examined and/or employ a variety of detectionmethods including but not limited to chromogenic, fluorescent,luminescent, or isotopic labels. A detailed description of bindingaffinities and kinetics can be found in Paul, W. E., ed., FundamentalImmunology, 4th Ed., Lippincott-Raven, Philadelphia (1999), whichfocuses on antibody-immunogen interactions.

For example a modification that enhances Fc binding to one or morepositive regulators (e.g., FcγRIIIA) while leaving unchanged or evenreducing Fc binding to the negative regulator FcγRIIB would be morepreferable for enhancing ADCC activity. Alternatively, a modificationthat reduced binding to one or more positive regulator and/or enhancedbinding to FcγRIIB would be preferable for reducing ADCC activity.Accordingly, the ratio of binding affinities (e.g., equilibriumdissociation constants (K_(D))) can indicate if the ADCC activity of anFc variant is enhanced or decreased. For example a decrease in the ratioof FcγRIIIA/FcγRIIB equilibrium dissociation constants (K_(D)), willcorrelate with improved ADCC activity, while an increase in the ratiowill correlate with a decrease in ADCC activity. Additionally,modifications that enhanced binding to C1q would be preferable forenhancing CDC activity while modification that reduced binding to C1qwould be preferable for reducing or eliminating CDC activity.

In one embodiment, the Fc variants of the invention bind FcγRIIIA withincreased affinity relative to a comparable molecule. In anotherembodiment, the Fc variants of the invention bind FcγRIIIA withincreased affinity and bind FcγRIIB with a binding affinity that isunchanged relative to a comparable molecule. In still anotherembodiment, the Fc variants of the invention bind FcγRIIIA withincreased affinity and bind FcγRIIB with a decreased affinity relativeto a comparable molecule. In yet another embodiment, the Fc variants ofthe invention have a ratio of FcγRIIIA/FcγRIIB equilibrium dissociationconstants (K_(D)) that is decreased relative to a comparable molecule.

In one embodiment, the Fc variant protein has enhanced binding to one ormore Fc ligand relative to a comparable molecule. In another embodiment,the Fc variant protein has an affinity for an Fc ligand that is at least2 fold, or at least 3 fold, or at least 5 fold, or at least 7 fold, or aleast 10 fold, or at least 20 fold, or at least 30 fold, or at least 40fold, or at least 50 fold, or at least 60 fold, or at least 70 fold, orat least 80 fold, or at least 90 fold, or at least 100 fold, or at least200 fold greater than that of a comparable molecule. In a specificembodiment, the Fc variant protein has enhanced binding to an Fcreceptor. In another specific embodiment, the Fc variant protein hasenhanced binding to the Fc receptor FcγRIIIA. In still another specificembodiment, the Fc variant protein has enhanced binding to the Fcreceptor FcRn. In yet another specific embodiment, the Fc variantprotein has enhanced binding to C1q relative to a comparable molecule.

In one embodiment of the present invention, antibodies specifically bindCD19 and antigenic fragments thereof with a dissociation constant orK_(d) (k_(off)/k_(on)) of less than 10⁻⁵ M, or of less than 10⁻⁶ M, orof less than 10⁻⁷ M, or of less than 10⁻⁸M, or of less than 10⁻⁹ M, orof less than 10⁻¹⁰ M, or of less than 10⁻¹¹ M, or of less than 10⁻¹² M,or of less than 10⁻¹³ M.

In another embodiment, the antibody of the invention binds to CD19and/or antigenic fragments thereof with a K_(off) of less than 1×10⁻³s⁻¹, or less than 3×10⁻³ s⁻¹. In other embodiments, the antibody bindsto CD19 and antigenic fragments thereof with a K_(off) of less than 10⁻³s⁻¹, less than 5×10⁻³ s⁻¹, less than 10⁻⁴ s⁻¹, less than 5×10⁻⁴ s⁻¹,less than 10⁻⁵ s⁻¹, less than 5×10⁻⁵ s⁻¹, less than 10⁻⁶ s⁻¹, less than5×10⁻⁶ s⁻¹, less than 10⁻⁷ s⁻¹, less than 5×10⁻⁷ s⁻¹, less than 10⁻⁸s⁻¹, less than 5×10⁻⁸ s⁻¹, less than 10⁻⁹ s⁻¹, less than 5×10⁻⁹ s⁻¹, orless than 10⁻¹° s⁻¹.

In another embodiment, the antibody of the invention binds to CD19and/or antigenic fragments thereof with an association rate constant ork_(on) rate of at least 10⁵M⁻¹ s⁻¹, at least 5×10⁵M⁻¹ s¹, at least 10⁶M⁻¹ s⁻¹, at least 5×10⁶ M⁻¹ s⁻¹, at least 10⁷M⁻¹ s¹, at least 5×10⁷ M⁻¹s⁻¹, or at least 10⁸M⁻¹ s⁻¹, or at least 10⁹ M⁻¹ s⁻¹.

In another embodiment, an Fc variant of the invention has an equilibriumdissociation constant (K_(D)) that is decreased between about 2 fold andabout 10 fold, or between about 5 fold and about 50 fold, or betweenabout 25 fold and about 250 fold, or between about 100 fold and about500 fold, or between about 250 fold and about 1000 fold relative to acomparable molecule. In another embodiment, an Fc variant of theinvention has an equilibrium dissociation constant (K_(D)) that isdecreased between 2 fold and 10 fold, or between 5 fold and 50 fold, orbetween 25 fold and 250 fold, or between 100 fold and 500 fold, orbetween 250 fold and 1000 fold relative to a comparable molecule. In aspecific embodiment, said Fc variants have an equilibrium dissociationconstants (K_(D)) for FcγRIIIA that is reduced by at least 2 fold, or atleast 3 fold, or at least 5 fold, or at least 7 fold, or a least 10fold, or at least 20 fold, or at least 30 fold, or at least 40 fold, orat least 50 fold, or at least 60 fold, or at least 70 fold, or at least80 fold, or at least 90 fold, or at least 100 fold, or at least 200fold, or at least 400 fold, or at least 600 fold, relative to acomparable molecule.

The serum half-life of proteins comprising Fc regions may be increasedby increasing the binding affinity of the Fc region for FcRn. In oneembodiment, the Fc variant protein has enhanced serum half life relativeto comparable molecule.

“Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to aform of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs)present on certain cytotoxic cells (e.g., Natural Killer (NK) cells,neutrophils, and macrophages) enables these cytotoxic effector cells tobind specifically to an antigen-bearing target cell and subsequentlykill the target cell with cytotoxins. Specific high-affinity IgGantibodies directed to the surface of target cells “arm” the cytotoxiccells and are absolutely required for such killing. Lysis of the targetcell is extracellular, requires direct cell-to-cell contact, and doesnot involve complement. It is contemplated that, in addition toantibodies, other proteins comprising Fc regions, specifically Fc fusionproteins, having the capacity to bind specifically to an antigen-bearingtarget cell will be able to effect cell-mediated cytotoxicity. Forsimplicity, the cell-mediated cytotoxicity resulting from the activityof an Fc fusion protein is also referred to herein as ADCC activity.

The ability of any particular Fc variant protein to mediate lysis of thetarget cell by ADCC can be assayed. To assess ADCC activity an Fcvariant protein of interest is added to target cells in combination withimmune effector cells, which may be activated by the antigen antibodycomplexes resulting in cytolysis of the target cell. Cytolysis isgenerally detected by the release of label (e.g. radioactive substrates,fluorescent dyes or natural intracellular proteins) from the lysedcells. Useful effector cells for such assays include peripheral bloodmononuclear cells (PBMC) and Natural Killer (NK) cells. Specificexamples of in vitro ADCC assays are described in Wisecarver et al.,1985, 79:277-282; Bruggemann et al., 1987, J Exp Med, 166:1351-1361;Wilkinson et al., 2001, J Immunol Methods, 258:183-191; Patel et al.,1995, J Immunol Methods, 184:29-38. Alternatively, or additionally, ADCCactivity of the Fc variant protein of interest may be assessed in vivo,e.g., in an animal model such as that disclosed in Clynes et al., 1998,PNAS USA, 95:652-656.

In one embodiment, an Fc variant protein has enhanced ADCC activityrelative to a comparable molecule. In a specific embodiment, an Fcvariant protein has ADCC activity that is at least 2 fold, or at least 3fold, or at least 5 fold or at least 10 fold or at least 50 fold or atleast 100 fold greater than that of a comparable molecule. In anotherspecific embodiment, an Fc variant protein has enhanced binding to theFc receptor FcγRIIIA and has enhanced ADCC activity relative to acomparable molecule. In other embodiments, the Fc variant protein hasboth enhanced ADCC activity and enhanced serum half life relative to acomparable molecule.

“Complement dependent cytotoxicity” and “CDC” refer to the lysing of atarget cell in the presence of complement. The complement activationpathway is initiated by the binding of the first component of thecomplement system (C1q) to a molecule, an antibody for example,complexed with a cognate antigen. To assess complement activation, a CDCassay, e.g. as described in Gazzano-Santoro et al., 1996, J. Immunol.Methods, 202:163, may be performed. In one embodiment, an Fc variantprotein has enhanced CDC activity relative to a comparable molecule. Ina specific embodiment, an Fc variant protein has CDC activity that is atleast 2 fold, or at least 3 fold, or at least 5 fold or at least 10 foldor at least 50 fold or at least 100 fold greater than that of acomparable molecule. In other embodiments, the Fc variant protein hasboth enhanced CDC activity and enhanced serum half life relative to acomparable molecule.

In one embodiment, the present invention provides formulations, whereinthe Fc region comprises a non-naturally occurring amino acid residue atone or more positions selected from the group consisting of 234, 235,236, 239, 240, 241, 243, 244, 245, 247, 252, 254, 256, 262, 263, 264,265, 266, 267, 269, 296, 297, 298, 299, 313, 325, 326, 327, 328, 329,330, 332, 333, and 334 as numbered by the EU index as set forth inKabat. Optionally, the Fc region may comprise a non-naturally occurringamino acid residue at additional and/or alternative positions known toone skilled in the art (see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375;6,737,056; PCT Patent Publications WO 01/58957; WO 02/06919; WO04/016750; WO 04/029207; WO 04/035752 and WO 05/040217).

In a specific embodiment, the present invention provides an Fc variantprotein formulation, wherein the Fc region comprises at least onenon-naturally occurring amino acid residue selected from the groupconsisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V,234F, 235A, 235D, 235R, 235W, 235P, 235S, 235N, 235Q, 235T, 235H, 235Y,235I, 235V, 235F, 236E, 239D, 239E, 239N, 239Q, 239F, 239T, 239H, 239Y,2401, 240A, 240T, 240M, 241W, 241 L, 241Y, 241E, 241 R. 243W, 243L 243Y,243R, 243Q, 244H, 245A, 247V, 247G, 252Y, 254T, 256E, 262I, 262A, 262T,262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M,264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T,266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q,296D, 296N, 296S, 296T, 296L, 296I, 296H, 269G, 297S, 297D, 297E, 298H,298I, 298T, 298F, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F,325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327G, 327W, 327N,327L, 328S, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H,328A, 329F, 329H, 329Q, 330K, 330G, 330T, 330C, 330L, 330Y, 330V, 330I,330F, 330R, 330H, 332D, 332S, 332W, 332F, 332E, 332N, 332Q, 332T, 332H,332Y, and 332A as numbered by the EU index as set forth in Kabat.Optionally, the Fc region may comprise additional and/or alternativenon-naturally occurring amino acid residues known to one skilled in theart (see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; PCTPatent Publications WO 01/58957; WO 02/06919; WO 04/016750; WO04/029207; WO 04/035752 and WO 05/040217).

In another embodiment, the present invention provides an Fc variantprotein formulation, wherein the Fc region comprises at least anon-naturally occurring amino acid at one or more positions selectedfrom the group consisting of 239, 330 and 332, as numbered by the EUindex as set forth in Kabat. In a specific embodiment, the presentinvention provides an Fc variant protein formulation, wherein the Fcregion comprises at least one non-naturally occurring amino acidselected from the group consisting of 239D, 330L and 332E, as numberedby the EU index as set forth in Kabat. Optionally, the Fc region mayfurther comprise additional non-naturally occurring amino acid at one ormore positions selected from the group consisting of 252, 254, and 256,as numbered by the EU index as set forth in Kabat. In a specificembodiment, the present invention provides an Fc variant proteinformulation, wherein the Fc region comprises at least one non-naturallyoccurring amino acid selected from the group consisting of 239D, 330Land 332E, as numbered by the EU index as set forth in Kabat and at leastone non-naturally occurring amino acid at one or more positions areselected from the group consisting of 252Y, 254T and 256E, as numberedby the EU index as set forth in Kabat.

In one embodiment, the Fc variants of the present invention may becombined with other known Fc variants such as those disclosed in Ghetieet al., 1997, Nat. Biotech. 15:637-40; Duncan et al, 1988, Nature332:563-564; Lund et al., 1991, J. Immunol., 147:2657-2662; Lund et al,1992, Mol. Immunol., 29:53-59; Alegre et al, 1994, Transplantation57:1537-1543; Hutchins et al., 1995, Proc Natl. Acad Sci USA,92:11980-11984; Jefferis et al, 1995, Immunol Lett., 44:111-117; Lund etal., 1995, Faseb J., 9:115-119; Jefferis et al, 1996, Immunol Lett.,54:101-104; Lund et al, 1996, J. Immunol., 157:4963-4969; Armour et al.,1999, Eur J Immunol 29:2613-2624; Idusogie et al, 2000, J. Immunol.,164:4178-4184; Reddy et al, 2000, J. Immunol., 164:1925-1933; Xu et al.,2000, Cell Immunol., 200:16-26; Idusogie et al, 2001, J. Immunol.,166:2571-2575; Shields et al., 2001, J Biol. Chem., 276:6591-6604;Jefferis et al, 2002, Immunol Lett., 82:57-65; Presta et al., 2002,Biochem Soc Trans., 30:487-490); U.S. Pat. Nos. 5,624,821; 5,885,573;5,677,425; 6,165,745; 6,277,375; 5,869,046; 6,121,022; 5,624,821;5,648,260; 6,528,624; 6,194,551; 6,737,056; 6,821,505; 6,277,375; U.S.Patent Publication Nos. 2004/0002587 and PCT Publications WO 94/29351;WO 99/58572; WO 00/42072; WO 02/060919; WO 04/029207; WO 04/099249; WO04/063351. Also encompassed by the present invention are Fc regionswhich comprise deletions, additions and/or modifications. Still othermodifications/substitutions/additions/deletions of the Fc domain will bereadily apparent to one skilled in the art.

Methods for generating non-naturally occurring Fc regions are known inthe art. For example, amino acid substitutions and/or deletions can begenerated by mutagenesis methods, including, but not limited to,site-directed mutagenesis (Kunkel, Proc. Natl. Acad. Sci. USA,82:488-492 (1985)), PCR mutagenesis (Higuchi, in “PCR Protocols: A Guideto Methods and Applications”, Academic Press, San Diego, pp. 177-183(1990)), and cassette mutagenesis (Wells et al., Gene, 34:315-323(1985)). Preferably, site-directed mutagenesis is performed by theoverlap-extension PCR method (Higuchi, in “PCR Technology: Principlesand Applications for DNA Amplification”, Stockton Press, New York, pp.61-70 (1989)). Alternatively, the technique of overlap-extension PCR(Higuchi, ibid.) can be used to introduce any desired mutation(s) into atarget sequence (the starting DNA). For example, the first round of PCRin the overlap-extension method involves amplifying the target sequencewith an outside primer (primer 1) and an internal mutagenesis primer(primer 3), and separately with a second outside primer (primer 4) andan internal primer (primer 2), yielding two PCR segments (segments A andB). The internal mutagenesis primer (primer 3) is designed to containmismatches to the target sequence specifying the desired mutation(s). Inthe second round of PCR, the products of the first round of PCR(segments A and B) are amplified by PCR using the two outside primers(primers 1 and 4). The resulting full-length PCR segment (segment C) isdigested with restriction enzymes and the resulting restriction fragmentis cloned into an appropriate vector. As the first step of mutagenesis,the starting DNA (e.g., encoding an Fc fusion protein, an antibody orsimply an Fc region), is operably cloned into a mutagenesis vector. Theprimers are designed to reflect the desired amino acid substitution.Other methods useful for the generation of variant Fc regions are knownin the art (see, e.g., U.S. Pat. Nos. 5,624,821; 5,885,573; 5,677,425;6,165,745; 6,277,375; 5,869,046; 6,121,022; 5,624,821; 5,648,260;6,528,624; 6,194,551; 6,737,056; 6,821,505; 6,277,375; U.S. PatentPublication Nos. 2004/0002587 and PCT Publications WO 94/29351; WO99/58572; WO 00/42072; WO 02/060919; WO 04/029207; WO 04/099249; WO04/063351).

In some embodiments, an Fc variant protein comprises one or moreengineered glycoforms, i.e., a carbohydrate composition that iscovalently attached to the molecule comprising an Fc region. Engineeredglycoforms may be useful for a variety of purposes, including but notlimited to enhancing or reducing effector function. Engineeredglycoforms may be generated by any method known to one skilled in theart, for example by using engineered or variant expression strains, byco-expression with one or more enzymes, for example DIN-acetylglucosaminyltransferase III (GnTI11), by expressing a moleculecomprising an Fc region in various organisms or cell lines from variousorganisms, or by modifying carbohydrate(s) after the molecule comprisingFc region has been expressed. Methods for generating engineeredglycoforms are known in the art, and include but are not limited tothose described in Umana et al., 1999, Nat. Biotechnol., 17:176-180;Davies et al., 20017 Biotechnol Bioeng., 74:288-294; Shields et al.,2002, J Biol. Chem., 277:26733-26740; Shinkawa et al., 2003, J Biol.Chem., 278:3466-3473) U.S. Pat. No. 6,602,684; U.S. Ser. No. 10/277,370;U.S. Ser. No. 10/113,929; PCT WO 00/61739A1; PCT WO 01/292246A1; PCT WO02/311140A1; PCT WO 02/30954A1; Potillegent™ technology (Biowa, Inc.,Princeton, N.J.); GlycoMAb™ glycosylation engineering technology(GLYCART biotechnology AG, Zurich, Switzerland). See, e.g., WO 00061739;EA01229125; US 20030115614; Okazaki et al., 2004, JMB, 336: 1239-49.

5.1.18. Glycosylation of Antibodies

In still another embodiment, the glycosylation of antibodies utilized inaccordance with the invention is modified. For example, an aglycosylatedantibody can be made (i.e., the antibody lacks glycosylation).Glycosylation can be altered to, for example, increase the affinity ofthe antibody for a target antigen. Such carbohydrate modifications canbe accomplished by, for example, altering one or more sites ofglycosylation within the antibody sequence. For example, one or moreamino acid substitutions can be made that result in elimination of oneor more variable region framework glycosylation sites to therebyeliminate glycosylation at that site. Such aglycosylation may increasethe affinity of the antibody for antigen. Such an approach is describedin further detail in U.S. Pat. Nos. 5,714,350 and 6,350,861.Alternatively, one or more amino acid substitutions can be made thatresult in elimination of a glycosylation site present in the Fc region(e.g., Asparagine 297 of IgG). Furthermore, a glycosylated antibodiesmay be produced in bacterial cells which lack the necessaryglycosylation machinery.

Additionally or alternatively, an antibody can be made that has analtered type of glycosylation, such as a hypofucosylated antibody havingreduced amounts of fucosyl residues or an antibody having increasedbisecting GlcNAc structures. Such altered glycosylation patterns havebeen demonstrated to increase the ADCC ability of antibodies. Suchcarbohydrate modifications can be accomplished by, for example,expressing the antibody in a host cell with altered glycosylationmachinery. Cells with altered glycosylation machinery have beendescribed in the art and can be used as host cells in which to expressrecombinant antibodies of the invention to thereby produce an antibodywith altered glycosylation. See, for example, Shields, R. L. et al.,(2002) J. Biol. Chem., 277:26733-26740; Umana et al., (1999) Nat.Biotech., 17:176-1, as well as, European Patent No: EP 1,176,195; PCTPublications WO 03/035835; WO 99/54342. See also Li et al., 2006, Nat.Biotech 24: 210-215; and published U.S. patent applications:US2006/0040353; US2006/034830; US2006/0034829; US2006/0034828;US2006/0029604 and US2006/0024304, which describe altered glycosylationof antibodies.

5.2. Manufacture/Production of Anti-CD19 Antibodies

Once a desired anti-CD19 antibody is engineered, the anti-CD19 antibodycan be produced on a commercial scale using methods that are well-knownin the art for large scale manufacturing of antibodies. For example,this can be accomplished using recombinant expressing systems such as,but not limited to, those described below.

5.2.1. Recombinant Expression Systems

Recombinant expression of an antibody of the invention or variantthereof, generally requires construction of an expression vectorcontaining a polynucleotide that encodes the antibody. Once apolynucleotide encoding an antibody molecule or a heavy or light chainof an antibody, or portion thereof (preferably, but not necessarily,containing the heavy or light chain variable domain), of the inventionhas been obtained, the vector for the production of the antibodymolecule may be produced by recombinant DNA technology using techniqueswell-known in the art. See, e.g., U.S. Pat. No. 6,331,415, which isincorporated herein by reference in its entirety. Thus, methods forpreparing a protein by expressing a polynucleotide containing anantibody encoding nucleotide sequence are described herein. Methodswhich are well-known to those skilled in the art can be used toconstruct expression vectors containing antibody coding sequences andappropriate transcriptional and translational control signals. Thesemethods include, for example, in vitro recombinant DNA techniques,synthetic techniques, and in vivo genetic recombination. The invention,thus, provides replicable vectors comprising a nucleotide sequenceencoding an antibody molecule of the invention, a heavy or light chainof an antibody, a heavy or light chain variable domain of an antibody ora portion thereof, or a heavy or light chain CDR, operably linked to apromoter. Such vectors may include the nucleotide sequence encoding theconstant region of the antibody molecule (see, e.g., InternationalPublication Nos. WO 86/05807 and WO 89/01036; and U.S. Pat. No.5,122,464) and the variable domain of the antibody may be cloned intosuch a vector for expression of the entire heavy, the entire lightchain, or both the entire heavy and light chains.

In an alternate embodiment, the anti-CD19 antibodies of the compositionsand methods of the invention can be made using targeted homologousrecombination to produce all or portions of the anti-CD19 antibodies(see, U.S. Pat. Nos. 6,063,630, 6,187,305, and 6,692,737). In certainembodiments, the anti-CD19 antibodies of the compositions and methods ofthe invention can be made using random recombination techniques toproduce all or portions of the anti-CD19 antibodies (see, U.S. Pat. Nos.6,361,972, 6,524,818, 6,541,221, and 6,623,958). Anti-CD19 antibodiescan also be produced in cells expressing an antibody from a genomicsequence of the cell comprising a modified immunoglobulin locus usingCre-mediated site-specific homologous recombination (see, U.S. Pat. No.6,091,001). Where human antibody production is desired, the host cellshould be a human cell line. These methods may advantageously be used toengineer stable cell lines which permanently express the antibodymolecule.

Once the expression vector is transferred to a host cell by conventionaltechniques, the transfected cells are then cultured by conventionaltechniques to produce an antibody of the invention. Thus, the inventionincludes host cells containing a polynucleotide encoding an antibody ofthe invention or fragments thereof, or a heavy or light chain thereof,or portion thereof, or a single-chain antibody of the invention,operably linked to a heterologous promoter. In preferred embodiments forthe expression of double-chained antibodies, vectors encoding both theheavy and light chains may be co-expressed in the host cell forexpression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to expressthe anti-CD19 antibodies of the invention or portions thereof that canbe used in the engineering and generation of anti-CD19 antibodies (see,e.g., U.S. Pat. No. 5,807,715). For example, mammalian cells such asChinese hamster ovary cells (CHO), in conjunction with a vector such asthe major intermediate early gene promoter element from humancytomegalovirus is an effective expression system for antibodies(Foecking et al., Gene, 45:101 (1986); and Cockett et al.,Bio/Technology, 8:2 (1990)). In addition, a host cell strain may bechosen which modulates the expression of inserted antibody sequences, ormodifies and processes the antibody gene product in the specific fashiondesired. Such modifications (e.g., glycosylation) and processing (e.g.,cleavage) of protein products may be important for the function of theprotein. Different host cells have characteristic and specificmechanisms for the post-translational processing and modification ofproteins and gene products. Appropriate cell lines or host systems canbe chosen to ensure the correct modification and processing of theantibody or portion thereof expressed. To this end, eukaryotic hostcells which possess the cellular machinery for proper processing of theprimary transcript, glycosylation, and phosphorylation of the geneproduct may be used. Such mammalian host cells include but are notlimited to CHO, VERO, BHK, Hela, COS, MDCK, 293, 3T3, W138, BT483,Hs578T, HTB2, BT2O and T47D, NS0 (a murine myeloma cell line that doesnot endogenously produce any immunoglobulin chains), CRL7O3O andHsS78Bst cells.

In preferred embodiments, human cell lines developed by immortalizinghuman lymphocytes can be used to recombinantly produce monoclonal humananti-CD19 antibodies. In preferred embodiments, the human cell linePER.C6. (Crucell, Netherlands) can be used to recombinantly producemonoclonal human anti-CD19 antibodies.

In bacterial systems, a number of expression vectors may beadvantageously selected depending upon the use intended for the antibodymolecule being expressed. For example, when a large quantity of such anantibody is to be produced, for the generation of pharmaceuticalcompositions comprising an anti-CD19 antibody, vectors which direct theexpression of high levels of fusion protein products that are readilypurified may be desirable. Such vectors include, but are not limited to,the E. coli expression vector pUR278 (Ruther et al., EMBO, 12:1791(1983)), in which the antibody coding sequence may be ligatedindividually into the vector in frame with the lac Z coding region sothat a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985,Nucleic Acids Res., 13:3101-3109 (1985); Van Heeke & Schuster, 1989, J.Biol. Chem., 24:5503-5509 (1989)); and the like. pGEX vectors may alsobe used to express foreign polypeptides as fusion proteins withglutathione 5-transferase (GST). In general, such fusion proteins aresoluble and can easily be purified from lysed cells by adsorption andbinding to matrix glutathione agarose beads followed by elution in thepresence of free glutathione. The pGEX vectors are designed to includethrombin or factor Xa protease cleavage sites so that the cloned targetgene product can be released from the GST moiety.

In an insect system, Autographa californica nuclear polyhedrosis virus(AcNPV) is used as a vector to express foreign genes. The virus grows inSpodoptera frugiperda cells. The antibody coding sequence may be clonedindividually into non-essential regions (for example, the polyhedringene) of the virus and placed under control of an AcNPV promoter (forexample, the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems maybe utilized. In cases where an adenovirus is used as an expressionvector, the antibody coding sequence of interest may be ligated to anadenovirus transcription/translation control complex, e.g., the latepromoter and tripartite leader sequence. This chimeric gene may then beinserted in the adenovirus genome by in vitro or in vivo recombination.Insertion in a non-essential region of the viral genome (e.g., region E1or E3) will result in a recombinant virus that is viable and capable ofexpressing the antibody molecule in infected hosts (e.g., see, Logan &Shenk, Proc. Natl. Acad. Sci. USA, 81:355-359 (1984)). Specificinitiation signals may also be required for efficient translation ofinserted antibody coding sequences. These signals include the ATGinitiation codon and adjacent sequences. Furthermore, the initiationcodon should generally be in phase with the reading frame of the desiredcoding sequence to ensure translation of the entire insert. Theseexogenous translational control signals and initiation codons can be ofa variety of origins, both natural and synthetic. The efficiency ofexpression may be enhanced by the inclusion of appropriate transcriptionenhancer elements, transcription terminators, etc. (see, e.g., Bittneret al., Methods in Enzymol., 153:51-544 (1987)).

For long-term, high-yield production of recombinant proteins, stableexpression is preferred. For example, cell lines which stably expressthe antibody molecule may be engineered. Rather than transientexpression systems that use replicating expression vectors which containviral origins of replication, host cells can be transformed with DNAcontrolled by appropriate expression control elements (e.g., promoter,enhancer, sequences, transcription terminators, polyadenylation sites,etc.), and a selectable marker. Following the introduction of theforeign DNA, engineered cells may be allowed to grow for 1-2 days in anenriched media, and then are switched to a selective media. Theselectable marker in the recombinant plasmid confers resistance to theselection and allows cells to stably integrate the plasmid into theirchromosomes and grow to form foci which in turn can be cloned andexpanded into cell lines. Plasmids that encode the anti-CD19 antibodycan be used to introduce the gene/cDNA into any cell line suitable forproduction in culture. Alternatively, plasmids called “targetingvectors” can be used to introduce expression control elements (e.g.,promoters, enhancers, etc.) into appropriate chromosomal locations inthe host cell to “activate” the endogenous gene for anti-CD19antibodies.

A number of selection systems may be used, including, but not limitedto, the herpes simplex virus thymidine kinase (Wigler et al., Cell,11:223 (1977)), hypoxanthineguanine phosphoribosyltransferase (Szybalska& Szybalski, Proc. Natl. Acad. Sci. USA, 48:202 (1992)), and adeninephosphoribosyltransferase (Lowy et al., Cell, 22:8-17 (1980)) genes canbe employed in tk⁻, hgprt⁻ or aprT⁻ cells, respectively. Also,antimetabolite resistance can be used as the basis of selection for thefollowing genes: dhfr, which confers resistance to methotrexate (Wigleret al., Natl. Acad. Sci. USA, 77:357 (1980); O'Hare et al., Proc. Natl.Acad. Sci. USA, 78:1527 (1981)); gpt, which confers resistance tomycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78:2072(1981)); neo, which confers resistance to the aminoglycoside G-418 (Wuand Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol.Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); andMorgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIB TECH11(5):155-215 (1993)); and hygro, which confers resistance to hygromycin(Santerre et al., Gene, 30:147 (1984)). Methods commonly known in theart of recombinant DNA technology may be routinely applied to select thedesired recombinant clone, and such methods are described, for example,in Ausubel et al. (eds.), Current Protocols in Molecular Biology, JohnWiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, ALaboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13,Dracopoli et al. (eds.), Current Protocols in Human Genetics, John Wiley& Sons, NY (1994); Colberre-Garapin et al., 1981, J. Mol. Biol., 150:1,which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vectoramplification (for a review, see, Bebbington and Hentschel, The use ofvectors based on gene amplification for the expression of cloned genesin mammalian cells in DNA cloning, Vol. 3, Academic Press, New York(1987)). When a marker in the vector system expressing antibody isamplifiable, increase in the level of inhibitor present in culture ofhost cell will increase the number of copies of the marker gene. Sincethe amplified region is associated with the antibody gene, production ofthe antibody will also increase (Crouse et al., Mol. Cell. Biol., 3:257(1983)). Antibody expression levels may be amplified through the userecombinant methods and tools known to those skilled in the art ofrecombinant protein production, including technologies that remodelsurrounding chromatin and enhance transgene expression in the form of anactive artificial transcriptional domain.

The host cell may be co-transfected with two expression vectors of theinvention, the first vector encoding a heavy chain derived polypeptideand the second vector encoding a light chain derived polypeptide. Thetwo vectors may contain identical selectable markers which enable equalexpression of heavy and light chain polypeptides. Alternatively, asingle vector may be used which encodes, and is capable of expressing,both heavy and light chain polypeptides. In such situations, the lightchain should be placed before the heavy chain to avoid an excess oftoxic free heavy chain (Proudfoot, Nature 322:562-565 (1986); andKohler, 1980, Proc. Natl. Acad. Sci. USA, 77:2197-2199 (1980)). Thecoding sequences for the heavy and light chains may comprise cDNA orgenomic DNA.

Once an antibody molecule of the invention has been produced byrecombinant expression, it may be purified by any method known in theart for purification of an immunoglobulin molecule, for example, bychromatography (e.g., ion exchange, affinity, particularly by affinityfor the specific antigen after Protein A, and sizing columnchromatography), centrifugation, differential solubility, or by anyother standard technique for the purification of proteins. Further, theantibodies of the present invention or fragments thereof may be fused toheterologous polypeptide sequences described herein or otherwise knownin the art to facilitate purification.

5.2.2. Antibody Purification and Isolation

When using recombinant techniques, the antibody can be producedintracellularly, in the periplasmic space, or directly secreted into themedium. If the antibody is produced intracellularly, as a first step,the particulate debris, either host cells or lysed fragments, isremoved, for example, by centrifugation or ultrafiltration. Carter etal., Bio/Technology, 10:163-167 (1992) describe a procedure forisolating antibodies which are secreted into the periplasmic space of E.coli. Briefly, cell paste is thawed in the presence of sodium acetate(pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30min. Cell debris can be removed by centrifugation. Where the antibodymutant is secreted into the medium, supernatants from such expressionsystems are generally first concentrated using a commercially availableprotein concentration filter, for example, an Amicon or MilliporePellicon ultrafiltration unit. A protease inhibitor such as PMSF may beincluded in any of the foregoing steps to inhibit proteolysis andantibiotics may be included to prevent the growth of adventitiouscontaminants.

The antibody composition prepared from the cells can be purified using,for example, hydroxylapatite chromatography, hydrophobic interactionchromatography, ion exchange chromatography, gel electrophoresis,dialysis, and/or affinity chromatography either alone or in combinationwith other purification steps. The suitability of protein A as anaffinity ligand depends on the species and isotype of any immunoglobulinFc domain that is present in the antibody mutant. Protein A can be usedto purify antibodies that are based on human γ1, γ2, or γ4 heavy chains(Lindmark et al., J. Immunol. Methods, 62:1-13 (1983)). Protein G isrecommended for all mouse isotypes and for human γ3 (Guss et al., EMBOJ., 5:15671575 (1986)). The matrix to which the affinity ligand isattached is most often agarose, but other matrices are available.Mechanically stable matrices such as controlled pore glass orpoly(styrenedivinyl)benzene allow for faster flow rates and shorterprocessing times than can be achieved with agarose. Where the antibodycomprises a CH₃ domain, the Bakerbond ABX resin (J. T. Baker,Phillipsburg, N.J.) is useful for purification. Other techniques forprotein purification such as fractionation on an ion-exchange column,ethanol precipitation, Reverse Phase HPLC, chromatography on silica,chromatography on heparin, SEPHAROSE chromatography on an anion orcation exchange resin (such as a polyaspartic acid column),chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are alsoavailable depending on the antibody to be recovered.

Following any preliminary purification step(s), the mixture comprisingthe antibody of interest and contaminants may be subjected to low pHhydrophobic interaction chromatography using an elution buffer at a pHbetween about 2.5-4.5, preferably performed at low salt concentrations(e.g., from about 0-0.25 M salt).

5.3 Therapeutic Anti-CD19 Antibodies

The anti-CD19 antibody used in the compositions and methods of theinvention is preferably a human antibody or a humanized antibody thatpreferably mediates human ADCC, or is selected from known anti-CD19antibodies that preferably mediate human ADCC. In certain embodiments,the anti-CD19 antibodies can be chimeric antibodies. In preferredembodiments, anti-CD19 antibody is a monoclonal human, humanized, orchimeric anti-CD19 antibody. The anti-CD19 antibody used in thecompositions and methods of the invention is preferably a human antibodyor a humanized antibody of the IgG1 or IgG3 human isotype. In otherembodiments, the anti-CD19 antibody used in the compositions and methodsof the invention is preferably a human antibody or a humanized antibodyof the IgG2 or IgG4 human isotype that preferably mediates ADCC.

While such antibodies can be generated using the techniques describedabove, in other embodiments of the invention, the murine antibodiesHB12a and HB12b as described herein or other commercially availableanti-CD19 antibodies can be chimerized, humanized, or made into humanantibodies.

For example, known anti-CD19 antibodies that can be used include, butare not limited to, HD37 (IgG1) (DAKO, Carpinteria, Calif.), BU12 (G.D.Johnson, University of Birmingham, Birmingham, United Kingdom), 4G7(IgG1) (Becton-Dickinson, Heidelberg, Germany), J4.119 (Beckman Coulter,Krefeld, Germany), B43 (PharMingen, San Diego, Calif.), SJ25C1 (BDPharMingen, San Diego, Calif.), FMC63 (IgG2a) (Chemicon Int'l.,Temecula, Calif.) (Nicholson et al., Mol. Immunol., 34:1157-1165 (1997);Pietersz et al., Cancer Immunol. Immunotherapy, 41:53-60 (1995); andZola et al., Immunol. Cell Biol., 69:411-422 (1991)), B4 (IgG1) (BeckmanCoulter, Miami, Fla.) Nadler et al., J. Immunol., 131:244-250 (1983),and/or HD237 (IgG2b) (Fourth International Workshop on Human LeukocyteDifferentiation Antigens, Vienna, Austria, 1989; and Pezzutto et al., J.Immunol., 138:2793-2799 (1987)).

In certain embodiments, the anti-CD19 antibody of the inventioncomprises the heavy chain of HB12a comprising an amino acid sequence ofSEQ ID NO:2 (FIG. 5A). In other embodiments, the anti-CD19 antibody ofthe invention comprises the heavy chain of HB12b comprising an aminoacid sequence of SEQ ID NO:4 (FIG. 5B).

In certain embodiments, the anti-CD19 antibody of the inventioncomprises the light chain of HB12a comprising an amino acid sequence ofSEQ ID NO:16 (FIG. 6A). In other embodiments, the anti-CD19 antibody ofthe invention comprises the light chain of HB12b comprising an aminoacid sequence of SEQ ID NO:18 (FIG. 6B).

In certain embodiments, the antibody is an isotype switched variant of aknown antibody (e.g., to an IgG1 or IgG3 human isotype) such as thosedescribed above (e.g., HB12a or HB12b).

The anti-CD19 antibodies used in the compositions and methods of theinvention can be naked antibodies, immunoconjugates or fusion proteins.Preferably the anti-CD19 antibodies described above for use in thecompositions and methods of the invention are able to reduce or depleteB cells and circulating immunoglobulin in a human treated therewith.Depletion of B cells can be in circulating B cells, or in particulartissues such as, but not limited to, bone marrow, spleen, gut-associatedlymphoid tissues, and/or lymph nodes. Such depletion may be achieved viavarious mechanisms such as antibody-dependent cell-mediated cytotoxicity(ADCC) and/or complement dependent cytotoxicity (CDC), inhibition of Bcell proliferation and/or induction of B cell death (e.g., viaapoptosis). By “depletion” of B cells it is meant a reduction incirculating B cells and/or B cells in particular tissue(s) by at leastabout 25%, 40%, 50%, 65%, 75%, 80%, 85%, 90%, 95% or more as describedherein. In particular embodiments, virtually all detectable B cells aredepleted from the circulation and/or particular tissue(s). By“depletion” of circulating immunoglobulin (Ig) it is meant a reductionby at least about 25%, 40%, 50%, 65%, 75%, 80%, 85%, 90%, 95% or more asdescribed herein. In particular embodiments, virtually all detectable Igis depleted from the circulation.

5.3.1. Screening of Antibodies for Human CD19 Binding

Binding assays can be used to identify antibodies that bind the humanCD19 antigen. Binding assays may be performed either as direct bindingassays or as competition-binding assays. Binding can be detected usingstandard ELISA or standard Flow Cytometry assays. In a direct bindingassay, a candidate antibody is tested for binding to human CD19 antigen.In certain embodiments, the screening assays comprise, in a second step,determining the ability to cause cell death or apoptosis of B cellsexpressing human CD19. Competition-binding assays, on the other hand,assess the ability of a candidate antibody to compete with a knownanti-CD19 antibody or other compound that binds human CD19.

In a direct binding assay, the human CD19 antigen is contacted with acandidate antibody under conditions that allow binding of the candidateantibody to the human CD19 antigen. The binding may take place insolution or on a solid surface. Preferably, the candidate antibody ispreviously labeled for detection. Any detectable compound may be usedfor labeling, such as but not limited to, a luminescent, fluorescent, orradioactive isotope or group containing same, or a nonisotopic label,such as an enzyme or dye. After a period of incubation sufficient forbinding to take place, the reaction is exposed to conditions andmanipulations that remove excess or non-specifically bound antibody.Typically, it involves washing with an appropriate buffer. Finally, thepresence of a CD19-antibody complex is detected.

In a competition-binding assay, a candidate antibody is evaluated forits ability to inhibit or displace the binding of a known anti-CD19antibody (or other compound) to the human CD19 antigen. A labeled knownbinder of CD19 may be mixed with the candidate antibody, and placedunder conditions in which the interaction between them would normallyoccur, with and without the addition of the candidate antibody. Theamount of labeled known binder of CD19 that binds the human CD19 may becompared to the amount bound in the presence or absence of the candidateantibody.

In a preferred embodiment, to facilitate antibody antigen complexformation and detection, the binding assay is carried out with one ormore components immobilized on a solid surface. In various embodiments,the solid support could be, but is not restricted to, polycarbonate,polystyrene, polypropylene, polyethylene, glass, nitrocellulose,dextran, nylon, polyacrylamide and agarose. The support configurationcan include beads, membranes, microparticles, the interior surface of areaction vessel such as a microtiter plate, test tube or other reactionvessel. The immobilization of human CD19, or other component, can beachieved through covalent or non-covalent attachments. In oneembodiment, the attachment may be indirect, i.e., through an attachedantibody. In another embodiment, the human CD19 antigen and negativecontrols are tagged with an epitope, such as glutathione S-transferase(GST) so that the attachment to the solid surface can be mediated by acommercially available antibody such as anti-GST (Santa CruzBiotechnology).

For example, such an affinity binding assay may be performed using thehuman CD19 antigen which is immobilized to a solid support. Typically,the non-mobilized component of the binding reaction, in this case thecandidate anti-CD19 antibody, is labeled to enable detection. A varietyof labeling methods are available and may be used, such as luminescent,chromophore, fluorescent, or radioactive isotope or group containingsame, and nonisotopic labels, such as enzymes or dyes. In a preferredembodiment, the candidate anti-CD19 antibody is labeled with afluorophore such as fluorescein isothiocyanate (FITC, available fromSigma Chemicals, St. Louis).

Finally, the label remaining on the solid surface may be detected by anydetection method known in the art. For example, if the candidateanti-CD19 antibody is labeled with a fluorophore, a fluorimeter may beused to detect complexes.

Preferably, the human CD19 antigen is added to binding assays in theform of intact cells that express human CD19 antigen, or isolatedmembranes containing human CD19 antigen. Thus, direct binding to humanCD19 antigen may be assayed in intact cells in culture or in animalmodels in the presence and absence of the candidate anti-CD19 antibody.A labeled candidate anti-CD19 antibody may be mixed with cells thatexpress human CD19 antigen, or with crude extracts obtained from suchcells, and the candidate anti-CD19 antibody may be added. Isolatedmembranes may be used to identify candidate anti-CD19 antibodies thatinteract with human CD19. For example, in a typical experiment usingisolated membranes, cells may be genetically engineered to express humanCD19 antigen. Membranes can be harvested by standard techniques and usedin an in vitro binding assay. Labeled candidate anti-CD19 antibody(e.g., fluorescent labeled antibody) is bound to the membranes andassayed for specific activity; specific binding is determined bycomparison with binding assays performed in the presence of excessunlabeled (cold) candidate anti-CD19 antibody. Alternatively, solublehuman CD19 antigen may be recombinantly expressed and utilized innon-cell based assays to identify antibodies that bind to human CD19antigen. The recombinantly expressed human CD19 polypeptides can be usedin the non-cell based screening assays. Alternatively, peptidescorresponding to one or more of the binding portions of human CD19antigen, or fusion proteins containing one or more of the bindingportions of human CD19 antigen can be used in non-cell based assaysystems to identify antibodies that bind to portions of human CD19antigen. In non-cell based assays the recombinantly expressed human CD19is attached to a solid substrate such as a test tube, microtiter well ora column, by means well-known to those in the art (see, Ausubel et al.,supra). The test antibodies are then assayed for their ability to bindto human CD19 antigen.

Alternatively, the binding reaction may be carried out in solution. Inthis assay, the labeled component is allowed to interact with itsbinding partner(s) in solution. If the size differences between thelabeled component and its binding partner(s) permit such a separation,the separation can be achieved by passing the products of the bindingreaction through an ultrafilter whose pores allow passage of unboundlabeled component but not of its binding partner(s) or of labeledcomponent bound to its partner(s). Separation can also be achieved usingany reagent capable of capturing a binding partner of the labeledcomponent from solution, such as an antibody against the binding partnerand so on.

In one embodiment, for example, a phage library can be screened bypassing phage from a continuous phage display library through a columncontaining purified human CD19 antigen, or derivative, analog, fragment,or domain, thereof, linked to a solid phase, such as plastic beads. Byaltering the stringency of the washing buffer, it is possible to enrichfor phage that express peptides with high affinity for human CD19antigen. Phage isolated from the column can be cloned and affinities canbe measured directly. Knowing which antibodies and their amino acidsequences confer the strongest binding to human CD19 antigen, computermodels can be used to identify the molecular contacts between CD19antigen and the candidate antibody.

In another specific embodiment of this aspect of the invention, thesolid support is membrane containing human CD19 antigen attached to amicrotiter dish. Candidate antibodies, for example, can bind cells thatexpress library antibodies cultivated under conditions that allowexpression of the library members in the microtiter dish. Librarymembers that bind to the human CD19 are harvested. Such methods, aregenerally described by way of example in Parmley and Smith, 1988, Gene,73:305-318; Fowlkes et al., 1992, BioTechniques, 13:422-427; PCTPublication No. WO94/18318; and in references cited hereinabove.Antibodies identified as binding to human CD19 antigen can be of any ofthe types or modifications of antibodies described above.

In certain embodiments, the screening assays comprise, in a second step,determining the ability to cause cell death or apoptosis of B cellsexpressing human CD19. Assays utilizing viable dyes, methods ofdetecting and analyzing caspases, and assays measuring DNA breaks can beused to assess the apoptotic activity of cells cultured in vitro with ananti-CD19 antibody of interest. For example, Annexin V or TdT-mediateddUTP nick-end labeling (TUNEL) assays can be carried out as described inDecker et al., Blood, 103:2718-2725 (2004) to detect apoptotic activity.The TUNEL assay involves culturing the cells of interest withfluorescein-labeled dUTP for incorporation into DNA strand breaks. Thecells are then processed for analysis by flow cytometry. The Annexin Vassay detects the exposure of phosphatidylserine (PS) on the outside ofthe plasma membrane using a fluorescein-conjugated antibody thatspecifically recognizes the exposed PS on the surface of apoptoticcells. In conjunction, a viable dye such as propidium iodide can be usedto exclude late apoptotic cells from early apoptotic cells. The cells ofinterest are stained with the antibody and are analyzed by flowcytometry. Moreover, techniques for assaying apoptotic activity of anantibody are well-known in the art. See, e.g., Chaouchi et al., J.Immunol., 154(7): 3096-104 (1995); Pedersen et al., Blood, 99(4):1314-1318 (2002); Alberts et al., Molecular Biology of the Cell;Steensma et al., Methods Mol. Med., 85: 323-32, (2003)).

5.3.2. Screening of Antibodies for Human ADCC Effector Function

Antibodies of the human IgG class are preferred for use in the inventionbecause they have functional characteristics such a long half-life inserum and can mediate various effector functions (Monoclonal Antibodies:Principles and Applications, Wiley-Liss, Inc., Chapter 1 (1995)). Thehuman IgG class antibody is further classified into the following 4subclasses: IgG1, IgG2, IgG3 and IgG4. A large number of studies have sofar been conducted for ADCC and CDC and apoptotic activity as effectorfunctions of the IgG class antibody, and it has been reported that amongantibodies of the human IgG class, the IgG1 subclass has the highestADCC activity and CDC activity in humans (Chemical Immunology, 65, 88(1997)).

Expression of ADCC activity and CDC activity and apoptotic activity ofthe human IgG1 subclass antibodies generally involves binding of the Fcregion of the antibody to a receptor for an antibody (hereinafterreferred to as “FcγR”) existing on the surface of effector cells such askiller cells, natural killer cells or activated macrophages. Variouscomplement components can be bound. Regarding the binding, it has beensuggested that several amino acid residues in the hinge region and thesecond domain of C region (hereinafter referred to as “Cγ2 domain”) ofthe antibody are important (Eur. J. Immunol., 23, 1098 (1993),Immunology, 86, 319 (1995), Chemical Immunology, 65, 88 (1997)) and thata sugar chain in the Cγ2 domain (Chemical Immunology, 65, 88 (1997)) isalso important.

The anti-CD19 antibodies of the invention can be modified with respectto effector function, e.g., so as to enhance ADCC and/or complementdependent cytotoxicity (CDC) and/or apoptotic activity of the antibody.This may be achieved by introducing one or more amino acid substitutionsin the Fc region of an antibody. Alternatively or additionally, cysteineresidue(s) may be introduced in the Fc region, allowing for interchaindisulfide bond formation in this region. In this way a homodimericantibody can be generated that may have improved internalizationcapability and or increased complement-mediated cell killing and ADCC(Caron et al., J. Exp. Med., 176:1191-1195 (1992) and Shopes, J.Immunol., 148:2918-2922 (1992)). Heterobifunctional cross-linkers canalso be used to generate homodimeric antibodies with enhanced anti-tumoractivity (Wolff et al., Cancer Research, 53:2560-2565 (1993)).Antibodies can also be engineered to have two or more Fc regionsresulting in enhanced complement lysis and ADCC capabilities (Stevensonet al., Anti-Cancer Drug Design, (3)219-230 (1989)).

Other methods of engineering Fc regions of antibodies so as to altereffector functions are known in the art (e.g., U.S. Patent PublicationNo. 20040185045 and PCT Publication No. WO 2004/016750, both to Koeniget al., which describe altering the Fc region to enhance the bindingaffinity for FcγRIIB as compared with the binding affinity for FCγRIIA;see also PCT Publication Nos. WO 99/58572 to Armour et al., WO 99/51642to Idusogie et al., and U.S. Pat. No. 6,395,272 to Deo et al.; thedisclosures of which are incorporated herein in their entireties).Methods of modifying the Fc region to decrease binding affinity toFcγRIIB are also known in the art (e.g., U.S. Patent Publication No.20010036459 and PCT Publication No. WO 01/79299, both to Ravetch et al.,the disclosures of which are incorporated herein in their entireties).Modified antibodies having variant Fc regions with enhanced bindingaffinity for FcγRIIIA and/or FcγRIIA as compared with a wild type Fcregion have also been described (e.g., PCT Publication No. WO2004/063351, to Stavenhagen et al.; the disclosure of which isincorporated herein in its entirety).

At least four different types of FcγR have been found, which arerespectively called FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), andFcγRIV. In human, FcγRII and FcγRIII are further classified into FcγRIIaand FcγRIIb, and FcγRIIIa and FcγRIIIb, respectively. FcγR is a membraneprotein belonging to the immunoglobulin superfamily, FcγRII, FcγRIII,and FcγRIV have an α chain having an extracellular region containing twoimmunoglobulin-like domains, FcγRI has an α chain having anextracellular region containing three immunoglobulin-like domains, as aconstituting component, and the α chain is involved in the IgG bindingactivity. In addition, FcγRI and FcγRIII have a γ chain or ζ chain as aconstituting component which has a signal transduction function inassociation with the α chain (Annu. Rev. Immunol., 18, 709 (2000), Annu.Rev. Immunol., 19, 275 (2001)). FcγRIV has been described by Bruhns etal., Clin. Invest. Med., (Canada) 27:3 D (2004).

To assess ADCC activity of an anti-CD19 antibody of interest, an invitro ADCC assay can be used, such as that described in U.S. Pat. No.5,500,362 or 5,821,337. Useful effector cells for such assays includeperipheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.For example, the ability of any particular antibody to mediate lysis ofthe target cell by complement activation and/or ADCC can be assayed. Thecells of interest are grown and labeled in vitro; the antibody is addedto the cell culture in combination with immune cells which may beactivated by the antigen antibody complexes; i.e., effector cellsinvolved in the ADCC response. The antibody can also be tested forcomplement activation. In either case, cytolysis of the target cells isdetected by the release of label from the lysed cells. In fact,antibodies can be screened using the patient's own serum as a source ofcomplement and/or immune cells. The antibodies that are capable ofmediating human ADCC in the in vitro test can then be usedtherapeutically in that particular patient. Alternatively, oradditionally, ADCC activity of the molecule of interest may be assessedin vivo, e.g., in an animal model such as that disclosed in Clynes etal., PNAS (USA), 95:652-656 (1998). Moreover, techniques for modulating(i.e., increasing or decreasing) the level of ADCC, and optionally CDCactivity, and optionally apoptotic activity of an antibody arewell-known in the art. See, e.g., U.S. Pat. No. 6,194,551. (see, e.g.,Chaouchi et al., J. Immunol., 154(7): 3096-104 (1995); Pedersen et al.,Blood, 99(4): 1314-1318 (2002); Alberts et al., Molecular Biology of theCell; Steensma et al., Methods Mol. Med., 85: 323-32, (2003)).Antibodies of the present invention preferably are capable or have beenmodified to have the ability of inducing ADCC and/or CDC and/or anapoptotic response. Preferably, such assays to determined ADCC functionare practiced using humans effector cells to assess human ADCC function.

5.3.3. Immunoconjugates and Fusion Proteins

According to certain aspects of the invention, therapeutic agents ortoxins can be conjugated to chimerized, human, or humanized anti-CD19antibodies for use in the compositions and methods of the invention. Incertain embodiments, these conjugates can be generated as fusionproteins. Examples of therapeutic agents and toxins include, but are notlimited to, members of the enediyne family of molecules, such ascalicheamicin and esperamicin. Chemical toxins can also be taken fromthe group consisting of duocarmycin (see, e.g., U.S. Pat. No. 5,703,080and U.S. Pat. No. 4,923,990), methotrexate, doxorubicin, melphalan,chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide,bleomycin and 5-fluorouracil. Examples of chemotherapeutic agents alsoinclude adriamycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(ara-c), cyclophosphamide, thiotepa, taxotere (docetaxel), busulfan,cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine,bleomycin, etoposide, ifosfamide, mitomycin c, mitoxantrone,vincreistine, vinorelbine, carboplatin, teniposide, daunomycin,caminomycin, aminopterin, dactinomycin, mitomycins, esperamicins (see,U.S. Pat. No. 4,675,187), melphalan, and other related nitrogenmustards.

In other embodiments, for example, “CVB” (1.5 g/m² cyclophosphamide,200-400 mg/m² etoposide, and 150-200 mg/m² carmustine) can be used inthe combination therapies of the invention. CVB is a regimen used totreat non-Hodgkin's lymphoma (Patti et al., Eur. J. Haematol., 51: 18(1993)). Other suitable combination chemotherapeutic regimens arewell-known to those of skill in the art. See, for example, Freedman etal., “Non-Hodgkin's Lymphomas,” in Cancer Medicine, Volume 2, 3rdEdition, Holland et al. (eds.), pp. 2028-2068 (Lea & Febiger 1993). Asan illustration, first generation chemotherapeutic regimens fortreatment of intermediate-grade non-Hodgkin's lymphoma include C-MOPP(cyclophosphamide, vincristine, procarbazine and prednisone) and CHOP(cyclophosphamide, doxorubicin, vincristine, and prednisone). A usefulsecond generation chemotherapeutic regimen is m-BACOD (methotrexate,bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone,and leucovorin), while a suitable third generation regimen is MACOP-B(methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone,bleomycin, and leucovorin). Additional useful drugs include phenylbutyrate and brostatin-1.

Other toxins that can be used in the immunoconjugates of the inventioninclude poisonous lectins, plant toxins such as ricin, abrin, modeccin,botulina, and diphtheria toxins. Of course, combinations of the varioustoxins could also be coupled to one antibody molecule therebyaccommodating variable cytotoxicity. Illustrative of toxins which aresuitably employed in the combination therapies of the invention arericin, abrin, ribonuclease, DNase I, Staphylococcal enterotoxin-A,pokeweed anti-viral protein, gelonin, diphtherin toxin, Pseudomonasexotoxin, and Pseudomonas endotoxin. See, for example, Pastan et al.,Cell, 47:641 (1986), and Goldenberg et al., Cancer Journal forClinicians, 44:43 (1994). Enzymatically active toxins and fragmentsthereof which can be used include diphtheria A chain, non-binding activefragments of diphtheria toxin, exotoxin A chain (from Pseudomonasaeruginosa), ricin A chain, abrin A chain, modeccin A chain,alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacaamericana proteins (PAPI, PAPII, and PAP-S), Momordica charantiainhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin,mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.See, for example, WO 93/21232 published Oct. 28, 1993.

Suitable toxins and chemotherapeutic agents are described in Remington'sPharmaceutical Sciences, 19th Ed. (Mack Publishing Co. 1995), and inGoodman and Gilman's the Pharmacological Basis of Therapeutics, 7th Ed.(MacMillan Publishing Co. 1985). Other suitable toxins and/orchemotherapeutic agents are known to those of skill in the art.

The anti-CD19 antibody of the present invention may also be used inADEPT by conjugating the antibody to a prodrug-activating enzyme whichconverts a prodrug (e.g., a peptidyl chemotherapeutic agent, see,WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378and U.S. Pat. No. 4,975,278. The enzyme component of the immunoconjugateuseful for ADEPT includes any enzyme capable of acting on a prodrug insuch a way so as to covert it into its more active, cytotoxic form.

Enzymes that are useful in the method of this invention include, but arenot limited to, alkaline phosphatase useful for convertingphosphate-containing prodrugs into free drugs; arylsulfatase useful forconverting sulfate-containing prodrugs into free drugs; cytosinedeaminase useful for converting non-toxic 5-fluorocytosine into theanti-cancer drug, 5-fluorouracil; proteases, such as serratia protease,thermolysin, subtilisin, carboxypeptidases and cathepsins (such ascathepsins B and L), that are useful for converting peptide-containingprodrugs into free drugs; D-alanylcarboxypeptidases, useful forconverting prodrugs that contain D-amino acid substituents;carbohydrate-cleaving enzymes such as β-galactosidase and neuraminidaseuseful for converting glycosylated prodrugs into free drugs; β-lactamaseuseful for converting drugs derivatized with α-lactams into free drugs;and penicillin amidases, such as penicillin V amidase or penicillin Gamidase, useful for converting drugs derivatized at their aminenitrogens with phenoxyacetyl or phenylacetyl groups, respectively, intofree drugs. Alternatively, antibodies with enzymatic activity, alsoknown in the art as “abzymes,”, can be used to convert the prodrugs ofthe invention into free active drugs (see, e.g., Massey, Nature, 328:457-458 (1987)). Antibody-abzyme conjugates can be prepared as describedherein for delivery of the abzyme as desired to portions of a humanaffected by a B cell malignancy or an autoimmune disease or disorder.

The enzymes of this invention can be covalently bound to the antibody bytechniques well-known in the art such as the use of theheterobifunctional crosslinking reagents discussed above. Alternatively,fusion proteins comprising at least the antigen-binding region of anantibody of the invention linked to at least a functionally activeportion of an enzyme of the invention can be constructed usingrecombinant DNA techniques well-known in the art (see, e.g., Neubergeret al., Nature, 312: 604-608 (1984)).

Covalent modifications of the anti-CD19 antibody of the invention areincluded within the scope of this invention. They may be made bychemical synthesis or by enzymatic or chemical cleavage of the antibody,if applicable. Other types of covalent modifications of the anti-CD19antibody are introduced into the molecule by reacting targeted aminoacid residues of the antibody with an organic derivatizing agent that iscapable of reacting with selected side chains or the N- or C-terminalresidues.

Cysteinyl residues most commonly are reacted with α-haloacetates (andcorresponding amines), such as chloroacetic acid or chloroacetamide, togive carboxymethyl or carboxyamidomethyl derivatives. Similarly,iodo-reagents may also be used. Cysteinyl residues also are derivatizedby reaction with bromotrifluoroacetone, α-bromo-β-(5-imidozoyl)propionicacid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyldisulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate,2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

Histidyl residues are derivatized by reaction with diethylpyrocarbonateat pH 5.5-7.0 because this agent is relatively specific for the histidylside chain. Para-bromophenacyl bromide also is useful; the reaction ispreferably performed in 0.1 M sodium cacodylate at pH 6.0.

Lysyl and amino-terminal residues are reacted with succinic or othercarboxylic acid anhydrides. Derivatization with these agents has theeffect of reversing the charge of the lysinyl residues. Other suitablereagents for derivatizing α-amino-containing residues and/orε-amino-containing residues include imidoesters such as methylpicolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride,trinitrobenzenesulfonic acid, 0-methylisourea, 2,4-pentanedione, andtransaminase-catalyzed reaction with glyoxylate.

Arginyl residues are modified by reaction with one or severalconventional reagents, among them phenylglyoxal, 2,3-butanedione,1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residuesgenerally requires that the reaction be performed in alkaline conditionsbecause of the high pKa of the guanidine functional group. Furthermore,these reagents may react with the ε-amino groups of lysine as well asthe arginine epsilon-amino group.

The specific modification of tyrosyl residues may be made, withparticular interest in introducing spectral labels into tyrosyl residuesby reaction with aromatic diazonium compounds or tetranitromethane. Mostcommonly, N-acetylimidizole and tetranitromethane are used to formO-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosylresidues are iodinated using ¹²⁵I or ¹³¹I to prepare labeled proteinsfor use in radioimmunoassay.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified byreaction with carbodiimides (R—N═C═N—R′), where R and R′ are differentalkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide.Furthermore, aspartyl and glutamyl residues are converted to asparaginyland glutaminyl residues by reaction with ammonium ions.

Glutaminyl and asparaginyl residues are frequently deamidated to thecorresponding glutamyl and aspartyl residues, respectively. Theseresidues are deamidated under neutral or basic conditions. Thedeamidated form of these residues falls within the scope of thisinvention.

Other modifications include hydroxylation of proline and lysine,phosphorylation of hydroxyl groups of seryl or threonyl residues,methylation of the α-amino groups of lysine, arginine, and histidineside chains (T. E. Creighton, Proteins: Structure and MolecularProperties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)),acetylation of the N-terminal amine, and amidation of any C-terminalcarboxyl group.

Another type of covalent modification involves chemically orenzymatically coupling glycosides to the antibody. These procedures areadvantageous in that they do not require production of the antibody in ahost cell that has glycosylation capabilities for N- or O-linkedglycosylation. Depending on the coupling mode used, the sugar(s) may beattached to (a) arginine and histidine, (b) free carboxyl groups, (c)free sulfhydryl groups such as those of cysteine, (d) free hydroxylgroups such as those of serine, threonine, or hydroxyproline, (e)aromatic residues such as those of phenylalanine, tyrosine, ortryptophan, or (f) the amide group of glutamine. These methods aredescribed in WO 87/05330 published 11 Sep. 1987, and in Aplin andWriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

5.4. Pharmaceutical Formulations, Administration and Dosing

The pharmaceutical formulations of the invention contain as the activeingredient human, humanized, or chimeric anti-CD19 antibodies. Theformulations contain naked antibody, immunoconjugate, or fusion proteinin an amount effective for producing the desired response in a unit ofweight or volume suitable for administration to a human patient, and arepreferably sterile. The response can, for example, be measured bydetermining the physiological effects of the anti-CD19 antibodycomposition, such as, but not limited to, circulating B cell depletion,tissue B cell depletion, regression of a B cell malignancy or anautoimmune disease or disorder, or decrease of disease symptoms. Theresponse can also be measured by determining the physiological effectsof the anti-CD19 antibody composition such as circulating immunoglobulindepletion, or a reduction in the incidence, severity, or duration ofGVHD, a rejection episode, or a post-transplantation lymphoproliferativedisorder. Other assays will be known to one of ordinary skill in the artand can be employed for measuring the level of the response.

5.4.1. Pharmaceutical Formulations

An anti-CD19 antibody composition may be formulated with apharmaceutically-acceptable carrier. The term “pharmaceuticallyacceptable” means one or more non-toxic materials that do not interferewith the effectiveness of the biological activity of the activeingredients. Such preparations may routinely contain salts, bufferingagents, preservatives, compatible carriers, and optionally othertherapeutic agents. Such pharmaceutically acceptable preparations mayalso routinely contain compatible solid or liquid fillers, diluents orencapsulating substances which are suitable for administration into ahuman. When used in medicine, the salts should be pharmaceuticallyacceptable, but non-pharmaceutically acceptable salts may convenientlybe used to prepare pharmaceutically-acceptable salts thereof and are notexcluded from the scope of the invention. Such pharmacologically andpharmaceutically-acceptable salts include, but are not limited to, thoseprepared from the following acids: hydrochloric, hydrobromic, sulfuric,nitric, phosphoric, maleic, acetic, salicylic, citric, boric, formic,malonic, succinic, and the like. Also, pharmaceutically-acceptable saltscan be prepared as alkaline metal or alkaline earth salts, such assodium, potassium or calcium salts. The term “carrier” denotes anorganic or inorganic ingredient, natural or synthetic, with which theactive ingredient is combined to facilitate the application. Thecomponents of the pharmaceutical compositions also are capable of beingco-mingled with the antibodies of the present invention, and with eachother, in a manner such that there is no interaction which wouldsubstantially impair the desired pharmaceutical efficacy.

According to certain aspects of the invention, the anti-CD19 antibodycompositions can be prepared for storage by mixing the antibody orimmunoconjugate having the desired degree of purity with optionalphysiologically acceptable carriers, excipients or stabilizers(Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed.(1999)), in the form of lyophilized formulations or aqueous solutions.Acceptable carriers, excipients, or stabilizers are nontoxic torecipients at the dosages and concentrations employed, and includebuffers such as phosphate, citrate, and other organic acids;antioxidants including ascorbic acid and methionine; preservatives (suchas octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride, benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptide; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrolidone; amino acids such as glycine, glutamine, asparagine,histidine, arginine, or lysine; monosaccharides, disaccharides, andother carbohydrates including glucose, mannose, or dextrins; chelatingagents such as EDTA; sugars such as sucrose, mannitol, trehalose orsorbitol; salt-forming counter-ions such as sodium; metal complexes(e.g., Zn-protein complexes); and/or non-ionic surfactants such asTWEEN, PLURONICS™ or polyethylene glycol (PEG).

The anti-CD19 antibody compositions also may contain, optionally,suitable preservatives, such as: benzalkonium chloride; chlorobutanol;parabens and thimerosal.

The anti-CD19 antibody compositions may conveniently be presented inunit dosage form and may be prepared by any of the methods well-known inthe art of pharmacy. All methods include the step of bringing the activeagent into association with a carrier which constitutes one or moreaccessory ingredients. In general, the compositions are prepared byuniformly and intimately bringing the active compound into associationwith a liquid carrier, a finely divided solid carrier, or both, andthen, if necessary, shaping the product.

Compositions suitable for parenteral administration convenientlycomprise a sterile aqueous or non-aqueous preparation of anti-CD19antibody, which is preferably isotonic with the blood of the recipient.This preparation may be formulated according to known methods usingsuitable dispersing or wetting agents and suspending agents. The sterileinjectable preparation also may be a sterile injectable solution orsuspension in a non-toxic parenterally-acceptable diluent or solvent,for example, as a solution in 1,3-butane diol. Among the acceptablevehicles and solvents that may be employed are water, Ringer's solution,and isotonic sodium chloride solution. In addition, sterile, fixed oilsare conventionally employed as a solvent or suspending medium. For thispurpose any bland fixed oil may be employed including synthetic mono- ordi-glycerides. In addition, fatty acids such as oleic acid may be usedin the preparation of injectables. Carrier formulation suitable fororal, subcutaneous, intravenous, intramuscular, etc. administration canbe found in Remington's Pharmaceutical Sciences, Mack Publishing Co.,Easton, Pa. In certain embodiments, carrier formulation suitable forvarious routes of administration can be the same or similar to thatdescribed for RITUXAN™. See, Physicians' Desk Reference (MedicalEconomics Company, Inc., Montvale, N.J., 2005), pp. 958-960 and1354-1357, which is incorporated herein by reference in its entirety. Incertain embodiments of the invention, the anti-CD19 antibodycompositions are formulated for intravenous administration with sodiumchloride, sodium citrate dihydrate, polysorbate 80, and sterile waterwhere the pH of the composition is adjusted to approximately 6.5. Thoseof skill in the art are aware that intravenous injection provides auseful mode of administration due to the thoroughness of the circulationin rapidly distributing antibodies. Intravenous administration, however,is subject to limitation by a vascular barrier comprising endothelialcells of the vasculature and the subendothelial matrix. Still, thevascular barrier is a more notable problem for the uptake of therapeuticantibodies by solid tumors. Lymphomas have relatively high blood flowrates, contributing to effective antibody delivery. Intralymphaticroutes of administration, such as subcutaneous or intramuscularinjection, or by catheterization of lymphatic vessels, also provide auseful means of treating B cell lymphomas or autoimmune diseases ordisorders. In preferred embodiments, anti-CD19 antibodies of thecompositions and methods of the invention are self-administeredsubcutaneously. In such preferred embodiments, the composition isformulated as a lyophilized drug or in a liquid buffer (e.g., PBS and/orcitrate) at about 50 mg/mL.

The formulation herein may also contain more than one active compound asnecessary for the particular indication being treated, preferably thosewith complementary activities that do not adversely affect each other.For example, it may be desirable to further provide an immunosuppressiveagent. Such molecules are suitably present in combination in amountsthat are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsule prepared,for example, by coacervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsule and poly-(methylmethacylate) microcapsule,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

The formulations to be used for in vivo administration are typicallysterile. This is readily accomplished by filtration through sterilefiltration membranes.

Sustained-release preparations may be prepared. Suitable examples ofsustained-release preparations include semipermeable matrices of solidhydrophobic polymers containing the anti-CD19 antibody, which matricesare in the form of shaped articles, e.g., films, or microcapsule.Examples of sustained-release matrices include polyesters, hydrogels(for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acidand γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,degradable lactic acid-glycolic acid copolymers such as the LUPRONDEPOT™ (injectable microspheres composed of lactic acid-glycolic acidcopolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid.While polymers such as ethylene-vinyl acetate and lactic acid-glycolicacid enable release of molecules for over 100 days, certain hydrogelsrelease proteins for shorter time periods. When encapsulated antibodiesremain in the body for a long time, they may denature or aggregate as aresult of exposure to moisture at 37° C., resulting in a loss ofbiological activity and possible changes in immunogenicity. Rationalstrategies can be devised for stabilization depending on the mechanisminvolved. For example, if the aggregation mechanism is discovered to beintermolecular S—S bond formation through thio-disulfide interchange,stabilization may be achieved by modifying sulfhydryl residues,lyophilizing from acidic solutions, controlling moisture content, usingappropriate additives, and developing specific polymer matrixcompositions. In certain embodiments, the pharmaceutically acceptablecarriers used in the compositions of the invention do not affect humanADCC or CDC.

The anti-CD19 antibody compositions disclosed herein may also beformulated as immunoliposomes. A “liposome” is a small vesicle composedof various types of lipids, phospholipids and/or surfactant which isuseful for delivery of a drug (such as the anti-CD19 antibodiesdisclosed herein) to a human. The components of the liposome arecommonly arranged in a bilayer formation, similar to the lipidarrangement of biological membranes. Liposomes containing the antibodiesof the invention are prepared by methods known in the art, such asdescribed in Epstein et al., Proc. Natl. Acad. Sci. USA, 82:3688 (1985);Hwang et al., Proc. Natl. Acad. Sci. USA, 77:4030 (1980); and U.S. Pat.Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation timeare disclosed in U.S. Pat. No. 5,013,556. Particularly useful liposomescan be generated by the reverse phase evaporation method with a lipidcomposition comprising phosphatidylcholine, cholesterol andPEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes areextruded through filters of defined pore size to yield liposomes withthe desired diameter. The antibody of the present invention can beconjugated to the liposomes as described in Martin et al., J. Biol.Chem., 257: 286-288 (1982) via a disulfide interchange reaction. Atherapeutic agent can also be contained within the liposome. See,Gabizon et al., J. National Cancer Inst., (19)1484 (1989).

Some of the preferred pharmaceutical formulations include, but are notlimited to:

(a) A sterile, preservative-free liquid concentrate for intravenous(i.v.) administration of anti-CD19 antibody, supplied at a concentrationof 10 mg/ml in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials.The product can be formulated for i.v. administration using sodiumchloride, sodium citrate dihydrate, polysorbate and sterile water forinjection. For example, the product can be formulated in 9.0 mg/mLsodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7 mg/mLpolysorbate 80, and sterile water for injection. The pH is adjusted to6.5.

(b) A sterile, lyophilized powder in single-use glass vials forsubcutaneous (s.c.) injection. The product can be formulated withsucrose, L-histidine hydrochloride monohydrate, L-histidine andpolysorbate 20. For example, each single-use vial can contain 150 mganti-CD19 antibody, 123.2 mg sucrose, 6.8 mg L-histidine hydrochloridemonohydrate, 4.3 mg L-histidine, and 3 mg polysorbate 20. Reconstitutionof the single-use vial with 1.3 ml sterile water for injection yieldsapproximately 1.5 ml solution to deliver 125 mg per 1.25 ml (100 mg/ml)of antibody.

(c) A sterile, preservative-free lyophilized powder for intravenous (IV)administration. The product can be formulated with α-trehalosedihydrate, L-histidine HCl, histidine and polysorbate 20 USP. Forexample, each vial can contain 440 mg anti-CD19 antibody, 400 mgα,α-trehalose dihydrate, 9.9 mg L-histidine HCl, 6.4 mg L-histidine, and1.8 mg polysorbate 20, USP. Reconstitution with 20 ml of bacteriostaticwater for injection (BWFI), USP, containing 1.1% benzyl alcohol as apreservative, yields a multi-dose solution containing 21 mg/ml antibodyat a pH of approximately 6.

(d) A sterile, lyophilized powder for intravenous infusion in which theanti-CD19 antibody is formulated with sucrose, polysorbate, monobasicsodium phosphate monohydrate, and dibasic sodium phosphate dihydrate.For example, each single-use vial can contain 100 mg antibody, 500 mgsucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium phosphatemonohydrate, and 6.1 mg dibasic sodium phosphate dihydrate. Nopreservatives are present. Following reconstitution with 10 ml sterilewater for injection, USP, the resulting pH is approximately 7.2.

(e) A sterile, preservative-free solution for subcutaneousadministration supplied in a single-use, 1 ml pre-filled syringe. Theproduct can be formulated with sodium chloride, monobasic sodiumphosphate dihydrate, dibasic sodium phosphate dihydrate, sodium citrate,citric acid monohydrate, mannitol, polysorbate 80 and water forinjection, USP. Sodium hydroxide may be added to adjust pH to about 5.2.

For example, each syringe can be formulated to deliver 0.8 ml (40 mg) ofdrug product. Each 0.8 ml contains 40 mg anti-CD19 antibody, 4.93 mgsodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mgdibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 citricacid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80 and water forinjection, USP.

(f) A sterile, preservative-free, lyophilized powder contained in asingle-use vial that is reconstituted with sterile water for injection(SWFI), USP, and administered as a subcutaneous (s.c.) injection. Theproduct can be formulated with sucrose, histidine hydrochloridemonohydrate, L-histidine, and polysorbate. For example, a 75 mg vial cancontain 129.6 mg or 112.5 mg of the anti-CD19 antibody, 93.1 mg sucrose,1.8 mg L-histidine hydrochloride monohydrate, 1.2 mg L-histidine, and0.3 mg polysorbate 20, and is designed to deliver 75 mg of the antibodyin 0.6 ml after reconstitution with 0.9 ml SWFI, USP. A 150 mg vial cancontain 202.5 mg or 175 mg anti-CD19 antibody, 145.5 mg sucrose, 2.8 mgL-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mgpolysorbate 20, and is designed to deliver 150 mg of the antibody in 1.2ml after reconstitution with 1.4 ml SWFI, USP.

(g) A sterile, hyophilized product for reconstitution with sterile waterfor injection. The product can be formulated as single-use vials forintramuscular (IM) injection using mannitol, histidine and glycine. Forexample, each single-use vial can contain 100 mg antibody, 67.5 mg ofmannitol, 8.7 mg histidine and 0.3 mg glycine, and is designed todeliver 100 mg antibody in 1.0 ml when reconstituted with 1.0 ml sterilewater for injection. Alternatively, each single-use vial can contain 50mg antibody, 40.5 mg mannitol, 5.2 mg histidine and 0.2 mg glycine, andis designed to deliver 50 mg of antibody when reconstituted with 0.6 mlsterile water for injection.

(h) A sterile, preservative-free solution for intramuscular (IM)injection, supplied at a concentration of 100 mg/ml. The product can beformulated in single-use vials with histidine, glycine, and sterilewater for injection. For example, each single-use vial can be formulatedwith 100 mg antibody, 4.7 mg histidine, and 0.1 mg glycine in a volumeof 1.2 ml designed to deliver 100 mg of antibody in 1 ml. Alternatively,each single-use vial can be formulated with 50 mg antibody, 2.7 mghistidine and 0.08 mg glycine in a volume of 0.7 ml or 0.5 ml designedto deliver 50 mg of antibody in 0.5 ml.

In certain embodiments, the pharmaceutical composition of the inventionis stable at 4° C. In certain embodiments, the pharmaceuticalcomposition of the invention is stable at room temperature.

5.4.2. Antibody Half-Life

In certain embodiments, the half-life of an anti-CD19 antibody of thecompositions and methods of the invention is at least about 4 to 7 days.In certain embodiments, the mean half-life of the anti-CD19 antibody ofthe compositions and methods of the invention is at least about 2 to 5days, 3 to 6 days, 4 to 7 days, 5 to 8 days, 6 to 9 days, 7 to 10 days,8 to 11 days, 8 to 12, 9 to 13, 10 to 14, 11 to 15, 12 to 16, 13 to 17,14 to 18, 15 to 19, or 16 to 20 days. In other embodiments the half-lifeof an anti-CD19 antibody of the compositions and methods of theinvention can be up to about 50 days. In certain embodiments, thehalf-lives of the antibodies of the compositions and methods of theinvention can be prolonged by methods known in the art. Suchprolongation can in turn reduce the amount and/or frequency of dosing ofthe antibody compositions of the invention. Antibodies with improved invivo half-lives and methods for preparing them are disclosed in U.S.Pat. No. 6,277,375; and International Publication Nos. WO 98/23289 andWO 97/3461.

The serum circulation of the anti-CD19 antibodies of the invention invivo may also be prolonged by attaching inert polymer molecules such ashigh molecular weight polyethyleneglycol (PEG) to the antibodies with orwithout a multifunctional linker either through site-specificconjugation of the PEG to the N- or C-terminus of the antibodies or viaepsilon-amino groups present on lysyl residues. Linear or branchedpolymer derivatization that results in minimal loss of biologicalactivity will be used. The degree of conjugation can be closelymonitored by SDS-PAGE and mass spectrometry to ensure proper conjugationof PEG molecules to the antibodies. Unreacted PEG can be separated fromantibody-PEG conjugates by size-exclusion or by ion-exchangechromatography. PEG-derivatized antibodies can be tested for bindingactivity as well as for in vivo efficacy using methods known to those ofskill in the art, for example, by immunoassays described herein.

Plasma half-life of the antibodies of the compositions may be prolongedby altering the amino acid sequence of the antibody by introducing oneor more changes in the heavy and/or light chain gene nucleic acidsequence to produce the desired amino acid change. Such changes couldinclude but are not limited to changes in the variable region frameworkregions and/or in the Fc constant region. The techniques for alteringantibody gene sequences are well known in the art.

Further, the antibodies of the compositions and methods of the inventioncan be conjugated to albumin in order to make the antibody more stablein vivo or have a longer half-life in vivo. The techniques are wellknown in the art, see, e.g., International Publication Nos. WO 93/15199,WO 93/15200, and WO 01/77137; and European Patent No. EP 413, 622, allof which are incorporated herein by reference.

5.4.3. Administration and Dosing

In accordance with the present invention, each of the methods ofadministration and doses described herein can be used in the anti-CD19immunotherapy protocols described below.

Administration of the compositions of the invention to a human patientcan be by any route, including but not limited to intravenous,intradermal, transdermal, subcutaneous, intramuscular, inhalation (e.g.,via an aerosol), buccal (e.g., sub-lingual), topical (i.e., both skinand mucosal surfaces, including airway surfaces), intrathecal,intraarticular, intraplural, intracerebral, intra-arterial,intraperitoneal, oral, intralymphatic, intranasal, rectal or vaginaladministration, by perfusion through a regional catheter, or by directintralesional injection. In a preferred embodiment, the compositions ofthe invention are administered by intravenous push or intravenousinfusion given over defined period (e.g., 0.5 to 2 hours). Thecompositions of the invention can be delivered by peristaltic means orin the form of a depot, although the most suitable route in any givencase will depend, as is well known in the art, on such factors as thespecies, age, gender and overall condition of the subject, the natureand severity of the condition being treated and/or on the nature of theparticular composition (i.e., dosage, formulation) that is beingadministered. In particular embodiments, the route of administration isvia bolus or continuous infusion over a period of time, once or twice aweek. In other particular embodiments, the route of administration is bysubcutaneous injection given in one or more sites (e.g. thigh, waist,buttocks, arm), optionally once or twice weekly. In one embodiment, thecompositions, and/or methods of the invention are administered on anoutpatient basis.

In certain embodiments, the dose of a composition comprising anti-CD19antibody is measured in units of mg/kg of patient body weight. In otherembodiments, the dose of a composition comprising anti-CD19 antibody ismeasured in units of mg/kg of patient lean body weight (i.e., bodyweight minus body fat content). In yet other embodiments, the dose of acomposition comprising anti-CD19 antibody is measured in units of mg/m²of patient body surface area. In yet other embodiments, the dose of acomposition comprising anti-CD19 antibody is measured in units of mg perdose administered to a patient. Any measurement of dose can be used inconjunction with the compositions and methods of the invention anddosage units can be converted by means standard in the art.

Those skilled in the art will appreciate that dosages can be selectedbased on a number of factors including the age, sex, species andcondition of the subject (e.g., stage of B cell malignancy or activityof autoimmune disease or disorder), physical condition of the transplantrecipient or donor, the desired degree of cellular or autoimmuneantibody depletion, the disease to be treated and/or the particularantibody or antigen-binding fragment being used and can be determined byone of skill in the art.

In certain embodiments, the particular dosages will vary depending onwhether the regimen is indicated for pre-transplant conditioning,post-transplant maintenance, or post-transplant treatment of an acute orchronic rejection. For example, a higher dose may be required for thetreatment of an active rejection episode than that required forpre-transplant conditioning or post-transplant maintenance regimens. Incertain embodiments, the particular dosages chosen for pre- orpost-transplant prophylaxis may also be affected by factors such aswhether the patient is assessed as being at a high, intermediate, or lowrisk of developing a humoral response. For example, a patient at highrisk for developing a humoral immune response may require a higherprophylactic dose than a patient assessed as being at low risk. In otherembodiments, additional factors affecting dose may include whether thereare clinical indications of an early or a late stage humoral rejection.For example, a lower dose may be required for treatment of an earlystage rejection, such as a latent, silent, or preclinical humoralresponse, while a higher dose may be required to treat a more advancedstage of rejection, such as one exhibiting indications of graftdysfunction. In certain embodiments, the particular dosages chosen willvary depending on whether the anti-CD19 antibody compositions of theinvention comprise or are used in combination with a therapeutic regimenfor the treatment or prevention of GVHD, graft rejection, orpost-transplant lymphoproliferative disorder. In a particularembodiment, a lower dose is used when the anti-CD19 antibodycompositions of the invention are used in combination with one or moreother therapeutic agents. In a preferred embodiment, the dose of one ormore other therapeutic agents used in combination with the antibodiesand compositions of the invention is lower than the dose that wouldotherwise be required.

Effective amounts of the compositions of the invention may beextrapolated from dose-response curves derived from in vitro testsystems or from animal model (e.g., the cotton rat or monkey or GVHD orrejection) test systems. Models and methods for evaluation of theeffects of antibodies are known in the art (Wooldridge et al., Blood,89(8): 2994-2998 (1997), Sato et al., Mol Immunol. 42(7):821-831 (2005),Liu et al., Arthritis Rheum. 50(6):1884-1896 (2004), Nanki et al., JImmunol. 173(11):7010-7016 (2004), incorporated by reference herein inits entirety). In certain embodiments, for a particular B cellmalignancy or an autoimmune disease or disorder, therapeutic regimensstandard in the art for antibody therapy can be used with thecompositions and methods of the invention.

Similarly, for certain embodiments in which a particular regimen such aspre-transplant conditioning, post-transplant maintenance, orpost-transplant treatment of an acute or chronic rejection, therapeuticregimens standard in the art for antibody therapy can be used with thecompositions and methods of the invention. In one embodiment, theregimen is a pre-transplant conditioning regimen and the compositionsand methods of the invention are used to condition the recipient or thegraft, or both the graft and the recipient.

Examples of dosing regimens that can be used in the methods of theinvention include, but are not limited to, daily, three times weekly(intermittent), weekly, or every 14 days. In certain embodiments, dosingregimens include, but are not limited to, monthly dosing or dosing every6-8 weeks.

Those skilled in the art will appreciate that dosages are generallyhigher and/or frequency of administration greater for initial treatmentas compared with maintenance regimens.

In embodiments of the invention, the anti-CD19 antibodies bind to Bcells and, thus, can result in more efficient (i.e., at lower dosage)depletion of B cells (as described herein). Higher degrees of bindingmay be achieved where the density of human CD19 on the surface of apatient's B cells is high. In exemplary embodiments, dosages of theantibody (optionally in a pharmaceutically acceptable carrier as part ofa pharmaceutical composition) are at least about 0.0005, 0.001, 0.05,0.075, 0.1, 0.25, 0.375, 0.5, 1, 2.5, 5, 10, 20, 37.5, or 50 mg/m²and/or less than about 500, 475, 450, 425, 400, 375, 350, 325, 300, 275,250, 225, 200, 175, 150, 125, 100, 75, 60, 50, 37.5, 20, 15, 10, 5, 2.5,1, 0.5, 0.375, 0.1, 0.075 or 0.01 mg/m². In certain embodiments, thedosage is between about 0.0005 to about 200 mg/m², between about 0.001and 150 mg/m², between about 0.075 and 125 mg/m², between about 0.375and 100 mg/m², between about 2.5 and 75 mg/m², between about 10 and 75mg/m², and between about 20 and 50 mg/m². In related embodiments, thedosage of anti-CD19 antibody used is at least about 0.1, 0.2, 0.3, 0.4,0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5,7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14,14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5 mg/kgof body weight of a patient. In certain embodiments, the dose of nakedanti-CD19 antibody used is at least about 1 to 10, 5 to 15, 10 to 20, or15 to 25 mg/kg of body weight of a patient. In certain embodiments, thedose of anti-CD19 antibody used is at least about 1 to 20, 3 to 15, or 5to 10 mg/kg of body weight of a patient. In preferred embodiments, thedose of anti-CD19 antibody used is at least about 5, 6, 7, 8, 9, or 10mg/kg of body weight of a patient. In certain embodiments, a singledosage unit of the antibody (optionally in a pharmaceutically acceptablecarrier as part of a pharmaceutical composition) can be at least about0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70,72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104,106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132,134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160,162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188,190, 192, 194, 196, 198, 200, 204, 206, 208, 210, 212, 214, 216, 218,220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246,248, or 250, 300, 350, 375, or 1500 micrograms/m². In other embodiments,dose is up to 1 g per single dosage unit.

All of the above doses are exemplary and can be used in conjunction withthe compositions and methods of the invention, however where ananti-CD19 antibody is used in conjunction with a toxin orradiotherapeutic agent the lower doses described above are preferred. Incertain embodiments, where the patient has low levels of CD19 density,the lower doses described above are preferred.

Similarly, where an anti-CD19 antibody is used in conjunction with atoxin, a radiotherapeutic, an immunosuppressive agent or anantilymphocytic agent, the lower doses described above are preferred. Incertain embodiments, where the patient has low levels of CD19 density,the lower doses described above are preferred. In a preferredembodiment, the inclusion of one or more anti-CD19 antibody compositionsof the invention in a therapeutic regimen comprising one or moreimmunosuppressive agents requires a lower dose of the one or moreimmunosuppressive agents than the dose required in the absence of theanti-CD19 antibody compositions.

In certain embodiments of the invention where chimeric anti-CD19antibodies are used, the dose or amount of the chimeric antibody isgreater than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16mg/kg of patient body weight. In other embodiments of the inventionwhere chimeric anti-CD19 antibodies are used, the dose or amount of thechimeric antibody is less than about 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4,0.3, 0.2, or 0.1 mg/kg of patient body weight.

In some embodiments of the methods of this invention, antibodies and/orcompositions of this invention can be administered at a dose lower thanabout 375 mg/m²; at a dose lower than about 37.5 mg/m²; at a dose lowerthan about 0.375 mg/m²; and/or at a dose between about 0.075 mg/m² andabout 125 mg/m². In preferred embodiments of the methods of theinvention, dosage regimens comprise low doses, administered at repeatedintervals. For example, in one embodiment, the compositions of theinvention can be administered at a dose lower than about 375 mg/m² atintervals of approximately every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20,25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 125, 150, 175, or 200 days.

The specified dosage can result in B cell depletion in the human treatedusing the compositions and methods of the invention for a period of atleast about 1, 2, 3, 5, 7, 10, 14, 20, 30, 45, 60, 75, 90, 120, 150, or180 days or longer. In certain embodiments, pre-B cells (not expressingsurface immunoglobulin) are depleted. In certain embodiments, mature Bcells (expressing surface immunoglobulin) are depleted. In otherembodiments, all non-malignant types of B cells can exhibit depletion.Any of these types of B cells can be used to measure B cell depletion. Bcell depletion can be measured in bodily fluids such as blood serum, orin tissues such as bone marrow. In preferred embodiments of the methodsof the invention, B cells are depleted by at least 30%, 40%, 50%, 60%,70%, 80%, 90%, or 100% in comparison to B cell levels in the patientbeing treated before use of the compositions and methods of theinvention. In preferred embodiments of the methods of the invention, Bcells are depleted by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or100% in comparison to typical standard B cell levels for humans. Inrelated embodiments, the typical standard B cell levels for humans aredetermined using patients comparable to the patient being treated withrespect to age, sex, weight, and other factors.

In certain embodiments of the invention, a dosage of about 125 mg/m² orless of an antibody or antigen-binding fragment results in B celldepletion for a period of at least about 7, 14, 21, 30, 45, 60, 90, 120,150, or 200 days. In another representative embodiment, a dosage ofabout 37.5 mg/m² or less depletes B cells for a period of at least about7, 14, 21, 30, 45, 60, 90, 120, 150, or 200 days. In still otherembodiments, a dosage of about 0.375 mg/m² or less results in depletionof B cells for at least about 7, 14, 21, 30, 45 or 60 days. In anotherembodiment, a dosage of about 0.075 mg/m² or less results in depletionof B cells for a period of at least about 7, 14, 21, 30, 45, 60, 90,120, 150, or 200 days. In yet other embodiments, a dosage of about 0.01mg/m², 0.005 mg/m² or even 0.001 mg/m² or less results in depletion of Bcells for at least about 3, 5, 7, 10, 14, 21, 30, 45, 60, 90, 120, 150,or 200 days. According to these embodiments, the dosage can beadministered by any suitable route, but is optionally administered by asubcutaneous route.

As another aspect, the invention provides the discovery that B celldepletion and/or treatment of B cell disorders can be achieved at lowerdosages of antibody or antibody fragments than employed in currentlyavailable methods. Thus, in another embodiment, the invention provides amethod of depleting B cells and/or treating a B cell disorder, orpreventing GVHD, humoral rejection, or post-transplantlymphoproliferative disorder, comprising administering to a human aneffective amount of an antibody that specifically binds to CD19, whereina dosage of about 500, 475, 450, 425, 400, 375, 350, 325, 300, 275, 250,225, 200, 175, 150, 125, 100, 75, 60, 50, 37.5, 20, 10, 5, 2.5, 1, 0.5,0.375, 0.25, 0.1, 0.075, 0.05, 0.001, 0.0005 mg/m² or less results in adepletion of B cells (circulating and/or tissue B cells) and/or adepletion of circulating immunoglobulin of at least 25%, 35%, 50%, 60%,75%, 80%, 85%, 90%, 95%, 98% or more for a period at least about 3, 5,7, 10, 14, 21, 30, 45, 60, 75, 90, 120, 150, 180, or 200 days or longer.In representative embodiments, a dosage of about 125 mg/m² or 75 mg/m²or less results in at least about 50%, 75%, 85% or 90% depletion of Bcells and/or a depletion of circulating immunoglobulin for at leastabout 7, 14, 21, 30, 60, 75, 90, 120, 150 or 180 days. In otherembodiments, a dosage of about 50, 37.5 or 10 mg/m² results in at leastabout a 50%, 75%, 85% or 90% depletion of B cells and/or a depletion ofcirculating immunoglobulin for at least about 7, 14, 21, 30, 60, 75, 90,120 or 180 days. In still other embodiments, a dosage of about 0.375 or0.1 mg/m² results in at least about a 50%, 75%, 85% or 90% depletion ofB cells and/or a depletion of circulating immunoglobulin for at leastabout 7, 14, 21, 30, 60, 75 or 90 days. In further embodiments, a dosageof about 0.075, 0.01, 0.001, or 0.0005 mg/m² results in at least about a50%, 75%, 85% or 90% depletion of B cells and/or a depletion ofcirculating immunoglobulin for at least about 7, 14, 21, 30, or 60 days.

In certain embodiments of the invention, the dose can be escalated orreduced to maintain a constant dose in the blood or in a tissue, suchas, but not limited to, bone marrow. In related embodiments, the dose isescalated or reduced by about 2%, 5%, 8%, 10%, 15%, 20%, 30%, 40%, 50%,60%, 70%, 80%, 90%, and 95% in order to maintain a desired level of theantibody of the compositions and methods of the invention.

In certain embodiments, the invention provides a method of depleting Bcells and/or a method of depleting immunoglobulin (Ig) and/or treatingor preventing GVHD or humoral rejection, comprising contacting a graftex vivo with an amount of one or more of the anti-CD19 antibodycompositions of the invention sufficient to deplete B cells and/or Igfrom the graft.

In certain embodiments, the dosage can be adjusted and/or the infusionrate can be reduced based on patient's immunogenic response to thecompositions and methods of the invention.

According to one aspect of the methods of the invention, a loading doseof the anti-CD19 antibody and/or composition of the invention can beadministered first followed by a maintenance dose until the B cellmalignancy or autoimmune disease or disorder being treated progresses oris followed by a defined treatment course (e.g., CAMPATH™, MYLOTARG™, orRITUXAN™, the latter of which allow patients to be treated for a definednumber of doses that has increased as additional data have beengenerated).

In another aspect of the methods of the invention, a loading dose of theanti-CD19 antibody and/or composition of the invention can beadministered first followed by a maintenance dose which is administereduntil the GVHD, rejection episode, or post-transplantationlymphoproliferative disorder being treated is ameliorated. In oneembodiment, the loading dose and/or maintenance dose of the anti-CD19antibody and/or composition of the invention is followed by a definedtreatment course comprising one or more immunosuppressive agents ortherapies.

According to another aspect of the methods of the invention, a patientmay be pretreated with the compositions and methods of the invention todetect, minimize immunogenic response, or minimize adverse effects ofthe compositions and methods of the invention. In some embodiments, thepatient is a transplant recipient who may be pretreated with thecompositions and methods of the invention to desensitize, minimizeimmunogenic response, or minimize adverse effects of the compositionsand methods of the invention.

5.4.4. Toxicity Testing

The tolerance, toxicity and/or efficacy of the compositions and/ortreatment regimens of the present invention can be determined bystandard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., for determining the LD50 (the dose lethal to 50% of thepopulation), the ED50 (the dose therapeutically effective in 50% of thepopulation), and IC50 (the dose effective to achieve a 50% inhibition).In a preferred embodiment, the dose is a dose effective to achieve atleast a 60%, 70%, 80%, 90%, 95%, or 99% depletion of circulating B cellsor circulating immunoglobulin, or both. The dose ratio between toxic andtherapeutic effects is the therapeutic index and it can be expressed asthe ratio LD50/ED50. Therapies that exhibit large therapeutic indicesare preferred. While therapies that exhibit toxic side effects may beused, care should be taken to design a delivery system that targets suchagents to CD19-expressing cells in order to minimize potential damage toCD19-negative cells and, thereby, reduce side effects.

Data obtained from the cell culture assays and animal studies can beused in formulating a range of dosages of the compositions and/ortreatment regimens for use in humans. The dosage of such agents liespreferably within a range of circulating concentrations that include theED50 with little or no toxicity. The dosage may vary within this rangedepending upon the dosage form employed and the route of administrationutilized. For any therapy used in the methods of the invention, thetherapeutically effective dose can be estimated by appropriate animalmodels. Depending on the species of the animal model, the dose is scaledfor human use according to art-accepted formulas, for example, asprovided by Freireich et al., Quantitative comparison of toxicity ofanticancer agents in mouse, rat, monkey, dog, and human, CancerChemotherapy Reports, NCI-1966 40:219-244. Data obtained from cellculture assays can be useful for predicting potential toxicity. Animalstudies can be used to formulate a specific dose to achieve acirculating plasma concentration range that includes the IC50 (i.e., theconcentration of the test compound that achieves a half-maximalinhibition of symptoms) as determined in cell culture. Such informationcan be used to more accurately determine useful doses in humans. Plasmadrug levels may be measured, for example, by high performance liquidchromatography, ELISA, or by cell-based assays.

5.5. Patient Diagnosis and Therapeutic Regimens

Oncology

According to certain aspects of the invention, the treatment regimen anddose used with the compositions and methods of the invention is chosenbased on a number of factors including, but not limited to, the stage ofthe B cell disease or disorder being treated. Appropriate treatmentregimens can be determined by one of skill in the art for particularstages of a B cell disease or disorder in a patient or patientpopulation. Dose response curves can be generated using standardprotocols in the art in order to determine the effective amount of thecompositions of the invention for treating patients having differentstages of a B cell or disease or disorder. In general, patients havingmore advanced stages of a B cell disease or disorder will require higherdoses and/or more frequent doses which may be administered over longerperiods of time in comparison to patients having an early stage B celldisease or disorder.

The anti-CD19 antibodies, compositions and methods of the invention canbe practiced to treat B cell diseases, including B cell malignancies.The term “B cell malignancy” includes any malignancy that is derivedfrom a cell of the B cell lineage. Exemplary B cell malignanciesinclude, but are not limited to: B cell subtype non-Hodgkin's lymphoma(NHL) including low grade/follicular NHL, small lymphocytic (SL) NHL,intermediate grade/follicular NHL, intermediate grade diffuse NHL, highgrade immunoblastic NHL, high grade lymphoblastic NHL, high grade smallnon-cleaved cell NHL; mantle-cell lymphoma, and bulky disease NHL;Burkitt's lymphoma; multiple myeloma; pre-B acute lymphoblastic leukemiaand other malignancies that derive from early B cell precursors; commonacute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL)including immunoglobulin-mutated CLL and immunoglobulin-unmutated CLL;hairy cell leukemia; Null-acute lymphoblastic leukemia; Waldenstrom'sMacroglobulinemia; diffuse large B cell lymphoma (DLBCL) includinggerminal center B cell-like (GCB) DLBCL, activated B cell-like (ABC)DLBCL, and type 3 DLBCL; pro-lymphocytic leukemia; light chain disease;plasmacytoma; osteosclerotic myeloma; plasma cell leukemia; monoclonalgammopathy of undetermined significance (MGUS); smoldering multiplemyeloma (SMM); indolent multiple myeloma (IMM); Hodgkin's lymphomaincluding classical and nodular lymphocyte pre-dominant type;lymphoplasmacytic lymphoma (LPL); and marginal-zone lymphoma includinggastric mucosal-associated lymphoid tissue (MALT) lymphoma.

The inventors have shown that the inventive antibodies and compositionscan deplete mature B cells. Thus, as another aspect, the invention canbe employed to treat mature B cell malignancies (i.e., express Ig on thecell surface) including but not limited to follicular lymphoma,mantle-cell lymphoma, Burkitt's lymphoma, multiple myeloma, diffuselarge B-cell lymphoma (DLBCL) including germinal center B cell-like(GCB) DLBCL, activated B cell-like (ABC) DLBCL, and type 3 DLBCL,Hodgkin's lymphoma including classical and nodular lymphocytepre-dominant type, lymphoplasmacytic lymphoma (LPL), marginal-zonelymphoma including gastric mucosal-associated lymphoid tissue (MALT)lymphoma, and chronic lymphocytic leukemia (CLL) includingimmunoglobulin-mutated CLL and immunoglobulin-unmutated CLL.

Further, CD19 is expressed earlier in B cell development than, forexample, CD20, and is therefore particularly suited for treating pre-Bcell and immature B cell malignancies (i.e., do not express Ig on thecell surface), for example, in the bone marrow. Illustrative pre-B celland immature B cell malignancies include, but are not limited to, acutelymphoblastic leukemia. In other particular embodiments, the inventioncan be practiced to treat extranodal tumors.

Autoimmune Diseases or Disorders

In other aspects of the invention, the treatment regimen and dose usedwith the compositions and methods of the invention is chosen based on anumber of factors including, but not limited to, the stage of theautoimmune disease or disorder being treated. Appropriate treatmentregimens can be determined by one of skill in the art for particularstages of a autoimmune disease or disorder in a patient or patientpopulation. Dose response curves can be generated using standardprotocols in the art in order to determine the effective amount of thecompositions of the invention for treating patients having differentstages of a autoimmune disease or disorder. In general, patients havingmore activity of a autoimmune disease or disorder will require higherdoses and/or more frequent doses which may be administered over longerperiods of time in comparison to patients having less activity of anautoimmune disease or disorder.

The anti-CD19 antibodies, compositions and methods of the invention canbe practiced to treat an autoimmune disease or disorder. The term“autoimmune disease or disorder” refers to a condition in a subjectcharacterized by cellular, tissue and/or organ injury caused by animmunologic reaction of the subject to its own cells, tissues and/ororgans. The term “inflammatory disease” is used interchangeably with theterm “inflammatory disorder” to refer to a condition in a subjectcharacterized by inflammation, preferably chronic inflammation.Autoimmune disorders may or may not be associated with inflammation.Moreover, inflammation may or may not be caused by an autoimmunedisorder. Thus, certain disorders may be characterized as bothautoimmune and inflammatory disorders. Exemplary autoimmune diseases ordisorders include, but are not limited to: alopecia areata, ankylosingspondylitis, antiphospholipid syndrome, autoimmune Addison's disease,autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia,autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmunethrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy,celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome(CFIDS), chronic inflammatory demyelinating polyneuropathy,Churg-Strauss syndrome, cicatrical pemphigoid, CREST syndrome, coldagglutinin disease, Crohn's disease, discoid lupus, essential mixedcryoglobulinemia, diabetes, eosinophilic fascites,fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease,Guillain-Barre, Hashimoto's thyroiditis, Henoch-Schönlein purpura,idiopathic pulmonary fibrosis, idiopathic/autoimmune thrombocytopeniapurpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupuserthematosus, Ménière's disease, mixed connective tissue disease,multiple sclerosis, type 1 or immune-mediated diabetes mellitus,myasthenia gravis, pemphigus-related disorders (e.g., pemphigusvulgaris), pernicious anemia, polyarteritis nodosa, polychrondritis,polyglandular syndromes, polymyalgia rheumatica, polymyositis anddermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis,psoriasis, psoriatic arthritis, Raynauld's phenomenon, Reiter'ssyndrome, Rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren'ssyndrome, stiff-man syndrome, systemic lupus erythematosis (SLE),Sweet's syndrome, Still's disease, lupus erythematosus, takayasuarteritis, temporal arteristis/giant cell arteritis, ulcerative colitis,uveitis, vasculitides such as dermatitis herpetiformis vasculitis,vitiligo, and Wegener's granulomatosis. Examples of inflammatorydisorders include, but are not limited to, asthma, encephilitis,inflammatory bowel disease, chronic obstructive pulmonary disease(COPD), allergic disorders, septic shock, pulmonary fibrosis,undifferentitated spondyloarthropathy, undifferentiated arthropathy,arthritis, inflammatory osteolysis, graft versus host disease,urticaria, Vogt-Koyanagi-Hareda syndrome and chronic inflammationresulting from chronic viral or bacteria infections.

CD19 is expressed on mature B cells as well as earlier in B celldevelopment than, for example, CD20, and is therefore particularlysuited for depleting pre-B cells and immature B cells (i.e., do notexpress Ig on the cell surface), for example, in the bone marrow.

Transplantation

According to certain aspects of the invention, the treatment regimen anddose used with the compositions and methods of the invention is chosenbased on a number of factors including, for example, clinicalmanifestation that place a patient at risk for developing a humoralrejection, or clinical evidence that such a rejection is developing. Theterms “humoral” and “antibody-mediated” are used interchangeably herein.

The criteria for assessing the risk that a patient will develop ahumoral rejection are established according to the knowledge and skillin the art. In one embodiment, a positive complement dependentcytotoxicity or antiglobulin enhanced complement dependent cytotoxicitycrossmatch indicates that a patient is at high risk for humoralrejection. In one embodiment, a positive crossmatch or a prior positivecomplement dependent cytotoxicity or anti-globulin enhanced complementdependent cytotoxicity crossmatch indicates that a patient is at anintermediate risk for humoral rejection. In one embodiment, a negativecrossmatch indicates that a patient is at a low risk for humoralrejection.

Appropriate treatment regimens can be determined by one of skill in theart for the particular patient or patient population. In particularembodiments, the treatment regimen is a pre-transplant conditioningregimen, a post-transplant maintenance regimen, or post-transplanttreatment regimen for an acute or a chronic rejection. In certainembodiments, the particular regimen is varied for a patient who isassessed as being at a high or intermediate risk of developing a humoralresponse, compared with the regimen for a patient who is assessed asbeing at a low risk of developing a humoral response.

In certain embodiments, the particular regimen is varied according tothe stage of humoral rejection, with more aggressive therapy beingindicated for patients at later stages of rejection. The stages ofhumoral rejection may be classified according to the knowledge and skillin the art. For example, the stages of humoral rejection may beclassified as one of stages I to IV according to the following criteria:Stage I Latent Response, characterized by circulating anti-donoralloantibodies, especially anti-HLA antibodies; Stage II SilentReaction, characterized by circulating anti-donor alloantibodies,especially anti-HLA antibodies, and C4d deposition, but withouthistologic changes or graft dysfunction; Stage III SubclinicalRejection: characterized by circulating anti-donor alloantibodies,especially anti-HLA antibodies, C4d deposition, and tissue pathology,but without graft dysfunction; Stage IV Humoral Rejection: characterizedby circulating anti-donor alloantibodies, especially anti-HLAantibodies, C4d deposition, tissue pathology, and graft dysfunction.

Dose response curves can be generated using standard protocols in theart in order to determine the effective amount of the compositions ofthe invention for use in a particular regimen, for example, inconditioning regimens prior to transplantation, and inpost-transplantation regimens for prophylaxis and treatment of GVHD,humoral rejection, or post-transplantation lymphoproliferativedisorders. In general, patients at high risk for developing a humoralrejection and those already exhibiting one or more clinical indicatorsof rejection will require higher doses and/or more frequent doses whichmay be administered over longer periods of time in comparison topatients who are not at high risk or who do not exhibit any indicationsof active rejection.

The anti-CD19 antibodies, compositions and methods of the invention canbe practiced to treat or prevent GVHD, humoral rejection, orpost-transplantation lymphoproliferative disorders, either alone or incombination with other therapeutic agents or treatment regimens. Othertherapeutic regimens for the treatment or prevention of GVHD, humoralrejection, or post-transplantation lymphoproliferative disorders maycomprise, for example, one or more of anti-lymphocyte therapy, steroidtherapy, antibody depletion therapy, immunosuppression therapy, andplasmapheresis.

Anti-lymphocyte therapy may comprise the administration to thetransplant recipient of anti-thymocyte globulins, also referred to asthymoglobulin. Anti-lymphocyte therapy may also comprise theadministration of one or more monoclonal antibodies directed against Tcell surface antigens. Examples of such antibodies include, withoutlimitation, OKT3™ (muromonab-CD3), CAMPATH™-1H (alemtuzumab),CAMPATH™-1G, CAMPATH™-1M, SIMULECT™ (basiliximab), and ZENAPAX™(daclizumab). In a specific embodiment, the anti-lymphocyte therapycomprises one or more additional antibodies directed against B cells,including, without limitation, RITUXAN™ (rituximab).

Steroid therapy may comprise administration to the transplant recipientof one or more steroids selected from the group consisting of cortisol,prednisone, methyl prednisolone, dexamethazone, and indomethacin.Preferably, one or more of the steroids are corticosteroids, includingwithout limitation, cortisol, prednisone, and methylprednisolone.

Antibody depletion therapy may include, for example, administration tothe transplant recipient of intravenous immunoglobulin. Antibodydepletion therapy may also comprise immunoadsorption therapy applied tothe graft ex vivo, prior to transplantation. Immunoadsorption may beaccomplished using any suitable technique, for example, protein Aaffinity, or antibody based affinity techniques using antibodiesdirected against T cell or B cell surface markers such as anti-CD3antibodies, anti-CD19 antibodies, anti-CD20 antibodies, and anti-CD22antibodies.

Immunosuppression therapy may comprise the administration of one or moreimmunosuppressive agents such as inhibitors of cytokine transcription(e.g., cyclosporin A, tacrolimus), nucleotide synthesis (e.g.,azathiopurine, mycophenolate mofetil), growth factor signal transduction(e.g., sirolimus, rapamycin), and the T cell interleukin 2 receptor(e.g., daclizumab, basiliximab). In a particular embodiment, animmunosuppressant agent used in combination with the compositions andmethods of the invention includes one or more of the following:adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporin A(“CyA”), cytoxin, fludarabine, 5-fluorouracil, methotrexate,mycophenolate mofetil (MOFETIL), nonsteroidal anti-inflammatories(NSAIDs), rapamycin, and tacrolimus (FK506). Immunosuppressive agentsmay also comprise inhibitors of complement, for example, solublecomplement receptor-1, anti-05 antibody, or a small molecule inhibitorof C1s, for example as described in Buerke et al. (J. Immunol., 2001167:5375-80).

In one embodiment, the compositions and methods of the invention areused in combination with one or more therapeutic regimens forsuppressing humoral rejection, including, without limitation, tacrolimusand mycophenolate mofetil therapy, immunoadsorption, intravenousimmunoglobulin therapy, and plasmapheresis.

5.5.1. Diagnosis and Staging of B Cell Malignancies

The progression of cancer, such as a B cell disease or disorder capableof tumor formation (e.g., non-Hodgkin lymphoma, diffuse large B celllymphoma, follicular lymphoma, and Burkitt lymphoma) is typicallycharacterized by the degree to which the cancer has spread through thebody and is often broken into the following four stages which areprognostic of outcome. Stage I: The cancer is localized to a particulartissue and has not spread to the lymph nodes. Stage II: The cancer hasspread to the nearby lymph nodes, i.e., metastasis. Stage III: Thecancer is found in the lymph nodes in regions of the body away from thetissue of origin and may comprise a mass or multiple tumors as opposedto one. Stage IV: The cancer has spread to a distant part of the body.The stage of a cancer can be determined by clinical observations andtesting methods that are well known to those of skill in the art. Thestages of cancer described above are traditionally used in conjunctionwith clinical diagnosis of cancers characterized by tumor formation, andcan be used in conjunction with the compositions and methods of thepresent invention to treat B cell diseases and disorders. Typicallyearly stage disease means that the disease remains localized to aportion of a patient's body or has not metastasized.

With respect to non-tumor forming B cell diseases and disorders such asbut not limited to multiple myeloma, the criteria for determining thestage of disease differs. The Durie-Salmon Staging System has beenwidely used. In this staging system, clinical stage of disease (stage I,II, or III) is based on several measurements, including levels of Mprotein, the number of lytic bone lesions, hemoglobin values, and serumcalcium levels. Stages are further divided according to renal (kidney)function (classified as A or B). According to the Durie-Salmon StagingSystem Stage I (low cell mass) is characterized by all of the following:Hemoglobin value >10 g/dL; Serum calcium value normal or ≦12 mg/dL; Bonex-ray, normal bone structure (scale 0) or solitary bone plasmacytomaonly; and Low M-component production rate: IgG value <5 g/dL, IgA value<3 g/d, Bence Jones protein <4 g/24 h. Stage I patients typically haveno related organ or tissue impairment or symptoms. Stage II(intermediate cell mass) is characterized by fitting neither stage I norstage III. Stage III (high cell mass) is characterized by one or more ofthe following: Hemoglobin value <8.5 g/dL; Serum calcium value >12mg/dL; Advanced lytic bone lesions (scale 3); High M-componentproduction rate: IgG value >7 g/dL, IgA value >5 g/dL, Bence Jonesprotein >12 g/24 h Subclassification (either A or B), where A isRelatively normal renal function (serum creatinine value <2.0 mg/dL) andB is Abnormal renal function (serum creatinine value ≧2.0 mg/dL).

Another staging system for myeloma is the International Staging System(ISS) for myeloma. This system can more effectively discriminate betweenstaging groups and is based on easily measured serum levels of beta2-microglobulin (β2-M) and albumin. According to the ISS for myeloma,Stage I is characterized by β2-M <3.5 and Albumin ≧3.5, Stage II ischaracterized by β2-M <3.5 and albumin <3.5 or β2-M 3.5-5.5, and StageIII is characterized by β2-M >5.5 (Multiple Myeloma Research Foundation,New Canaan, Conn.).

The stage of a B cell malignancy in a patient is a clinicaldetermination. As indicated above, with respect to solid tumors, thespread, location, and number of tumors are the primary factors in theclinical determination of stage. Determination of stage in patients withnon-tumor forming B cell malignancies can be more complex requiringserum level measurements as described above.

The descriptions of stages of B cell diseases and disorders above arenot limiting. Other characteristics known in the art for the diagnosisof B cell diseases and disorders can be used as criteria for patients todetermine stages of B cell diseases or disorders.

5.5.2. Diagnosis of Autoimmune Diseases or Disorders

The diagnosis of an autoimmune disease or disorder is complicated inthat each type of autoimmune disease or disorder manifests differentlyamong patients. This heterogeneity of symptoms means that multiplefactors are typically used to arrive at a clinical diagnosis. Generally,clinicians use factors, such as, but not limited to, the presence ofautoantibodies, elevated cytokine levels, specific organ dysfunction,skin rashes, joint swelling, pain, bone remodeling, and/or loss ofmovement as primarily indicators of an autoimmune disease or disorder.For certain autoimmune diseases or disorders, such as RA and SLE,standards for diagnosis are known in the art. For certain autoimmunediseases or disorders, stages of disease have been characterized and arewell known in the art. These art recognized methods for diagnosingautoimmune diseases and disorders as well as stages of disease andscales of activity and/or severity of disease that are well known in theart can be used to identify patients and patient populations in need oftreatment for an autoimmune disease or disorder using the compositionsand methods of the invention.

5.5.3. Clinical Criteria for Diagnosing B Cell Malignancies

Diagnostic criteria for different B cell malignancies are known in theart. Historically, diagnosis is typically based on a combination ofmicroscopic appearance and immunophenotype. More recently, moleculartechniques such as gene-expression profiling have been applied todevelop molecular definitions of B cell malignancies (see, e.g., Shafferet al., Nature 2:920-932 (2002)). Exemplary methods for clinicaldiagnosis of particular B cell malignancies are provided below. Othersuitable methods will be apparent to those skilled in the art.

5.5.3.1. Follicular NHL

In general, most NHL (with the exception of mantle-cell lymphoma) havehighly mutated immunoglobulin genes that appear to be the result ofsomatic hypermutation (SHM). The most common genetic abnormalities inNHL are translocations and mutations of the BCL6 gene.

Follicular NHL is often an indolent B cell lymphoma with a folliculargrowth pattern. It is the second most common lymphoma in the UnitedStates and Western Europe. The median age at which this disease presentsis 60 years and there is a slight female predominance. Painlesslymphadenopathy is the most common symptom. Tests often indicateinvolvement of the blood marrow and sometimes the peripheral blood.Follicular NHL is divided into cytologic grades based on the proportionof large cells in the follicle with the grades forming a continuum fromfollicular small cleaved-cell to large-cell predominance. (See, S.Freedman, et al., Follicular Lymphoma, pp. 367-388, In Non-Hodgkin'sLymphomas, P. Mauch et al., eds., Lippincott Williams & Wilkins,Philadelphia, Pa. (2004); T. Lister et al., Follicular Lymphoma, pp.309-324, In Malignant Lymphoma, B. Hancock et al., eds., OxfordUniversity Press, New York, N.Y. (2000)).

Most follicular NHL is characterized by a translocation betweenchromosomes 14 and 18 resulting in overexpression of BCL2. FollicularNHL is also characterized by both SHM and ongoing SHM and a geneexpression profile similar to germinal center (GC) B cells (see, e.g.,Shaffer et al., Nature 2:920-932 (2002)), which are the putative cellsof origin for this malignancy. Heavy and light chain rearrangements aretypical. The tumor cells of this disease express monoclonal surfaceimmunoglobulin with most expressing IgM. Nearly all follicular NHL tumorcells express the antigens CD19, CD20, CD79a, CD21, CD35 and CD10 butlack expression of CD5 and CD43. Paratrabecular infiltration with smallcleaved cells is observed in the bone marrow. (See, S. Freedman et al.,Follicular Lymphoma, pp. 367-388, In Non-Hodgkin's Lymphomas, P. Mauchet al., eds., Lippincott Williams & Wilkins, Philadelphia, Pa. (2004);T. Lister et al., Follicular Lymphoma, pp. 309-324, In MalignantLymphoma, B. Hancock et al., eds., Oxford University Press, New York,N.Y. (2000)).

Diagnosis of follicular NHL generally relies on biopsy of an excisednode in order to evaluate tissue architecture and cytological features.Fine-needle aspirations are usually not adequate since this procedure isless likely to provide tissue that can be evaluated and it fails toprovide enough tissue for additional tests. Bilateral bone marrowbiopsies are also indicated since involvement can be patchy. Additionaldiagnostic procedures include chest x-rays, chest, abdomen, neck andpelvis computed tomography (CT) scans, complete blood count, andchemistry profile. Flow cytometry and immunohistochemistry can be usedto distinguish between follicular NHL and other mature B cell lymphomas.(See, S. Freedman et al., Follicular Lymphoma, pp. 367-388, InNon-Hodgkin's Lymphomas, P. Mauch et al., eds., Lippincott Williams &Wilkins, Philadelphia, Pa. (2004); T. Lister et al., FollicularLymphoma, pp. 309-324, In Malignant Lymphoma, B. Hancock et al., eds.,Oxford University Press, New York, N.Y. (2000))

5.5.3.2. Mantle-Cell Lymphoma

Mantle-cell lymphoma localizes to the mantle region of secondaryfollicles and is characterized by a nodular and/or diffuse growthpattern. Mantle-cell lymphoma patients have median age of 60-65 yearswith the disease affecting predominantly males. For diagnostic purposes,the usual presenting feature is a generalized lymphadenopathy.Additionally, the spleen is often enlarged. This B cell lymphoma isassociated with a t(11;14) between the IgH locus and cyclin D1 gene,which results in overexpression of cyclin D1. More than 50% of casesshow additional chromosomal abnormalities. Mantle-cell lymphoma istypically not characterized by SHM. (See, W. Hiddemann et al., MantleCell Lymphoma, pp. 461-476, In Non-Hodgkin's Lymphomas, P. Mauch et al.,eds., Lippincott Williams & Wilkins, Philadelphia, Pa. (2004); D.Weisenburger et al., Mantle Cell Lymphoma, pp. 28-41, In MalignantLymphoma, B. Hancock et al., eds., Oxford University Press, New York,N.Y. (2000)).

Immunophenotyping (flow cytometry or frozen section)immunohistochemistry of mantle cell lymphoma cells shows them to nearlyalways be monoclonal, bearing surface IgM. Mantle cell lymphoma cellshave also been noted to bear surface IgD. The cells express the antigensCD19, CD20, CD22 and CD24, but not CD23. They also express surfaceantigens CD5 but not for CD10, distinguishing them from true folliclecenter-cell lymphomas which are almost always CD5 negative. Frequently,extranodal involvement is found including bone marrow infiltration andtumors of the liver and gastrointestinal tract. Mild anemia and leukemicexpression is not uncommon with mantle-cell lymphoma. (See, A. Lal etal., Role of Fine Needle Aspiration in Lymphoma, pp. 181-220, In W. Finnet al., eds., Hematopathology in Oncology, Kluwer Academic Publishers,Norwell, Mass. (2004); W. Hiddemann et al., Mantle Cell Lymphoma, pp.461-476, In Non-Hodgkin's Lymphomas, P. Mauch et al., eds., LippincottWilliams & Wilkins, Philadelphia, Pa. (2004)).

Diagnosis of mantle-cell lymphoma involves examination of the peripheralblood as well as bone marrow and lymph node biopsies. In addition,cytogenetic studies and immunophenotyping are useful in differentialdiagnosis. (See, W. Hiddemann, et al., Mantle Cell Lymphoma pp. 461-476,In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds., Lippincott Williams& Wilkins, Philadelphia, Pa. (2004); D. Weisenburger, et al., MantleCell Lymphoma, pp. 28-41, In Malignant Lymphoma, B. Hancock, et al.,eds., Oxford University Press, New York, N.Y. (2000)).

5.5.3.3. Burkitt's Lymphoma

Burkitt's lymphoma is an aggressive B cell lymphoma typically observedin children and young adults and is usually associated with bulkydisease of the jaw and/or abdomen. Approximately 20% of patients havebone marrow involvement. An endemic form of Burkitt's lymphoma involvesEpstein-Barr virus (EBV) infection of malignant cells; the sporadic formis independent of EBV infection. A translocation of c-myc toimmunoglobulin loci, which results in deregulation of the c-myc gene, ischaracteristic of this disease (t(8;14)(q24;q32)). Interestingly,deletions of the c-myc sequences appear to be involved in the sporadicform of the disease, while the endemic form usually involves pointmutations or insertions. (See, V. Pappa, et al., Molecular Biology, pp.133-157, In Malignant Lymphoma, B. Hancock, et al., eds., OxfordUniversity Press, New York, N.Y. (2000)). Burkitt's lymphoma is alsocharacterized by SHM, and the malignant cells have a gene expressionprofile similar to GC B cells, suggesting that this malignancy isderived from GC B cells.

Immunophenotype of Burkett's lymphoma shows the cells of this diseaseexpress CD19, CD20, CD22, and CD79a, but not CD5, CD23, cyclin D orterminal deoxynucleotidyl transferase. Frequently, these cells arepositive for CD10 and BCL6 and usually negative for BCL2. (See, I.Magrath, et al., Burkitt's Lymphoma, pp. 477-501, In Non-Hodgkin'sLymphomas, P. Mauch, et al., eds., Lippincott Williams & Wilkins,Philadelphia, Pa. (2004)).

High grade B cell Burkitt's-like lymphoma is a lymphoma borderlinebetween Burkitt's lymphoma and large B cell lymphoma. The cells of thislymphoma express CD19 and CD20 but expression of CD10, which is nearlyalways present in true Burkitt's lymphoma, is frequently absent. Becauseof this and other characteristics, some believe this lymphoma should beclassified as a diffuse large B cell lymphoma. (See, K. Maclennan,Diffuse Aggressive B cell Lymphoma, pp. 49-54, In Malignant Lymphoma, B.Hancock, et al., eds., Oxford University Press, New York, N.Y. (2000)).

Diagnosis of Burkitt's lymphoma generally relies on detection of thetranslocation associated with this lymphoma; thus, conventionalcytogenetic analysis is usually performed. Long distance polymerasechain reaction techniques and fluorescent in situ hybridization (FISH)have been used to detect Ig-myc junctions in the translocations andother genetic alterations associated with this disease. (See, R.Siebert, et al., Blood 91:984-990 (1998); T. Denyssevych, et al.,Leukemia, 16:276-283 (2002)).

5.5.3.4. Diffuse Large B Cell Lymphoma (DLBCL)

DLBCL is the most common non-Hodgkin's lymphoma and can arise from smallB cell lymphoma, follicular lymphoma or marginal zone lymphoma.Typically, patients present with lymphadenopathy; however, a largepercent of patients present in extranodal sites as well, withgastrointestinal involvement being the most common. Bone marrowinvolvement is observed in about 15% of patients. (See, Armitage, etal., Diffuse Large B cell Lymphoma, pp. 427-453, In Non-Hodgkin'sLymphomas, P. Mauch, et al., eds., Lippincott Williams & Wilkins,Philadelphia, Pa. (2004)). Heterogeneity in clinical, biological andmorphological characteristics makes this group of lymphomas difficult tosubclassify. However, two distinct subgroups have been identified withone expressing genes characteristic of germinal center B cells(GC-DLBCL) and the other overexpressing genes in peripheral blood Bcells. Survival rates are significantly better for patients withGC-DLBCL than those with activated B cell type (ABC)-DLBCL. (See, W.Chan, Archives of Pathology and Laboratory Medicine 128(12): 1379-1384(2004)).

DLBCLs express the cell surface antigens CD19, CD20, CD22, and CD79a.CD10 is expressed in the large majority of cases and CD5 expression isobserved in about 10% of cases. (See, K. Maclennan, Diffuse Aggressive Bcell Lymphoma, pp. 49-54, In Malignant Lymphoma, B. Hancock, et al.,eds., Oxford University Press, New York, N.Y. (2000)). DLBCL is oftenmarked by abnormalities of BCL6 and/or translocations of BCL2 to the IgHlocus. GC B cell like (GC) DLBCL is characterized by SHM with highlymutated immunoglobulin genes and ongoing SHM in malignant clones with aGC B cell-like gene expression profile. Most GC DLBCL have undergoneimmunoglobulin class switching. ABC-DLBCL is characterized by high levelexpression of NF-κB target genes including BCL2, interferon regulatoryfactor 4, CD44, FLIP and cyclin D. SHM, but not ongoing SHM, is present,and ABC-DLBCL does not have a GC B cell gene expression profile. Almostall ABC-DLBCL express a high level of IgM.

5.5.3.5. Extranodal Marginal Zone Lymphoma

Extranodal marginal-zone lymphoma is an extranodal lymphoma that occursin organs normally lacking organized lymphoid tissue (e.g., stomach,salivary glands, lungs and thyroid glands). It is largely a disease thataffects older adults with a median age of over 60 years. Often, chronicinflammation or autoimmune processes precede development of thelymphoma. Gastric mucosal-associated lymphoid tissue (MALT) lymphoma,the most common type of marginal-zone lymphoma, is associated withHelicobacter pylori infection. Studies have shown a resolution ofsymptoms with eradication of the H. pylori infection following anantibiotic regimen. The presenting symptoms for gastric MALT lymphomainclude nonspecific dyspepsia, epigastric pain, nausea, gastrointestinalbleeding and anemia. Systemic symptoms are uncommon, as are elevatedlevels of lactate acid dehydrogenase. (See, J. Yahalom, et al.,Extranodal Marginal Zone B cell Lymphoma of Mucosa-Associated LymphoidTissue, pp. 345-360, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds.,Lippincott Williams & Wilkins, Philadelphia, Pa. (2004); J. Radford,Other Low-Grade Non-Hodgkin's Lymphomas, pp. 325-330, In MalignantLymphoma, B. Hancock, et al., eds., Oxford University Press, New York,N.Y. (2000). Systemic B symptoms include fevers greater than 38° C. forlonger than 2 weeks without sign of infection, night sweats, extremefatigue or unintentional weight loss of greater than or equal to 10% ofbody weight over the previous 6 months).

The immunophenotye of MALT lymphoma is characterized by expression ofCD20, CD79a, CD21 and CD35 and lack of expression of CD5, CD23, andCD10. About half of MALT lymphomas express CD43. The immunoglobulintypically expressed in the tumor cells of this disease is IgM while IgDis not expressed. These features are critical in distinguishing thislymphoma from other small B cell lymphomas such as mantle cell lymphoma,lymphocytic lymphoma and follicular lymphoma. Trisomy 3 has beenreported in 60% of MALT lymphoma cases. In 25-40% of gastric andpulmonary MALT lymphomas a t(11;18) is observed. This translocation isobserved much less frequently in other MALT lymphomas. T(11;18) isassociated with nuclear expression of BCL10. (See, J. Yahalom, et al.,Extranodal Marginal Zone B cell Lymphoma of Mucosa-Associated LymphoidTissue, pp. 345-360, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds.,Lippincott Williams & Wilkins, Philadelphia, Pa. (2004)). Marginal-zonelymphomas are generally characterized by SHM and ongoing SHM.

Diagnostic procedures include immunophenotyping or flow cytometry todetermine the identity of the cell surface markers. In addition,molecular genetic analysis should be done to determine the presence oft(11;18) as this is an indicator that the disease will not respond toantibiotics. Histology can be used to determine the presence of H.pylori. Additional tests should include a complete blood count, basicbiochemical tests including that for lactate acid dehydrogenase; CTscans of the abdomen, chest and pelvis and a bone marrow biopsy. (See,J. Yahalom, et al., Extranodal Marginal Zone B cell Lymphoma ofMucosa-Associated Lymphoid Tissue, pp. 345-360, In Non-Hodgkin'sLymphomas, P. Mauch, et al., eds., Lippincott Williams & Wilkins,Philadelphia, Pa. (2004)).

5.5.3.6. Nodal Marginal Zone B Cell Lymphoma

Nodal Marginal Zone B cell Lymphoma is a relatively newly classifiedlymphoma thus little has been published on it. It is a primary nodal Bcell lymphoma sharing genetic and morphological characteristics withextranodal and splenic marginal zone lymphomas, but does not localize tothe spleen or extranodally. Hepatitis C virus has been reported to beassociated with this lymphoma as has Sjögren's syndrome. (See, F.Berger, et al., Nodal Marginal Zone B cell Lymphoma, pp. 361-365, InNon-Hodgkin's Lymphomas, P. Mauch, et al., eds., Lippincott Williams &Wilkins, Philadelphia, Pa. (2004)).

Nodal marginal zone lymphoma has a heterogeneous cytology andmorphology. Due to its relatively high proportion of large cells thislymphoma, unlike the other marginal lymphomas (splenic and extranodal),cannot be classified as true low grade B cell lymphoma. The genetic andimmunological phenotype of nodal marginal zone lymphoma includesexpression of CD19, CD20, BCL2, sIgM and cytoplasmic IgG (cIg). Thesecells do not express CD5, CD10, CD23, CD43 or cyclin D1. Thetranslocation characteristic of MALT lymphoma, t(11;18), is not observedfor nodal marginal zone lymphoma. These characteristics aid in thedifferential diagnosis of this lymphoma from other small B celllymphomas. (See, F. Berger, et al., Nodal Marginal Zone B cell Lymphoma,pp. 361-365, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds.,Lippincott Williams & Wilkins, Philadelphia, Pa. (2004)).

5.5.3.7. Splenic Marginal Zone Lymphoma

Splenic Marginal Zone Lymphoma is an indolent micro-nodular B celllymphoma with a characteristic clinical presentation of prominentsplenomegaly and infiltration of the peripheral blood and the bonemarrow. In addition, a relatively high level of liver involvement hasbeen reported. A role for hepatitis C virus has been postulated for thislymphoma. The immunophenotype of splenic marginal zone lymphoma istypically CD20⁺, IgD⁺, BCL2⁺, p27⁺, CD3⁻, CD5⁻, CD10⁻, CD23⁻, CD38⁻,CD43⁻, BCL-6⁻, and cyclin D1⁻. Genetic characteristics include a 7qdeletion, p53 alterations and SHM. (See, M. Piris, et al., SplenicMarginal Zone Lymphoma, pp. 275-282, In Non-Hodgkin's Lymphomas, P.Mauch, et al., eds., Lippincott Williams & Wilkins, Philadelphia, Pa.(2004)).

Diagnosis generally relies on immunophenotyping to determine theidentity of the cell surface markers. Genetic and biochemical analysis,in combination with data on cell surface markers, help to differentiatethis lymphoma from other small B cell lymphomas. (See, M. Piris, et al.,Splenic Marginal Zone Lymphoma, pp. 275-282, In Non-Hodgkin's Lymphomas,P. Mauch, et al., eds., Lippincott Williams & Wilkins, Philadelphia, Pa.(2004)).

5.5.3.8. Acute (B Cell) Lymphocytic Leukemia (All)

ALL is a marrow-based neoplasm largely affecting children with thehighest incidence between 1-5 years. Most common symptoms atpresentation include fatigue, lethargy, fever and bone and joint pain.Fatigue and lethargy correlates with the degree of anemia present. Anelevated white blood cell count is common at presentment. Radiographs ofthe chest often show skeletal lesions. Extramedullary spread is commonand involves the central nervous system, testes, lymph nodes, liver,spleen and kidney. Anterior mediastinal masses are observed in onlyabout 5-10% of newly diagnosed cases. (See, J. Whitlock, et al., AcuteLymphocytic Leukemia, pp. 2241-2271, In Wintrobe's Clinical Hematology,Tenth Edition, G. Lee, et al., eds. Williams & Wilkins, Baltimore, Md.(1999)).

The immunophenotype of ALL is CD10⁺, CD19⁺, CD20⁺, and CD24⁺. Pre-B cellALL cells express cytoplasmic but not surface immunoglobulin, whilemature B cell ALL (which accounts for only 1-2% of ALL cases) isdistinguished from other leukemias of B cell lineage by the expressionof surface immunoglobulin. Cytogenetic characteristics of ALL includest(8;14), t(2;8) and t(8;22). Although rarely detected at the cytogeneticlevel t(12;21) may be the most common cytogenetic abnormality associatedwith childhood ALL (observed in about 25% of cases). (See, M. Kinney, etal., Classification and Differentiation of the Acute Leukemias, pp.2209-2240, In Wintrobe's Clinical Hematology, Tenth Edition, G. Lee, etal., eds. Williams & Wilkins, Baltimore, Md. (1999); J Whitlock, et al.,Acute Lymphocytic Leukemia, pp. 2241-2271; In Wintrobe's ClinicalHematology, Tenth Edition, G. Lee, et al., eds. Williams & Wilkins,Baltimore, Md., (1999)).

Precise diagnosis of acute leukemia usually relies on a bone aspirateand biopsy. Aspirate smears are used for morphological, immunologicaland cytological assessments. The demonstration of lymphoblasts in thebone marrow is diagnostic of ALL. The presence of greater than 5%leukemic lymphoblast cells in the bone marrow confirms ALL diagnosis butmost require greater than 25% for a definitive diagnosis. Lumbarpunctures are used to diagnose central nervous system involvement. Serumuric acids levels and serum lactate dehydrogenase levels have been foundto be elevated in ALL. (See, M. Kinney, et al., Classification andDifferentiation of the Acute Leukemias, pp. 2209-2240, In Wintrobe'sClinical Hematology, Tenth Edition, G. Lee, et al., eds. Williams &Wilkins, Baltimore, Md. (1999); J. Whitlock, et al., Acute LymphocyticLeukemia, pp. 2241-2271; In Wintrobe's Clinical Hematology, TenthEdition, G. Lee, et al., eds. Williams & Wilkins, Baltimore, Md.,(1999)).

5.5.3.9. Chronic Lymphocytic Leukemia (CLL)/Small B Cell LymphocyticLymphoma (SLL)

CLL/SLL is the most common type of leukemia. When the disease involvesthe peripheral blood and bone marrow it is referred to as CLL. However,when the lymph nodes and other tissues are infiltrated by cells that areimmunologically and morphologically identical to those in CLL, but whereleukemic characteristics of the disease are absent, then the disease isreferred to as SLL. This disease largely afflicts the elderly with agreater incidence of the disease occurring in men than women. Painlesslymphadenopathy is the most common finding at presentation.Hypogammaglobulinemia is common with most cases of CLL/SLL exhibitingreduced levels of all immunoglobulins rather than any particularsubclass of immunoglobulins. Asymptomatic patients are frequentlydiagnosed during routine blood counts (lymphocyte count of over5000×10⁹/L). As many as 20% of CLL/SLL cases report B symptoms. Anadditional diagnostic feature is infiltration of the bone marrow by morethan 30% by immature lymphocytes. Lymph node biopsies generally showinfiltration of involved nodes with well-differentiated lymphocytes.Autoimmune phenomena are often associated with CLL/SLL includingautoimmune hemolytic anemia and immune thrombocytopenia. (See, J.Gribben, et al., Small B cell Lymphocytic Lymphoma/Chronic LymphocyticLeukemia and Prolymphocytic Leukemia, pp. 243-261, In Non-Hodgkin'sLymphomas, P. Mauch, et al., eds., Lippincott Williams & Wilkins,Philadelphia, Pa. (2004); K. Maclennan, Diffuse Indolent B cellNeoplasms, pp. 43-47, In Malignant Lymphoma, B. Hancock, et al., eds.,Oxford University Press, New York, N.Y. (2000); Clinical Oncology, A.Neal, et al., Neal, Hoskin and Oxford University Press, co-publ., NewYork, N.Y. (2003))

In contrast with many of the low-grade B cell malignancies, nonrandomreciprocal translocations are rarely found in CLL/SLL. However, othercytogenetic abnormalities have been reported including deletions at13q14, 11q22-23 and 17q13, with the latter two involving the p53 locus.Approximately 20% of cases exhibit trisomy 12. An elevated level of B-2microglobulin, higher levels of CD38 expression and the production oftumor necrosis factor-alpha are all characteristic of CLL/SLL. Theimmunophenotype of CLL/SLL is very diagnostic and includes weakexpression of surface immunoglobulin usually IgM, or IgM and IgG, aswell as expression of the cell antigens CD19, CD20 and usually CD5 andCD23. (See, J. Gribben, et al., Small B cell LymphocyticLymphoma/Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia, pp.243-261, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds., LippincottWilliams & Wilkins, Philadelphia, Pa. (2004); K. Maclennan, DiffuseIndolent B cell Neoplasms, pp. 43-47, In Malignant Lymphoma, B. Hancock,et al., eds., Oxford University Press, New York, N.Y. (2000)).

5.5.3.10. B Cell Prolymphocytic Leukemia (PLL)

PLL, once considered a variant of CLL, is now understood to be adistinct disease. PLL is generally a disease of elderly men and ischaracterized by a very high white blood cell count (greater than200×10⁹/L) and splenomegaly. Additional symptoms include anemia andthrombocytopenia. Prolymphocytes in PLL comprise more than 55% of thecells in the blood and bone marrow. In contrast with CLL, autoimmunephenomena are rarely observed in PLL. (See, J. Gribben, et al., Small Bcell Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia andProlymphocytic Leukemia, pp. 243-261, In Non-Hodgkin's Lymphomas, P.Mauch, et al., eds., Lippincott Williams & Wilkins, Philadelphia, Pa.(2004)).

The immunophenotype of PLL is characterized by expression of CD19, CD21,CD22, CD24 and FMC7. The cells of PLL do not express CD23 and most donot express CD5. PLL cells exhibit complex chromosomal abnormalities,with deletions at 13q14 and 11q23 being some of the most frequent. Thepattern of p53 mutation in PLL cells is different from that observed forCLL. Differential diagnosis usually relies on complete blood count,histological, immunophenotypic, and genetic analyses. (See, J. Gribben,et al., Small B cell Lymphocytic Lymphoma/Chronic Lymphocytic Leukemiaand Prolymphocytic Leukemia, pp. 243-261, In Non-Hodgkin's Lymphomas, P.Mauch, et al., eds., Lippincott Williams & Wilkins, Philadelphia, Pa.(2004)).

5.5.3.11. Hairy Cell Leukemia (HCL)

HCL is a rare, indolent chronic leukemia affecting more men than womenand largely those of middle age. The typical symptoms include massivesplenomegaly and pancytopenia. The peripheral blood and bone marrowcontain the typical “hairy cells,” which are B lymphocytes withcytoplasmic projections. Over 90% of HCL patients have bone marrowinfiltration. (See, Clinical Oncology, A. Neal, et al., Neal, Hoskin andOxford University Press, co-publ., New York, N.Y. (2003); J. Johnston,Hairy Cell Leukemia, pp. 2428-2446, In Wintrobe's Clinical Hematology,Tenth Edition, G. Lee et al., eds. Williams & Wilkins, Baltimore, Md.(1999)).

Cytogenetic analysis has shown that clonal abnormalities are present in19% of cases and involve numerical and structural abnormalities ofchromosomes 5, 7 and 14. The serum level of TNF-α is elevated in hairycell leukemia and correlates with tumor burden. Hairy cell leukemiacells express surface immunoglobulins (IgG and IgM) and CD11 c, CD19,CD20, CD22 and typically CD25. In addition, FMC7, HC-2 and CD103 areexpressed. HCL cells do not express CD5 or CD 10. Diagnosis generallyinvolves the use of bone marrow aspirates, cytogenetics, blood smearsand immunophenotyping. (See, Clinical Oncology, A. Neal, et al., Neal,Hoskin and Oxford University Press, co-publ., New York, N.Y. (2003); J.Johnston, Hairy Cell Leukemia, pp. 2428-2446, In Wintrobe's ClinicalHematology, Tenth Edition, G. Lee et al., eds. Williams & Wilkins,Baltimore, Md. (1999)).

5.5.3.12. Precursor B Cell Lymphoblastic Lymphoma/Pre-B Cell AcuteLymphoblastic Leukemia/Lymphoblastic Lymphoma

Precursor B cell lymphoblastic lymphoma/pre-B cell acute lymphoblasticleukemia/Lymphoblastic lymphoma is a disease of precursor T or B cells.The T and B cell lymphoblastic lymphomas are morphologically identical,but clinical distinctions may be made based on degree of bone marrowinfiltration or bone marrow involvement. 85-90% of lymphoblasticlymphomas are T-cell derived with the remainder being B cell derived.Lymphoblastic lymphoma has a median age of 20 years with a malepredominance. Peripheral lymph node involvement is a common feature atpresentation, occurring especially in the cervical, supraclavicular andaxillary regions. This disease frequently presents with bone marrowinvolvement. Central nervous system is less common at presentment butoften appears in cases of relapse. Other sites of involvement caninclude liver, spleen, bone, skin, pharynx and testes (See, J.Sweetenham, et al., Precursor B- and T-Cell Lymphoblastic Lymphoma, pp.503-513, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds., LippincottWilliams & Wilkins, Philadelphia, Pa. (2004)).

Precursor B cell lymphoblastic lymphomas express immature markers B cellmarkers such as CD99, CD34 and terminal deoxynucleotidyl transferase.These cells also express CD79a, CD19, and sometimes CD20 and typicallylack expression of CD45 and surface immunoglobulin. Translocations at11q23, as well as t(9;22)(q34;q11.2) and t(12;21)(p13;q22), have beenassociated with poor prognosis. Good prognosis is associated withhyperdiploid karyotype, especially that associated with trisomy 4, 10,and 17 and t(12;21)(p13;q22). (See, J. Sweetenham, et al., Precursor B-and T-Cell Lymphoblastic Lymphoma, pp. 503-513, In Non-Hodgkin'sLymphomas, P. Mauch, et al., eds., Lippincott Williams & Wilkins,Philadelphia, Pa. (2004)).

Diagnostic tests include lymph node biopsies, blood tests, x-rays, CTscans, and lumbar punctures to examine the cerebralspinal fluid formalignant cells.

5.5.3.13. Primary Mediastinal Large B Cell Lymphoma

Primary mediastinal large B cell lymphoma is a diffuse large B celllymphoma occurring predominantly in young women and characterized by alocally invasive anterior mediastinal mass originating in the thymus.Distant spread to peripheral nodes and bone marrow involvement isunusual. Systemic symptoms are common. While this disease resemblesnodal large cell lymphomas, it has distinct genetic, immunological, andmorphological characteristics.

The immunophenotype of tumor cells of primary mediastinal large B celllymphoma are often surface immunoglobulin negative but do express such Bcell associated antigens as CD19, CD20, CD22, and CD79a. CD10 and BCL6are also commonly expressed. Expression of plasma cell associatedmarkers CD 15, CD30, epithelial membrane antigen (EMA) is rare. BCL6 andc-myc gene arrangements are also uncommon. The presence of clonalimmunoglobulin rearrangements, immunoglobulin variable region and genehypermutation along with BCL6 hypermutation suggest that this lymphomaderives from a mature germinal center or post-germinal center B cell.The chromosomal translocations that seem to be associated with tumors ofthis disease are similar to those observed in other forms of diffuselarge cell lymphoma. (See, P. Zinzani, et al., Primary Mediastinal LargeB cell Lymphoma, pp. 455-460, In Non-Hodgkin's Lymphomas, P. Mauch, etal., eds., Lippincott Williams & Wilkins, Philadelphia, Pa. (2004)).

The diagnostic evaluation for primary mediastinal large B cell lymphomagenerally includes a complete physical examination, completehematological and biochemical analysis, total-body computerizedtomography and bone marrow biopsy. Gallium-67 scanning is a useful testfor staging, response to treatment and for assessment of relapse. (See,P. Zinzani et al., Primary Mediastinal Large B cell Lymphoma, pp.455-460, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds., LippincottWilliams & Wilkins, Philadelphia, Pa. (2004)).

The immunophenotype of this disease shows expression of the B cellassociated antigens CD19, CD20, CD22, and CD79a and a lack of expressionof CD5, CD10, and CD23. Presence of strong surface immunoglobulin andCD20, the lack of expression of CD5, and CD23 and the presence ofcytoplasmic immunoglobulin are characteristics that aid indistinguishing this disease from chronic lymphocytic leukemia. Alsodiagnostic of this disease is t(9;14)(p13;q32). (See, A. Rohatiner, etal., Lymphoplasmacytic Lymphoma and Waldström's Macroglobulinemia, pp.263-273, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds., LippincottWilliams & Wilkins, Philadelphia, Pa. (2004); K. Maclennan, DiffuseIndolent B cell Neoplasms, pp. 43-47, In Malignant Lymphoma, B. Hancock,et al., eds., Oxford University Press, New York, N.Y. (2000); R.Chaganti, et al., Cytogenetics of Lymphoma, pp. 809-824, InNon-Hodgkin's Lymphomas, P. Mauch, et al., eds., Lippincott Williams &Wilkins, Philadelphia, Pa. (2004)).

Diagnostic tests typically include a complete blood count, renal andliver function tests, CT scans, biopsy and aspiration of the bonemarrow, protein electrophoresis to quantify and characterize theparaprotein and serum viscosity. Measurement of β₂-microglobulin is usedas a prognostic test. (See, A. Rohatiner, et al., LymphoplasmacyticLymphoma and Waldström's Macroglobulinemia, pp. 263-273, InNon-Hodgkin's Lymphomas, P. Mauch, et al., eds., Lippincott Williams &Wilkins, Philadelphia, Pa. (2004)).

5.5.3.14. Lymphoplasmacytic Lymphoma (LPL)/LymphoplasmacyticImmunocytoma/Waldström'S Macroglobulinemia

LPL/Lymphoplasmacytic immunocytoma/Waldström's Macroglobulinemia is anodal lymphoma that is usually indolent, and often involves bone marrow,lymph nodes and spleen. This is generally a disease of older adults withmales slightly predominating. Most patients have monoclonal IgMparaprotein in their serum (>3 g/dL) resulting in hyperviscosity of theserum. Tumor cells have a plasmacytic morphology. A subset of LPL ischaracterized by recurrent translocations between chromosomes 9 and 14,which involves the PAX5 and immunoglobulin heavy-chain loci. LPL ischaracterized by SHM as well as ongoing SHM, and is believed to bederived from post-GC B cells. (See, A. Rohatiner, et al.,Lymphoplasmacytic Lymphoma and Waldström's Macroglobulinemia, pp.263-273, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds., LippincottWilliams & Wilkins, Philadelphia, Pa. (2004); K. Maclennan, DiffuseIndolent B cell Neoplasms, pp. 43-47, In Malignant Lymphoma, B. Hancock,et al., eds., Oxford University Press, New York, N.Y. (2000); A. Lal, etal., Role of Fine Needle Aspiration in Lymphoma, pp. 181-220, In W.Finn, et al., eds., Hematopathology in Oncology, Kluwer AcademicPublishers, Norwell, Mass. (2004)).

5.5.3.15. Null-Acute Lymphoblastic Leukemia

Null-acute lymphoblastic leukemia is a subset of ALL which lacks B- orT-cell characteristics. Phenotypic analysis of leukemic blasts shows atypical null ALL pattern, i.e., CD10 (common ALL antigen)-negative,strongly HLA-DR-positive, and CD19 (B4)-positive (see Katz et al. (1988)Blood 71(5):1438-47)

5.5.3.16. Hodgkin'S Lymphoma

Hodgkin's lymphoma usually arises in the lymph nodes of young adults. Itcan be divided into classical subtype and a less common nodularlymphocytic predominant subtype.

The classical type exhibits SHM, but not ongoing SHM, and does not havea GC B cell gene expression profile. The nodular lymphocyte predominanttype, in contrast, is characterized by SHM and ongoing SHM and a GC Bcell gene expression profile. While the two types differ clinically andbiologically, they do share certain features such as a lack ofneoplastic cells within a background of benign inflammatory cells. B.Schnitzer et al., Hodgkin Lymphoma, pp. 259-290, In W. Finn and L.Peterson, eds., Hematopathology in Oncology, Kluwer Academic Publishers,Norwell, Mass. (2004)).

The most common features at presentation are painless enlargement oflymph nodes, usually in the neck, but occasionally in the inguinalregion. Waxing and waning of nodes is also characteristic of thisdisease. B symptoms are observed in about one-third of patients.Isolated extranodal involvement is rare and in cases where disseminationhas occurred extranodal involvement is observed about 10-20% of thetime. (See, P. Johnson et al., Hodgkin's Disease: Clinical Features, pp.181-204, In Malignant Lymphoma, B. Hancock, et al., eds., OxfordUniversity Press, New York, N.Y. (2000)).

Reed-Sternberg (RS) cells are the malignant cells of Hodgkin's lymphoma.RS cells and their variants express CD15, CD25, CD30 and transferrinreceptor. In addition these cells express polyclonal cytoplasmicimmunoglobulin. In most cases of Hodgkin's lymphoma the RS cells do notexpress CD45, a feature that aids in distinguishing this disease fromnon-Hodgkin's Lymphomas. Epstein Barr virus has been demonstrated to bepresent in Reed-Sternberg cells in about one-half of Hodgkin's lymphomacases but its role is unclear.

Diagnosis is most frequently made by lymph node biopsy. Additionaldiagnostic tests include a full blood count (often hematological testsare normal; white blood cell counts of less than 1.0×10⁹/L are seen inabout 20% of cases), erythrocyte sedimentation rate (often elevated inadvanced stages of the disease), biochemical tests includingelectrolytes, urea, creatinine, urate, calcium (hypercalcemia is rarebut when present is associated with extensive bone involvement), liverblood tests, lactate dehydrogenase (elevated levels often associatedwith advanced disease), albumin and beta₂-microglobulin (β2-M).Lymphanigiograms and chest x-rays and CT scans of the chest, abdomen andpelvis are important in identifying abnormal lymph nodes and the extentof extranodal involvement. Bone marrow biopsies are typically consideredoptional as bone marrow involvement is unusual and the results of suchbiopsies appear not to affect clinical management or prognosis.Splenechtomies are not usually performed today as it rarely influencesmanagement and CT or MRI imaging provides information on splenic status.Significantly elevated levels of p55, TNF and sICAM-1 are correlated tothe stage of the disease, presence of symptoms and complete responserate. (See, P. Johnson, et al., Hodgkin's Disease: Clinical Features,pp. 181-204, In Malignant Lymphoma, B. Hancock, et al., eds., OxfordUniversity Press, New York, N.Y. (2000); Clinical Oncology, A. Neal, etal., Neal, Hoskin and Oxford University Press, co-publ., New York, N.Y.(2003); R. Stein, Hodgkin's Disease, pp. 2538-2571, In Wintrobe'sClinical Hematology, Tenth Edition, G. Lee et al., eds. Williams &Wilkins, Baltimore, Md. (1999)).

5.5.3.17. Multiple Myeloma

Multiple myeloma is a malignancy of plasma cells. Neoplastic cells arelocated in the bone marrow, and osteolytic bone lesions arecharacteristic. Reciprocal chromosomal translocations between one of theimmunoglobulin loci and a variety of other genes, e.g., cyclin D1,cyclin D3, c-MAF, MMSET (multiple myeloma SET-domain protein) orfibroblast growth factor receptor 3 are believed to be the primaryoncogenic events. Multiple myeloma is characterized by SHM, and theputative cell of origin is a post-GC B cell. Multiple myeloma istypically first identified by symptoms such as recurrent infection,fatigue, pain, and kidney problems and is confirmed with clinicaltesting (see, for example, Cancer: Principles and Practice of Oncology.6th edition. DeVita, V. T., Hellman, S, and Rosenberg, S. A. editors.2001 Lippincott Williams and Wilkins Philadelphia, Pa. 19106 pp.2465-2499).

In certain embodiments, patients who are candidates for treatment by thecompositions and methods of the invention can undergo further diagnostictests on blood and/or urine to confirm the diagnosis or suspicion ofmultiple myeloma including, but not limited to, complete blood count(CBC) tests to determine if the types of cells reported in a CBC arewithin their normal ranges which are well known in the art, bloodchemistry profile to determine whether levels of various bloodcomponents, such as albumin, blood urea nitrogen (BUN), calcium,creatinine, and lactate dehydrogenase (LDH), deviate from standardvalues. Serum levels of beta₂-microglobulin (β₂-M) can also be examinedand surrogate markers for IL-6, a growth factor for myeloma cells.Urinalysis can be used to measure the levels of protein in the urine.Electrophoresis can be used to measure the levels of various proteins,including M protein in the blood (called serum protein electrophoresis,or SPEP) or urine (called urine electrophoresis, or UEP). An additionaltest, called immunofixation electrophoresis (IFE) orimmunoelectrophoresis, may also be performed to provide more specificinformation about the type of abnormal antibody proteins present.Assessing changes and proportions of various proteins, particularly Mprotein, can be used to track the progression of myeloma disease andresponse to treatment regimens. Multiple myeloma is characterized by alarge increase in M protein which is secreted by the myeloma tumorcells.

Diagnostic tests on bone can also be conducted to confirm the diagnosisor suspicion of multiple myeloma including, but not limited to, X-raysand other imaging tests—including a bone (skeletal) survey, magneticresonance imaging (MRI), and computerized axial tomography (CAT), alsoknown as computed tomography (CT)—can assess changes in the bonestructure and determine the number and size of tumors in the bone. Bonemarrow aspiration or bone marrow biopsy can be used to detect anincrease in the number of plasma cells in the bone marrow. Aspirationrequires a sample of liquid bone marrow, and biopsy requires a sample ofsolid bone tissue. In both tests, samples are preferably taken from thepelvis (hip bone). The sturnum (breast bone) can also be used foraspiration of bone marrow.

Patients with multiple myeloma are typically categorized into thefollowing three groups that help define effective treatment regimens.Monoclonal gammopathy of undetermined significance (MGUS) is typicallycharacterized by a serum M protein level of less than 3 g/dL, bonemarrow clonal plasma cells of less than 10%, no evidence of other B celldisorders, and no related organ or tissue impairment, such ashypercalcemia (increased serum calcium levels), impaired kidney functionnoted by increased serum creatinine, anemia, or bone lesions.Asymptomatic myelomas are typically stage I and includes smolderingmultiple myeloma (SMM) and indolent multiple myeloma (IMM). SMM ischaracterized by serum M protein greater than or equal to 3 g/dL and IMMis characterized by bone marrow clonal plasma cells greater than orequal to 10% of the bone marrow cells. Symptomatic myeloma ischaracterized by M protein in serum and/or urine and includes Stage IImultiple myeloma characterized by the presence of bone marrow clonalplasma cells or plasmacytoma and Stage III multiple myelomacharacterized by related organ or tissue impairment.

Osteosclerotic myeloma is a component of the rare POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy andskin lesions). Peak incidence is at 40 to 50 years of age. Systemicfeatures include skeletal lesions, marrow-plasma cells <5%, a normalCBC, increased platelets, and organomegaly. The CSF has a high proteinwith no cells present. The M-protein levels are low (<3 g/dl, median=1.1g/dl); heavy chain class—usually α or γ; light chain class—usually λ;rare urine monoclonal and occasional cryoglobulinemia. Neuropathy occursin 50% of the patients with weakness both proximal and distal, sensoryloss is greater in larger than small fibers; and demyelination and longdistal latency.

Smoldering multiple myeloma patients generally present with stabledisease for months/years; no anemia, bone lesions, renal insufficiencyor hypercalcemia; have >10% plasma cells in bone marrow and monoclonalserum protein. The criteria for smoldering multiple myeloma iscompatible with the diagnosis of multiple myeloma; however, there is noevidence of progressive course. These are cases with a slow progression,the tumor cell mass is low at diagnosis and the percentage of bonemarrow plasma cells in S phase is low (<0.5%). Characteristic clinicalfeatures include: serum M protein levels >3 g/dL and/or bone marrowplasma cells ≧10%; absence of anemia, renal failure, hypercalcemia,lytic bone lesions.

Indolent (or asymptomatic) multiple myeloma is a multiple myelomadiagnosed by chance in the absence of symptoms, usually after screeninglaboratory studies. Indolent multiple myeloma is similar to smolderingmyeloma but with few bone lesions and mild anemia. Most cases ofindolent multiple myeloma develop overt multiple myeloma within 3 years.Diagnostic criteria are the same as for multiple myeloma except: no bonelesions or one asymptomatic lytic lesion (X-ray survey); M componentlevel <3 g/dL for IgG, 2 g/dL for IgA urine light chain <4 g/24 h;hemoglobin >10 g/dl, serum calcium normal, serum creatinine <2 mg/dL,and no infections.

5.5.3.18. Solitary Plasmacytoma

Solitary plasmacytoma is one of a spectrum of plasma cell neoplasmswhich range from benign monoclonal gammopathy to solitary plasmacytomato multiple myeloma. Approximately seventy percent of all solitaryplasmacytoma cases eventually result in multiple myeloma. These diseasesare characterized by a proliferation of B cells which produce thecharacteristic paraprotein. Solitary plasmacytoma results in aproliferation of clonal plasma cells in a solitary site, usually asingle bone or extramedullary tissue site. Diagnostic criteria ofsolitary plasmacytoma include a histologically confirmed single lesion,normal bone biopsy, negative skeletal survey, no anemia, normal calciumand renal function. Most cases exhibit minimally elevated serumM-protein (paraprotein). The median age at diagnosis is 50-55, about5-10 years younger than the median age for multiple myeloma. (See, C.Wilson, The Plasma Cell Dycrasias, pp. 113-144, In W. Finn and L.Peterson, eds., Hematopathology in Oncology, Kluwer Academic Publishers,Norwell, Mass. (2004), S. Chaganti, et al., Cytogenetics of Lymphoma,pp. 809-824, In Non-Hodgkin's Lymphomas, P. Mauch, et al., eds.,Lippincott Williams & Wilkins, Philadelphia, Pa., (2004)).

The immunophenotypic and genetic features of plasmacytoma appear to besimilar to multiple myeloma.

5.5.3.19. Light Chain Disease/Light Chain Deposition Disease (LCDD)

LCDD is a plasma cell dycrasias disorder caused by the over-synthesis ofimmunoglobulin light chains (usually kappa light chains) that aredeposited in tissues. Patients commonly present with organ dysfunction,weakness, fatigue and weight loss. In approximately 80% of cases of LCDDa monoclonal immunoglobulin is detected. Detection of monoclonal kappalight chains using immunofluorescent techniques is limited by thetendency of light chains to give excess background staining, therefore,ultrastructural immunogold labeling may be necessary. (See, C. Wilson,The Plasma Cell Dycrasias, pp. 113-144, In W. Finn and L. Peterson,eds., Hematopathology in Oncology, Kluwer Academic Publishers, Norwell,Mass. (2004)).

5.5.3.20. Plasma Cell Leukemia (PCL),

PCL, a plasma cell dycrasias, is a rare aggressive variant of multiplemyeloma. The criteria for plasma cell leukemia is a peripheral bloodabsolute plasma cell count of greater than 2×10⁹/L or plasma cellsgreater than 20% of white blood cells. Determination of the presence ofa CD138⁺ population with cytoplasmic light chain restriction by flowcytometry will distinguish PCL from lymphoid neoplasm with plasmacyticfeatures. PCL cells are also characterized by the lack of surface lightchain and CD19 expression, and either no or weak expression of CD45.About 50% of cases of PCL express CD20 and about 50% lack expression ofCD56. The genetic abnormalities observed in PCL patients are the same asthose observed for multiple myeloma patients but they are found athigher frequency in PCL. (See, C. Wilson, The Plasma Cell Dycrasias, pp.113-144, In W. Finn and L. Peterson, eds., Hematopathology in Oncology,Kluwer Academic Publishers, Norwell, Mass., (2004)).

Plasma cell leukemia has two forms: if initial diagnosis is based onleukemic phase of myeloma then the primary form is present, otherwise itis secondary. Primary plasma cell leukemia is associated with a youngerage, hepatosplenomegaly, lymphadenopathy, and fewer lytic bone lesionsbut poorer prognosis than the secondary form. The peripheral blood ofplasma cell leukemic patients has greater than 20% plasma cells withabsolute count of 2000/ml or more.

5.5.3.21. Monoclonal Gammopathy of Unknown Significance (MGUS)

MGUS is a relatively common condition characterized by the presence ofelectrophoretically homogeneous immunoglobulins or benign M-components.The occurrence of this condition appears to increase with age. Mostindividuals carrying the M-components never develop malignant plasmacell dycrasias, such as multiple myeloma. However, some individuals withthis condition have associated malignant conditions. When symptomatic,patients can have enlarged liver or spleen and pleuroneuropathy. (See,J. Foerster, Plasma Cell Dycrasias: General Considerations, pp.2612-2630, In Wintrobe's Clinical Hematology, Tenth Edition, G. Lee etal., eds. Williams & Wilkins, Baltimore, Md. (1999)).

MGUS can be differentiated from multiple myeloma by the presence ofincreased number of monoclonal plasma cells circulating in theperipheral blood. The serological characteristics of M-components areidentical to other plasma cell dycrasias conditions, however, the totalconcentration of M-component is usually less than 30 g/L. Theparaprotein is usually IgG; however multiple paraproteins may be presentincluding IgG, IgA, IgM. The relative amount of each of the individualimmunoglobulin classes is typically proportional to that found in normalserum. Proteinemia or proteinuria is rare. Serial measurements ofM-protein levels in the blood and urine, and continued monitoring of theclinical and laboratory features (including protein electrophoresis) isthe most reliable method of differentiating MGUS from early stage plasmacell dycrasias. In Wintrobe's Clinical Hematology, Tenth Edition, G. Leeet al., eds. Williams & Wilkins, Baltimore, Md. (1999)).

5.5.3.22. Mature B Cell Malignancies

The inventors have shown that the inventive anti-CD19 compositions candeplete mature B cells. Thus, as another aspect, the invention can bepracticed to treat mature B cell malignancies including but not limitedto follicular lymphoma, mantle-cell lymphoma, Burkitt's lymphoma,multiple myeloma, diffuse large B-cell lymphoma (DLBCL) includinggerminal center B cell-like (GCB) DLBCL, activated B cell-like (ABC)DLBCL, and type 3 DLBCL, Hodgkin's lymphoma including classical andnodular lymphocyte pre-dominant type, lymphoplasmacytic lymphoma (LPL),marginal-zone lymphoma including gastric mucosal-associated lymphoidtissue (MALT) lymphoma, and chronic lymphocytic leukemia (CLL) includingimmunoglobulin-mutated CLL and immunoglobulin-unmutated CLL.

5.5.3.23. Pre-B Cell Malignancies:

Further, CD19 is expressed earlier in B cell development than, forexample, CD20, and is therefore particularly suited for treating pre-Bcell and immature B cell malignancies, e.g., in the bone marrow.Representative pre-B cell and immature B cell malignancies include butare not limited to mantle cell lymphoma, pre-B cell acute lymphoblasticleukemia, precursor B cell lymphoblastic lymphoma, and othermalignancies characterized by CD19 expression.

5.5.4. Diagnosis and Clinical Criteria for Autoimmune Diseases orDisorders

Diagnostic criteria for different autoimmune diseases or disorders arealso known in the art. Historically, diagnosis is typically based on acombination of physical symptoms. More recently, molecular techniquessuch as gene-expression profiling have been applied to develop moleculardefinitions of autoimmune diseases or disorders. Exemplary methods forclinical diagnosis of particular autoimmune diseases or disorders areprovided below. Other suitable methods will be apparent to those skilledin the art. In certain embodiments of the invention, patients with lowlevels of autoimmune disease activity or patients with an early stage ofan autoimmune disease (for diseases where stages are recognized) can beidentified for treatment using the anti-CD19 antibody compositions andmethods of the invention. The early diagnosis of autoimmune disease isdifficult due to the general symptoms and overlap of symptoms amongdiseases. In such embodiments, a patient treated at an early stage orwith low levels of an autoimmune disease activity has symptomscomprising at least one symptom of an autoimmune disease or disorder. Inrelated embodiments, a patient treated at an early stage or with lowlevels of an autoimmune disease has symptoms comprising at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 symptoms of an autoimmunedisease or disorder. The symptoms may be of any autoimmune diseases anddisorders or a combination thereof. Examples of autoimmune disease anddisorder symptoms are described below.

5.5.4.1. Rheumatoid Arthritis

Rheumatoid arthritis is a chronic disease, mainly characterized byinflammation of the lining, or synovium, of the joints. It can lead tolong-term joint damage, resulting in chronic pain, loss of function anddisability. Identifying patients or patient populations in need oftreatment for rheumatoid arthritis is a process. There is no definitivetest that provides a positive or negative diagnosis of rheumatoidarthritis. Clinicians rely on a number of tools including, medicalhistories, physical exams, lab tests, and X-rays.

Physical symptoms vary widely among patients and commonly include, butare not limited to, joint swelling, joint tenderness, loss of motion injoints, joint malalignment, bone remodeling, fatigue, stiffness(particularly in the morning and when sitting for long periods of time),weakness, flu-like symptoms (including a low-grade fever), painassociated with prolonged sitting, the occurrence of flares of diseaseactivity followed by remission or disease inactivity, rheumatoid nodulesor lumps of tissue under the skin (typically found on the elbows, theycan indicate more severe disease activity), muscle pain, loss ofappetite, depression, weight loss, anemia, cold and/or sweaty hands andfeet, and involvement of the glands around the eyes and mouth, causingdecreased production of tears and saliva (Sjögren's syndrome). ForSjogren's specifically, the following references may be used, Fox etal., Arthritis Rheum., (1986) 29:577-586, and Vitali et al., Ann. Rheum.Dis., (2002). 61:554-558.

Apart form physical symptoms, clinicians commonly use tests, such as,but not limited to, complete blood count, erythrocyte sedimentation rate(ESR or sed rate), C-reactive protein, rheumatoid factor, anti-DNAantibodies, antinuclear antibodies (ANA), anti-cardiolipin antibodies,imaging studies, radiographs (X-rays), magnetic resonance imaging (MRI)of joints or organs, joint ultrasound, bone scans, and bone densitometry(DEXA). These tests are examples of tests that can be used inconjunction with the compositions and methods of the invention to checkfor abnormalities that might exist (i.e., identify patients or patientpopulations in need of treatment) or to monitor side effects of drugsand check progress.

Early symptoms of rheumatoid arthritis commonly are found in the smallerjoints of the fingers, hands and wrists. Joint involvement is usuallysymmetrical, meaning that if a joint hurts on the left hand, the samejoint will hurt on the right hand. In general, more joint erosionindicates more severe disease activity.

Symptoms of more advanced disease activity include damage to cartilage,tendons, ligaments and bone, which causes deformity and instability inthe joints. The damage can lead to limited range of motion, resulting indaily tasks (grasping a fork, combing hair, buttoning a shirt) becomingmore difficult. Skin ulcers, greater susceptibility to infection, and ageneral decline in health are also indicators of more advanced diseaseactivity.

Progression of rheumatoid arthritis is commonly divided into threestages. The first stage is the swelling of the synovial lining, causingpain, warmth, stiffness, redness and swelling around the joint. Secondis the rapid division and growth of cells, or pannus, which causes thesynovium to thicken. In the third stage, the inflamed cells releaseenzymes that may digest bone and cartilage, often causing the involvedjoint to lose its shape and alignment, more pain, and loss of movement.

Molecular techniques can also be used to identify patients or patientpopulations in need of treatment. For example, rheumatoid arthritis hasbeen shown to be associated with allelic polymorphisms of the humanleukocyte antigen (HLA)-DR4 and HLA-DRB1 genes (Ollier and Winchester,1999, Genes and Genetics of Autoimmunity. Basel, Switzerland; Stastny,1978, N. Engl J Med 298:869-871; and Gregersen et al., 1987, ArthritisRheum 30:1205-1213). Rheumatoid arthritis patients frequently expresstwo disease-associated HLA-DRB1*04 alleles (Weyand et al., 1992 AnnIntern Med 117:801-806). Patients can be tested for allelicpolymorphisms using methods standard in the art. MHC genes are not theonly germline-encoded genes influencing susceptibility to RA that can beused to diagnose or identify patients or patient populations in need oftreatment. Female sex clearly increases the risk, and female patientsdevelop a different phenotype of the disease than do male patients. Anymolecular indicators of rheumatoid arthritis can be used to identifypatients or patient populations in need of treatment with the anti-CD19antibody compositions and methods of the invention.

Methods for determining activity of rheumatoid arthritis in a patient inrelation to a scale of activity are well known in the art and can beused in connection with the pharmaceutical compositions and methods ofthe invention. For example, the American College of RheumatologistsScore (ACR score) can be used to determine the activity of rheumatoidarthritis of a patient or a patient population. According to thismethod, patients are given a score that correlates to improvement. Forexample, patients with a 20% improvement in factors defined by the ACRwould be given an ACR20 score.

Initially, a patient exhibiting the symptoms of rheumatoid arthritis maybe treated with an analgesic. In other embodiments, a patient diagnosedwith or exhibiting the symptoms of rheumatoid arthritis is initiallytreated with nonsteroidal anti-inflammatory (NSAID) compounds. As thedisease progresses and/or the symptoms increase in severity, rheumatoidarthritis may be treated by the administration of steroids such as butnot limited to dexamethasone and prednisone. In more severe cases, achemotherapeutic agent, such as but not limited to methotrexate orcytoxin may be administered to relieve the symptoms of rheumatoidarthritis.

In certain instances, rheumatoid arthritis may be treated byadministration of gold, while in other instances a biologic, such as anantibody or a receptor (or receptor analog) may be administered.Examples of such therapeutic antibodies are Rituxin and Remicade. Anillustrative example of a soluble receptor that can be administered totreat rheumatoid arthritis is Enbrel.

In extremely severe cases of rheumatoid arthritis, surgery may beindicated. Surgical approaches may include, but not be limited to:synovectomy to reduce the amount of inflammatory tissue by removing thediseased synovium or lining of the joint; arthroscopic surgery to taketissue samples, remove loose cartilage, repair tears, smooth a roughsurface or remove diseased synovial tissue; osteotomy, meaning “to cutbone,” this procedure is used to increase stability by redistributingthe weight on the joint; joint replacement surgery or arthroplasty forthe surgical reconstruction or replacement of a joint; or arthrodesis orfusion to fuse two bones together.

In certain embodiments of the methods of invention, a patient can betreated with an anti-CD19 antibody prior, concurrent, or subsequent toany of the therapies disclosed above. Moreover, the anti-CD19 antibodiesof the present invention may be administered in combination with any ofthe analgesic, NSAID, steroid, or chemotherapeutic agents noted above,as well as in combination with a biologic administered for the treatmentof rheumatoid arthritis.

5.5.4.2. Systemic Lupus Erythematosis (SLE)

Systemic lupus erythematosis (SLE) is a chronic (long-lasting) rheumaticdisease which affects joints, muscles and other parts of the body.Patients or patient populations in need of treatment for SLE can beidentified by examining physical symptoms and/or laboratory testresults. Physical symptoms vary widely among patients. For example, inSLE, typically 4 of the following 11 symptoms exist before a patient isdiagnosed with SLE: 1) malar rash: rash over the cheeks; 2) discoidrash: red raised patches; 3) photosensitivity: reaction to sunlight,resulting in the development of or increase in skin rash; 4) oralulcers: ulcers in the nose or mouth, usually painless; 5) arthritis:nonerosive arthritis involving two or more peripheral joints (arthritisin which the bones around the joints do not become destroyed); 6)serositis pleuritis or pericarditis: (inflammation of the lining of thelung or heart); 7) renal disorder: excessive protein in the urine(greater than 0.5 gm/day or 3+ on test sticks) and/or cellular casts(abnormal elements the urine, derived from red and/or white cells and/orkidney tubule cells); 8) neurologic disorder: seizures (convulsions)and/or psychosis in the absence of drugs or metabolic disturbances whichare known to cause such effects; 9) hematologic disorder: hemolyticanemia or leukopenia (white blood count below 4,000 cells per cubicmillimeter) or lymphopenia (less than 1,500 lymphocytes per cubicmillimeter) or thrombocytopenia (less than 100,000 platelets per cubicmillimeter) (The leukopenia and lymphopenia must be detected on two ormore occasions. The thrombocytopenia must be detected in the absence ofdrugs known to induce it); 10) antinuclear antibody: positive test forantinuclear antibodies (ana) in the absence of drugs known to induce it;and/or 11) immunologic disorder: positive anti-double stranded anti-DNAtest, positive anti-sm test, positive antiphospholipid antibody such asanticardiolipin, or false positive syphilis test (vdrl).

Other physical symptoms that may be indicative of SLE include, but arenot limited to, anemia, fatigue, fever, skin rash, muscle aches, nausea,vomiting and diarrhea, swollen glands, lack of appetite, sensitivity tocold (Raynaud's phenomenon), and weight loss.

Laboratory tests can also be used to identify patients or patientpopulations in need of treatment. For example, a blood test can be usedto detect a autoantibodies found in the blood of almost all people withSLE. Such tests may include but are not limited to tests for antinuclearantibodies (ANA) in the absence of drugs known to induce it (Rahman, A.and Hiepe, F., Lupus. (2002), 11(12):770-773), anti-double strandedanti-DNA (Keren, D. F., Clin. Lab. Med., (2002), 22(2):447-474.),anti-Sm, antiphospholipid antibody such as anticardiolipin (Gezer, S.Dis. Mon., 2003, 49(12):696-741), or false positive syphilis tests(VDRL).

Other tests may include a complement test (C3, C4, CH50, CH100) can beused to measure the amount of complement proteins circulating in theblood (Manzi et al., Lupus, 2004, 13(5):298-303), a sedimentation rate(ESR) or C-reactive protein (CRP) may be used to measure inflammationlevels, a urine analysis can be used to detect kidney problems, chestX-rays may be taken to detect lung damage, and an EKG can be used todetect heart problems.

Chronic SLE is associated with accumulating collateral damage toinvolved organ, particularly the kidney. Accordingly, early therapeuticintervention is desirable, i.e. prior to, for example, kidney failure.Available treatments for SLE are similar to those available forrheumatoid arthritis. These include initial treatments, either with ananalgesic or a nonsteroidal anti-inflammatory (NSAID) compound. As thedisease progresses and/or the symptoms increase in severity, SLE may betreated by the administration of steroids such as but not limited todexamethasone and prednisone.

In more severe cases, a chemotherapeutic agent, such as but not limitedto methotrexate or cytoxin may be administered to relieve the symptomsof SLE. However, this approach is not preferred where the patient is afemale of child-bearing age. In such instances, those therapeuticapproaches that do not interfere with the reproductive capacity of thepatient are strongly preferred.

In certain instances, SLE may be treated by administration of abiologic, such as an antibody or a receptor (or receptor analog).Examples of such therapeutic antibodies are Rituxin and Remicade. Anillustrative example of a soluble receptor for an inflammatory cytokinethat can be administered to treat SLE is Enbrel.

In certain embodiments of the methods of invention, a patient can betreated with an anti-CD19 antibody prior, concurrent, or subsequent toany of the therapies disclosed above that are used for the treatment ofSLE. Moreover, the anti-CD19 antibodies of the present invention may beadministered in combination with any of the analgesic, NSAID, steroid,or chemotherapeutic agents noted above, as well as in combination with abiologic administered for the treatment of SLE.

5.5.4.3. Idiopathic/Autoimmune Thrombocytopenia Purpura (ITP)

Idiopathic/autoimmune thrombocytopenia purpura (ITP) is a disorder ofthe blood characterized by immunoglobulin G (IgG) autoantibodies thatinteract with platelet cells and result in the destruction of thoseplatelet cells. Typically, the antibodies are specific to plateletmembrane glycoproteins. The disorder may be acute (temporary, lastingless than 2 months) or chronic (persisting for longer than 6 months).Patients or patient populations in need of treatment for ITP can beidentified by examining a patient's medical history, physical symptoms,and/or laboratory test results. (Provan, D., and Newland, A., Br. J.Haematol. (2002), 118(4):933-944; George, J. N., Curr. Hematol. (2003),2(5):381-387; Karptkin, S., Autoimmunity. (2004), 37(4):363-368; Cines,D. B., and Blanchette, V. S., N. Engl. J. Med. (2002), 346(13)995-1008).

Physical symptoms include purplish-looking areas of the skin and mucousmembranes (such as the lining of the mouth) where bleeding has occurredas a result of a decrease in the number of platelet cells. The mainsymptom is bleeding, which can include bruising (“ecchymosis”) and tinyred dots on the skin or mucous membranes (“petechiae”). In someinstances bleeding from the nose, gums, digestive or urinary tracts mayalso occur. Rarely, bleeding within the brain occurs. Common signs,symptoms, and precipitating factors also include, but are not limitedto, abrupt onset (childhood ITP), gradual onset (adult ITP), nonpalpablepetechiae, purpura, menorrhagia, epistaxis, gingival bleeding,hemorrhagic bullae on mucous membranes, signs of GI bleeding,menometrorrhagia, evidence of intracranial hemorrhage, nonpalpablespleen, retinal hemorrhages, recent live virus immunization (childhoodITP), recent viral illness (childhood ITP), spontaneous bleeding whenplatelet count is less than 20,000/mm³, and bruising tendency.

Laboratory test that can be used to diagnose ITP include, but are notlimited to, a complete blood count test, or a bone marrow examination toverify that there are adequate platelet-forming cells (megakaryocyte) inthe marrow and to rule out other diseases such as metastatic cancer andleukemia. Isolated thrombocytopenia is the key finding regardinglaboratory evaluation. Giant platelets on peripheral smear areindicative of congenital thrombocytopenia. A CT scan of the head may bewarranted if concern exists regarding intracranial hemorrhage.

The current treatments for ITP include, platelet transfusions andsplenectomy. Other treatments include, the administration ofglucocorticoids, administration of immunosuppressive agents,administration of agents that enhance platelet production, such asIL-11, and agents that activate megakaryocytes to produce platelets,such as thrombopoietin (TPO).

In more severe cases, a chemotherapeutic agent, such as but not limitedto vincristine and vinblastine may be administered to relieve thesymptoms of ITP. However, this approach is not preferred where thepatient is a female of child-bearing age. In such instances, thosetherapeutic approaches that do not interfere with the reproductivecapacity of the patient are strongly preferred.

In certain instances, ITP may be treated by administration of abiologic, such as an antibody or a receptor (or receptor analog).Examples of such therapeutic antibodies are anti-CD20 antibodies, suchas, Rituximab.

In certain embodiments of the methods of invention, a patient can betreated with an anti-CD19 antibody prior, concurrent, or subsequent toany of the therapies disclosed above that are used for the treatment ofITP. Moreover, the anti-CD19 antibodies of the present invention may beadministered in combination with any of the agents noted above, as wellas in combination with a biologic administered for the treatment of ITP.

5.5.4.4. Pemphigus and Pemphigoid-Related Disorders

Both pemphigus- and pemphigoid-related disorders are a heterogenousgroup of autoimmune diseases characterized by a blistering condition ofthe skin and/or mucosal surfaces. In both diseases, the blistering iscaused by autoimmune antibodies that recognize various proteinsexpressed on the surface of epithelial cells in the dermis and/orepidermis.

In patients with pemphigus-related disease, the blistering occurs withinthe epidermis and is due to the binding of autoantibodies specific fordesmoglein 1 (Dsg1) and/or desmoglein 3 (Dsg3). The classic subtypes ofpemphigus can be distinguished according to anti-desmoglein antibodyspecificities. Patients with pemphigus foliaceus (PF) produce anti-Dsg1antibodies only. Patients with pemphigus vulgaris (PV) andparaneoplastic pemphigus (PNP) produce anti-Dsg3 antibodies if theirlesions are restricted to mucosal tissues. In contrast, PV and PNPpatients with lesions of the skin and mucosa produce both anti-Dsg1 and-Dsg3 autoantibodies. (Nagasaka, T. et al., J. Clin. Invest. 2004,114:1484-1492; Seishema, M. et al., Arch Dermatol., 2004.140(12):1500-1503; Amagai, M., j. Dermatol. Sci., 1999. 20(2):92-102)

In patients with pemphigoid-related disease including but not limitedto, bulous phemphigoid, urticarial bulous pemphigoid, cicatricialpemphigoid, epidermolysis bullosa acquisita, and Linear IgA bullousdermatosis, the blistering occurs at the interface of the dermis withthe epidermis. The most common form of pemphigoid disease is bulouspemphigoid (BP) which is characterized by the presence of autoantibodiesthat bind the bullous pemphigoid antigen 180 (BP180), bullous pemphigoidantigen 230 (BP230), laminin 5, and/or beta 4 integrin. (Fontao, L. etal., Mol. Biol. Cell. 2003), 14(5):1978-1992; Challacombe, S. J. et al,Acta Odontol. Scand. (2001), 59(4):226-234.)

Patients or patient populations in need of treatment for pemphigus- orpemphigoid-related disorders can be identified by examining a patient'smedical history, physical symptoms, and/or laboratory test results(reviewed in: Mutasim, D. F., Drugs Aging. (2003), 20(9):663-681; Yeh,S. W. et al., Dermatol. Ther. (2003), 16(3):214-223; Rosenkrantz, W. S.,Vet. Dermatol., 15(2):90-98.).

Typically, diagnosis of these pemphigus- or pemphigoid-related disordersis made by skin biopsy. The biopsy skin sample is examinedmicroscopically to determine the anatomical site of the blister (e.g.epidermis or between dermis and epidermis). These findings arecorrelated with direct or indirect immunohistochemical analyses todetect the presence of autoantibodies at the site of the lesion. Serumsamples from patients may also be examined for the presence ofcirculating autoantibodies using an ELISA-based test for specificproteins. Several ELISA-based assays have been described for detectionof desmoglein antibodies in human samples (Hashimoto, T., Arch.Dermatol. Res. (2003), 295 Suppl. 1:S2-11). The presence of thesedesmoglein autoantibodies in biopsy samples is diagnistic of pemphigus.

Clinically, pemphigus vulgaris can be diagnosed by the presence ofblisters in the mouth. Inflammation or erosions may also be present inthe lining of the eye and eyelids, and the membranes of the nose orgenital tract. Half of the patients also develop blisters or erosions ofthe skin, often in the groin, underarm, face, scalp and chest areas.Pemphigus foliaceus is a superficial, relatively mild form of pemphigus.It usually manifests on the face and scalp, but also involves the backand chest. Lesions do not occur in the mouth. The blisters are moreconfined to the outermost surface and often itch. Paraneoplasticpemphigus is very rare and generally occurs in people who have cancer.The lesions are painful and affect the mouth, lips and esophagus(swallowing tube) as well as the skin. Due to involvement of theairways, signs of respiratory disease may occur and can belife-threatening.

The current treatments for pemphigus or pemphigoid-related diseaseincludes the topical administration of creams and ointments to alleviatethe discomfort associated with the skin condition, the administration ofanti-inflammatory agents or the administration of immunosuppressiveagents.

In certain embodiments of the methods of invention, a patient can betreated with an anti-CD19 antibody prior, concurrent, or subsequent toany of the therapies disclosed above that are used for the treatment ofpemphigoid or pemphigoid related disease. Moreover, the anti-CD19antibodies of the present invention may be administered in combinationwith any of the agents noted above.

5.5.4.5. Autoimmune Diabetes

According to certain aspects of the invention, a patient in need oftreatment for autoimmune diabetes, also known as type 1A diabetes, canbe treated with the anti-CD19 antibody compositions and methods of theinvention. Type 1A diabetes is an autoimmune disease caused by thesynergistic effects of genetic, environmental, and immunologic factorsthat ultimately destroy the pancreatic beta cells. The consequences ofpancreatic beta cell destruction is a decrease in beta cell mass,insulin production/secretion declines and blood glucose levels graduallyrise.

Patients or patient populations in need of treatment for type 1Adiabetes can be identified by examining a patient's medical history,physical symptoms, and/or laboratory test results. Symptoms often comeon suddenly and include, but are not limited to, low or non-existentblood insulin levels, increased thirst, increased urination, constanthunger, weight loss, blurred vision, and/or fatigue. Overt diabetes doesnot usually become evident until a majority of beta cells are destroyed(>80%). Typically, diabetes is clinically diagnosed if a patient has arandom (without regard to time since last meal) blood glucoseconcentration ≧11.1 mmol/L (200 mg/dL) and/or a fasting (no caloricintake for at least 8 hours) plasma glucose ≧7.0 mmol/L (126 mg/dI)and/or a two-hour plasma glucose ≧11.1 mmol/L (200 mg/dL). Ideally,these tests should be repeated on different days with comparable resultsbefore diagnosis is confirmed. (Harrison's Principles of InternalMedicine, 16^(th) ed./editors, Dennis L. Kasper, et al. The McGraw-HillCompanies, Inc. 2005 New York, N.Y.).

Although the precise etiology of type 1A diabetes is unknown, thereexists clear genetic linkage to specific HLA serotypes. In particular,autoimmune diabetes is associated with HLA DR3 and DR4 serotypes. Thepresence of both DR3 and DR4 confers the highest known genetic risk.Susceptibility to autoimmune diabetes is also linked to HLA class II(HLA-DQB1 *0302. In contrast, HLA haplotypes with DRB1-1501 andDQA1-0102-DQB1-0602 are associated with protection from type 1A diabetes(Redondo, M. J. et al., J. Clin. Endocrinol. Metabolism (2000),10:3793-3797.)

The destruction of the insulin producing beta islet cells can beaccompanied by islet cell autoantibodies, activated lymphocyticinfiltrates in the pancreas and draining lymph nodes, T lymphocytesresponsive to islet cell proteins, and release of inflammatory cytokineswithin the islets (Harrison's Principles of Internal Medicine, 16^(th)ed./editors, Dennis L. Kasper et al., The McGraw-Hill Companies, Inc.2005, New York, N.Y.).

Autoantibodies associated with type 1A diabetes include but are notlimited to antibodies that bind insulin, glutamic acid decarboxylase(GAD), ICA-512/IA-2, phogrin, islet ganglioside and carboxypeptidase H(Gianani, R. and Eisenbarth, G. S. Immunol. Rev. (2005), 204:232-249;Kelemen, K. et al, J. Immunol. (2004), 172(6):3955-3962); Falorni, A.and Borozzetti, A., Best Pract. Res. Clin. Endocrinol. Metab. 2005,19(1):119-133.)

The current treatments for autoimmune diabetes include theadministration of vitamin D, corticosteroids, agents which control bloodpressure and agents that control glycemia (blood sugar levels).

In certain embodiments of the methods of invention, a patient can betreated with an anti-CD19 antibody prior, concurrent, or subsequent toany of the therapies disclosed above that are used for the treatment ofautoimmune diabetes. Moreover, the anti-CD19 antibodies of the presentinvention may be administered in combination with any of the agentsnoted above.

5.5.4.6. Systemic Sclerosis (Scleroderma) and Related Disorders

Systemic sclerosis also known as Scleroderma encompasses a heterogeneousgroup of diseases including but not limited to, Limited cutaneousdisease, Diffuse cutaneous disease, Sine scleroderma, Undifferentiatedconnective tissue disease, Overlap syndromes, Localized scleroderma,Morphea, Linear scleroderma, En coup de saber, Scleredema adultorum ofBuschke, Scleromyxedema, Chronic graft-vs.-host disease, Eosinophilicfasciitis, Digital sclerosis in diabetes, and Primary anylooidosis andanyloidosis associated with multiple myeloma. (Reviewed in: Harrison'sPrinciples of Internal Medicine, 16^(th) ed./editors, Dennis L. Kasper,et al. The McGraw-Hill Companies, Inc. 2005 New York, N.Y.).

Clinical features associated with scleroderma can include Raynaud'sphenomenon, skin thickening, subcutaneious calcinosis, telangiectasia,arthralgias/arthritis, myopathy, esophageal dysmotility. pulmonaryfibrosis, isolated pulmonary arterial hypertension, congestive heartfailure and renal crisis. The extent to which an patient displays one ormore of these disease manifestations can influence the diagnosis andpotential treatment plan.

Autoantibodies include: Anti-topioisomerase 1, anticentromere, anti-RNApolymerase I, II, and/or III, anti-Th RNP, anti-U, RNP(anti-fibrillarin), anti-PM/Sci, anti-nuclear antibodies (ANA).

Identification of patients and patient populations in need of treatmentof scleroderma can be based on clinical history and physical findings.Patients or patient populations in need of treatment for scleroderma canbe identified by examining a patient's medical history, physicalsymptoms, and/or laboratory test results. Diagnosis may be delayed inpatients without significant skin thickening. Laboratory, X-ray,pulmonary function tests, and skin or renal (kidney) biopsies can beused to determine the extent and severity of internal organ involvement.

In the early months or years of disease onset, scleroderma may resemblemany other connective tissue diseases, such as, but not limited to,Systemic Lupus Erythematosus, Polymyositis, and Rheumatoid Arthritis.

The most classic symptom of systemic sclerosis (scleroderma) issclerodactyl). Initial symptoms include swollen hands, which sometimesprogress to this tapering and claw-like deformity. Not everyone withscleroderma develops this degree of skin hardening. Other symptoms caninclude morphea, linear sclerodactyl) (hardened fingers), Raynaud'ssyndrome, calcinosis, and telangiectasia.

Blood tests such as antinuclear antibody (ANA) tests can be used in thediagnosis of both localized and systemic scleroderma. For example,anti-centromere antibodies (ACA) and anti-Scl-70 antibodies areindicative of patients in need of treatment for systemic sclerosis (Hoet al., 2003, Arthritis Res Ther., 5:80-93); anti-topo II alpha antibodyare indicative of patients in need of treatment for local scleroderma;and anti-topo 1 alpha antibody are indicative of patients in need oftreatment for systemic scleroderma. Several types of scleroderma andmethods for diagnosing these types are recognized and well known in theart, including, but not limited to, juvenile scleroderma (Foeldvari,2002, Curr Opin Rheumatol, 14:699-703; Cefle et al., 2004, Int J ClinPract., 58:635-638); localized scleroderma; Nodular Scleroderma(Cannick, 2003, J. Rheumatol., 30:2500-2502); and Systemic scleroderma,including, but not limited to, Calcinosis, Raynaud's, Esophagus,Sclerodactyl), and Telangiectasia (CREST), limited systemic scleroderma,and diffuse systemic scleroderma. Systemic scleroderma is also known assystemic sclerosis (SSc). It may also be referred to as ProgressiveSystemic Sclerosis (PSSc), or Familial Progressive Systemic Sclerosis(FPSSc) (Nadashkevich et al., 2004, Med Sci Monit., 10:CR615-621;Frances et al., 2002, Rev Prat. 52:1884-90). Systemic sclerosis is amultisystem disorder characterized by the presence of connective tissuesclerosis, vascular abnormalities concerning small-sized arteries andthe microcirculation, and autoimmune changes.

The type of systemic scleroderma known as CREST is not characterized byany skin tightening. CREST is characterized by Calcinosis (calciumdeposits), usually in the fingers; Raynaud's; loss of muscle control ofthe Esophagus, which can cause difficulty swallowing; Sclerodactyl), atapering deformity of the bones of the fingers; and Telangiectasia,small red spots on the skin of the fingers, face, or inside of themouth. Typically two of these symptoms is sufficient for diagnosis ofCREST. CREST may occur alone, or in combination with any other form ofScleroderma or with other autoimmune diseases.

Limited Scleroderma is characterized by tight skin limited to thefingers, along with either pitting digital ulcers (secondary toRaynaud's) and/or lung fibrosis. The skin of the face and neck may alsobe involved in limited scleroderma.

Diffuse Scleroderma is diagnosed whenever there is proximal tight skin.Proximal means located closest to the reference point. Proximal tightskin can be skin tightness above the wrists or above the elbows.Typically, a patient with skin tightness only between their elbows andtheir wrists will receive a diagnosis of either diffuse or limitedsystemic Scleroderma, depending on which meaning of proximal thediagnosing clinician uses.

The current therapies for scleroderma include extracorporealphotophoresis following 6-methoxypsoralen, and autologous stem celltransplant,

The current treatments for scleroderma include the administration of thefollowing agents, penicillamine, cholchicine, interferon alpha,interpheron gamma, chlorambucil, cyclosporine, 5-fluorouracil,cyclophosphamide, minocycline, thalidomide, etanercept, or methotrexate.

5.5.5. Diagnosis and Clinical Criteria for Transplantation

The present invention provides antibodies, compositions and methods fortreating and preventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder in human transplant recipients. Thecompositions and methods of the invention can be used regardless of theparticular indications which gave rise to the need for a transplant.Similarly, the use of the compositions and methods of the invention forthe treatment and prevention of GVHD, humoral rejection, andpost-transplant lymphoproliferative disorders is not limited by theparticular type of tissue which is intended for transplantation or whichhas been transplanted.

In one embodiment, the invention provides compositions and methods forthe prevention of humoral rejection in a human transplant recipientwherein the transplant recipient is identified as a patient or patientpopulation at increased risk for developing a humoral rejection. Suchpatients may also be referred to as “sensitized.” The criteria for theidentification of sensitized patients is known to the skilledpractitioner. Such criteria may include, for example, patients havingdetectable levels of circulating antibodies against HLA antigens, e.g.,anti-HLA alloantibodies. Such criteria may also include patients whohave undergone previous transplantations, a pregnancy, or multiple bloodtransfusions. Patients who are at an increased risk for humoralrejection also include those having imperfect donor-recipient HLAmatching, and those transplantations which are ABO-incompatible.Sensitized individuals are preferred candidates for pretreatment orconditioning prior to transplantation. Sensitized individuals are alsopreferred candidates for post-transplantation maintenance regimens forthe prevention of humoral rejection.

In one embodiment, the antibodies, compositions, and methods of theinvention comprise or are used in combination with a therapeutic regimenfor the treatment of an acute or chronic rejection. In particularembodiments, the rejection is characterized as a Stage I, a Stage II, aStage III, or a Stage IV humoral rejection.

In one embodiment, the antibodies, compositions, and methods of theinvention comprise or are used in combination with a therapeutic regimenfor the treatment of an early stage humoral rejection. In particularembodiments, the early stage humoral rejection is a Stage I, II, or IIIrejection. Clinical indications of an early stage humoral rejection aredetermined according to the knowledge and skill in the art and mayinclude, for example, the development in the patient of circulatingdonor-specific anti-HLA antibodies, the presence of complement markersof antibody activity such as C4d and C3d deposits in graft biopsies, andthe presence of anti-HLA antibodies in graft biopsies. Other indicatorsof an early stage humoral rejection are known to the skilledpractitioner and may include, for example, the development ofantiendothelial antibodies, especially antivimentin antibodies, and thedevelopment of nonclassical MHC class I-related chain A (MICA)alloantibodies.

In one embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for thetreatment of humoral rejection characterized in part by graftdysfunction. In particular embodiments, the patient or patientpopulation in need of treatment for humoral rejection is identifiedaccording to criteria known in the art for graft dysfunction. Examplesof such criteria for particular types of grafts are provided in thesections that follow. In other embodiments, the patient or patientpopulation in need of treatment for humoral rejection is identifiedaccording to other criteria that are particular to the type of tissuegraft, such as histological criteria. Examples of such criteria are alsoprovided in the sections that follow.

5.5.5.1. Bone Marrow Transplants

The compositions and methods of the invention are useful for treating orpreventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder in a bone marrow transplant recipient. Inone embodiment, the compositions and methods of the invention compriseor are used in combination with a pre-transplant conditioning regimen.

In one embodiment, the compositions and methods of the invention areused to deplete B cells from a bone marrow graft prior totransplantation. The graft may be from any suitable source, for example,cord blood stem cells, peripheral blood stem cells, or a bone marrowtap. Peripheral blood stem cells may be harvested from donor bloodfollowing a suitable conditioning regimen. Suitable regimens are knownin the art and may include, for example, administration of one or moreof the following to the donor prior to harvesting the donor blood:NEUPOGEN, cytokines such as GM-CSF, low dose chemotherapeutic regimens,and chemokine therapy. The graft may be either allogeneic or autologousto the transplant recipient. The graft may also be a xenograft.

The compositions and methods of the invention are useful in a number ofcontexts in which there is a hematopoietic indication for bone marrowtransplantation. In one embodiment, an autologous bone marrow graft isindicated for a B cell leukemia or lymphoma, preferably acutelymphoblastic leukemia (“ALL”) or non-Hodgkins lymphoma, and thecompositions and methods of the invention are used for the depletion ofresidual malignant cells contaminating the graft. In one embodiment, anautologous bone marrow transplant is indicated for patients unable toclear a viral infection, for example a viral infection associated withEpstein Barr virus (EBV), human immunodeficiency virus (HIV), orcytomegalovirus (CMV), and the anti-CD19 antibody compositions andmethods of the invention are used to deplete the graft of B cells whichmay harbor the virus. In another embodiment, the graft is an allogeneicgraft and the anti-CD19 antibody compositions and methods of theinvention are used for depleting donor B cells from the graft asprophylaxis against GVHD.

In one embodiment, the indication is a B cell associated autoimmunecondition and the compositions and methods of the invention are used todeplete the deleterious B cells from the patient without the need forchemotherapy or radiation therapy conditioning regimens. In oneembodiment, the compositions of the invention are administered incombination with a chemotherapy or radiation therapy regimen, whichregimen comprises a lower dose of one or more chemotherapeutic agents,or a lower dose of radiation, than the dose that is administered in theabsence of the compositions of the invention. In one embodiment, thepatient receives an autologous bone marrow graft subsequent tochemotherapy or radiation therapy, wherein the graft is depleted ofdeleterious B cells prior to transplantation using the compositions andmethods described herein.

A patient or patient population in need of, or likely to benefit from, abone marrow transplant is identified according to the knowledge andskill in the art. Examples of patients that may be candidates for bonemarrow transplantation include patients who have undergone chemotherapyor radiation therapy for the treatment of a cancer or an autoimmunedisease or disorder, and patients who are unable to clear a viralinfection residing in cells of the immune system.

5.5.5.2. Liver Transplants

The compositions and methods of the invention are useful for treating orpreventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder in a liver transplant recipient. Inparticular embodiments, the rejection is an acute or a chronicrejection. In one embodiment, the compositions and methods of theinvention are used for the prevention of GVHD, humoral rejection, andpost-transplant lymphoproliferative disorder in a liver transplantrecipient. In one embodiment, the compositions and methods of theinvention comprise or are used in combination with a pre-transplantconditioning regimen. In one embodiment, the compositions of theinvention are administered to the transplant recipient. In oneembodiment, the compositions of the invention are contacted with thegraft, ex vivo, prior to transplantation.

The liver transplant may be from any suitable source as determinedaccording to the knowledge and skill in the art. In one embodiment, theliver is an HLA-matched allogeneic graft. In another embodiment, theliver is a xenograft, preferably from a pig donor. In one embodiment,the liver is used ex vivo to filter the patient's blood, e.g.,extracorporeal perfusion. Extracorporeal perfusion is a form of liverdialysis in which the patient is surgically connected to a livermaintained outside the body. This procedure is sometimes referred to as“bioartificial liver.” In accordance with this embodiment, thecompositions and methods of the invention are used to prevent thedevelopment of antibodies against liver antigens which may contaminatethe patient's blood.

In one embodiment, the compositions and methods of the inventioncomprise an improved therapeutic regimen for the treatment andprevention of GVHD, humoral rejection, and post-transplantlymphoproliferative disorder. In a particular embodiment, thecompositions and methods of the invention comprise an improvedtherapeutic regimen, wherein the improvement lies in a decreasedincidence and/or severity of complications associated with traditionalimmunosuppressive agents. In one embodiment, the incidence and/orseverity of nephrotoxicity, hepatotoxicity, and hirsutism is reducedcompared with traditional regimens relying on cyclosporin A or othercalcineurin inhibitors. In one embodiment, the incidence and/or severityof obesity, osteodystrophy, diabetes mellitus and susceptibility tobacterial and viral infections is reduced compared with traditionalregimens relying on corticosteroids.

In a preferred embodiment, the compositions and methods of the inventionare used in combination with lower doses of one or more traditionalimmunosuppressive agents than the doses that are used in the absence ofanti-lymphocyte antibody therapy. Preferably, the lower doses result ina decreased incidence and/or severity of one or more complicationsassociated with the one or more traditional immunosuppressive agents.

A patient or patient population in need of, or likely to benefit from, aliver transplant is identified according to the knowledge and skill inthe art. Examples of patients that may be candidates for livertransplantation include persons having one or more of the followingconditions, diseases, or disorders: acute liver failure, amyloidosis,bilirubin excretion disorders, biliary atresia, Budd-Chiari syndrome,chronic active autoimmune hepatitis, cirrhosis (either associated withviral hepatitis including hepatitis B and hepatitis C, alcoholiccirrhosis, or primary biliary cirrhosis), cholangitis, congenital factorVIII or IX disorder, copper metabolism disorders, cystic fibrosis,glycogenesis, hypercholesterolemia, lipidoses, mucopolysaccharidosis,primary sclerosing cholangitis, porphyrin metabolism disorders, purineand pyrimidine metabolism disorders, and primary benign and malignantneoplasms, especially of the liver and intrahepatic bile ducts, biliarysystem, biliary passages, or digestive system.

The clinical criteria for the identification of a patient or patientpopulation in need of, or likely to benefit from, a liver transplant canbe determined according to the knowledge and skill in the art. Suchcriteria may include, for example, one or more of the followingsymptoms: fatigue, weight loss, upper abdominal pain, purities,jaundice, liver enlargement, discolored urine, elevated alkalinephosphatase, and gamma glutamylpeptidase activity, elevated bilirubinlevels, decreased serum albumin, elevated liver-specific enzymes, lowbile production, increased blood urea nitrogen, increased creatinineand/or presence of anti-neutrophil cytoplasmic antibodies (ANCA) titers,recurrent variceal hemorrhage, intractable ascites, spontaneousbacterial peritonitis, refractory encephalopathy, severe jaundice,exacerbated synthetic dysfunction, sudden physiologic deterioration, andfulminant hepatic failure.

5.5.5.3. Kidney (Renal) Transplants

The compositions and methods of the invention are useful for treating orpreventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder in a renal transplant recipient. As usedherein, the term “renal transplant” encompasses the transplant of akidney and the combined transplant of a kidney and a pancreas. Inparticular embodiments, the rejection is characterized as an acuterejection or a chronic rejection.

In one embodiment, the compositions and methods of the inventioncomprise or are used in combination with a pre-transplant conditioningregimen. In one embodiment, a single dose of one or more of thecompositions of the present invention is effective to reduce panelreactive antibodies and deplete B cells in the patient or patientpopulation. In another embodiment, multiple doses of one or more of thecompositions of the invention are effective to reduce panel reactiveantibodies and deplete B cells in the patient or patient population. Inone embodiment, a single dose of one or more of the compositions of thepresent invention is administered in combination with one or moreimmunosuppressive agents and is effective to reduce panel reactiveantibodies and deplete B cells in the patient or patient population.

In certain embodiments, the compositions and methods of the inventionare for treating or preventing GVHD and graft rejection in a patienthaving received a renal transplant. In one embodiment, the patient hasnot yet exhibited clinical signs of rejection. In a related embodiment,the compositions and methods of the invention comprise or are used incombination with a maintenance regimen for the prevention of graftrejection in the transplant recipient. In one embodiment, thecompositions and methods of the invention are for the treatment of asubclinical humoral rejection. In a related embodiment, the patient orpatient population in need of treatment for a subclinical humoralrejection is indicated by the detection of CD4 deposition in a biopsyfrom the graft or by the detection of circulating anti-HLA antibodies.

In one embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for thetreatment of an acute or chronic rejection episode in a transplantrecipient. In one embodiment, the patient or patient population in needof treatment for an acute or chronic rejection episode is identified bythe detection of one or more clinical indicators of rejection. Inspecific embodiments, the one or more clinical indicators of rejectionare detected one to six weeks post-transplantation. In one embodiment,the one or more clinical indicators of rejection are detected 6, 12, 18,24, 36, 48, or 60 months post-transplantation. In a preferredembodiment, the acute rejection is biopsy-confirmed acute humoralrejection.

In one embodiment, one or more of the compositions of the inventioncomprise a therapeutic regimen for the treatment of acute rejection. Ina particular embodiment, the therapeutic regimen further comprises oneor more of the following: plasmapheresis, tacrolimus/mycophenolate,intravenous immunoglobulin, immunoadsorption with protein A, andanti-CD20 antibody. In one embodiment, the patient has been on animmunosuppressive protocol prior to the development of the rejection. Ina particular embodiment, the immunosuppressive protocol includes one ormore of cyclosporine, azathioprine, and steroid therapy.

Clinical indicators of acute humoral rejection are known in the art andinclude, for example, a sudden severe deterioration of renal function,the development of oliguria, and compromised renal perfusion. Additionalindicators include, for example, inflammatory cells in peritubularcapillaries on biopsy and circulating donor-specific alloantibodies. Inone embodiment, the patient presents with one or more of the followingdiagnostic criteria for a humoral rejection of a renal allograft: (1)morphological evidence of acute tissue injury; (2) evidence of antibodyaction, such as C4d deposits or immunoglobulin and complement inarterial fibrinoid necrosis; and (3) detectable circulating antibodiesagainst donor HLA antigens or donor endothelial antigens. In oneembodiment, the patient presents with all three of the above diagnosticcriteria.

In one embodiment, the patient presents with one or more of theforegoing diagnostic criteria of acute humoral rejection and thecompositions of the present invention are used in combination with oneor more of the following immunosuppressive agents to treat the acutehumoral rejection: intravenous immunoglobulin, anti-thymocyte globulins,anti-CD20 antibody, mycophenolate mofetil, or tacrolimus. In anotherembodiment, the compositions of the invention are used in combinationwith one or more immunosuppressive agents and a procedure for theremoval of alloantibodies from the patient, such as plasmapheresis orimmunoadsorption.

In one embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for thetreatment of a chronic renal allograft rejection. In one embodiment, oneor more of the compositions of the invention are used alone or incombination with one or more immunosuppressive agents, including forexample, anti-CD154 (CD40L), tacrolimus, sirolimus, and mizoribin. In apreferred embodiment, one or more of the anti-CD19 antibodies of theinvention are used in combination with tacrolimus and mycophenolate.

Clinical indicators of chronic rejection in the kidneys are known in theart and may include, for example, arterial intimal fibrosis with intimalmononuclear cells (chronic allograft vasculopathy), duplication of theglomerular basement membranes (chronic allograft glomerulopathy),lamination of the peritubular basement membrane, C4d in peritubularcapillaries, and detectable circulating donor HLA-reactive antibodies.In a preferred embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen to treatchronic rejection before graft lesions develop.

In another embodiment, the patient or patient population in need oftreatment is identified as having one or more clinical indicators oftransplant glomerulopathy. In a related embodiment, the compositions ofthe invention comprise or are used in combination with a therapeuticregimen comprising one or more therapeutic agents. In a preferredembodiment, the therapeutic regimen is effective to stabilize renalfunction and inhibit graft rejection. In a particular embodiment, theone or more therapeutic agents include angiotensin converting enzyme(ACE) inhibitors and/or receptor antagonists, intravenousimmunoglobulin, anti-thymocyte globulins, anti-CD20 antibody,mycophenolate mofetil, or tacrolimus. Preferably, the anti-CD19antibodies of the invention are used in combination with mycophenolatemofetil and tacrolimus, with or without other therapeutic agents.Plasmapheresis may also be used as part of the therapeutic regimen.

A patient or patient population in need of, or likely to benefit from, arenal transplant is identified according to the knowledge and skill inthe art. Examples of patients that may be candidates for renaltransplantation include patients diagnosed with amyloidosis, diabetes(type I or type II), glomerular disease (e.g., glomerulonephritis),gout, hemolytic uremic syndrome, HIV, hereditary kidney disease (e.g.,polycystic kidney disease, congenital obstructive uropathy, cystinosis,or prune bell syndrome), other kidney disease (e.g., acquiredobstructive nephropathy, acute tubular necrosis, acute intersititialnephritis), rheumatoid arthritis, systemic lupus erythematosus, orsickle cell anemia. Other candidates for renal transplant includepatients having insulin deficiency, high blood pressure, severe injuryor burns, major surgery, heart disease or heart attack, liver disease orliver failure, vascular disease (e.g., progressive systemic sclerosis,renal artery thrombosis, scleroderma), vesicoureteral reflux, andcertain cancers (e.g., incidental carcinoma, lymphoma, multiple myeloma,renal cell carcinoma, Wilms tumor). Other candidates for renaltransplant may include, for example, heroin users, persons who haverejected a previous kidney or pancreas graft, and persons undergoing atherapeutic regimen comprising antibiotics, cyclosporin, orchemotherapy.

The compositions and methods of the invention are useful for treating orpreventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder in a cardiac transplant recipient. Inparticular embodiments, the rejection is an acute or a chronicrejection. In one embodiment, the compositions and methods of theinvention comprise or are used in combination with a pre-transplantconditioning regimen.

In certain embodiments, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for thetreatment of acute humoral rejection in a cardiac transplant recipient.In a particular embodiment, the therapeutic regimen further comprisesone or more of the following: plasmapheresis, intravenousimmunoglobulin, and anti-CD20 antibody therapy. The patient or patientpopulation in need of treatment for an acute humoral rejection isidentified by the detection of one or more of the clinical indicationsof acute humoral rejection. Examples of clinical indicators of acutehumoral rejection may include one or more of the following: hemodynamicdysfunction, defined by shock, hypotension, decreased cardiac output,and a rise in capillary wedge or pulmonary artery pressure. In aparticular embodiment, the acute humoral rejection is diagnosed within6, 12, 18, 24, 36, 48, or 60 months post-transplantation.

In one embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for theprevention of rejection in a cardiac transplant recipient. In oneembodiment, the transplant recipient in need of prophylaxis againstrejection is identified as a patient or patient population having one ormore of the following risk factors: female sex, cytomegalovirusseropositivity, elevated response to panel reactive antibodies, positivepre- and/or post-transplant crossmatch, and presensitization withimmunosuppressive agents.

In one embodiment, the compositions and methods of the invention are forthe treatment or prevention of graft deterioration in a heart transplantrecipient. In one embodiment, the transplant recipient in need oftreatment for, or prophylaxis against, graft deterioration is identifiedas a patient or patient population having one or more of the followingclinical indications of humoral rejection: deposition of immunoglobulin,C1q, C3, and/or C4d in capillaries, evidence of CD68-positive cellswithin capillaries, and evidence of infiltration of the graft byinflammatory cells upon biopsy. In one embodiment, the compositions ofthe present invention are used in combination with one or more of thefollowing immunosuppressive agents to treat graft deterioration in aheart transplant recipient: intravenous immunoglobulin, anti-thymocyteglobulins, anti-CD20 antibody, mycophenolate mofetil, or tacrolimus. Inanother embodiment, the anti-CD19 antibody compositions of the inventionare used in combination with one or more immunosuppressive agents and aprocedure for the removal of alloantibodies from the patient, such asplasmapheresis or immunoadsorption.

In one embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for thetreatment of chronic cardiac rejection, preferably chronic allograftvasculopathy, also referred to as transplant coronary artery disease. Inanother embodiment, the compositions and methods of the inventioncomprise or are used in combination with a therapeutic regimen for theprevention of transplant coronary artery disease in a patient or patientpopulation at risk. The criteria for identifying a patient or patientpopulation at risk of developing transplant coronary artery disease areknown in the art and may include, for example, patients having poorlymatched transplants, patients who develop circulating anti-HLAantibodies, and patients who develop one or more clinical indications ofhumoral rejection early after cardiac transplant.

A patient or patient population in need of, or likely to benefit from, aheart transplant is identified according to the knowledge and skill inthe art. Examples of patients that may be candidates for hearttransplantation include those who have been diagnosed with any of thefollowing diseases and disorders: coronary artery disease,cardiomyopathy (noninflammatory disease of the heart), heart valvedisease with congestive heart failure, life-threatening abnormal heartrhythms that do not respond to other therapy, idiopathic cardiomyopathy,ischemic cardiomyopathy, dilated cardiomyopathy, ischemiccardiomyopathy, and congenital heart disease for which no conventionaltherapy exists or for which conventional therapy has failed.

The clinical criteria for the identification of a patient or patientpopulation in need of, or likely to benefit from, a heart transplant canbe determined according to the knowledge and skill in the art. Suchcriteria may include, for example, one or more of the following:ejection fraction less than 25%, intractable angina or malignant cardiacarrhythmias unresponsive to conventional therapy, and pulmonary vascularresistance of less than 2 Wood units. In addition, the patient orpatient population in need of a heart transplant may be identified byperforming a series of tests according to the knowledge and skill in theart. Such tests include, for example, resting and stressechocardiograms, EKG, assay of blood creatinine levels, coronaryarteriography, and cardiopulmonary evaluation including right- andleft-heart catheterization.

5.5.5.4. Lung Transplants

The compositions and methods of the invention are useful for treating orpreventing GVHD, humoral rejection, and post-transplantlymphoproliferative disorder in a lung transplant recipient. Inparticular embodiments, the rejection is characterized as an acute or achronic rejection. In one embodiment, the compositions and methods ofthe invention comprise or are used in combination with a pre-transplantconditioning regimen.

A patient or patient population in need of, or likely to benefit from, alung transplant is identified according to the knowledge and skill inthe art. Examples of patients that may be candidates for lungtransplantation include patients having one of the following diseases orconditions: bronchiectasis, chronic obstructive pulmonary disease,cystic fibrosis, Eisenmenger syndrome or congenital heart disease withEisenmenger syndrome. emphysema, eosinophilic granuloma of the lung, orhistiocytosis X, inhalation/burn trauma, lymphangioleiomyomatosis (LAM),primary pulmonary hypertension, pulmonary fibrosis (scarring of thelung), or sarcoidosis.

The clinical criteria for the identification of a patient or patientpopulation in need of, or likely to benefit from, a lung transplant canbe determined according to the knowledge and skill in the art. Suchcriteria may include, for example, one or more of the following: Chronicobstructive pulmonary disease (COPD) and alpha1-antitrypsin deficiencyemphysema characterized by one or more of the following indicators:postbronchodilator FEV1 of less than 25% predicted, resting hypoxemia,i.e., PaO₂ of less than 55-60 mm Hg, hypercapnia. secondary pulmonaryhypertension, a rapid rate of decline in FEV1, or life-threateningexacerbations; cystic fibrosis characterized by one or more of thefollowing indicators: postbronchodilator FEV1 of less than 30%predicted, resting hypoxemia, hypercapnia, or increasing frequency andseverity of exacerbations; idiopathic pulmonary fibrosis characterizedby one or more of the following indicators: vital capacity (VC) and TLCof less than 60-65% predicted, and resting hypoxemia; secondarypulmonary hypertension characterized by clinical, radiographic, orphysiologic progression while on medical therapy; primary pulmonaryhypertension characterized by one or more of the following indicators:NYHA functional class III or IV, mean right atrial pressure of greaterthan 10 mm Hg, mean pulmonary arterial pressure of greater than 50 mmHg, cardiac index of less than 2.5 L/min/m², and failure of therapy withlong-term prostacyclin infusion.

5.5.5.5. Post-Transplant Lymphoproliferative Disorder

The immunosuppression necessary for successful transplantation can giverise to a post-transplant lymphoproliferative disorder of B cell origin.Generally, a post-transplant lymphoproliferative disorder is associatedwith Epstein-Barr virus infected cells. Post-transplantlymphoproliferative disorder (PTLD) can range in severity from a benignself-limiting mononucleosis-like syndrome to an aggressive non-Hodgkinslymphoma. The compositions and methods of the present invention may beused to treat PTLD arising from any transplant. Preferably, thetransplant is a solid organ transplant, for example, a heart transplant,a liver transplant, a kidney transplant, or a combined kidney-pancreastransplant. In a preferred embodiment, the compositions and methods ofthe invention are used to treat PTLD as part of a therapeutic regimenthat includes a temporary cessation or reduction of otherimmunosuppressive therapy.

In one embodiment, the anti-CD19 antibody compositions of the inventionare administered as part of a therapeutic regimen including one or moreof the following: high dose intravenous gamma globulin, a cytokine, ananti-viral agent, and an anti-CD20 monoclonal antibody. Preferably, thetherapeutic regimen includes a temporary cessation or reduction ofimmunosuppression therapy. In a preferred embodiment, intravenous gammaglobulin is administered at a daily dose of 0.4 g/kg for 1 to 5 days,preferably for 3 days, and the cytokine is interferon alpha administeredfor at least 7 days. In one embodiment, one or more cytokines is used inthe regimen. In one embodiment, one or more anti-viral agents is used inthe regimen. The anti-viral agent may be selected from any suitableanti-viral agent known to those of skill in the art. In one embodiment,the anti-viral agent is aciclovir or ganciclovir. Preferably theanti-viral agent is administered for at least one or two weeks. Theanti-viral agent may also be administered for longer periods, forexample, 1 month, 2 months, 3 months, 4 months, or 5 months.

5.5.6. Determining CD19 Density In a Sample or Subject

While not required, assays for CD19 density can be employed to furthercharacterize the patient's diagnosis. Methods of determining the densityof antibody binding to cells are known to those skilled in the art (See,e.g., Sato et al., J. Immunology, 165:6635-6643 (2000); which disclosesa method of assessing cell surface density of specific CD antigens).Other standard methods include Scatchard analysis. For example, theantibody or fragment can be isolated, radiolabeled, and the specificactivity of the radiolabeled antibody determined. The antibody is thencontacted with a target cell expressing CD19. The radioactivityassociated with the cell can be measured and, based on the specificactivity, the amount of antibody or antibody fragment bound to the celldetermined.

Alternatively, fluorescence activated cell sorting (FACS) analysis canbe employed. Generally, the antibody or antibody fragment is bound to atarget cell expressing CD19. A second reagent that binds to the antibodyis then added, for example, a fluorochrome labeled anti-immunoglobulinantibody. Fluorochrome staining can then be measured and used todetermine the density of antibody or antibody fragment binding to thecell.

As another suitable method, the antibody or antibody fragment can bedirectly labeled with a detectable label, such as a fluorophore, andbound to a target cell. The ratio of label to protein is determined andcompared with standard beads with known amounts of label bound thereto.Comparison of the amount of label bound to the cell with the knownstandards can be used to calculate the amount of antibody bound to thecell.

In yet another aspect, the present invention provides a method fordetecting in vitro or in vivo the presence and/or density of CD19 in asample or individual. This can also be useful for monitoring disease andeffect of treatment and for determining and adjusting the dose of theantibody to be administered. The in vivo method can be performed usingimaging techniques such as PET (positron emission tomography) or SPECT(single photon emission computed tomography). Alternatively, one couldlabel the anti-CD19 antibody with Indium using a covalently attachedchelator. The resulting antibody can be imaged using standard gammacameras the same way as ZEVALIN™ (Indium labeled anti-CD20 mAb) (BiogenIdec) is used to image CD20 antigen.

In one embodiment, the in vivo method can be performed by contacting asample to be tested, optionally along with a control sample, with ahuman anti-CD19 antibody of the invention under conditions that allowfor formation of a complex between an antibody of the invention and thehuman CD19 antigen. Complex formation is then detected (e.g., using anFACS analysis or Western blotting). When using a control sample alongwith the test sample, a complex is detected in both samples and anystatistically significant difference in the formation of complexesbetween the samples is indicative of the presence of human CD19 in thetest sample.

In other embodiments, mean fluorescence intensity can be used as ameasure of CD19 density. In such embodiments, B cells are removed from apatient and stained with CD19 antibodies that have been labeled with afluorescent label and the fluorescence intensity is measured using flowcytometry. Fluorescence intensities can be measured and expressed as anaverage of intensity per B cell. Using such methods, mean fluorescenceintensities that are representative of CD19 density can be compared fora patient before and after treatment using the methods and compositionsof the invention, or between patients and normal levels of hCD19 on Bcells.

In patients where the density of CD19 expression on B cells has beendetermined, the density of CD19 may influence the determination and/oradjustment of the dosage and/or treatment regimen used with theanti-CD19 antibody of the compositions and methods of the invention. Forexample, where density of CD19 is high, it may be possible to useanti-CD19 antibodies that less efficiently mediate ADCC in humans. Incertain embodiments, where the patient treated using the compositionsand methods of the invention has a low CD19 density, a higher dosage ofthe anti-CD19 antibody of the compositions and methods of the inventionmay be used. In other embodiments, where the patient treated using thecompositions and methods of the invention has a low CD19 density, a lowdosage of the anti-CD19 antibody of the compositions and methods of theinvention may be used. In certain embodiments, where the patient treatedusing the compositions and methods of the invention has a high CD19density, a lower dosage of the anti-CD19 antibody of the compositionsand methods of the invention may be used. In certain embodiments, CD19density can be compared to CD20 density in a patient, CD19 density canbe compared to an average CD19 density for humans or for a particularpatient population, or CD19 density can be compared to CD19 levels inthe patient prior to therapy or prior to onset of a B cell or anautoimmune disease or disorder. In certain embodiments, the patienttreated using the compositions and methods of the invention has a B cellmalignancy or an autoimmune disease or disorder where CD19 is present onthe surface of B cells.

5.6 Immunotherapeutic Protocols

In accordance with the present invention, each of the immunotherapeuticprotocols described herein can utilize the routes and methods ofadministration and doses described in any of the preceding sections.

The anti-CD19 antibody compositions used in the therapeuticregimen/protocols, referred to herein as “anti-CD19 immunotherapy” canbe naked antibodies, immunoconjugates and/or fusion proteins. Thecompositions of the invention can be used as a single agent therapy orin combination with other therapeutic agents or regimens. The anti-CD19antibodies or immunoconjugates can be administered prior to,concurrently with, or following the administration of one or moretherapeutic agents. Therapeutic agents that can be used in combinationtherapeutic regimens with the compositions of the invention include anysubstance that inhibits or prevents the function of cells and/or causesdestruction of cells. Examples, include, but are not limited to,radioactive isotopes, chemotherapeutic agents, and toxins such asenzymatically active toxins of bacterial, fungal, plant or animalorigin, or fragments thereof.

The therapeutic regimens described herein, or any desired treatmentregimen can be tested for efficacy using a transgenic animal model suchas the mouse model described below, which expresses human CD19 antigenin addition to or in place of native CD19 antigen. Thus, an anti-CD19antibody treatment regimen can be tested in an animal model to determineefficacy before administration to a human.

The anti-CD19 antibodies, compositions and methods of the invention canbe practiced to treat B cell diseases, including B cell malignancies.The term “B cell malignancy” includes any malignancy that is derivedfrom a cell of the B cell lineage. Exemplary B cell malignanciesinclude, but are not limited to: B cell subtype non-Hodgkin's lymphoma(NHL) including low grade/follicular, NHL, small lymphocytic (SL) NHL,intermediate grade/follicular NHL, intermediate grade diffuse NHL, highgrade immunoblastic NHL, high grade lymphoblastic NHL, high grade smallnon-cleaved cell NHL; mantle-cell lymphoma, and bulky disease NHL;Burkitt's lymphoma; multiple myeloma; pre-B acute lymphoblastic leukemiaand other malignancies that derive from early B cell precursors; commonacute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL)including immunoglobulin-mutated CLL and immunoglobulin-unmutated CLL;hairy cell leukemia; Null-acute lymphoblastic leukemia; Waldenstrom'sMacroglobulinemia; diffuse large B cell lymphoma (DLBCL) includinggerminal center B cell-like (GCB) DLBCL, activated B cell-like (ABC)DLBCL, and type 3 DLBCL; pro-lymphocytic leukemia; light chain disease;plasmacytoma; osteosclerotic myeloma; plasma cell leukemia; monoclonalgammopathy of undetermined significance (MGUS); smoldering multiplemyeloma (SMM); indolent multiple myeloma (IMM); Hodgkin's lymphomaincluding classical and nodular lymphocyte pre-dominant type;lymphoplasmacytic lymphoma (LPL); and marginal-zone lymphoma includinggastric mucosal-associated lymphoid tissue (MALT) lymphoma

The inventors have shown that the inventive antibodies and compositionscan deplete mature B cells. Thus, as another aspect, the invention canbe employed to treat mature B cell malignancies (i.e., express Ig on thecell surface) including but not limited to follicular lymphoma,mantle-cell lymphoma, Burkitt's lymphoma, multiple myeloma, diffuselarge B-cell lymphoma (DLBCL) including germinal center B cell-like(GCB) DLBCL, activated B cell-like (ABC) DLBCL, and type 3 DLBCL,Hodgkin's lymphoma including classical and nodular lymphocytepre-dominant type, lymphoplasmacytic lymphoma (LPL), marginal-zonelymphoma including gastric mucosal-associated lymphoid tissue (MALT)lymphoma, and chronic lymphocytic leukemia (CLL) includingimmunoglobulin-mutated CLL and immunoglobulin-unmutated CLL.

Further, CD19 is expressed earlier in B cell development than, forexample, CD20, and is therefore particularly suited for treating pre-Bcell and immature B cell malignancies (i.e., do not express Ig on thecell surface), for example, in the bone marrow. Illustrative pre-B celland immature B cell malignancies include but are not limited to acutelymphoblastic leukemia

In other particular embodiments, the invention can be practiced to treatextranodal tumors.

In some embodiments, the anti-CD19 antibodies, compositions and methodsof the invention can be practiced to treat autoimmune diseases ordisorders.

In other embodiments, therapeutic agents that can be used in combinationtherapeutic regimens with the compositions of the invention include anysubstance that inhibits or prevents the function of cells and/or causesdestruction of cells. Preferably, the agent inhibits or prevents thefunction of lymphocytes and/or causes destruction of lymphocytes.Examples, include, but are not limited to, immunosuppressive agents suchas inhibitors of cytokine transcription (e.g., cyclosporin A,tacrolimus), nucleotide synthesis (e.g., azathiopurine, mycophenolatemofetil), growth factor signal transduction (e.g., sirolimus,rapamycin), and the T cell interleukin 2 receptor (e.g., daclizumab,basiliximab). In a preferred embodiment, the immunosuppressant agentincludes one or more of the following: adriamycin, azathiopurine,busulfan, cyclophosphamide, cyclosporin A (CyA), cytoxin, fludarabine,5-fluorouracil, methotrexate, mycophenolate mofetil (MOFETIL),nonsteroidal anti-inflammatories (NSAIDs), rapamycin, and tacrolimus(FK506). Other examples include radioactive isotopes, chemotherapeuticagents, and toxins such as enzymatically active toxins of bacterial,fungal, plant or animal origin, or fragments thereof.

5.6.1. Anti-CD19 Immunotherapy

In accordance with the present invention “anti-CD19 immunotherapy”encompasses the administration of any of the anti-CD19 antibodies of theinvention in accordance with any of the therapeutic regimens describedherein. The anti-CD19 antibodies can be administered as nakedantibodies, or immunoconjugates or fusion proteins.

Anti-CD19 immunotherapy encompasses the administration of the anti-CD19antibody as a single agent therapeutic for the treatment of a B cellmalignancy, treatment of an autoimmune disease or disorder, orprevention of GVHD, humoral rejection, or post-transplantlymphoproliferative disorder. Anti-CD19 immunotherapy encompassesmethods of treating an early stage disease resulting from a B cellmalignancy, methods of treating a human patient with a low level ofactivity of an autoimmune disease or disorder, and/or methods oftreating a human patient at increased risk for developing GVHD, humoralrejection, or post-transplant lymphoproliferative disorder.

According to certain aspects of the invention, the anti-CD19 antibodyused in the compositions and methods of the invention, is a nakedantibody. In related embodiments, the dose of naked anti-CD19 antibodyused is at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10,10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17,17.5, 18, 18.5, 19, 19.5, 20, 20.5 mg/kg of body weight of a patient. Incertain embodiments, the dose of naked anti-CD19 antibody used is atleast about 1 to 10, 5 to 15, 10 to 20, or 15 to 25 mg/kg of body weightof a patient. In certain embodiments, the dose of naked anti-CD19antibody used is at least about 1 to 20, 3 to 15, or 5 to 10 mg/kg ofbody weight of a patient. In preferred embodiments, the dose of nakedanti-CD19 antibody used is at least about 5, 6, 7, 8, 9, or 10 mg/kg ofbody weight of a patient.

In certain embodiments, the dose comprises about 375 mg/m² of anti-CD19antibody administered weekly for 4 to 8 consecutive weeks. In certainembodiments, the dose is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, or 15 mg/kg of body weight of the patient administeredweekly for 4 to 8 consecutive weeks.

The exemplary doses of anti-CD19 antibody described above can beadministered as described herein. In one embodiment, the above doses aresingle dose injections. In other embodiments, the doses are administeredover a period of time. In other embodiments, the doses are administeredmultiple times over a period of time. The period of time may be measuredin days, months or weeks. Multiple doses of the anti-CD19 antibody canbe administered at intervals suitable to achieve a therapeutic benefitwhile balancing toxic side effects. For example, where multiple dosesare used, it is preferred to time the intervals to allow for recovery ofthe patient's monocyte count prior to the repeat treatment withantibody. This dosing regimen will optimize the efficiency of treatment,since the monocyte population reflects ADCC function in the patient.

In certain embodiments, the compositions of the invention areadministered to a human patient as long as the patient is responsive totherapy. In other embodiments, the compositions of the invention areadministered to a human patient as long as the patient's disease doesnot progress. In related embodiments, the compositions of the inventionare administered to a human patient until a patient's disease does notprogress or has not progressed for a period of time, then the patient isnot administered the compositions of the invention unless the diseasereoccurs or begins to progress again.

In other embodiments, the compositions of the invention are administeredto a human patient until the GVHD or rejection episode subsides. Inanother embodiment, the compositions of the invention are administeredto a human patient until graft function is substantially restored, thenthe patient is not administered the compositions of the invention unlessanother rejection episode is indicated. In one embodiment, thecompositions of the invention are administered to a human patient untilthe lymphoproliferative disorder has been ameliorated as indicated by areduction in the number of circulating B-lymphocytes and/or a reductionin the level of circulating immunoglobulin.

For example, a patient can be treated with any of the above doses forabout 4 to 8 weeks, during which time the patient is monitored fordisease progression (i.e., activity of an autoimmune disease ordisorder). If disease progression stops or reverses, then the patientwill not be administered the compositions of the invention until thatpatient relapses, i.e., the disease being treated reoccurs orprogresses. Upon this reoccurrence or progression, the patient can betreated again with the same dosing regimen initially used or using otherdoses described above.

In certain embodiments, the compositions of the invention can beadministered as a loading dose followed by multiple lower doses(maintenance doses) over a period of time. In such embodiments, thedoses may be timed and the amount adjusted to maintain effective B celldepletion. In preferred embodiments, the loading dose is about 10, 11,12, 13, 14, 15, 16, 17, or 18 mg/kg of patient body weight and themaintenance dose is at least about 5 to 10 mg/kg of patient body weight.In preferred embodiments, the maintenance dose is administered atintervals of every 7, 10, 14 or 21 days. The maintenance doses can becontinued indefinitely, until toxicity is present, until platelet countdecreases, until there is no disease progression, until the patientgenerates an immune response to the drug, or until disease progresses toa terminal state. In yet other embodiments, the compositions of theinvention are administered to a human patient until the diseaseprogresses to a terminal stage.

In some embodiments, the maintenance doses can be continuedindefinitely, until toxicity is present, until platelet count decreases,until there is no evidence of GVHD or rejection, until the patientgenerates an immune response against the anti-CD19 antibodycompositions, or until disease progresses to a terminal state.

In embodiments of the invention where circulating monocyte levels of apatient are monitored as part of a treatment regimen, doses of anti-CD19antibody administered may be spaced to allow for recovery of monocytecount. For example, a composition of the invention may be administeredat intervals of every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days.

In embodiments of the invention where an anti-CD19 antibody isconjugated to or administered in conjunction with a toxin, one skilledin the art will appreciate that the dose of anti-CD19 antibody can beadjusted based on the toxin dose and that the toxin dose will depend onthe specific type of toxin being used. Typically, where a toxin is used,the dose of anti-CD19 antibody will be less than the dose used with anaked anti-CD19 antibody. The appropriate dose can be determined for aparticular toxin using techniques well known in the art. For example, adose ranging study can be conducted to determine the maximum tolerateddose of anti-CD19 antibody when administered with or conjugated to atoxin.

In embodiments of the invention where an anti-CD19 antibody isconjugated to or administered in conjunction with a radiotherapeuticagent, the dose of the anti-CD19 antibody will vary depending on theradiotherapeutic used. In certain preferred embodiments, a two stepprocess is used. First, the human patient is administered a compositioncomprising a naked anti-CD19 antibody and about 6, 7, 8, 9, or 10 dayslater a small amount of the radiotherapeutic is administered. Second,once the tolerance, distribution, and clearance of the low dose therapyhas been determined, the patient is administered a dose of the nakedanti-CD19 antibody followed by a therapeutic amount of theradiotherapeutic is administered. Such treatment regimens are similar tothose approved for treatment of Non-Hodgkin's lymphoma using ZEVALIN™(Indium labeled anti-CD20 mAb) (Biogen Idec) or BEXXAR™ (GSK, CoulterPharmaceutical).

5.6.1.1. Oncology

Anti-CD19 immunotherapy encompasses methods of treating a B cellmalignancy wherein the anti-CD19 antibody mediates ADCC. Anti-CD19immunotherapy encompasses methods of treating a B cell malignancy,wherein the anti-CD19 antibody is administered before the patient hasreceived any treatment for the malignancy, whether that therapy ischemotherapy, radio chemical based therapy or surgical therapy.

In a preferred embodiment, a human subject having a B cell malignancycan be treated by administering a human or humanized antibody thatpreferably mediates human ADCC. In cases of early stage disease, orsingle agent therapies, any anti-CD19 antibody that preferably mediatesADCC can be used in the human subjects (including murine and chimericantibodies); however, human and humanized antibodies are preferred.

Antibodies of the IgG1 or IgG3 human isotypes are preferred for therapy.However, the IgG2 or IgG4 human isotypes can be used, provided theymediate human ADCC. Such effector function can be assessed by measuringthe ability of the antibody in question to mediate target cell lysis byeffector cells in vitro or in vivo.

The dose of antibody used should be sufficient to deplete circulating Bcells. Progress of the therapy can be monitored in the patient byanalyzing blood samples. Other signs of clinical improvement can be usedto monitor therapy.

Methods for measuring depletion of B cells that can be used inconnection with the compositions and methods of the invention are wellknown in the art and include, but are not limited to the followingembodiments. In one embodiment, circulating B cells depletion can bemeasured with flow cytometry using a reagent other than an anti-CD19antibody that binds to B cells to define the amount of B cells. In otherembodiments, antibody levels in the blood can be monitored usingstandard serum analysis. In such embodiments, B cell depletion isindirectly measured by defining the amount to an antibody known to beproduced by B cells. The level of that antibody is then monitored todetermine the depletion and/or functional depletion of B cells. Inanother embodiment, B cell depletion can be measured by immunochemicalstaining to identify B cells. In such embodiments, B cells extractedfrom patient tissues can be placed on microscope slides, labeled andexamined for presence or absence. In related embodiments, a comparisonis made between B cells extracted prior to therapy and after todetermine differences in the presence of B cells.

Tumor burden can be measured and used in connection with thecompositions and methods of the invention. Methods for measuring tumorburden are well known in the art and include, but are not limited to thefollowing embodiments. In certain embodiments, PET scans can be used tomeasure metabolic activity and identify areas of higher activity whichare indicative of tumors. CT scans and MRI can also be used to examinesoft tissue for the presence and size of tumors. In other embodiments,bone scans can be used to measure tumor volume and location. In yetother embodiments, tumor burden can be measured by examining the bloodflow into and out of a tumor using doppler technology (e.g.,ultrasound). In such embodiments, changes in blood flow over time ordeviations from normal blood flow in the appropriate tissue of a patientcan be used to calculate an estimate to tumor burden. Such methods formeasuring tumor burden can be used prior to and following the methods oftreatment of the invention.

In preferred embodiments of the methods of the invention B cells aredepleted and/or tumor burden is decreased while ADCC function ismaintained.

In embodiments of the invention where the anti-CD19 antibody isadministered as a single agent therapy, the invention contemplates useof different treatment regimens.

According to certain aspects of the invention, the anti-CD19 antibodyused in the compositions and methods of the invention, is a nakedantibody. In related embodiments, the dose of naked anti-CD19 antibodyused is at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10,10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17,17.5, 18, 18.5, 19, 19.5, 20, 20.5 mg/kg of body weight of a patient. Incertain embodiments, the dose of naked anti-CD19 antibody used is atleast about 1 to 10, 5 to 15, 10 to 20, or 15 to 25 mg/kg of body weightof a patient. In certain embodiments, the dose of naked anti-CD19antibody used is at least about 1 to 20, 3 to 15, or 5 to 10 mg/kg ofbody weight of a patient. In preferred embodiments, the dose of nakedanti-CD19 antibody used is at least about 5, 6, 7, 8, 9, or 10 mg/kg ofbody weight of a patient.

In certain embodiments, the dose comprises about 375 mg/m² of anti-CD19antibody administered weekly for 4 to 8 consecutive weeks. In certainembodiments, the dose is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, or 15 mg/kg of body weight of the patient administeredweekly for 4 to 8 consecutive weeks.

The exemplary doses of anti-CD19 antibody described above can beadministered as described in herein. In one embodiment, the above dosesare single dose injections. In other embodiments, the doses areadministered over a period of time. In other embodiments, the doses areadministered multiple times over a period of time. The period of timemay be measured in days, months or weeks. Multiple doses of theanti-CD19 antibody can be administered at intervals suitable to achievea therapeutic benefit while balancing toxic side effects. For example,where multiple doses are used, it is preferred to time the intervals toallow for recovery of the patient's monocyte count prior to the repeattreatment with antibody. This dosing regimen will optimize theefficiency of treatment, since the monocyte population reflects ADCCfunction in the patient.

In certain embodiments, the compositions of the invention areadministered to a human patient as long as the patient is responsive totherapy. In other embodiments, the compositions of the invention areadministered to a human patient as long as the patient's disease doesnot progress. In related embodiments, the compositions of the inventionare administered to a human patient until a patient's disease does notprogress or has not progressed for a period of time, then the patient isnot administered the compositions of the invention unless the diseasereoccurs or begins to progress again. For example, a patient can betreated with any of the above doses for about 4 to 8 weeks, during whichtime the patient is monitored for disease progression. If diseaseprogression stops or reverses, then the patient will not be administeredthe compositions of the invention until that patient relapses, i.e., thedisease being treated reoccurs or progresses. Upon this reoccurrence orprogression, the patient can be treated again with the same dosingregimen initially used or using other doses described above.

In certain embodiments, the compositions of the invention can beadministered as a loading dose followed by multiple lower doses(maintenance doses) over a period of time. In such embodiments, thedoses may be timed and the amount adjusted to maintain effective B celldepletion. In preferred embodiments, the loading dose is about 10, 11,12, 13, 14, 15, 16, 17, or 18 mg/kg of patient body weight and themaintenance dose is at least about 5 to 10 mg/kg of patient body weight.In preferred embodiments, the maintenance dose is administered atintervals of every 7, 10, 14 or 21 days. The maintenance doses can becontinued indefinitely, until toxicity is present, until platelet countdecreases, until there is no disease progression, until the patientgenerates an immune response to the drug, or until disease progresses toa terminal state. In yet other embodiments, the compositions of theinvention are administered to a human patient until the diseaseprogresses to a terminal stage.

In embodiments of the invention where circulating monocyte levels of apatient are monitored as part of a treatment regimen, doses of anti-CD19antibody administered may be spaced to allow for recovery of monocytecount. For example, a composition of the invention may be administeredat intervals of every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days.

In embodiments of the invention where an anti-CD19 antibody isconjugated to or administered in conjunction with a toxin, one skilledin the art will appreciate that the dose of anti-CD19 antibody can beadjusted based on the toxin dose and that the toxin dose will depend onthe specific type of toxin being used. Typically, where a toxin is used,the dose of anti-CD19 antibody will be less than the dose used with anaked anti-CD19 antibody. The appropriate dose can be determined for aparticular toxin using techniques well known in the art. For example, adose ranging study can be conducted to determine the maximum tolerateddose of anti-CD19 antibody when administered with or conjugated to atoxin.

In embodiments of the invention where an anti-CD19 antibody isconjugated to or administered in conjunction with a radiotherapeuticagent, the dose of the anti-CD19 antibody will vary depending on theradiotherapeutic used. In certain preferred embodiments, a two stepprocess is used. First, the human patient is administered a compositioncomprising a naked anti-CD19 antibody and about 6, 7, 8, 9, or 10 dayslater a small amount of the radiotherapeutic is administered. Second,once the tolerance, distribution, and clearance of the low dose therapyhas been determined, the patient is administered a dose of the nakedanti-CD19 antibody followed by a therapeutic amount of theradiotherapeutic is administered. Such treatment regimens are similar tothose approved for treatment of Non-Hodgkin's lymphoma using ZEVALIN™(Indium labeled anti-CD20 mAb) (Biogen Idec) or BEXXAR™ (GSK, CoulterPharmaceutical).

5.6.1.2. Autoimmune Diseases and Disorders

In other embodiments, Anti-CD19 immunotherapy encompasses methods oftreating a human patient with a high level of activity of an autoimmunedisease or disorder. Anti-CD19 immunotherapy encompasses methods oftreating a human patient with an early stage of an autoimmune disease ordisorder that has been characterized by stages. Anti-CD19 immunotherapyencompasses methods of treating a human patient with an late stage of anautoimmune disease or disorder that has been characterized by stages.Anti-CD19 immunotherapy encompasses methods of treating an autoimmunedisease or disorder wherein the anti-CD19 antibody mediates ADCC, CDC,or apoptosis. Anti-CD19 immunotherapy encompasses methods of treating anautoimmune disease or disorder, wherein the anti-CD19 antibody isadministered before the patient has received any treatment for theautoimmune disease or disorder.

In a preferred embodiment, a human subject having an autoimmune diseaseor disorder can be treated by administering an anti-CD19 antibody. Incertain embodiments, the anti-CD19 antibody is a human or humanizedantibody that preferably mediates human ADCC. In cases of early stagedisease, or single agent therapies, any anti-CD19 antibody thatpreferably mediates ADCC can be used in the human subjects (includingmurine and chimeric antibodies); however, human and humanized antibodiesare preferred.

Antibodies of the IgG1 or IgG3 human isotypes are preferred for therapy.However, the IgG2 or IgG4 human isotypes can be used, provided theymediate human ADCC. Such effector function can be assessed by measuringthe ability of the antibody in question to mediate target cell lysis byeffector cells in vitro or in vivo.

The dose of antibody used should be sufficient to deplete circulating Bcells. Progress of the therapy can be monitored in the patient byanalyzing blood samples. Other signs of clinical improvement can be usedto monitor therapy.

Methods for measuring depletion of B cells that can be used inconnection with the compositions and methods of the invention are wellknown in the art and include, but are not limited to the followingembodiments. In one embodiment, circulating B cells depletion can bemeasured with flow cytometry using a reagent other than an anti-CD19antibody that binds to B cells to define the amount of B cells. In otherembodiments, antibody levels in the blood can be monitored usingstandard serum analysis. In such embodiments, B cell depletion isindirectly measured by defining the amount to an antibody known to beproduced by B cells. The level of that antibody is then monitored todetermine the depletion and/or functional depletion of B cells. Inanother embodiment, B cell depletion can be measured by immunochemicalstaining to identify B cells. In such embodiments, B cells extractedfrom patient tissues can be placed on microscope slides, labeled andexamined for presence or absence. In related embodiments, a comparisonis made between B cells extracted prior to therapy and after todetermine differences in the presence of B cells.

In embodiments of the invention where the anti-CD19 antibody isadministered as a single agent therapy, the invention contemplates useof different treatment regimens. The treatment regimens can comprise oneor more treatment cycles depending on the activity of an autoimmunedisease or disorder. Generally if disease activity is low, then fewercycles of treatment are administered. If more than one cycle is needed,the time between any two treatment cycles may be fixed or variable toaccommodate patient-specific differences in disease activity, diseaseresponsiveness, drug tolerability, recovery times, pharmacokinetic (PK)parameters, and/or pharmacological response(s). For example, in certainembodiments, the time between any two treatment cycles can be about 2months, 4 months, 8 months, 12 months, 18 months, or 24 months. Incertain embodiments, the time between any two treatment cycles can beabout 1 month, 3 months, 5 months, 9 months, 11 months, 17 months, 19months, 21 months, or 25 months. In certain embodiments, the timebetween any two treatment cycles can be about 2 to 4, 3 to 5, 6 to 8, 7to 9, 8 to 10, 9 to 11, 10 to 12, 11 to 13, 12 to 14, 13 to 15, 14 to16, 15 to 17, 16 to 18, 17 to 19, 18 to 20, 19 to 21, 20 to 22, 21 to23, or 22 to 24 months. In certain embodiments, the time between any twotreatment cycles is about 24 months.

The number of injections of the anti-CD19 antibody compositions of theinvention per cycle may be fixed or variable to allow forpatient-specific differences in disease activity, diseaseresponsiveness, drug tolerability, recovery times, PK parameters, and/orpharmacological response(s). In certain embodiments, the number ofinjections per cycle can be 1, 2, 3, 4, 5, or 6 injections. In certainembodiments, the number of injections per cycle is 1 injection.

For any injection, the administered dose of the anti-CD19 antibodycompositions of the invention may be fixed or variable to allow forinitial drug loading and/or to account for patient-specific differencesin mass, body surface area, disease activity, disease responsiveness,drug tolerability, recovery times, PK parameters, and/or pharmacologicalresponse(s). In certain embodiments, the administered dose per injectionof the anti-CD19 antibody compositions of the invention is about 0.1mg/Kg of patient body weight, 0.3 mg/Kg of patient body weight, 1.0mg/Kg of patient body weight, 2.0 mg/Kg of patient body weight, 4.0mg/Kg of patient body weight, or 10 mg/Kg of patient body weight. Incertain embodiments, the administered dose per injection of theanti-CD19 antibody compositions of the invention is about 0.1 to 0.3,0.3 to 0.5, 0.5 to 0.7, 0.7 to 0.9, 0.9 to 1.1, 1.1 to 1.3, 1.3 to 1.5,1.5 to 1.7, 1.7 to 1.9, 1.9 to 2.1, 2.1 to 2.3, 2.3 to 2.5, 2.5 to 2.7,2.7 to 2.9, 2.9 to 3.1, 3.1 to 3.3, 3.3 to 3.5, 3.5 to 3.7, 3.7 to 3.9,3.9 to 4.1, 4.1 to 4.3, 4.3 to 4.5, 4.5 to 4.7, 4.7 to 4.9, 4.9 to 5.1,5.1 to 5.3, 5.3 to 5.5, 5.5 to 5.7, 5.7 to 5.9, 5.9 to 6.1, 6.1 to 6.3,6.3 to 6.5, 6.5 to 6.7, 6.7 to 6.9, 6.9 to 7.1, 7.1 to 7.3, 7.3 to 7.5,7.5 to 7.7, 7.7 to 7.9, 7.9 to 8.1, 8.1 to 8.3, 8.3 to 8.5, 8.5 to 8.7,8.7 to 8.9, 8.9 to 9.1, 9.1 to 9.3, 9.3 to 9.5, 9.5 to 9.7, 9.7 to 9.9,or 9.9 to 10.1 mg/Kg of patient body weight. In certain embodiments, theadministered dose per injection is about 0.3 mg/Kg of patient bodyweight.

If more than one injection is needed, the time between any twoinjections of the anti-CD19 antibody compositions of the invention maybe fixed or variable to accommodate patient-specific differences indisease activity, disease responsiveness, drug tolerability, recoverytimes, PK parameters, and/or pharmacological response(s). In certainembodiments, the time between any two injections is about 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28 days, 29, 30, 32, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, or 45 days. In certain embodiments, the time between any twoinjections is about 1 to 3, 1 to 5, 1 to 10, 1 to 15, 1 to 20, 1 to 25,1 to 30, 1 to 35, 1 to 40, or 1 to 45 days. In certain embodiments, thetime between any two injections is 1 day.

According to certain aspects of the invention, the anti-CD19 antibodyused in the compositions and methods of the invention, is a nakedantibody. In related embodiments, the dose of naked anti-CD19 antibodyused is at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10,10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17,17.5, 18, 18.5, 19, 19.5, 20, 20.5 mg/kg of body weight of a patient. Incertain embodiments, the dose of naked anti-CD19 antibody used is atleast about 1 to 10, 5 to 15, 10 to 20, or 15 to 25 mg/kg of body weightof a patient. In certain embodiments, the dose of naked anti-CD19antibody used is at least about 1 to 20, 3 to 15, or 5 to 10 mg/kg ofbody weight of a patient. In preferred embodiments, the dose of nakedanti-CD19 antibody used is at least about 5, 6, 7, 8, 9, or 10 mg/kg ofbody weight of a patient.

In certain embodiments, the dose comprises about 375 mg/m² of anti-CD19antibody administered weekly for 4 to 8 consecutive weeks. In certainembodiments, the dose is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, or 15 mg/kg of body weight of the patient administeredweekly for 4 to 8 consecutive weeks.

The exemplary doses of anti-CD19 antibody described above can beadministered as described herein. In one embodiment, the above doses aresingle dose injections. In other embodiments, the doses are administeredover a period of time. In other embodiments, the doses are administeredmultiple times over a period of time. The period of time may be measuredin days, months or weeks. Multiple doses of the anti-CD19 antibody canbe administered at intervals suitable to achieve a therapeutic benefitwhile balancing toxic side effects. For example, where multiple dosesare used, it is preferred to time the intervals to allow for recovery ofthe patient's monocyte count prior to the repeat treatment withantibody. This dosing regimen will optimize the efficiency of treatment,since the monocyte population reflects ADCC function in the patient.

In certain embodiments, the compositions of the invention areadministered to a human patient as long as the patient is responsive totherapy. In other embodiments, the compositions of the invention areadministered to a human patient as long as the patient's disease doesnot progress. In related embodiments, the compositions of the inventionare administered to a human patient until a patient's disease does notprogress or has not progressed for a period of time, then the patient isnot administered the compositions of the invention unless the diseasereoccurs or begins to progress again. For example, a patient can betreated with any of the above doses for about 4 to 8 weeks, during whichtime the patient is monitored for disease progression (i.e., activity ofan autoimmune disease or disorder). If disease progression stops orreverses, then the patient will not be administered the compositions ofthe invention until that patient relapses, i.e., the disease beingtreated reoccurs or progresses. Upon this reoccurrence or progression,the patient can be treated again with the same dosing regimen initiallyused or using other doses described above.

In certain embodiments, the compositions of the invention can beadministered as a loading dose followed by multiple lower doses(maintenance doses) over a period of time. In such embodiments, thedoses may be timed and the amount adjusted to maintain effective B celldepletion. In preferred embodiments, the loading dose is about 10, 11,12, 13, 14, 15, 16, 17, or 18 mg/kg of patient body weight and themaintenance dose is at least about 5 to 10 mg/kg of patient body weight.In preferred embodiments, the maintenance dose is administered atintervals of every 7, 10, 14 or 21 days. The maintenance doses can becontinued indefinitely, until toxicity is present, until platelet countdecreases, until there is no disease progression, until the patientgenerates an immune response to the drug, or until disease progresses toa terminal state. In yet other embodiments, the compositions of theinvention are administered to a human patient until the diseaseprogresses to a terminal stage.

In embodiments of the invention where circulating monocyte levels of apatient are monitored as part of a treatment regimen, doses of anti-CD19antibody administered may be spaced to allow for recovery of monocytecount. For example, a composition of the invention may be administeredat intervals of every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days.

In embodiments of the invention where an anti-CD19 antibody isconjugated to or administered in conjunction with a toxin, one skilledin the art will appreciate that the dose of anti-CD19 antibody can beadjusted based on the toxin dose and that the toxin dose will depend onthe specific type of toxin being used. Typically, where a toxin is used,the dose of anti-CD19 antibody will be less than the dose used with anaked anti-CD19 antibody. The appropriate dose can be determined for aparticular toxin using techniques well known in the art. For example, adose ranging study can be conducted to determine the maximum tolerateddose of anti-CD19 antibody when administered with or conjugated to atoxin.

In embodiments of the invention where an anti-CD19 antibody isconjugated to or administered in conjunction with a radiotherapeuticagent, the dose of the anti-CD19 antibody will vary depending on theradiotherapeutic used. In certain preferred embodiments, a two stepprocess is used. First, the human patient is administered a compositioncomprising a naked anti-CD19 antibody and about 6, 7, 8, 9, or 10 dayslater a small amount of the radiotherapeutic is administered. Second,once the tolerance, distribution, and clearance of the low dose therapyhas been determined, the patient is administered a dose of the nakedanti-CD19 antibody followed by a therapeutic amount of theradiotherapeutic is administered. Such treatment regimens are similar tothose approved for treatment of Non-Hodgkin's lymphoma using ZEVALIN™(Indium labeled anti-CD20 mAb) (Biogen Idec) or BEXXAR™ (GSK, CoulterPharmaceutical).

5.6.1.3. Transplantation

In further embodiments, Anti-CD19 immunotherapy encompasses methods oftreating a human patient with an early stage of GVHD, humoral rejection,or post-transplant lymphoproliferative disorder that has beencharacterized by stages. Anti-CD19 immunotherapy encompasses methods oftreating a human patient with an late stage of GVHD, humoral rejection,or post-transplant lymphoproliferative disorder that has beencharacterized by stages. Anti-CD19 immunotherapy encompasses methods oftreating or preventing GVHD, humoral rejection, or post-transplantlymphoproliferative disorder wherein the anti-CD19 antibody mediatesADCC, CDC, or apoptosis. Anti-CD19 immunotherapy encompasses methods oftreating GVHD, humoral rejection, or post-transplant lymphoproliferativedisorder, wherein the anti-CD19 antibody is administered before thepatient has received any other treatment for the GVHD, humoralrejection, or post-transplant lymphoproliferative disorder.

In a preferred embodiment, a human subject experiencing GVHD, humoralrejection, or post-transplant lymphoproliferative disorder can betreated by administering an anti-CD19 antibody. In certain embodiments,the anti-CD19 antibody is a human or humanized antibody that preferablymediates human ADCC. In cases of an early stage of GVHD, humoralrejection, or post-transplant lymphoproliferative disorder, anyanti-CD19 antibody that preferably mediates ADCC can be used in thehuman subjects (including murine and chimeric antibodies); however,human and humanized antibodies are preferred.

Antibodies of the IgG1 or IgG3 human isotypes are preferred for therapy.However, the IgG2 or IgG4 human isotypes can be used, provided theymediate human ADCC. Such effector function can be assessed by measuringthe ability of the antibody in question to mediate target cell lysis byeffector cells in vitro or in vivo.

The dose of antibody used should be sufficient to deplete circulating Bcells or to deplete B cells from a graft, or to deplete circulatingimmunoglobulin (Ig) in the recipient, or to deplete both circulating Bcells and immunoglobulin in the recipient. Progress of the therapy canbe monitored in the patient by analyzing blood samples. Other signs ofclinical improvement can be used to monitor therapy.

Methods for measuring depletion of B cells and Ig that can be used inconnection with the compositions and methods of the invention arewell-known in the art and include, but are not limited to the followingembodiments. In one embodiment, circulating B cell depletion can bemeasured with flow cytometry using a reagent other than an anti-CD19antibody that specifically binds to B cells thereby allowing them to beidentified and enumerated. In other embodiments, B cell and Ig levels inthe blood can be monitored using standard serum analysis. In suchembodiments, B cell depletion is indirectly measured by defining theamount to an antibody known to be produced by B cells. The level of thatantibody is then monitored to determine the depletion and/or functionaldepletion of B cells. In another embodiment, B cell depletion can bemeasured by immunochemical staining to identify B cells. In suchembodiments, B cells or tissues or serum comprising B cells extractedfrom a patient can be placed on microscope slides, labeled and examinedfor presence or absence. In related embodiments, a comparison is madebetween B cells extracted prior to therapy and after to determinedifferences in the presence of B cells.

In embodiments of the invention where the anti-CD19 antibody isadministered as a single agent therapy, the invention contemplates useof different treatment regimens. The treatment regimens can comprise oneor more treatment cycles depending on whether the regimen is indicatedfor pre-transplant conditioning, post-transplant maintenance, orpost-transplant treatment of an acute or chronic rejection. Theparticular regimen may also depend on whether the patient is assessed asbeing at high, intermediate, or low risk of developing a humoralresponse. In the context of rejection, the apparent stage of the humoralresponse to the graft may influence the treatment regimen chosen.Preferably, for pre-transplant conditioning, a single cycle isadministered. The single cycle may be administered to the recipient orto the graft, or to both the recipient and the graft. Forpost-transplant maintenance or prevention of GVHD, humoral rejection, orlymphoproliferative disorder, preferably multiple cycles areadministered. For the treatment of a rejection episode, preferably asingle high dose cycle is administered followed by one or more lowerdoses, either alone or in combination with other therapeutic regimens.The other therapeutic regimens may comprise, for example, one or moreantibodies directed against T cells or B cells, antibiotics, anti-viralagents, antibody depletion therapies, or immunosuppressive agents. Ifmore than one cycle is needed, the time between any two treatment cyclesmay be fixed or variable to accommodate patient-specific differencesincluding the patient's risk assessment for developing GVHD, a humoralrejection, or a lymphoproliferative disorder; or the stage of humoralrejection in a patient already presenting with rejection. Otherpatient-specific differences include, for example, responsiveness totherapy, drug tolerability, recovery times, pharmacokinetic (PK)parameters, and/or pharmacological response(s). For example, in certainembodiments, the time between any two treatment cycles can be about 2,4, 6, 8, or 10 days; 2 months, 4 months, 8 months, 12 months, 18 months,or 24 months. In certain embodiments, the time between any two treatmentcycles can be about 1, 3, 5, 7, or 9 days; 1 month, 3 months, 5 months,9 months, 11 months, 17 months, 19 months, 21 months, or 25 months. Incertain embodiments, the time between any two treatment cycles can beabout 2 to 4, 3 to 5, 6 to 8, 7 to 9, 8 to 10, 9 to 11, 10 to 12, 11 to13, 12 to 14, 13 to 15, 14 to 16, 15 to 17, 16 to 18, 17 to 19, 18 to20, 19 to 21, 20 to 22, 21 to 23, or 22 to 24 months. In certainembodiments, the time between any two treatment cycles is about 24months.

The number of injections of the anti-CD19 antibody compositions of theinvention per cycle may be fixed or variable to allow forpatient-specific differences including the patient's risk assessment fordeveloping GVHD, a humoral rejection, or a lymphoproliferative disorder;or the stage of humoral rejection in a patient already presenting withrejection. Other patient-specific differences include, for example,responsiveness to therapy, drug tolerability, recovery times, PKparameters, and/or pharmacological response(s). In certain embodiments,the number of injections per cycle can be 1, 2, 3, 4, 5, or 6injections. In certain embodiments, the number of injections per cycleis 1 injection.

For any injection, the administered dose of the anti-CD19 antibodycompositions of the invention may be fixed or variable to allow forinitial drug loading and/or to account for patient-specific differencesin mass, body surface area, disease activity, disease responsiveness,drug tolerability, recovery times, PK parameters, and/or pharmacologicalresponse(s). In certain embodiments, the administered dose per injectionof the anti-CD19 antibody compositions of the invention is about 0.1mg/kg of patient body weight, 0.3 mg/kg of patient body weight, 1.0mg/kg of patient body weight, 2.0 mg/kg of patient body weight, 4.0mg/kg of patient body weight, or 10 mg/kg of patient body weight. Incertain embodiments, the administered dose per injection of theanti-CD19 antibody compositions of the invention is about 0.1 to 0.3,0.3 to 0.5, 0.5 to 0.7, 0.7 to 0.9, 0.9 to 1.1, 1.1 to 1.3, 1.3 to 1.5,1.5 to 1.7, 1.7 to 1.9, 1.9 to 2.1, 2.1 to 2.3, 2.3 to 2.5, 2.5 to 2.7,2.7 to 2.9, 2.9 to 3.1, 3.1 to 3.3, 3.3 to 3.5, 3.5 to 3.7, 3.7 to 3.9,3.9 to 4.1, 4.1 to 4.3, 4.3 to 4.5, 4.5 to 4.7, 4.7 to 4.9, 4.9 to 5.1,5.1 to 5.3, 5.3 to 5.5, 5.5 to 5.7, 5.7 to 5.9, 5.9 to 6.1, 6.1 to 6.3,6.3 to 6.5, 6.5 to 6.7, 6.7 to 6.9, 6.9 to 7.1, 7.1 to 7.3, 7.3 to 7.5,7.5 to 7.7, 7.7 to 7.9, 7.9 to 8.1, 8.1 to 8.3, 8.3 to 8.5, 8.5 to 8.7,8.7 to 8.9, 8.9 to 9.1, 9.1 to 9.3, 9.3 to 9.5, 9.5 to 9.7, 9.7 to 9.9,or 9.9 to 10.1 mg/kg of patient body weight. In certain embodiments, theadministered dose per injection is about 0.3 mg/kg of patient bodyweight. If more than one injection is needed, the time between any twoinjections of the anti-CD19 antibody compositions of the invention maybe fixed or variable to accommodate patient-specific differencesincluding the patient's risk assessment for developing GVHD, a humoralrejection, or a lymphoproliferative disorder; or the stage of humoralrejection in a patient already presenting with rejection. Otherpatient-specific differences include, for example, disease activity,disease responsiveness to therapy, drug tolerability, recovery times, PKparameters, and/or pharmacological response(s). In certain embodiments,the time between any two injections is about 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 32, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or45 days. In certain embodiments, the time between any two injections isabout 1 to 3, 1 to 5, 1 to 10, 1 to 15, 1 to 20, 1 to 25, 1 to 30, 1 to35, 1 to 40, or 1 to 45 days. In certain embodiments, the time betweenany two injections is 1 day.

5.6.2. Combination Therapies

5.6.2.1. Combination with Immunoregulatory Agents

The anti-CD19 immunotherapy of the invention may also be used inconjunction with one or more immunoregulatory agents. In this approach,the use of chimerized antibodies is preferred; the use of human orhumanized anti-CD19 antibody is most preferred. The term“immunoregulatory agent” as used herein for combination therapy refersto substances that act to suppress, mask, or enhance the immune systemof the host.

Examples of immunomodulatory agents include, but are not limited to,proteinaceous agents such as cytokines, peptide mimetics, and antibodies(e.g., human, humanized, chimeric, monoclonal, polyclonal, Fvs, ScFvs,Fab or F(ab′)₂ fragments or epitope binding fragments), nucleic acidmolecules (e.g., antisense nucleic acid molecules, iRNA and triplehelices), small molecules, organic compounds, and inorganic compounds.In particular, immunomodulatory agents include, but are not limited to,methothrexate, leflunomide, cyclophosphamide, cytoxan, Immuran,cyclosporine A, minocycline, azathioprine, antibiotics (e.g., FK506(tacrolimus)), methylprednisolone (MP), corticosteroids, steroids,mycophenolate mofetil, rapamycin (sirolimus), mizoribine,deoxyspergualin, brequinar, malononitriloamindes (e.g., leflunamide), Tcell receptor modulators, and cytokine receptor modulators. Examples ofimmunosuppressants, include, but are not limited to, mycophenolatemofetil (CELLCEPT™), D-penicillamine (CUPRIMINE™, DEPEN™), methotrexate(RHEUMATREX™, TREXALL™), and hydroxychloroquine sulfate (PLAQUENIL™)

Immunomodulatory agents would also include substances that suppresscytokine production, downregulate or suppress self-antigen expression,or mask the MHC antigens. Examples of such agents include2-amino-6-aryl-5-substituted pyrimidines (see, U.S. Pat. No. 4,665,077),azathioprine (or cyclophosphamide, if there is an adverse reaction toazathioprine); bromocryptine; glutaraldehyde (which masks the MHCantigens, as described in U.S. Pat. No. 4,120,649); anti-idiotypicantibodies for MHC antigens and MHC fragments; cyclosporin A; steroidssuch as glucocorticosteroids, e.g., prednisone, methylprednisolone, anddexamethasone; cytokine or cytokine receptor antagonists includinganti-interferon-γ, -β, or -α antibodies; anti-tumor necrosis factor-αantibodies; anti-tumor necrosis factor-β antibodies; anti-interleukin-2antibodies and anti-IL-2 receptor antibodies; anti-L3T4 antibodies;heterologous anti-lymphocyte globulin; pan-T cell antibodies, preferablyanti-CD3 or anti-CD4/CD4a antibodies; soluble peptide containing a LFA-3binding domain (WO 90/08187 published Jul. 26, 1990); streptokinase;TGF-β; streptodornase; RNA or DNA from the host; FK506; RS-61443;deoxyspergualin; rapamycin; T cell receptor (U.S. Pat. No. 5,114,721); Tcell receptor fragments (Offner et al., Science, 251:430-432 (1991); WO90/11294; and WO 91/01133); and T cell receptor antibodies (EP 340,109)such as T10B9.

Examples of cytokines include, but are not limited to lymphokines,monokines, and traditional polypeptide hormones. Included among thecytokines are growth hormones such as human growth hormone, N-methionylhuman growth hormone, and bovine growth hormone; parathyroid hormone;thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoproteinhormones such as follicle stimulating hormone (FSH), thyroid stimulatinghormone (TSH), and luteinizing hormone (LH); hepatic growth factor;fibroblast growth factor; prolactin; placental lactogen; tumor necrosisfactor-α; mullerian-inhibiting substance; mouse gonadotropin-associatedpeptide; inhibin; activin; vascular endothelial growth factor; integrin;thrombopoiotin (TPO); nerve growth factors such as NGF-α;platelet-growth factor; transforming growth factors (TGFs) such as TGF-αand TGF-α; insulin-like growth factor-I and -II; erythropoietin (EPO);osteoinductive factors; interferons; colony stimulating factors (CSFs)such as macrophage-CSF (M-CSF); granulocyte-macrophage-CgP (GM-CSP); andgranulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1a, IL-2,IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15; atumor necrosis factor such as TNF-α or TNF-β; and other polypeptidefactors including LIF and kit ligand (KL). As used herein, the termcytokine includes proteins from natural sources or from recombinant cellculture and biologically active equivalents of the native sequencecytokines. In certain embodiments, the methods further includeadministering to the subject one or more immunomodulatory agents,preferably a cytokine Preferred cytokines are selected from the groupconsisting of interleukin-1 (IL-1), IL-2, IL-3, IL-12, IL-15, IL-18,G-CSF, GM-CSF, thrombopoietin, and γ interferon.

In certain embodiments, the immunomodulatory agent is a cytokinereceptor modulator. Examples of cytokine receptor modulators include,but are not limited to, soluble cytokine receptors (e.g., theextracellular domain of a TNF-α receptor or a fragment thereof, theextracellular domain of an IL-1β receptor or a fragment thereof, and theextracellular domain of an IL-6 receptor or a fragment thereof),cytokines or fragments thereof (e.g., interleukin (IL)-2, IL-3, IL-4,IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, TNF-α, TNF-β,interferon (IFN)-α, IFN-β, IFN-γ, and GM-CSF), anti-cytokine receptorantibodies (e.g., anti-IL-2 receptor antibodies, anti-IL-4 receptorantibodies, anti-IL-6 receptor antibodies, anti-IL-10 receptorantibodies, and anti-IL-12 receptor antibodies), anti-cytokineantibodies (e.g., anti-IFN receptor antibodies, anti-TNF-α antibodies,anti-IL-1β antibodies, anti-IL-6 antibodies, and anti-IL-12 antibodies).In a specific embodiment, a cytokine receptor modulator is IL-4, IL-10,or a fragment thereof. In another embodiment, a cytokine receptormodulator is an anti-IL-1β antibody, anti-IL-6 antibody, anti-IL-12receptor antibody, anti-TNF-α antibody. In another embodiment, acytokine receptor modulator is the extracellular domain of a TNF-αreceptor or a fragment thereof. In certain embodiments, a cytokinereceptor modulator is not a TNF-α antagonist.

In certain embodiments, the immunomodulatory agent is a T cell receptormodulator. Examples of T cell receptor modulators include, but are notlimited to, anti-T cell receptor antibodies (e.g., anti-CD4 antibodies(e.g., cM-T412 (Boeringer), IDEC-CE9.1® (IDEC and SKB), mAB 4162W94,Orthoclone and OKTcdr4a (Janssen-Cilag)), anti-CD3 antibodies, anti-CD5antibodies (e.g., an anti-CD5 ricin-linked immunoconjugate), anti-CD7antibodies (e.g., CHH-380 (Novartis)), anti-CD8 antibodies, anti-CD40ligand monoclonal antibodies, anti-CD52 antibodies (e.g., CAMPATH™-1H(Ilex)), anti-CD2 monoclonal antibodies) and CTLA4-immunoglobulin.

In certain embodiments, the immunomodulatory agent is a TNF-αantagonist. Examples of TNF-α antagonists include, but are not limitedto, antibodies (e.g., infliximab (REMICADE™; Centocor), D2E7 (AbbottLaboratories/Knoll Pharmaceuticals Co., Mt. Olive, N.J.), CDP571 whichis also known as HUMIRA™ and CDP-870 (both of Celltech/Pharmacia,Slough, U.K.), and TN3-19.12 (Williams et al., 1994, Proc. Natl. Acad.Sci. USA, 91:2762-2766; Thorbecke et al., 1992, Proc. Natl. Acad. Sci.USA, 89:7375-7379)) soluble TNF-α receptors (e.g., sTNF-R1 (Amgen),etanercept (ENBREL™; Immunex) and its rat homolog RENBREL™, solubleinhibitors of TNF-α derived from TNFrI, TNFrII (Kohno et al., 1990,Proc. Natl. Acad. Sci. USA, 87:8331-8335), and TNF-α Inh (Seckinger etal., 1990, Proc. Natl. Acad. Sci. USA, 87:5188-5192)), IL-10, TNFR-IgG(Ashkenazi et al., 1991, Proc. Natl. Acad. Sci. USA, 88:10535-10539),the murine product TBP-1 (Serono/Yeda), the vaccine CytoTAb(Protherics), antisense molecule 104838 (ISIS), the peptide RDP-58(SangStat), thalidomide (Celgene), CDC-801 (Celgene), DPC-333 (Dupont),VX-745 (Vertex), AGIX-4207 (AtheroGenics), ITF-2357 (Italfarmaco),NPI-13021-31 (Nereus), SCIO-469 (Scios), TACE targeter (Immunix/AHP),CLX-120500 (Calyx), Thiazolopyrim (Dynavax), auranofin (Ridaura)(SmithKline Beecham Pharmaceuticals), quinacrine (mepacrinedichlorohydrate), tenidap (Enablex), Melanin (Large Scale Biological),and anti-p38 MAPK agents by Uriach.

These immunoregulatory agents are administered at the same time or atseparate times from the anti-CD19 antibodies of the invention, and areused at the same or lesser dosages than as set forth in the art. Thepreferred immunoregulatory agent will depend on many factors, including,for example, type of autoimmune disease or disorder being treated, orwhether the treatment is prophylactic or whether it is to treat an earlyor later stage of GVHD or graft rejection, as well as the patient'shistory, but a general overall preference is that the agent be selectedfrom cyclosporin A, a glucocorticosteroid (most preferably prednisone ormethylprednisolone), OKT-3 monoclonal antibody, azathioprine,bromocryptine, heterologous anti-lymphocyte globulin, or a mixturethereof.

5.6.2.2. Combination with Anti-Inflammatory Agents and Therapies

The anti-CD19 immunotherapy of the invention of the present inventionmay also be in conjunction with an anti-inflammatory agent.Anti-inflammatory agents have exhibited success in treatment ofinflammatory and autoimmune disorders and are now a common and astandard treatment for such disorders. Any anti-inflammatory agentwell-known to one of skill in the art can be used in the compositionsand methods of the invention.

Non-limiting examples of anti-inflammatory agents include non-steroidalanti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs,beta-agonists, anticholingeric agents, and methyl xanthines. Examples ofNSAIDs include, but are not limited to, aspirin, ibuprofen, celecoxib(CELEBREX™), diclofenac (VOLTAREN™), etodolac (LODINET™), fenoprofen(NALFON™), indomethacin (INDOCINT™), ketoralac (TORADOL™), oxaprozin(DAYPRO™), nabumentone (RELAFEN™), sulindac (CLINORIL™), tolmentin(TOLECTIN™), rofecoxib (VIOXX™), naproxen (ALEVE™, NAPROSYN™),ketoprofen (ORUDIS™ and ACTRON™), nabumetone (RELAFEN™), diclofenac &misoprostol (ARTHROTEC™), ibuprofen (MOTRIN™, ADVIL™, NUPRIN™),ketorolac (TORADOL™), valdecoxib (BEXTRA™), meloxicam (MOBIC™),flurbiprofen (ANSAID™), and piroxicam (FELDENE™). Such NSAIDs functionby inhibiting a cyclooxygenase enzyme (e.g., COX-1 and/or COX-2).

Examples of steroidal anti-inflammatory drugs include, but are notlimited to, glucocorticoids, dexamethasone (DECADRON™), cortisone,hydrocortisone, prednisone (DELTASONE™), prednisolone, triamcinolone,azulfidine, and eicosanoids such as prostaglandins, thromboxanes, andleukotrienes.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) can also be used inconjunction with the anti-CD19 antibodies of the compositions andmethods of the invention. DMARDs work by suppressing the immune systemand decreasing inflammation, however DMARDs take time to show results incomparison to other drugs. Examples of DMARDs include, but are notlimited to, hydroxychloroquine (PLAQUENIL™), chlorambucil (LEUKERAN™),cyclosphosphamide (CYTOXAN™), leflunomide (ARAVA™), methotrexate, andcyclosporine (NEORAL™)

In certain embodiments, the anti-CD19 immunotherapy of the invention ofthe present invention may also be in conjunction with ananti-inflammatory therapy. A non-limiting example of such therapy isprotein-A immuoadsorption therapy. According to this therapy, apatient's blood is filtered to remove antibodies and immune complexesthat promote inflammation. This filtering can be achieved by methodswell known to those of skill in the art.

These anti-inflammatory agents and therapies are administered at thesame time or at separate times from the anti-CD19 antibodies of theinvention, and are used at the same or lesser dosages than as set forthin the art. The preferred anti-inflammatory agent will depend on manyfactors, including the type of autoimmune disease or disorder beingtreated, as well as the patient's history.

In some embodiments, these anti-inflammatory agents and therapies areadministered at the same time or at separate times from the anti-CD19antibodies of the invention, and are used at the same or lesser dosagesthan as set forth in the art. The preferred anti-inflammatory agent willdepend on many factors, including whether the treatment is prophylacticor whether it is to treat an early or later stage of GVHD or graftrejection, as well as the patient's history.

In other embodiments, these anti-inflammatory agents and therapies areadministered at the same time or at separate times from the anti-CD19antibodies of the invention, and are used at the same or lesser dosagesthan as set forth in the art. The preferred anti-inflammatory agent willdepend on many factors, including whether the treatment is prophylacticor whether it is to treat an early or later stage of GVHD or graftrejection, as well as the patient's history.

5.6.2.3. Combination with Therapeutic Antibodies

The anti-CD19 antibodies, compositions, and methods of the invention maybe administered in combination with one or more other antibodies,including, but not limited to, anti-CD19 antibodies, anti-CD20antibodies, anti-CD52 antibodies, and anti-CD22 antibodies (asdescribed, for example, in U.S. Patent Application Publication No.2005/0070693, U.S. Pat. No. 5,484,892, U.S. Patent ApplicationPublication No. 2004/0001828 of U.S. application Ser. No. 10/371,797,U.S. Patent Application Publication No. 2003/0202975 of U.S. applicationSer. No. 10/372,481, and U.S. Provisional Application Ser. No.60/420,472, the entire contents of each of which are incorporated byreference herein for their teachings of CD22 antigens and anti-CD22antibodies). The antibodies are preferably monoclonal antibodies. In oneembodiment, the anti-CD19 antibodies, compositions, and methods of theinvention are administered in combination with anti-CD20 antibodies,such as RITUXAN™ (C2B8; RITUXIMAB™; IDEC Pharmaceuticals). Otherexamples of therapeutic antibodies that can be used in combination withthe antibodies of the invention or used in the compositions of theinvention include, but are not limited to, HERCEPTIN™ (Trastuzumab;Genentech), MYLOTARG™ (Gemtuzumab ozogamicin; Wyeth Pharmaceuticals),CAMPATH™ (Alemtuzumab; Berlex), ZEVALIN™ (Ipritumomab tiuxetan; BiogenIdec), BEXXAR™(Tositumomab; GlaxoSmithKline Corixa), ERBITUX™(Cetuximab; Imclone), AVASTIN™ (Bevacizumab; Genentech), and LymphoStat™(Human Genome Sciences).

In certain embodiments, the anti-CD19 and anti-CD20 and/or anti-CD22antibodies can be administered, optionally in the same pharmaceuticalcomposition, in any suitable ratio. To illustrate, the ratio of theanti-CD19 and anti-CD20 antibody can be a ratio of about 1000:1, 500:1,250:1, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 19:1,18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1,6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9,1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:30,1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:250, 1:500, or 1:1000 ormore. Likewise, the ratio of the anti-CD19 and anti-CD22 antibody can bea ratio of about 1000:1, 500:1, 250:1, 100:1, 90:1, 80:1, 70:1, 60:1,50:1, 40:1, 30:1, 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1,11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4,1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17,1:18, 1:19, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100,1:250, 1:500, or 1:1000 or more.

5.6.2.4. Combination with Compounds that Enhance Monocyte or MacrophageFunction

In certain embodiments of the methods of the invention, a compound thatenhances monocyte or macrophage function (e.g., at least about 25%, 50%,75%, 85%, 90%, 95% or more) can be used in conjunction with theanti-CD19 immunotherapy. Such compounds are known in the art andinclude, without limitation, cytokines such as interleukins (e.g.,IL-12), and interferons (e.g., alpha or gamma interferon).

The compound that enhances monocyte or macrophage function orenhancement can be formulated in the same pharmaceutical composition asthe antibody, immunoconjugate or antigen-binding fragment. Whenadministered separately, the antibody/fragment and the compound can beadministered concurrently (within a period of hours of each other), canbe administered during the same course of therapy, or can beadministered sequentially (i.e., the patient first receives a course ofthe antibody/fragment treatment and then a course of the compound thatenhances macrophage/monocyte function or vice versa). In suchembodiments, the compound that enhances monocyte or macrophage functionis administered to the human subject prior to, concurrently with, orfollowing treatment with other therapeutic regimens and/or thecompositions of the invention. In one embodiment, the human subject hasa blood leukocyte, monocyte, neutrophil, lymphocyte, and/or basophilcount that is within the normal range for humans. Normal ranges forhuman blood leukocytes (total) is about 3.5-about 10.5 (10⁹/L). Normalranges for human blood neutrophils is about 1.7-about 7.0 (10⁹/L),monocytes is about 0.3-about 0.9 (10⁹/L), lymphocytes is about 0.9-about2.9 (10⁹/L), basophils is about 0-about 0.3 (10⁹/L), and eosinophils isabout 0.05-about 0.5 (10⁹/L). In other embodiments, the human subjecthas a blood leukocyte count that is less than the normal range forhumans, for example, at least about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5,0.6, 0.7, or 0.8 (10⁹/L) leukocytes.

This embodiment of the invention can be practiced with the antibodies,immunoconjugates or antibody fragments of the invention or with otherantibodies known in the art and is particularly suitable for subjectsthat are resistant to anti-CD19, anti-CD20 and/or anti-CD22 antibodytherapy (for example, therapy with existing antibodies such as C2B8),subjects that are currently being or have previously been treated withchemotherapy, subjects that have had a relapse in a B cell disorder,subjects that are immunocompromised, or subjects that otherwise have animpairment in macrophage or monocyte function. The prevalence ofpatients that are resistant to therapy or have a relapse in anautoimmune disease or disorder may be attributable, at least in part, toan impairment in macrophage or monocyte function. Thus, the inventionprovides methods of enhancing ADCC and/or macrophage and/or monocytefunction to be used in conjunction with the methods of administeringanti-CD19 antibodies and antigen-binding fragments.

5.6.2.5. Combination with Chemotherapeutic Agents

Anti-CD19 immunotherapy (using naked antibody, immunoconjugates, orfusion proteins) can be used in conjunction with other therapiesincluding but not limited to, chemotherapy, radioimmunotherapy (RIT),chemotherapy and external beam radiation (combined modality therapy,CMT), or combined modality radioimmunotherapy (CMRIT) alone or incombination, etc. In certain preferred embodiments, the anti-CD19antibody therapy of the present invention can be administered inconjunction with CHOP (Cyclophosphamide-Hydroxydoxorubicin-Oncovin(vincristine)-Prednisolone). As used herein, the term “administered inconjunction with” means that the anti-CD19 immunotherapy can beadministered before, during, or subsequent to the other therapyemployed.

In certain embodiments, the anti-CD19 immunotherapy is in conjunctionwith a cytotoxic radionuclide or radiotherapeutic isotope. For example,an alpha-emitting isotope such as ²²⁵Ac, ²²⁴Ac, ²¹¹AT, ²¹²Bi, ²¹³Bi,²¹²Pb, ²²⁴Ra, or ²²³Ra. Alternatively, the cytotoxic radionuclide may abeta-emitting isotope such as ¹⁸⁶Re, ¹⁸⁸Re, ⁹⁰Y, ¹³¹I, ⁶⁷Cu, ¹⁷⁷Lu,¹⁵³Sm, ¹⁶⁶Ho, or ⁶⁴Cu. Further, the cytotoxic radionuclide may emitAuger and low energy electrons and include the isotopes ¹²⁵I, ¹²³I or⁷⁷Br. In other embodiments the isotope may be ¹⁹⁸Au, ³²P, and the like.In certain embodiments, the amount of the radionuclide administered tothe subject is between about 0.001 mCi/kg and about 10 mCi/kg.

In some preferred embodiments, the amount of the radionuclideadministered to the subject is between about 0.1 mCi/kg and about 1.0mCi/kg. In other preferred embodiments, the amount of the radionuclideadministered to the subject is between about 0.005 mCi/kg and 0.1mCi/kg.

In certain embodiments, the anti-CD19 immunotherapy is in conjunctionwith a chemical toxin or chemotherapeutic agent. Preferably the chemicaltoxin or chemotherapeutic agent is selected from the group consisting ofan enediyne such as calicheamicin and esperamicin; duocarmycin,methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine,mitomycin C, cis-platinum, etoposide, bleomycin and 5-fluorouracil.

Suitable chemical toxins or chemotherapeutic agents that can be used incombination therapies with the anti-CD19 immunotherapy include membersof the enediyne family of molecules, such as calicheamicin andesperamicin. Chemical toxins can also be taken from the group consistingof duocarmycin (see, e.g., U.S. Pat. No. 5,703,080 and U.S. Pat. No.4,923,990), methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C,vindesine, mitomycin C, cis-platinum, etoposide, bleomycin and5-fluorouracil. Examples of chemotherapeutic agents also includeadriamycin, doxorubicin, 5-fluorouracil, cytosine arabinoside (Ara-C),cyclophosphamide, thiotepa, taxotere (docetaxel), busulfan, cytoxin,taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin,etoposide, ifosfamide, mitomycin c, mitoxantrone, vincreistine,vinorelbine, carboplatin, teniposide, daunomycin, caminomycin,aminopterin, dactinomycin, mitomycins, esperamicins (see, U.S. Pat. No.4,675,187), melphalan and other related nitrogen mustards.

In other embodiments, for example, “CVB” (1.5 g/m² cyclophosphamide,200-400 mg/m² etoposide, and 150-200 mg/m² carmustine) can be used inthe combination therapies of the invention. CVB is a regimen used totreat non-Hodgkin's lymphoma. Patti et al., Eur. J. Haematol. 51:18(1993). Other suitable combination chemotherapeutic regimens arewell-known to those of skill in the art. See, for example, Freedman etal., “Non-Hodgkin's Lymphomas,” in Cancer Medicine, Volume 2, 3rdEdition, Holland et al. (eds.), pp. 2028-2068 (Lea & Febiger 1993). Asan illustration, first generation chemotherapeutic regimens fortreatment of intermediate-grade non-Hodgkin's lymphoma include C-MOPP(cyclophosphamide, vincristine, procarbazine and prednisone) and, CHOP(cyclophosphamide, doxorubicin, vincristine, and prednisone). A usefulsecond generation chemotherapeutic regimen is, m-BACOD (methotrexate,bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone andleucovorin), while a suitable third generation regimen is MACOP-B(methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone,bleomycin and leucovorin). Additional useful drugs include phenylbutyrate and brostatin-1. In a preferred multimodal therapy, bothchemotherapeutic drugs and cytokines are co-administered with anantibody, immunoconjugate or fusion protein according to the presentinvention. The cytokines, chemotherapeutic drugs and antibody,immunoconjugate or fusion protein can be administered in any order, ortogether.

Other toxins that are preferred for use in the compositions and methodsof the invention include poisonous lectins, plant toxins such as ricin,abrin, modeccin, botulina and diphtheria toxins. Of course, combinationsof the various toxins could also be coupled to one antibody moleculethereby accommodating variable cytotoxicity. Illustrative of toxinswhich are suitably employed in the combination therapies of theinvention are ricin, abrin, ribonuclease, DNase I, Staphylococcalenterotoxin-A, pokeweed anti-viral protein, gelonin, diphtherin toxin,Pseudomonas exotoxin, and Pseudomonas endotoxin. See, for example,Pastan et al., Cell, 47:641 (1986), and Goldenberg et al., CancerJournal for Clinicians, 44:43 (1994). Enzymatically active toxins andfragments thereof which can be used include diphtheria A chain,non-binding active fragments of diphtheria toxin, exotoxin A chain (fromPseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain,alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacaamericana proteins (PAPI, PAPII, and PAP-S), momordica charantiainhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin,mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.See, for example, WO 93/21232 published Oct. 28, 1993.

Suitable toxins and chemotherapeutic agents are described in Remington'sPharmaceutical Sciences, 19th Ed. (Mack Publishing Co. 1995), and inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Ed.(MacMillan Publishing Co. 1985). Other suitable toxins and/orchemotherapeutic agents are known to those of skill in the art.

The anti-CD19 immunotherapy of the present invention may also be inconjunction with a prodrug-activating enzyme which converts a prodrug(e.g., a peptidyl chemotherapeutic agent, see, WO81/01145) to an activeanti-cancer drug. See, for example, WO 88/07378 and U.S. Pat. No.4,975,278. The enzyme component of such combinations includes any enzymecapable of acting on a prodrug in such a way so as to covert it into itsmore active, cytotoxic form. The term “prodrug” as used in thisapplication refers to a precursor or derivative form of apharmaceutically active substance that is less cytotoxic to tumor cellscompared to the parent drug and is capable of being enzymaticallyactivated or converted into the more active parent form. See, e.g.,Wilman, “Prodrugs in Cancer Chemotherapy” Biochemical SocietyTransactions, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stellaet al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery,”Directed Drug Delivery, Borchardt et al. (ed.), pp. 247-267, HumanaPress (1985). Prodrugs that can be used in combination with theanti-CD19 antibodies of the invention include, but are not limited to,phosphate-containing prodrugs, thiophosphate-containing prodrugs,sulfate-containing prodrugs, peptide-containing prodrugs, D-aminoacid-modified prodrugs, glycosylated prodrugs, α-lactam-containingprodrugs, optionally substituted phenoxyacetamide-containing prodrugs oroptionally substituted phenylacetamide-containing prodrugs,5-fluorocytosine and other 5-fluorouridine prodrugs which can beconverted into the more active cytotoxic free drug. Examples ofcytotoxic drugs that can be derivatized into a prodrug form for use inthis invention include, but are not limited to, those chemotherapeuticagents described above.

In certain embodiments, administration of the compositions and methodsof the invention may enable the postponement of toxic therapy and mayhelp avoid unnecessary side effects and the risks of complicationsassociated with chemotherapy and delay development of resistance tochemotherapy. In certain embodiments, toxic therapies and/or resistanceto toxic therapies is delayed in patients administered the compositionsand methods of the invention delay for up to about 6 months, 1, 2, 3, 4,5, 6, 7, 8, 9, or 10 years.

5.6.2.6. Combination with Therapeutic Antibodies

The anti-CD19 immunotherapy described herein may be administered incombination with other antibodies, including, but not limited to,anti-CD20 mAb, anti-CD52 mAb, anti-CD22 antibody (as described, forexample, in U.S. Pat. No. 5,484,892, U.S. patent publication number2004/0001828 of U.S. application Ser. No. 10/371,797, U.S. patentpublication number 2003/0202975 of U.S. application Ser. No. 10/372,481and U.S. provisional application Ser. No. 60/420,472, the entirecontents of each of which are incorporated by reference herein for theirteachings of CD22 antigens and anti-CD22 antibodies), and anti-CD20antibodies, such as RITUXAN™ (C2B8; RITUXIMAB™; Biogen Idec). Otherexamples of therapeutic antibodies that can be used in combination withthe antibodies of the invention or used in the compositions of theinvention include, but are not limited to, HERCEPTIN™ (Trastuzumab;Genentech), MYLOTARG™ (Gemtuzumab ozogamicin; Wyeth Pharmaceuticals),CAMPATH™ (Alemtuzumab; Berlex), ZEVALIN™ (Ipritumomab tiuxetan; BiogenIdec), BEXXAR™ (Tositumomab; GlaxoSmithKline Corixa), ERBITUX™(Cetuximab; Imclone), and AVASTIN™ (Bevacizumab; Genentech).

In certain embodiments, the anti-CD19 and anti-CD20 and/or anti-CD22 mAbcan be administered, optionally in the same pharmaceutical composition,in any suitable ratio. To illustrate, the ratio of the anti-CD19 andanti-CD20 antibody can be a ratio of about 1000:1, 500:1, 250:1, 100:1,90:1, 80:1, 70:1, 60;1, 50:1, 40:1, 30:1. 20:1, 19:1, 18:1, 17:1, 16:1,15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1,2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12,1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:30, 1:40, 1:50, 1:60,1:70, 1:80, 1:90, 1:100, 1:250, 1:500 or 1:1000 or more. Likewise, theratio of the anti-CD19 and anti-CD22 antibody can be a ratio of about1000:1, 500:1, 250:1, 100:1, 90:1, 80:1, 70:1, 60;1, 50:1, 40:1, 30:1.20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1,8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7,1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19,1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:250, 1:500 or1:1000 or more.

5.6.2.7. Combination Compounds that Enhance Monocyte or MacrophageFunction

In certain embodiments of the methods of the invention, a compound thatenhances monocyte or macrophage number or function (e.g., at least about25%, 50%, 75%, 85%, 90%, 95% or more) can be used in conjunction withthe anti-CD19 immunotherapy. Such compounds are known in the art andinclude, without limitation, cytokines such as interleukins (e.g.,IL-12), and interferons (e.g., alpha or gamma interferon).

The compound that enhances monocyte or macrophage function orenhancement can be formulated in the same pharmaceutical composition asthe antibody, immunoconjugate or antigen-binding fragment. Whenadministered separately, the antibody/fragment and the compound can beadministered concurrently (within a period of hours of each other), canbe administered during the same course of therapy, or can beadministered sequentially (i.e., the patient first receives a course ofthe antibody/fragment treatment and then a course of the compound thatenhances macrophage/monocyte function or vice versa). In suchembodiments, the compound that enhances monocyte or macrophage functionis administered to the human subject prior to, concurrently with, orfollowing treatment with other therapeutic regimens and/or thecompositions of the invention. In one embodiment, the human subject hasa blood leukocyte, monocyte, neutrophil, lymphocyte, and/or basophilcount that is within the normal range for humans. Normal range for humanblood leukocytes (total) is about 3.5-about 10.5 (10⁹/L). Normal rangefor human blood neutrophils is about 1.7-about 7.0 (10⁹/L), monocytes isabout 0.3-about 0.9 (10⁹/L), lymphocytes is about 0.9-about 2.9 (10⁹/L),basophils is about 0-about 0.3 (10⁹/L), and eosinophils is about0.05-about 0.5 (10⁹/L). In other embodiments, the human subject has ablood leukocyte count that is less than the normal range for humans, forexample at least about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, or0.8 (10⁹/L) leukocytes.

This embodiment of the invention can be practiced with the antibodies,immunoconjugates or antibody fragments of the invention or with otherantibodies known in the art and is particularly suitable for subjectsthat are resistant to anti-CD19, anti-CD20 and/or anti-CD22 antibodytherapy (for example, therapy with existing antibodies such as C2B8),subjects that are currently being or have previously been treated withchemotherapy, subjects that have had a relapse in a B cell disorder,subjects that are immunocompromised, or subjects that otherwise have animpairment in macrophage or monocyte function. The prevalence ofpatients that are resistant to therapy or have a relapse in a B celldisorder may be attributable, at least in part, to an impairment inmacrophage or monocyte function. Thus, the invention provides methods ofenhancing ADCC and/or macrophage and/or monocyte function to be used inconjunction with the methods of administering anti-CD19 antibodies andantigen-binding fragments.

5.6.2.8. Combination with Immunoregulatory Agents

The anti-CD19 immunotherapy of the present invention may also be used inconjunction with an immunoregulatory agent. In this approach, the use ofchimerized antibodies is preferred; the use of human or humanizedanti-CD19 antibody is most preferred. The term “immunoregulatory agent”as used herein for combination therapy refers to substances that act tosuppress, mask, or enhance the immune system of the host. This wouldinclude substances that suppress cytokine production, downregulate orsuppress self-antigen expression, or mask the MHC antigens. Examples ofsuch agents include 2-amino-6-aryl-5-substituted pyrimidines (see, U.S.Pat. No. 4,665,077), azathioprine (or cyclophosphamide, if there is anadverse reaction to azathioprine); bromocryptine; glutaraldehyde (whichmasks the MHC antigens, as described in U.S. Pat. No. 4,120,649);anti-idiotypic antibodies for MHC antigens and MHC fragments;cyclosporin A; steroids such as glucocorticosteroids, e.g., prednisone,methylprednisolone, and dexamethasone; cytokine or cytokine receptorantagonists including anti-interferon-γ, -β, or -α antibodies;anti-tumor necrosis factor-α antibodies; anti-tumor necrosis factor-βantibodies; anti-interleukin-2 antibodies and anti-IL-2 receptorantibodies; anti-L3T4 antibodies; heterologous anti-lymphocyte globulin;pan-T antibodies, preferably anti-CD3 or anti-CD4/CD4a antibodies;soluble peptide containing a LFA-3 binding domain (WO 90/08187 publishedJul. 26, 1990); streptokinase; TGF-β; streptodornase; RNA or DNA fromthe host; FK506; RS-61443; deoxyspergualin; rapamycin; T-cell receptor(U.S. Pat. No. 5,114,721); T-cell receptor fragments (Offner et al.,Science 251:430-432 (1991); WO 90/11294; and WO 91/01133); and T-cellreceptor antibodies (EP 340,109) such as T10B9. Examples of cytokinesinclude, but are not limited to lymphokines, monokines, and traditionalpolypeptide hormones. Included among the cytokines are growth hormonesuch as human growth hormone, N-methionyl human growth hormone, andbovine growth hormone; parathyroid hormone; thyroxine; insulin;proinsulin; relaxin; prorelaxin; glycoprotein hormones such as folliclestimulating hormone (FSH), thyroid stimulating hormone (TSH), andluteinizing hormone (LH); hepatic growth factor; fibroblast growthfactor; prolactin; placental lactogen; tumor necrosis factor-α;mullerian-inhibiting substance; mouse gonadotropin-associated peptide;inhibin; activin; vascular endothelial growth factor; integrin;thrombopoiotin (TPO); nerve growth factors such as NGF-α;platelet-growth factor; transforming growth factors (TGFs) such as TGF-αand TGF-α; insulin-like growth factor-I and -II; erythropoietin (EPO);osteoinductive factors; interferons; colony stimulating factors (CSFs)such as macrophage-CSF (M-CSF); granulocyte-macrophage-CgP (GM-CSP); andgranulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1a, IL-2,IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15; a tumornecrosis factor such as TNF-α or TNF-β; and other polypeptide factorsincluding LIF and kit ligand (KL). As used herein, the term cytokineincludes proteins from natural sources or from recombinant cell cultureand biologically active equivalents of the native sequence cytokines. Incertain embodiments, the methods further include administering to thesubject one or more immunomodulatory agents, preferably a cytokine.Preferred cytokines are selected from the group consisting ofinterleukin-1 (IL-1), IL-2, IL-3, IL-12, IL-15, IL-18, G-CSF, GM-CSF,thrombopoietin, and γ interferon.

These immunoregulatory agents are administered at the same time or atseparate times from the anti-CD19 antibodies of the invention, and areused at the same or lesser dosages than as set forth in the art. Thepreferred immunoregulatory agent will depend on many factors, includingthe type of disorder being treated, as well as the patient's history,but a general overall preference is that the agent be selected fromcyclosporin A, a glucocorticosteroid (most preferably prednisone ormethylprednisolone), OKT-3 monoclonal antibody, azathioprine,bromocryptine, heterologous anti-lymphocyte globulin, or a mixturethereof.

5.6.2.9. Combination with Other Therapeutic Agents

Agents that act on the tumor neovasculature can also be used inconjunction with anti-CD19 immunotherapy and include tubulin-bindingagents such as combrestatin A4 (Griggs et al., Lancet Oncol., 2:82,(2001)) and angiostatin and endostatin (reviewed in Rosen, Oncologist,5:20, 2000, incorporated by reference herein). Immunomodulators suitablefor use in combination with anti-CD19 antibodies include, but are notlimited to, of α-interferon, γ-interferon, and tumor necrosis factoralpha (TNFα). In certain embodiments, the therapeutic agents used incombination therapies using the compositions and methods of theinvention are peptides.

In certain embodiments, the anti-CD19 immunotherapy is in conjunctionwith one or more calicheamicin molecules. The calicheamicin family ofantibiotics are capable of producing double-stranded DNA breaks atsub-picomolar concentrations. Structural analogues of calicheamicinwhich may be used include, but are not limited to, γ1, γ21, γ31,N-acetyl-γ11, PSAG and 011 (Hinman et al., Cancer Research, 53:3336-3342(1993) and Lode et al., Cancer Research, 58: 2925-2928 (1998)).

Alternatively, a fusion protein comprising an anti-CD19 antibody of theinvention and a cytotoxic agent may be made, e.g., by recombinanttechniques or peptide synthesis.

In yet another embodiment, an anti-CD19 antibody of the invention may beconjugated to a “receptor” (such as streptavidin) for utilization intumor pretargeting wherein the antagonist-receptor conjugate isadministered to the patient, followed by removal of unbound conjugatefrom the circulation using a clearing agent and then administration of a“ligand” (e.g., biotin) which is conjugated to a therapeutic agent(e.g., a radionucleotide).

In certain embodiments, a treatment regimen includes compounds thatmitigate the cytotoxic effects of the anti-CD19 antibody compositions ofthe invention. Such compounds include analgesics (e.g., acetaminophen),bisphosphonates, antihistamines (e.g., chlorpheniramine maleate), andsteroids (e.g., dexamethasone, retinoids, deltoids, betamethasone,cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoids,mineralocorticoids, estrogen, testosterone, progestins).

In certain embodiments, the therapeutic agent used in combination withthe anti-CD19 immunotherapy of the invention is a small molecule (i.e.,inorganic or organic compounds having a molecular weight of less thanabout 2500 daltons). For example, libraries of small molecules may becommercially obtained from Specs and BioSpecs B.V. (Rijswijk, TheNetherlands), Chembridge Corporation (San Diego, Calif.), Comgenex USAInc. (Princeton, N.J.), and Maybridge Chemicals Ltd. (Cornwall PL34 OHW,United Kingdom).

In certain embodiments the anti-CD19 immunotherapy can be administeredin combination with an anti-bacterial agent. Non-limiting examples ofanti-bacterial agents include proteins, polypeptides, peptides, fusionproteins, antibodies, nucleic acid molecules, organic molecules,inorganic molecules, and small molecules that inhibit and/or reduce abacterial infection, inhibit and/or reduce the replication of bacteria,or inhibit and/or reduce the spread of bacteria to other cells orsubjects. Specific examples of anti-bacterial agents include, but arenot limited to, antibiotics such as penicillin, cephalosporin, imipenem,axtreonam, vancomycin, cycloserine, bacitracin, chloramphenicol,erythromycin, clindamycin, tetracycline, streptomycin, tobramycin,gentamicin, amikacin, kanamycin, neomycin, spectinomycin, trimethoprim,norfloxacin, rifampin, polymyxin, amphotericin B, nystatin,ketocanazole, isoniazid, metronidazole, and pentamidine.

In certain embodiments the anti-CD19 immunotherapy of the invention canbe administered in combination with an anti-fungal agent. Specificexamples of anti-fungal agents include, but are not limited to, azoledrugs (e.g., miconazole, ketoconazole (NIZORAL®), caspofungin acetate(CANCIDAS®), imidazole, triazoles (e.g., fluconazole (DIFLUCAN®)), anditraconazole (SPORANOX®)), polyene (e.g., nystatin, amphotericin B(FUNGIZONE®), amphotericin B lipid complex (“ABLC”) (ABELCET®),amphotericin B colloidal dispersion (“ABCD”) (AMPHOTEC®), liposomalamphotericin B (AMBISONE®)), potassium iodide (KI), pyrimidine (e.g.,flucytosine (ANCOBON®)), and voriconazole (VFEND®). Administration ofanti-bacterial and anti-fungal agents can mitigate the effects orescalation of infectious disease that may occur in the methods of theinvention where a patient's B cells are significantly depleted.

In certain embodiments of the invention, the anti-CD19 immunotherapy ofthe invention can be administered in combination with one or more of theagents described above to mitigate the toxic side effects that mayaccompany administration of the compositions of the invention. In otherembodiments, the anti-CD19 immunotherapy of the invention can beadministered in combination with one or more agents that are well knownin the art for use in mitigating the side effects of antibodyadministration, chemotherapy, toxins, or drugs.

In certain embodiments of the invention, where the anti-CD19immunotherapy composition of the invention is administered to treatmultiple myeloma or any other condition, the composition may beadministered in combination with or in treatment regimens with calciumchannel blockers, such as, but not limited to nifedipine (PROCARDIA®,ADALAT®), amlodopine (NORVASC®), isradipine (DYNACIRC®), diltiazem(CARDIZEM®, DILACOR XR®), nicardipine (CARDENE®), nisoldipine (SULAR®),and felodipine (PLENDIL®).

In certain embodiments of the invention, the compositions of theinvention may be administered in combination with or in treatmentregimens with angiotensin II receptor antagonists, such as, but notlimited to, losartan (COZAAR®) and valsartan (DIOVAN®).

In certain embodiments of the invention, the compositions of theinvention may be administered in combination with or in treatmentregimens with prazosin (MINIPRESS®), doxazosin (CARDURA®), andpentoxifylline (TRENTAL®).

In certain embodiments of the invention, the compositions of theinvention may be administered in combination with or in treatmentregimens with high-dose chemotherapy (melphalan, melphalan/prednisone(MP), vincristine/doxorubicin/dexamethasone (VAD), liposomaldoxorubicin/vincristine, dexamethasone (DVd), cyclophosphamide,etoposide/dexamethasone/cytarabine, cisplatin (EDAP)), stem celltransplants (e.g., autologous stem cell transplantation or allogeneicstem cell transplantation, and/or mini-allogeneic (non-myeloablative)stem cell transplantation), radiation therapy, steroids (e.g.,corticosteroids, dexamethasone, thalidomide/dexamethasone, prednisone,melphalan/prednisone), supportive therapy (e.g., bisphosphonates, growthfactors, antibiotics, intravenous immunoglobulin, low-dose radiotherapy,and/or orthopedic interventions), THALOMID™ (thalidomide, Celgene),and/or VELCADE™ (bortezomib, Millennium).

In embodiments of the invention where the anti-CD19 immunotherapy of theinvention are administered in combination with another antibody orantibodies and/or agent, the additional antibody or antibodies and/oragents can be administered in any sequence relative to theadministration of the antibody of this invention. For example, theadditional antibody or antibodies can be administered before,concurrently with, and/or subsequent to administration of the anti-CD19antibody or immunoconjugate of the invention to the human subject. Theadditional antibody or antibodies can be present in the samepharmaceutical composition as the antibody of the invention, and/orpresent in a different pharmaceutical composition. The dose and mode ofadministration of the antibody of this invention and the dose of theadditional antibody or antibodies can be the same or different, inaccordance with any of the teachings of dosage amounts and modes ofadministration as provided in this application and as are well known inthe art.

5.7. Use of Anti-CD19 Antibodies in Diagnosing Disease or MonitoringImmune Recognition

The present invention also encompasses anti-CD19 antibodies, andcompositions thereof, that immunospecifically bind to the human CD19antigen, which anti-CD19 antibodies are conjugated to a diagnostic ordetectable agent. In preferred embodiments, the antibodies are human orhumanized anti-CD19 antibodies. Such anti-CD19 antibodies can be usefulfor monitoring or prognosing the development or progression of a B cellmalignancyor an autoimmune disease or disorder as part of a clinicaltesting procedure, such as determining the efficacy of a particulartherapy. In addition, anti-CD19 antibodies can be useful for monitoringimmune system reconstitution following immunosuppressive therapy or bonemarrow transplantation. Such diagnosis, detection, and monitoring can beaccomplished by coupling an anti-CD19 antibody that immunospecificallybinds to the human CD19 antigen to a detectable substance including, butnot limited to, various enzymes, such as but not limited to, horseradishperoxidase, alkaline phosphatase, beta-galactosidase, oracetylcholinesterase; prosthetic groups, such as but not limited to,streptavidin/biotin and avidin/biotin; fluorescent materials, such asbut not limited to, umbelliferone, fluorescein, fluoresceinisothiocynate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride or phycoerythrin; luminescent materials, such as but notlimited to, luminol; bioluminescent materials, such as but not limitedto, luciferase, luciferin, and aequorin; radioactive materials, such asbut not limited to iodine (¹³¹I, ¹²⁵I, ¹²³I, ¹²¹I,), carbon (¹⁴C),sulfur (³⁵S), tritium (³H), indium (¹¹⁵In, ¹¹³In, ¹¹²In, ¹¹¹In,), andtechnetium (⁹⁹Tc), thallium (²⁰¹Ti) gallium (⁶⁸Ga, ⁶⁷Ga), palladium(¹⁰³Pd), molybdenum (⁹⁹Mo), xenon (¹³³Xe), fluorine (¹⁸F), ¹⁵³Sm, ¹⁷⁷Lu,¹⁵⁹Gd, ¹⁴⁹Pm, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁶⁶Ho, ⁹⁰Y, ⁴⁷Sc, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁴²Pr,¹⁰⁵Rh, ⁹⁷Ru, ⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn,⁷⁵Se, ¹¹³Sn, and ¹¹⁷Tin; positron emitting metals using various positronemission tomographies, nonradioactive paramagnetic metal ions, andmolecules that are radiolabelled or conjugated to specificradioisotopes. Any detectable label that can be readily measured can beconjugated to an anti-CD19 antibody and used in diagnosing B cellmalignancies or an autoimmune disease or disorder. The detectablesubstance may be coupled or conjugated either directly to an antibody orindirectly, through an intermediate (such as, for example, a linkerknown in the art) using techniques known in the art. See, e.g., U.S.Pat. No. 4,741,900 for metal ions which can be conjugated to antibodiesfor use as a diagnostics according to the present invention. In certainembodiments, the invention provides for diagnostic kits comprising ananti-CD19 antibody conjugated to a diagnostic or detectable agent.

5.8. Kits

The invention provides a pharmaceutical pack or kit comprising one ormore containers filled with a composition of the invention for theprevention, treatment, management or amelioration of a B cellmalignancy, or one or more symptoms thereof, potentiated by orpotentiating a B cell malignancy. The invention provides apharmaceutical pack or kit comprising one or more containers filled witha composition of the invention for the prevention, treatment, managementor amelioration of an autoimmune disease or disorder, or one or moresymptoms thereof, potentiated by or potentiating an autoimmune diseaseor disorder. The invention provides a pharmaceutical pack or kitcomprising one or more containers filled with a composition of theinvention for the prevention, treatment, management or amelioration ofGVHD, humoral rejection, or a post-transplant lymphoproliferativedisorder.

The present invention provides kits that can be used in theabove-described methods. In one embodiment, a kit comprises acomposition of the invention, in one or more containers. In anotherembodiment, a kit comprises a composition of the invention, in one ormore containers, and one or more other prophylactic or therapeuticagents useful for the prevention, management or treatment of a B cellmalignancy, or one or more symptoms thereof, potentiated by orpotentiating a B cell malignancy. In yet another embodiment, the kitcomprises a composition of the invention, in one or more containers, andone or more other prophylactic or therapeutic agents useful for theprevention, management or treatment of an autoimmune disease ordisorder, or one or more symptoms thereof, potentiated by orpotentiating an autoimmune disease or disorder in one or more othercontainers. In a further embodiment, the kit comprises a composition ofthe invention, in one or more containers, and one or more otherprophylactic or therapeutic agents useful for the prevention, managementor treatment of GVHD, graft rejection, or a post-transplantlymphoproliferative disorder in one or more other containers.Preferably, the kit further comprises instructions for preventing,treating, managing or ameliorating a B cell malignancy, an autoimmunedisorder, or GVHD, graft rejection, or a post-transplantlymphoproliferative disorder, as well as side effects and dosageinformation for method of administration. Optionally associated withsuch container(s) can be a notice in the form prescribed by agovernmental agency regulating the manufacture, use or sale ofpharmaceuticals or biological products, which notice reflects approvalby the agency of manufacture, use or sale for human administration.

6. EXAMPLES

In the examples below, a transgenic mouse model was used for evaluatinghuman CD19 directed immunotherapies. These data show that antibodiesthat both bind the CD19 antigen and mediate ADCC are effective atinducing B cell depletion in vivo, in subjects having effector cellsthat express FcγR, (preferably, FcγRIII or FcγRIV) and carry out ADCC.Such antibodies can be used to induce a durable depletion of B cells invivo, and in certain embodiments can eliminate virtually all B cellsfrom the circulation, spleen and lymph nodes. Surprisingly, bone marrowB cells and their precursors that express relatively low densities ofthe CD19 antigen are depleted as well. The effectiveness of B celldepletion is not dependent on which region of human CD19 an anti-CD19antibody binds, but is influenced by CD19 density (in the patientsample). The efficiency of B cell clearance may correlate with theanti-CD19 antibody's ability to mediate ADCC. The efficiency of B cellclearance using anti-CD19 antibodies may also correlate with hosteffector FcγR expression/function.

Materials and Methods

The murine HB12a and HB12b anti-CD19 antibodies described herein areexemplary of antibodies that bind to human CD19. Such antibodies can beused to engineer human, humanized, or chimeric anti-CD19 antibodiesusing the techniques described above. Human, humanized, or chimericanti-CD19 antibodies having the same specificity for human CD19 orportions thereof as the HB12a and HB12b antibodies are contemplated foruse in the compositions and methods of the invention. In particular,human, humanized, or chimeric anti-CD19 antibodies having the same orsimilar heavy chain CDR1, CDR2, and/or CDR3 regions as the HB12a orHB12b are contemplated for use in the compositions and methods of theinvention.

Antibody Generation and Sequence Analysis. The HB12a and HB12bantibodies were generated in Balb/c mice immunized with a mouse pre-Bcell line that was transfected with cDNAs encoding human CD19 (Zhou etal., Mol. Cell. Biol., 14:3884-94 (1994)). Both antibodies weresubmitted to the Fifth International Workshop and Conference on HumanLeukocyte Differentiation Antigens that was held in Boston on Nov. 3-7,1993.

Heavy chain gene utilization was determined using RNA extracted from1−5×10⁶ hybridoma cells using the RNEASY® Mini Kit (QIAGEN®, Valencia,Calif.). First strand cDNA was synthesized in a volume of 20 μL from 2μg of total RNA using 200 units of SUPERSCRIPT III® reversetranscriptase and first strand cDNA synthesis buffer from INVITROGEN®(Carlsbad, Calif.), 20 ng random hexamer primers and 20 units of RNAseinhibitor from PROMEGA® (Madison, Wis.), and 80 nmoles of dNTP fromDenville (Metuchen, N.J.). One μl of cDNA solution was used as templatefor PCR amplification of heavy chain (V_(H)) genes. PCR reactions werecarried out in a 50-μl volume of a reaction mixture composed of 10 mMTris-HCl (pH 8.3), 5 mM NH₄Cl, 50 mM KCl, 1.5 mM MgCl₂, 800 μM dNTP(Denville), 400 pmol of each primer, and 2.5 U of Taq DNA polymerase(Invitrogen) with 10% pfu proofreading polymerase (Stratagene, LaJolla,Calif.). For V_(L), PCR reactions were carried out in a 50-μl volume ofa reaction mixture composed of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5mM MgCl₂, 800 μM dNTP (Denville), 400 pmol of each primer, and 2.5 U ofTaq DNA polymerase (Invitrogen) spiked with 10% pfu proofreadingpolymerase (Stratagene). After a 3 min denaturation step, amplificationwas for 32 cycles (94° C. for 1 min, 58° C. for 1 min, 72° C. for 1 min)followed by a 10 minute extension at 72° C. (Thermocycler, PerkinElmer). Heavy chain cDNA was amplified using a promiscuous sense 5′V_(H) primer (MsV_(H)E; 5′ GGG AAT TCG AGG TGC AGC TGC AGG AGT CTG G 3′)(SEQ ID NO:19) as previously described (Kantor et al., J. Immunol.,158:1175-1186 (1997)) and an antisense primer complementary to the Cγcoding region (primer Cγ1; 5′ GAG TTC CAG GTC ACT GTC ACT GGC TCA GGG A3′) (SEQ ID NO:20).

Light chain gene utilization was determined using cytoplasmic RNAextracted as described for heavy chain. The 5′ variable regionnucleotide sequence was obtained from cDNA that was generated using theGeneRacer™ kit (Invitrogen). Total RNA was dephosphorylated with calfintestinal phosphatase. The 5′ cap structure was removed from intact,full-length mRNA with tobacco acid pyrophosphatase. A GeneRacer RNAoligo was ligated to the 5′ end of the mRNA using T4 RNA ligaseproviding a known 5′ priming site for GeneRacer PCR primers after themRNA was transcribed into cDNA. The ligated mRNA was reverse transcribedwith Superscript™ III RT and the GeneRacer random primer. The firststrand cDNA was amplified using the GeneRacer 5′ primer (homologous tothe GeneRacer RNA oligo) and a constant region specific antisense 3′primer (GAC TGA GGC ACC TCC AGA TGT TAA CTG) (SEQ ID NO:21). TouchdownPCR amplifications were carried out in a 50-μL volume with buffers asrecommended by Invitrogen, using 2.5 U of Taq DNA polymerase(Invitrogen) with 10% pfu proofreading polymerase (Stratagene) added.After a 2 min denaturation step, Taq and pfu was added and amplificationwas carried out in 3 steps: five cycles of 94° C. for 30 s, 72° C. for60 s; 5 cycles of 94° C. for 30 s, 72° C. for 60 s; 20 cycles of 94° C.for 30 s, 65° C. for 30 s, 72° C. for 60 s, followed by 10 min extensionat 72° C. 2.5 U of Taq was added and the extension allowed to proceedfor another 10 min to ensure intact 3′A-overhangs. Amplified PCRproducts were cloned into the pCR4-TOPO vector for sequencing andtransformed into OneShot® TOP10 competent cells. DNA inserts from 8clones was sequenced for each mAb light chain using the pCR4-TOPO vectorspecific “M13 Forward” and “M13 Reverse” primers, as described for heavychain.

The purified heavy and light chain PCR products were sequenced directlyin both directions using an ABI 377 PRISM® DNA sequencer afteramplification using the Perkin Elmer Dye Terminator Sequencing systemwith AmpliTaq® DNA polymerase and the same primers used for initial PCRamplification or pCR4-TOPO vector specific primers, as described forlight chain. The HB12a and HB12b heavy and light chain regions weresequenced completely on both the sense and anti-sense DNA strands.

Antibodies and Immunofluorescence Analysis. Monoclonal mouse anti-CD19antibodies that bind to the human CD19 antigen used herein includedHB12a (IgG 1) and HB12b (IgG 1), FMC63 (IgG2a, Chemicon International,Temecula, Calif.), B4 (IgG1, Beckman Coulter, Miami, Fla.) (Nadler etal., J. Immunol., 131:244-250 (1983)), and HD237 (IgG2b, FourthInternational Workshop on Human Leukocyte Differentiation Antigens,Vienna, Austria, 1989), an isotype switch variant of the HD37 antibody(Pezzutto et al., J. Immunol., 138:2793-2799 (1987)). Other antibodiesincluded: monoclonal mouse anti-CD19 antibody which binds to mouse CD19,MB19-1 (IgA) (Sato et al., J. Immunol., 157:4371-4378 (1996));monoclonal mouse CD20-specific antibodies (Uchida et al., Intl.Immunol., 16:119-129 (2004)); B220 antibody RA3-6B2 (DNAX Corp., PaloAlto, Calif.); Thy1.2 antibody (CALTAG™ Laboratories, Burlingame,Calif.); and CD5, CD43 and CD25 antibodies (BD PHARMINGEN™, FranklinLakes, N.J.). Isotype-specific and anti-mouse Ig or IgM antibodies werefrom Southern Biotechnology Associates, Inc. (Birmingham, Ala.).

The mouse pre-B cell line, 300.19 (Alt et al., Cell, 27:381-388 (1981)),transfected with hCD19 cDNA (Tedder and Isaacs, J. Immunol., 143:712-717(1989)), or single-cell leukocyte suspensions were stained on ice usingpredetermined optimal concentrations of each antibody for 20-30 minutesaccording to established methods (Zhou et al., Mol. Cell. Biol.,14:3884-3894 (1994)). Cells with the forward and side light scatterproperties of lymphocytes were analyzed on FACSCAN® or FACSCALIBUR® flowcytometers (Becton Dickinson, San Jose, Calif.). Background staining wasdetermined using unreactive control antibodies (CALTAG™ Laboratories,Burlingame, Calif.) with gates positioned to exclude ≧98% of the cells.For each sample examined, ten-thousand cells with the forward and sidelight scatter properties of mononuclear cells were analyzed for eachsample whenever possible, with fluorescence intensities shown on afour-decade log scale.

Mice. Transgenic mice expressing human CD19 (h19-1) and their wild-type(WT) littermates were produced as previously described (Zhou et al.,Mol. Cell. Biol., 14:3884-3894 (1994)). TG-1 mice were generated fromthe original h19-1 founders (C57BL/6×B6/SJL), and were crossed onto aC57BL/6 background for at least 7 generations. TG-2 mice were generatedfrom the original h19-4 founders (C57BL/6×B6/SJL). After multiplegenerations of backcrossing, TG-1^(+/+) mice were obtained the B cellsof which expressed cell surface density of human CD19 at about the samedensity found on human B cells. Human CD19 expressing mice have beenfurther described and used as a model in several studies (Engel et al.,Immunity, 3:39-50 (1995); Sato et al., Proc. Natl. Acad. Sci. USA,92:11558-11562 (1995); Sato et al., J. Immunol., 157:4371-4378 (1996);Tedder et al., Immunity, 6:107-118 (1997); Sato et al., J. Immunol.,158:4662-4669 (1997); Sato et al., J. Immunol., 159:3278-3287 (1997);Sato et al., Proc. Natl. Acad. Sci. USA, 94:13158-13162 (1997); Inaokiet al., J. Exp. Med., 186:1923-1931 (1997); Fujimoto et al., J.Immunol., 162:7088-7094 (1999); Fujimoto et al., Immunity, 11:191-200(1999); Satterthwaite et al., Proc. Natl. Acad. Sci. USA, 97:6687-6692(2000); Fujimoto et al., Immunity, 13:47-57 (2000); Sato et al., J.Immunol., 165:6635-6643 (2000); Zipfel et al., J. Immunol.,165:6872-6879 (2000); Qian et al., J. Immunol., 166:2412-2419 (2001);Hasegawa et al., J. Immunol., 167:2469-2478 (2001); Hasegawa et al., J.Immunol., 167:3190-3200 (2001); Fujimoto et al., J. Biol. Chem.,276:44820-44827 (2001); Fujimoto et al., J. Immunol., 168:5465-5476(2002); Saito et al., J. Clin. Invest., 109:1453-1462 (2002); Yazawa etal., Blood, 102:1374-80 (2003); Shoham et al., J. Immunol.,171:4062-4072 (2003)). CD19-deficient (CD19^(−/−)) mice and their WTlittermates are also as previously described (Engel et al., Immunity,3:39-50 (1995)). Expression of human CD19 in transgenic mice has beenshown to lower endogenous mouse CD19 expression (Sato et al., J.Immunol., 157:4371-4378 (1996); and Sato et al., J. Immunol.,158:4662-4669 (1997)) and hypotheses regarding this lowering ofendogenous mouse CD19 expression have also been assessed (Shoham et al.,J. Immunol., 171:4062-4072 (2003)). Densities of CD19 expression intransgenic mice expressing human CD19 have also been assessed (Sato etal., J. Immunol., 165:6635-6643 (2000)).

TG-1^(+/+) mice were bred with FcR (Fc receptor) common γ chain(FcRγ)-deficient mice (FcRγ^(−/−), B6.129P2-Fcergr1^(tm1)) from TaconicFarms (Germantown, N.Y.) to generate hCD19^(+/−) FcRγ^(−/−) and WTlittermates. Mice hemizygous for a c-Myc transgene (Eμu-cMycTG,C57Bl/6-J-TgN(IghMyc); The Jackson Laboratory, Bar Harbor, Me.) were asdescribed (Harris et al., J. Exp. Med., 167:353 (1988) and Adams et al.,Nature, 318:533 (1985)). c-MycTG mice (B6/129 background) were crossedwith hCD19TG-1^(+/+) mice to generate hemizygous hCD19TG-1^(+/−)cMycTG^(+/−) offspring as determined by PCR screening. Rag1^(−/−)(B6.129S7-Rag1^(tm1Mom)/J) mice were from The Jackson Laboratory.Macrophage-deficient mice were generated by tail vein injections ofclodronate-encapsulated liposomes (0.1 mL/10 gram body weight; SigmaChemical Co., St. Louis, Mo.) into C57BL/6 mice on day −2, 1 and 4 inaccordance with standard methods (Van Rooijen and Sanders, J. Immunol.Methods, 174:83-93 (1994)). All mice were housed in a specificpathogen-free barrier facility and first used at 6-9 weeks of age.

ELISAs. Serum Ig concentrations were determined by ELISA usingaffinity-purified mouse IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA (SouthernBiotechnology Associates, Inc.) to generate standard curves as described(Engel et al., Immunity, 3:39 (1995)). Serum IgM and IgG autoantibodylevels against dsDNA, ssDNA and histone were determined by ELISA usingcalf thymus double-stranded (ds) DNA (Sigma-Aldrich), boiled calf thymusDNA (which contains single-stranded (ss) DNA) or histone (Sigma-Aldrich)coated microtiter plates as described (Sato et al., J. Immunol.,157:4371 (1996)).

Immunotherapy. Sterile anti-CD19 and unreactive, isotype controlantibodies (0.5-250 μg) in 200 μL phosphate-buffered saline (PBS) wereinjected through lateral tail veins. All experiments used 250 μg ofantibody unless indicated otherwise. Blood leukocyte numbers werequantified by hemocytometer following red cell lysis, B220⁺ B cellfrequencies were determined by immunofluorescence staining with flowcytometry analysis. Antibody doses in humans and mice were comparedusing the Oncology Tool Dose Calculator(www.fda.gov/cder/cancer/animalframe.htm).

Immunizations. Two-month old WT mice were immunized i.p. with 50 μg of2,4,6-trinitrophenyl (TNP)-conjugated lipopolysaccharide (LPS) (Sigma,St. Louis, Mo.) or 25 μg 2,4-dinitrophenol-conjugated (DNP)-FICOLL®(Biosearch Technologies, San Rafael, Calif.) in saline. Mice were alsoimmunized i.p. with 100 μg of DNP-conjugated keyhole limpet hemocyanin(DNP-KLH, CALBIOCHEM®-NOVABIOCHEM® Corp., La Jolla, Calif.) in completeFreund's adjuvant and were boosted 21 days later with DNP-KLH inincomplete Freund's adjuvant. Mice were bled before and afterimmunizations as indicated. DNP- or TNP-specific antibody titers inindividual serum samples were measured in duplicate using ELISA platescoated with DNP-BSA (CALBIOCHEM®-NOVABIOCHEM® Corp., La Jolla, Calif.)or TNP-BSA (Biosearch Technologies, San Rafael, Calif.) according tostandard methods (Engel et al., Immunity, 3:39-50 (1995)). Sera fromTNP-LPS immunized mice were diluted 1:400, with sera from DNP-FICOLL®and DNP-BSA immunized mice diluted 1:1000 for ELISA analysis.

Tumor Studies. Spontaneous lymph node tumor from a hCD19TG-1^(+/−)c-mycTG^(+/−) mouse was isolated and expanded in vivo. Tumor cells(10⁻⁵/mouse) were administered i.v. to Rag^(−/−) recipient mice on day0, with FMC63 and isotype-matched control mAbs (250 μg/ml) given i.v. ondays 1 and 7. Blood leukocytes from recipient mice were isolated weeklywith the number of circulating mouse CD19⁺ B220⁺ cells quantified byimmunofluorescent staining with flow cytometry analysis.

Statistical Analysis. All data are shown as means±SEM. The Student'st-test was used to determine the significance of differences betweensample means.

Example 1 Human CD19 Expression in Transgenic Mice

The transgenic hCD19TG mice described herein or other transgenic animalsexpressing human CD19 can be used to assess different therapeuticregimens comprising human, humanized, or chimeric anti-CD19 antibodies,such as variations in dosing concentration, amount, or timing. Theefficacy in human patients of different therapeutic regimens can bepredicted using the two indicators described below, i.e., B celldepletion in certain bodily fluids and/or tissues and the ability of amonoclonal human or humanized anti-CD19 antibody to bind B cells. Inparticular embodiments, treatment regimens that are effective in humanCD19 transgenic mice can be used with the compositions and methods ofthe invention to treat B cell malignancies in humans.

In order to determine whether human CD19 was expressed on B cells fromtransgenic mice (hemizygous TG-1^(+/−)) expressing the human CD19transgene, B cells were extracted from the bone marrow, blood, spleenand peritoneal lavage of these mice. Human CD19 and mouse CD19expression were assessed in these cells by contacting the cells withmouse monoclonal anti-CD19 antibodies that bind CD19. Binding of theantibody to the B lineage cells was detected using two-colorimmunofluorescence staining with flow cytometry analysis.

The results are shown in FIG. 1A in graphs of the detected expression ofmurine CD19 (mCD19) (x-axis) plotted against the detected expression ofhuman CD19 (hCD19) (y-axis) for bone marrow (BM), blood, spleen andperitoneal lavage (PL). The units of the axis represent a four decadelog scale beginning with 1 on the lower left. The B4 anti-CD19 antibodythat binds to human CD19 (Beckman/Coulter) was used to visualize humanCD19 expression and the 1D3 CD19 antibody that binds to mouse CD19(PharMingen) was used to visualize mouse CD19 expression (also used forFIGS. 1B and 1C). While human CD19 expression increases incrementallyduring human B cell development, murine CD19 is expressed at high levelsduring mouse bone marrow B cell development. FIG. 1A shows that humanCD19 expression parallels mouse CD19 expression on peripheral B cellsfound in blood, spleen and peritoneal lavage (PL) demonstrating that themouse anti-hCD19 antibody (that binds human CD19) binds the peripheral Bcell populations. In addition, a small population of bone marrow (BM)derived B cells express endogenous mouse CD19 but not human CD19(monoclonal mouse anti-CD19 antibody that binds to human CD19). Thus,bone marrow B cells fall into two categories in hemizygous TG-1^(+/−)mice, mature B lineage cells that are hCD19⁺mCD19⁺ and less mature Blineage cells that are only mCD19⁺ (FIG. 1A). These results areconsistent with the findings of Zhou et al. (Mol. Cell. Biol.,14:3884-3894 (1994)) which indicated that human CD19 expression in thesetransgenic mice correlates with B cell maturation. All mature B cellswithin the blood, spleen, and peritoneal cavity were both hCD19⁺ andmCD19⁺.

The relative expression levels of mCD19 and hCD19, as assessed bymeasuring mean fluorescence intensity (mouse anti-CD19 for hCD19 andmouse anti-CD19 for mCD19) respectively, are shown in FIG. 1B. AmongTG-1 mice homozygous for the hCD19 transgene (TG-1^(+/−)), hCD19expression on blood borne B cells was comparable to hCD19 expression onhuman B cells. To compare the relative densities of hCD19 and mCD19expression in TG-1^(+/+) TG-1^(+/−), and TG-2^(+/+) transgenic mouselines, blood derived B cells were extracted and assayed for CD19expression as described above. The results are shown in FIG. 1B inhistograms showing the percent human CD19 expression for human blood Bcells, TG-1^(+/+), TG-1^(+/−) and TG-2^(+/+) blood B cells from hCD19TGmice (left) and the percent mouse CD19 expression for wild type (WT)mouse blood B cells, TG-1^(+/+), TG-1^(+/−), and TG-2^(+/+) CD19⁺ bloodB cells from hCD19TG mice (right). The values (linear values of meanfluorescent intensity) represent the mean relative densities of CD19expression (±SEM) compared to blood B cells from humans or wild-type(WT) mice (shown as 100%). The results show that in homozygousTG-1^(+/+) mice, blood B cells expressed hCD19 at densities as measuredby mean fluorescence intensities about 72% higher than human blood Bcells. Blood B cells in TG-1^(+/−) mice expressed hCD19 at densitiessimilar to human blood B cells, while blood B cells in TG-2^(+/+) miceexpressed hCD19 at densities 65% lower than human blood B cells.

Further comparisons of the relative densities of hCD19 and mCD19expression in B cells from TG-1 ^(+/−) mouse tissues are shown in FIG.1C in histograms showing the mean fluorescence intensities (MFI±SEM) ofanti-CD19 antibody staining for B cells from bone marrow, blood, spleen,lymph node, and PL for hCD19 (left) and mCD19 (right). The resultsdemonstrate that in TG-1^(+/−) mice, hCD19 was expressed at increasinglevels by B220⁺ cells in the bone marrow (63% of human bloodlevels)<blood (100%)<spleen (121%)=lymph node (120%) and <peritonealcavity (177%). Human CD19 expression had a small influence on mCD19expression. Levels of mRNA for hCD19 and mCD19 did not change.

To determine whether mouse anti-hCD19 antibodies (that bind to humanCD19) of the IgG1 (HB12a, HB12b, B4), IgG2a (FMC63) and IgG2b (HD237)isotypes react differently, blood and spleen B220⁺ B cells were isolatedfrom TG-1^(+/−) mice. The isolated cells were contacted in vitro withthe above-mentioned anti-CD19 antibodies and assessed for their abilityto bind human CD19 expressing transgenic mouse (hCD19TG) B cells usingmonoclonal antibody staining which was visualized using isotype-specificPE-conjugated secondary antibodies with flow cytometry analysis.

The results are shown in FIG. 1D in graphs of the fluorescence intensity(x-axis) versus the relative B cell number (y-axis) for IgG2b (murineisotype), IgG2a (murine isotype), and IgG1 (murine isotype) anti-CD19antibodies at 5 μg/mL. The fluorescence intensity of B220⁺ cells stainedwith anti-CD19 antibody are shown as solid lines and the fluorescenceintensity of the isotype-matched control (CTL) is shown as a dashedline. Each antibody reached saturating levels of reactivity with spleenB cells at a concentration of 5 μg/mL. The results demonstrate thatanti-CD19 antibody binding density on mouse blood and spleen B220⁺ Bcells from TG-1^(+/−) mice is uniform for the antibody isotypes testedand for both blood and spleen B cells.

To determine whether mean fluorescence intensities were independent ofanti-CD19 antibody isotype, the binding activity of individual anti-CD19antibodies (at 5 μg/mL) was assessed by staining a mouse pre-B cellline, 300.19, transfected with a hCD19 cDNA using the same anti-mouse Igsecondary antibody. Antibody staining (MFI±SEM) was visualized usingmouse Ig-specific PE-conjugated secondary antibody with flow cytometryanalysis. The results are shown in FIG. 1E in a histogram of anti-CD19antibody binding (as shown by staining intensity, y-axis) to hCD19cDNA-transfected 300.19 cells, for HB12a, HB12b, B4, FMC63, HD237anti-CD19 antibodies and a control antibody (CTL). Each antibody stainedcells with characteristic mean fluorescence intensities that wereindependent of anti-CD19 antibody isotype, with HB12b showing the lowestlevels of staining and HD237 demonstrating the highest. Thus, theresults shown demonstrate that 300.19 cells are a model in vitro systemfor the comparison of the ability of anti-CD19 antibodies to bind CD19in vitro.

Thus, taken together, the results shown in FIG. 1 demonstrate thathCD19TG mice and the 300.19 cells represent appropriate in vitro and invivo model systems for assessing the ability of anti-hCD19 antibodies tobind B cells when hCD19 is expressed over a range of densities.

FIGS. 1A-D represent results obtained with ≧3 mice of each genotype.

Example 2 Anti-CD19 Antibody Depletion of B Cells In Vivo

Mouse anti-CD19 antibodies (that bind to human CD19) were assessed fortheir ability to deplete hCD19TG (TG-1^(+/−)) blood, spleen, and lymphnode B cells in vivo. Each antibody was given to mice at either 250 or50 μg/mouse, a single dose about 10 to 50-fold lower than the 375 mg/m²dose primarily given four times for anti-CD20 therapy in humans (Maloneyet al., J. Clin. Oncol., 15:3266-74 (1997) and McLaughlin et al.,12:1763-9 (1998)).

The results are shown in FIG. 2A in a plot of B cell amount 7 daysfollowing CD19 or isotype-matched control (CTL) treatment with HB12a,HB12b, or FMC63 anti-CD19 antibodies or a control. Separate plots areprovided for lymph nodes, spleen and blood tissues for each anti-CD19antibody. The percentage of gated lymphocytes depleted at 7 days shownon each plot demonstrates representative B cell depletion from blood,spleen and lymph nodes of TG-1^(+/−) mice as determined byimmunofluorescence staining with flow cytometry analysis. FIG. 2B showsmean numbers (±SEM per ml) of B220⁺ blood B cells following treatmentwith anti-CD19 (closed circles) or isotype-control (open circles)antibodies. The value shown after time 0 represents data obtained at 1hour. FIG. 2C and FIG. 2D show spleen and lymph node B cell numbers(±SEM), respectively, after treatment of TG-1^(+/−) mice with anti-CD19(filled bars) or control (open bars) antibody at the indicated doses. InFIGS. 2B-D, significant differences between mean results for anti-CD19or isotype-control antibody treated mice (≧3 mice per data point) areindicated; *p<0.05, **p<0.01, in comparison to controls.

Each antibody depleted the majority of circulating B cells within onehour of treatment (FIG. 2B), with potent depleting effects on spleen andlymph node B cell frequencies (FIG. 2A) and numbers (FIGS. 2C-D) by dayseven. The HB12a antibody depleted 98% of blood B cells and 90-95% ofsplenic and lymph node B cells by day seven. Similarly, the HB12b, B4,FMC63, and HD237 antibodies depleted 99%, 96%, 99%, and 97% of blood Bcells, respectively. The HB12b, B4, FMC63, and HD237 antibodies depleted88-93%, 64-85%, 72-95%, and 88-90% of splenic and lymph node B cells,respectively. The few remaining peripheral B cells primarily representedphenotypically immature cells that were potential emigrants from thebone marrow. None of the CD19 antibodies had significant effects whengiven to WT mice, and isotype-matched control antibodies given underidentical conditions did not affect B cell numbers (FIGS. 2A-D). Thus,anti-hCD19 antibodies effectively depleted B cells from the circulation,spleen and lymph nodes of hCD19TG mice by day seven. A summary of B celldepletion in TG-1^(+/−) mice is provided in Table 1.

TABLE 1 Tissue B subset^(a) Control mAb^(b) CD19 % BM: B220⁺ 3.41 ± 0.50.82 ± 0.13 76** Pro-B 0.75 ± 0.1 0.97 ± 0.22 0  Pre-B 1.74 ± 0.5 0.10 ±0.01 94** immature 0.70 ± 0.1 0.04 ± 0.01 93** mature 0.86 ± 0.1 0.004 ±0.0  99** Blood: B220⁺ 0.82 ± 0.1 0.004 ± 0.0  99** Spleen: B220⁺ 25.2 ±2.2 1.7 ± 0.2 93** LN: B220⁺ 0.89 ± 0.1 0.06 ± 0.01 93** Peritoneum:B220⁺ 1.16 ± 0.1 0.37 ± 0.03 68** B1a 0.86 ± 0.1 0.31 ± 0.06 61** B20.34 ± 0.0 0.08 ± 0.02 73** ^(a)B cell subsets were: bone marrow (BM)pro-B (CD43⁺IgM⁻B220^(lo)), pre-B (CD43⁻IgM⁻B220^(lo)), immature B(IgM⁺B220^(lo)) mature B (IgM⁺B220^(hi)); peritoneal B1a(CD5⁺B220^(lo)), B2 (CD5⁻B220^(hi)). ^(b)Values (±SEM) indicate cellnumbers (×10⁻⁶) present in mice seven days after antibody treatment (250μg). BM values are for bilateral femurs. Blood numbers are per/ml. LNnumbers are for bilateral inguinal and axillary nodes. Mouse numbers areindicated in parentheses. Significant differences between means areindicated; *p < 0.05, **p < 0.01.

^(b)Values (±SEM) indicate cell numbers (×10⁻⁶) present in mice sevendays after antibody treatment (250 μg). BM values are for bilateralfemurs. Blood numbers are per/ml. LN numbers are for bilateral inguinaland axillary nodes. Mouse numbers are indicated in parentheses.Significant differences between means are indicated; *p<0.05, **p<0.01.

Depletion of Bone Marrow B Cells

Known anti-CD19 antibodies were tested in hCD19TG mice to determinewhether such antibodies were effective in depleting B cells from variousbodily fluids and tissues. The assays described herein can be used todetermine whether other anti-CD19 antibodies, for example, anti-CD19antibodies that bind to specific portions of the human CD19 antigen,will effectively deplete B cells. The results using anti-CD19 antibodiesidentified as capable of depleting B cells can be correlated to use inhumans. Antibodies with properties of the identified antibodies can beused in the compositions and methods of the invention for the treatmentof B cell malignancies in humans. FIGS. 3A-3F depict bone marrow B celldepletion following CD19 antibody treatment.

FIG. 3A shows graphs of the fluorescence intensity (x-axis) versus therelative B cell number (y-axis) for hCD19 and mCD19 expression byTG-1^(+/−) bone marrow B cell subpopulations assessed by four-colorimmunofluorescence staining with flow cytometry analysis of cells withthe forward- and side-scatter properties of lymphocytes. Pro-B cellswere defined as CD43⁺IgM⁻B220^(lo), pre-B cells were CD43⁻IgM⁻B220^(lo),immature B cells were IgM⁺B220^(lo) and mature B cells wereIgM⁺B220^(hi). Bar graphs (right) show relative mean MFI (±SEM) valuesfor CD19 expression by each B cell subset (≧3 mice/data point). As inhCD19TG mice (FIG. 1A), CD19 expression is heterogeneous in humans as Bcells mature and exit the bone marrow. Only a small fraction of pro-Bcells (20% CD43^(hi)IgM⁻B220^(lo)) expressed hCD19 in TG-1^(+/−) mice,while most pre-B cells were hCD19⁺ and the majority of mature B cells inthe bone marrow expressed hCD19 at relatively high levels. Half of pro-Bcells (55%, IgM⁻ B220⁺) expressed mCD19 in TG-1^(+/−) mice, while mCD19was expression by the majority of pre-B cells and mature B cells in thebone marrow at relatively high levels.

FIG. 3B shows depletion of hCD19 cells in hCD19TG mice seven daysfollowing FMC63 or isotype-matched control antibody (250 μg) treatmentassessed by two-color immunofluorescence staining with flow cytometryanalysis. Numbers represent the relative frequency of cells within theindicated gates. Results represent those obtained with three littermatepairs of each mouse genotype. Following CD19 antibody treatment, thevast majority of hCD19⁺ cells in the bone marrow of TG-1^(+/+),TG-1^(+/−) and TG-2^(+/+) mice were depleted by the FMC63 antibody givenat 250 μg/mouse.

FIG. 3C shows representative B220⁺ B cell depletion seven days followinganti-CD19 or isotype-matched control antibody (250 μg) treatment ofTG-1^(+/−) mice. Bar graph values represent the total number (±SEM) ofB220⁺ cells within the bilateral femurs of antibody treated mice.Significant differences between sample means (≧3 mice per group) areindicated; *p<0.05, **p<0.01. Unexpectedly, a large fraction of mCD19⁺pre-B cells that expressed hCD19 at low to undetectable levels were alsodepleted from the bone marrow. Consistent with this, the FMC63, HB12a,HB12b, B4 and HD237 antibodies depleted the majority of bone marrowB220⁺ cells.

FIG. 3D shows representative bone marrow B cell subset depletion sevendays following FMC63 or isotype-matched control antibody (250 μg)treatment of TG-1^(+/−) mice as assessed by three-colorimmunofluorescence staining IgM⁻B220^(lo) pro-/pre-B cells were furthersubdivided based on CD43 expression (lower panels). FIG. 3E showsrepresentative depletion or CD25⁺B220^(lo) pre-B cells of bone marrowseven days following FMC63 or isotype-matched control antibody (250 μg)treatment of hCD19TG mouse lines as assessed by two-colorimmunofluorescence staining Results are from experiments carried out ondifferent days so the gates were not identical. When the individual bonemarrow subpopulations were analyzed, the majority ofCD43^(hi)IgM⁻B220^(lo) pro-B cells (FIG. 3D) were not affected by FMC63antibody treatment in TG-1^(+/+), TG-1^(+/−) or TG-2^(+/+) mice, whilethe majority of CD25⁺CD43^(lo)IgM⁻B220^(lo) pre-B cells (FIG. 3E) weredepleted. FIG. 3F shows bar graphs indicating numbers (±SEM) of pro-B,pre-B, immature, and mature B cells within bilateral femurs seven daysfollowing FMC63 (closed bars) or control (open bars) antibody treatmentof ≦3 littermate pairs. The results demonstrate that the majority ofimmature and mature B cells were also depleted from the bone marrow ofTG-1^(+/+), TG-1^(+/−) and TG-2^(+/+) mice. Thus, most hCD19⁺ cells weredepleted from the bone marrow by CD19 antibody treatment, includingpre-B cells that expressed hCD19 at low levels.

Depletion of Peritoneal B Cells

Peritoneal cavity B cells in TG-1^(+/−) mice express hCD19 at higherlevels than other tissue B cells (FIG. 1A and FIG. 1C), primarily due tothe presence of CD5⁺IgM^(hi)B220^(lo) B1 cells that expressed hCD19 atapproximately 25% higher densities than the CD5⁻IgM^(lo)B220^(hi) subsetof conventional (B2) B cells (FIG. 4A). FIGS. 4B-4C demonstrate thatperitoneal cavity B cells are sensitive to anti-CD19 antibody treatment.

FIG. 4A shows plots of human and mouse CD19 expression (x-axis) versusthe relative number of peritoneal cavity CD5⁺B220⁺ B 1a andCD5⁻B220^(hi) B2 (conventional) B cells (y-axis). Single-cellsuspensions of peritoneal cavity lymphocytes were examined bythree-color immunofluorescence staining with flow cytometry analysis.Bar graphs represent mean MFI (±SEM) values for CD19 expression by 3littermate pairs of TG-1^(+/−) mice.

FIG. 4B shows depletion of peritoneal cavity B220 cells from TG-1^(+/−)mice treated with CD19 (HB12a, HB12b, and FMC63 at 250 μg; B4 and HD237at 50 μg) antibodies or control antibody (250 μg). Numbers represent therelative frequencies of B220⁺ cells within the indicated gates on dayseven. Bar graph values represent the total number (±SEM) of B220⁺ cellswithin the peritoneum of antibody treated mice (≧3 mice per group).Significant differences between sample means are indicated; *p<0.05,**p<0.01. The results demonstrate that anti-CD19 antibody treatment at250 μg/mouse depleted a significant portion of peritoneal B220⁺ B cellsby day seven. The results shown in FIG. 4B are in part explained by thedepletion of both B1 and conventional B2 cells. When hCD19 was expressedat the highest densities in TG-1^(+/+) mice, the majority of B1 and B2cells were depleted. However, CD19-mediated depletion of B1 and B2 cellswas less efficient in TG-1^(+/−) and TG-2^(+/+) mice where hCD19 levelswere lower. Thus, CD19 antibody treatment depleted peritoneal B1 and B2cells depending on their density of CD19 expression as assessed usingmean fluorescence intensity, although peritoneal B cells were moreresistant to anti-CD19 antibody-mediated depletion than spleen and lymphnode B cells.

FIG. 4C shows representative depletion of CD5⁺B220⁺ B1a andCD5⁻B220^(hi) B2 B cells seven days following anti-CD19 antibody orcontrol antibody treatment of hCD19TG mice. Numbers represent therelative frequencies of each B cell subset within the indicated gates.Bar graph values represent the total number (±SEM) of each cell subsetwithin the peritoneum of antibody treated mice (≧3 mice per group).Significant differences between sample means are indicated; *p<0.05,**p<0.01.

Distinct Anti-CD19 Antibodies Mediate B Cell Clearance

In order to determine whether HB12a and HB12b anti-CD19 antibodies aredistinct from known anti-CD19 antibodies, the amino acid sequence ofeach anti-CD19 antibody variable region used herein was analyzed (FIGS.5A and 5B, 6A and 6B, 7A and 7B).

FIG. 5A depicts the nucleotide (SEQ ID NO:1) and predicted amino acid(SEQ ID NO:2) sequences for heavy chain V_(H)-D-J_(H) junctionalsequences of the HB12a anti-CD19 antibody. Sequences that overlap withthe 5′ PCR primer are indicated by double underlining and may vary fromthe actual DNA sequence since redundant primers were used. Approximatejunctional borders between V, D, and J sequences are designated in thesequences by vertical bars O. Nucleotides in lower case letters indicateeither nucleotide additions at junctional borders or potential sites forsomatic hypermutation. The amino-terminal residue of the antibody (E) ismarked as residue 1.

FIG. 5B depicts the nucleotide (SEQ ID NO:3) and predicted amino acid(SEQ ID NO:4) sequences for heavy chain V_(H)-D-J_(H) junctionalsequences of the HB12b anti-CD19 antibody. Sequences that overlap withthe 5′ PCR primer are indicated by double underlining and may vary fromthe actual DNA sequence since redundant primers were used. Approximatejunctional borders between V, D, and J sequences are designated in thesequences by vertical bars O. Nucleotides in lower case letters indicateeither nucleotide additions at junctional borders or potential sites forsomatic hypermutation. The amino-terminal residue of the antibody (E) ismarked as residue 1.

FIG. 6A depicts the nucleotide (SEQ ID NO:15) and predicted amino acidsequence (SEQ ID NO:16) sequences for light chain Vκ-Jκ junctionalsequences of the HB12a anti-CD19 antibody. FIG. 6B depicts thenucleotide (SEQ ID NO:17) and predicted amino acid (SEQ ID NO:18)sequences for the light chain V-J junctional sequences of the HB12banti-CD19 antibody. The amino-terminal amino acid of the mature secretedprotein deduced by amino acid sequence analysis is numbered as number 1.Sequences that overlap with the 3′ PCR primer are indicated by doubleunderlining. Predicted junctional borders for the V-J-C regions areindicated (/) with J region nucleotides representing potential sites forsomatic hypermutation in bold.

FIGS. 7A and 7B depict the amino acid sequence alignment of publishedmouse anti-CD19 antibodies. FIG. 7A shows a sequence alignment for heavychain V_(H)-D-J_(H) junctional sequences including a consensus sequence(SEQ ID NO:5), HB12a (SEQ ID NO:2), 4G7 (SEQ ID NO:6), HB12b (SEQ IDNO:4), HD37 (SEQ ID NO:7), B43 (SEQ ID NO:8), and FMC63 (SEQ ID NO:9).Amino acid numbering and designation of the origins of the codingsequences for each antibody V, D and J region are according toconventional methods (Kabat et al., Sequences of Proteins ofImmunological Interest., U.S. Government Printing Office, Bethesda, Md.(1991)) where amino acid positions 1-94 and complementarity-determiningregions CDR1 and 2 are encoded by a V_(H) gene. A dash indicates a gapinserted in the sequence to maximize alignment of similar amino acidsequences. A dot indicates identity between each anti-CD19 antibody andthe consensus amino acid sequence for all antibodies. CDR regions arehighlighted for clarity. FIG. 7B shows light chain Vκ amino acidsequence analysis of anti-CD19 antibodies. Consensus sequence (SEQ IDNO:10), HB12a (SEQ ID NO:16); HB12b (SEQ ID NO:18); HD37 (SEQ ID NO:11),B43 (SEQ ID NO:12), FMC63 (SEQ ID NO:13), and 4G7 (SEQ ID NO:14) arealigned. Amino acid numbering and designation of the origins of thecoding sequence for each anti-CD19 antibody is according to conventionalmethods (Kabat et al., (1991) Sequences of Proteins of ImmunologicalInterest., U.S. Government Printing Office, Bethesda, Md.). The aminoacid following the predicted signal sequence cleavage site isnumbered 1. A dash indicates a gap inserted in the sequence to maximizealignment of similar amino acid sequences. CDR regions are highlighted(boxed) for clarity.

Since each anti-CD19 antibody examined in this study depletedsignificant numbers of B cells in vivo, the amino acid sequence of eachanti-CD19 antibody variable region was assessed to determine whetherthese antibodies differ in sequence and potentially bind to differentCD19 epitopes. Antibodies bind target antigens through molecularinteractions that are mediated by specific amino acids within thevariable regions of each antibody molecule. Thus, complex interactionsbetween protein antigens and the antibodies that bind to specificepitopes on these antigens are almost unique to each antibody and itsspecific amino acid sequence. This level of complexity in antigen andantibody interactions is a reflection of a diverse antibody repertoireto most protein antigens. While antibody interactions with targetantigens are primarily mediated by amino acids withincomplementarity-determining regions (CDR) of antibody molecules,framework amino acids are also critical to antigen-binding activity.Thus, structurally similar antibodies are likely to bind to the sameantigens or region of a target molecule, while structurally dissimilarantibodies with different V and CDR regions are likely to interact withdifferent regions of antigens through different molecular interactions.

Since antibodies that interact with and bind to the same molecularregion (or epitope) of a target antigen are structurally similar bydefinition, the amino acid sequences of HB12a, HB12b, FMC63 and otherpublished anti-CD19 antibodies were compared including the HD37(Kipriyanov et al., J. Immunol. Methods, 196:51-62 (1996); Le Gall etal., FEBS Letters, 453:164-168 (1999)), 2G7 (Meeker et al., Hybridoma,3:305-320 (1984); Brandl et al., Exp. Hematol., 27:1264-1270 (1999)),and B43 (Bejcek et al., Cancer Res., 55:2346-2351 (1995)) antibodies.The heavy chains of the anti-CD19 antibodies were generated throughdifferent combinations of V(D)J gene segments with the V regions derivedfrom the V1S39, V1S56, V1S136, or V2S 1 gene segments, D regions derivedfrom FL16.1 gene segments, and J regions derived from either J2 or J4gene segments (Table 2). The published heavy and light chain variableregions of the B43 and HD37 antibodies were virtually identical in aminoacid sequence (FIGS. 7A-B). This level of conservation reflects the factthat each of these antibodies is also remarkably similar at thenucleotide level, having identical V_(H)(D)J_(H) and V_(L)J_(L)junctions, with most differences accounted for by the use of redundantprimers to PCR amplify each cDNA sequence. This indicates that the HD37and B43 and antibodies share a common, if not identical, origin andtherefore bind to identical epitopes on the CD19 protein. The HB12a and4G7 antibodies were also distinct from other anti-CD19 antibodies.Although the heavy chain regions of the HB12a and 4G7 antibodies weresimilar and are likely to have derived from the same germlineV_(H)(D)J_(H) gene segments, different junctional borders were used forD-J_(H) assembly (FIG. 7A). The HB12b antibody utilized a distinct V_(H)gene segment (Table 2) and had distinctly different CDR3 sequences (FIG.7A) from the other anti-CD19 antibodies. The FMC63 antibody also had avery distinct amino acid sequence from the other anti-CD19 antibodies.

TABLE 2 Heavy Chain Light Chain V^(a) D J Accession #^(b) V J Accession# HB12a V1S136 (12, 8) FL16.1 J2 V1-133* J2* 01 01 J4* HB12b V1S56 (27,14) FL16.1 J2 V3-2*01 01 4G7 V1S136 (10, 8) FL16.1 J2 AJ555622 V2-137 J5AJ555479 B43 V1S39 (37, 17) FL16.1 J4 S78322 V3-4 J1 S78338 HD37 V1S39(34, 16) FL16.1 J4 X99230 V3-4 J1 X99232 FMC63 V2S1 (20, 16) FL16.1 J4Y14283 V10-96 J2 Y14284 N.D., not determined. ^(a)Numbers in parenthesisindicate the number of nucleotide differences between the CD19 antibodyencoding gene and the most homologous germline sequence identified incurrent databases, excluding regions overlapping with PCR primers.^(b)GENBANK ® accession numbers for gene sequences.

As shown in FIG. 7B, the HB12a, HB12b, FMC63, 4G7, and HD37/B43antibodies each utilize distinct light chain genes (FIG. 7B). Lightchains were generated from multiple V and J gene segments. The lack ofhomogeneity among these six anti-CD19 antibodies H and L chain sequencessuggests that these antibodies bind to several distinct sites on humanCD19. A comparison of amino acid sequences of paired heavy and lightchains further indicates that most of these anti-CD19 antibodies arestructurally distinct and will therefore bind human CD19 throughdifferent molecular interactions. Thus, the ability of anti-CD19antibodies to deplete B cells in vivo is not restricted to a limitednumber of antibodies that bind CD19 at identical sites, but is a generalproperty of anti-CD19 antibodies as a class.

CD19 Density Influences the Effectiveness of CD19 Antibody-Induced BCell Depletion

To determine whether an anti-CD19 antibody's ability to deplete B cellsis dependent on CD19 density, the HB12b and FMC63 anti-CD19 antibodieswere administered to mice having varying levels of CD19 expression. Theresults demonstrate that human CD19 density on B cells and antibodyisotype can influence the depletion of B cells in the presence of ananti-CD19 antibody. The same assay can be used to determine whetherother anti-CD19 antibodies can effectively deplete B cells and theresults can be correlated to treatment of human patients with varyinglevels of CD19 expression. Thus, the methods for examining CD19 presenceand density in human subjects described herein can be used to identifypatients or patient populations for which certain anti-CD19 antibodiescan deplete B cells and/or to determine suitable dosages.

The results presented above indicate that although all five anti-CD19antibodies tested were similarly effective in TG-1^(+/−) mice when usedat 250 or 50 μg, the extent of B cell depletion for B cells from bloodbone marrow and spleen appeared to correlate with antibody isotype,IgG2a>IgG1>IgG2b (FIGS. 2A-2D). Therefore, the effectiveness of theHB12b (IgG1) and FMC63 (IgG2a) antibodies was compared in homozygousTG-1^(+/+), heterozygous TG-1^(+/−) and homozygous TG-2^(+/+) mice thatexpress CD19 at different densities (FIGS. 1A-E).

To determine whether CD19 density influences the effectiveness ofanti-CD19 antibody-induced B cell depletion representative blood andspleen B cell depletion was examined in hCD19TG mice after HB12b (FIG.8A) or FMC63 (FIG. 8B) antibody treatment (7 days, 250 μg/mouse).Numbers indicate the percentage of gated B220⁺ lymphocytes. Bar graphsindicate numbers (±SEM) of blood (per mL) or spleen (total number) Bcells following treatment with anti-CD19 antibodies (closed bars) orisotype-control (open bars) antibodies. Significant differences betweenmean results for anti-CD19 antibody or isotype-control antibody treatedmice (≧3 mice per data point) are indicated; *p<0.05, **p<0.01.

The results presented in FIGS. 8A-8D demonstrate that CD19 densityinfluences the efficiency of B cell depletion by anti-CD19 antibodies invivo. Low-level CD19 expression in TG-2 mice had a marked influence oncirculating or tissue B cell depletion by the HB12b antibody on dayseven (FIG. 8A). Differences in CD19 expression by TG-1^(+/+),TG-1^(+/−) and TG-2^(+/+) mice also influenced circulating and tissue Bcell depletion by the FMC63 antibody but did not significantly altercirculating B cell depletion (FIG. 8B).

To further verify that CD19 density is an important factor in CD19mAb-mediated B cell depletion, the relative depletion rates ofCD19TG-1^(+/+) and CD19TG-2^(+/+) B cells were compared directly.Splenocytes from CD19TG-1^(+/+) and CD19TG-2^(+/+) mice weredifferentially labeled with CFSE by labeling unfractionated splenocytesfrom hCD19TG-1^(+/+) and hCD19TG-2^(+/+) mice were labeled with 0.1 and0.01 μM Vybrant™ CFDA SE (CFSE; Molecular Probes), respectively,according to the manufacture's instructions. The relative frequency ofB220⁺ cells among CFSE-labeled splenocytes was determined byimmunofluorescence staining with flow cytometry analysis. Subsequently,equal numbers of CFSE-labeled B220⁺ hCD19TG-1^(+/+) and hCD19TG-2^(+/+)splenocytes (2.5×10⁵) were injected into the peritoneal cavity of threewild type B6 mice. After 1 hour, the mice were given either FMC63 orcontrol mAb (250 μg, i.p.). After 24 hours, the labeled lymphocytes wererecovered with the relative frequencies of CFSE-labeled B220⁺ and B220⁻cells assessed by flow cytometry. The gates in each histogram in FIG. 8Cindicate the frequencies of B220⁺ cells within the CD19TG-1(CFSE^(high)) and CD19TG-2^(+/+) (CFSE^(low)) splenocyte populations.The bar graph indicates the number of CFSE labeled cell populationpresent in anti-CD19 mAb treated mice relative to control mAb-treatedmice. Results represent hCD19TG-1^(+/+) splenocytes (filled bars) andhCD19TG-2^(+/+) splenocytes (open bars) transferred into ≧3 wild typerecipient mice, with significant differences between sample means (±SEM)indicated; **p<0.01.

B cell clearance was assessed 24 hours after anti-CD19 or control mAbtreatment of individual mice. CD19TG-1^(+/+) B220⁺ B cells were depletedat significantly faster rates (p<0.01) than CD19TG-2^(+/+) B cells inanti-CD19 mAb-treated mice compared with control mAb-treated mice (FIG.8C). Furthermore, the relative frequency of CD19TG-1^(+/+) B220⁺ B cellsto CD19TG-2^(+/+) B220⁺ B cells in anti-CD19 mAb treated mice wassignificantly lower (p<0.01) than the ratio of CD19TG-1^(+/+) B220⁺ Bcells to CD19TG-2^(+/+) B220⁺ B cells in control mAb treated mice.Likewise, the numbers of CD19TG-1^(+/+) and CD19TG-2^(+/+) CFSE-labeledB220⁻ cells in anti-CD19 or control mAb mice were also comparable. Thus,CD19TG-1^(+/+) B cells that express high density CD19 were depleted at afaster rate than CD19TG-2^(+/+) B cells that express CD19 at a lowdensity.

FIG. 8D shows fluorescence intensity of B220⁺ cells stained with CD19(thick lines), CD20 (thin lines) or isotype-matched control (CTL, dashedlines) antibodies (5 μg/mL), with antibody staining visualized usingisotype-specific, PE-conjugated secondary antibody with flow cytometryanalysis. Results represent those obtained in 4 experiments. The resultsshow the relative anti-hCD19 and anti-mCD20 antibody binding densitieson spleen B220⁺ B cells from TG-1^(+/−) mice. The density of anti-mCD20antibody binding was 10-64% as high as anti-CD19 antibody bindingirrespective of which antibody isotype was used for each antibody (FIG.8D). Although mCD20 expression was generally lower than hCD19expression, the levels of hCD19 expression in TG-1+/− mice are stillcomparable to levels of hCD19 expression found on human B cells (FIG.1B). Thus, anti-CD19 antibodies effectively depleted TG-2^(+/+) B cellsthat expressed hCD19 at relatively low densities (FIG. 1B), althoughhigh level CD19 expression by TG-1^(+/+) and TG-1^(+/−) B cellsobfuscated the relative differences in effectiveness of IgG2a and IgG1antibodies. Although there is a direct inverse correlation betweennumbers of B cells and density of hCD19 expression in TG-1 and TG-2transgenic mice, density of hCD19 is an important factor contributing tothe depletion of B cells. Anti-CD19 antibody levels were saturated whenadministered at 250 μg/mouse (see, also, saturating levels in FIG. 12).Thus, free anti-CD19 antibody levels were in excess regardless of B cellnumber.

Example 3 Tissue B Cell Depletion is FcγR-Dependent

The following assays were used to determine whether B cell depletion byan anti-CD19 antibody was dependent on FcγR expression. Through aprocess of interbreeding hCD19tg with mice lacking expression of certainFcγR, mice were generated that expressed hCD19 and lacked expression ofcertain FcγR. Such mice were used in assays to assess the ability ofanti-CD19 antibodies to deplete B cells through pathways that involveFcγR expression, e.g., ADCC. Thus, anti-CD19 antibodies identified inthese assays can be used to engineer chimeric, human or humanizedanti-CD19 antibodies using the techniques described above. Suchantibodies can in turn be used in the compositions and methods of theinvention for the treatment of B cell malignanices in humans.

The innate immune system mediates B cell depletion following anti-CD20antibody treatment through FcγR-dependent processes. Mouse effectorcells express four different FcγR classes for IgG, the high-affinityFcγRI (CD64), and the low-affinity FcγRII (CD32), FcγRIII (CD16), andFcγRIV molecules. FcγRI, FcγRIII and FcγRIV are hetero-oligomericcomplexes in which the respective ligand-binding a chains associate witha common γ chain (FcRγ). FcRγ chain expression is required for FcγRassembly and for FcγR triggering of effector functions, includingphagocytosis by macrophages. Since FcRγ^(−/−) mice lack high-affinityFcγRI (CD64) and low-affinity FcγRIII (CD16) and FcγRIV molecules,FcRγ^(−/−) mice expressing hCD19 were used to assess the role of FcγR intissue B cell depletion following anti-CD19 antibody treatment. FIG. 9Ashows representative blood and spleen B cell depletion seven days afteranti-CD19 or isotype-control antibody treatment of FcRγ^(+/−) orFcRγ^(−/−) littermates. Numbers indicate the percentage of B220⁺lymphocytes within the indicated gates. FIG. 9B shows blood and tissue Bcell depletion seven days after antibody treatment of FcRγ^(−/−)littermates on day zero. For blood, the value shown after time zerorepresents data obtained at 1 hour. Bar graphs represent mean B220⁺ Bcell numbers (±SEM) after anti-CD19 (filled bars) or isotype-control(open bars) antibody treatment of mice (≧3 mice per group). Significantdifferences between mean results for anti-CD19 or isotype-controlantibody treated mice are indicated; *p<0.05, **p<0.01. The resultspresented in FIGS. 9A and 9B demonstrate that B cell depletion followinganti-CD19 antibody treatment is FcRγ-dependent. There were nosignificant changes in numbers of bone marrow, blood, spleen, lymph nodeand peritoneal cavity B cells in FcRγ^(−/−) mice following FMC63antibody treatment when compared with FcRγ^(−/−) littermates treatedwith a control IgG2a antibody. By contrast, anti-CD19 antibody treatmentdepleted most B cells in FcRγ^(+/−) littermates. Thus, anti-CD19antibody treatment primarily depletes blood and tissue B cells throughpathways that require FcγRI and FcγRIII expression.

FIG. 9C shows representative B cell numbers in monocyte-depletedhCD19TG-1^(+/−) mice. Mice were treated with clodronate-liposomes on day−2, 1 and 4, and given FMC63 (n=9), isotype control (n=6), or CD20 (n=3)mAb (250 μg) on day 0. Mice treated with PBS-liposomes and FMC63anti-CD19 antibody (n=3) served as controls. Representative blood andspleen B cell depletion is shown 7 days after antibody treatment withthe percentage of lymphocytes within the indicated gates indicated.

FIG. 9D shows blood and tissue B cell depletion 7 days after antibodytreatment as in (C). Bar graphs represent mean B220⁺ B cell numbers(±SEM) after antibody treatment of mice (≧3 mice per group). For blood,values indicate numbers of circulating B cells in PBS-treated mice withFMC63 anti-CD19 antibody (closed triangles), or monocyte-depleted micetreated with control antibody (open circles), CD20 antibody (closedsquares), or FMC63 anti-CD19 antibody (closed circles). Significantdifferences between mean results for isotype-control mAb-treated miceand other groups are indicated; *p<0.05, **p<0.01.

The results presented in FIG. 9 show B cell depletion followinganti-CD19 antibody treatment is FcRγ and monocyte-dependent. Micerendered macrophage-deficient by treatment with liposome-encapsulatedclodronate did not significantly deplete circulating B cells 1 day afterFMC63, anti-CD20 (MB20-11) or control anti-CD19 antibody treatment,while FMC63 antibody treatment eliminated circulating B cells in micetreated with PBS-loaded liposomes (FIGS. 9C-D). After 4-7 days,circulating B cell numbers were significantly depleted by both FMC63 andanti-CD20 antibody treatment, with anti-CD19 antibody treatment havingmore dramatic effects on B cell numbers in clodronate-treated mice.Similarly, anti-CD19 and anti-CD20 antibody treatment decreased bonemarrow B220⁺ cell numbers by 55% in clodronate-treated mice on day 7relative to control antibody treated littermates, while anti-CD19antibody treatment decreased bone marrow B220⁺ cell numbers by 88% inPBS-treated mice. Anti-CD19 antibody treatment decreased spleen B cellnumbers by 52% in clodronate-treated mice on day 7 relative to controlantibody treated littermates, while anti-CD20 antibody depleted B cellsminimally, and anti-CD19 antibody treatment decreased spleen B cellnumbers by 89% in PBS-treated mice. Both anti-CD19 and anti-CD20antibody treatment decreased lymph node B cell numbers by 48-53% inclodronate-treated mice on day seven relative to control antibodytreated littermates, while anti-CD19 antibody treatment decreased lymphnode B cell numbers by 93% in PBS-treated mice. In blood, spleen andlymph nodes, anti-CD19 antibody treatment was significantly lesseffective in clodronate-treated mice than in PBS-treated littermates(p<0.01). These findings implicate macrophages as major effector cellsfor depletion of CD19⁺ and CD20⁺ B cells in vivo, and indicate thatanti-CD19 antibody therapy may be more effective than anti-CD20 antibodytherapy when monocyte numbers or function are reduced.

Example 4 Anti-CD19 Antibody-Induced B Cell Depletion is Durable

In order to assess the efficacy and duration of B cell depletion, thehCD19TG mice were administered a single low dose 250 μg injection ofanti-CD19 antibody. FIGS. 10A-10C demonstrate duration and dose responseof B cell depletion following anti-CD19 antibody treatment. FIG. 10Ashows numbers of blood B220⁺ B cells and Thy-1⁺ T cells following FMC63or isotype-control antibody treatment of TG-1^(+/−) mice on day zero.Values represent mean (±SEM) results from six mice in each group. Theresults demonstrate that circulating B cells were depleted for 13 weekswith a gradual recovery of blood-borne B cells over the ensuing 13weeks. Thy-1⁺ T cell representation was not altered as a result ofanti-CD19 treatment.

FIGS. 10B-10C show representative tissue B cell depletion in the miceshown in FIG. 10A at 11, 16, and 30 weeks following antibody treatment.Numbers indicate the percentage of B220⁺ lymphocytes within theindicated gates. The results in FIG. 10B show that the bone marrow,blood, spleen, lymph node, and peritoneal cavity were essentially devoidof B cells 11 weeks after antibody treatment (significant differencesbetween sample means are indicated; *p<0.05, **p<0.01). After the firstappearance of circulating B cells, it took >10 additional weeks forcirculating B cell numbers to reach the normal range. By week 16post-antibody treatment, blood, spleen, LN and PL B cell numbers hadbegun to recover while the BM B cell compartment was not significantlydifferent from untreated controls as shown in FIG. 10C. By week 30, alltissues were repopulated with B cells at levels comparable to those innormal controls.

FIG. 10D shows anti-CD19 antibody dose responses for blood, bone marrowand spleen B cell depletion. Mice were treated with anti-CD19 antibodieson day zero with tissue B cells representation assessed on day seven.Results represent those obtained with three mice in each group for eachantibody dose. Control antibody doses were 250 μg. Significantdifferences between sample means are indicated; *p<0.05, **p<0.01. Asingle FMC63 antibody dose as low as 2 μg/mouse depleted significantnumbers of circulating B cells, while 10 μg the HB12b antibody wasrequired to significantly reduce circulating B cell numbers (FIG. 10D).Significant depletion of bone marrow and spleen B cells by day sevenrequired 5-fold higher antibody doses of 10-50 μg/mouse. Thus, CD19antibody treatment at relatively low doses can deplete the majority ofcirculating and tissue B cells for significant periods of time.

CD19 Persists on the B Cell Surface after Administration of Anti-CD19Antibody

Whether CD19 internalization influenced B cell depletion in vivo wasassessed by comparing cell-surface CD19 expression following HB12a,HB12b and FMC63 antibody treatment (250 μg).

FIGS. 11A-11C show cell surface CD19 expression and B cell clearance inTG-1^(+/−) mice treated with HB12a (FIG. 11A), HB12b (FIG. 11B), FMC63(FIG. 11C) or isotype-matched control antibody (250 μg) in vivo. At timezero (prior to anti-CD19 administration), and at 1, 4, and 24 hourspost-antibody administration, spleen B cells were harvested and assessedfor CD19 (thick line) and control (thin line) antibody binding bytreating cells with isotype-specific secondary antibody in vitro withflow cytometry analysis. Isolated B cells were also treated in vitrowith saturating concentrations of each CD19 antibody plusisotype-specific secondary antibody in vitro with flow cytometryanalysis to visualize total cell surface CD19 expression. Each timepoint represents results with one mouse. The results presented in FIGS.11A-11C demonstrate that cell surface CD19 is not eliminated from thecell surface following antibody binding in vivo and show that themajority of spleen B cells expressed uniform high levels of cell surfacehCD19 for up to 24 hours after antibody treatment although a subset of Bcells expressed reduced levels of hCD19 at 1 hour following FMC63antibody treatment (FIG. 11C). The results shown in FIGS. 11A-11C alsodemonstrate that the amount of CD19 on the surface of B cells isconstant, indicating that the capability of the B cells to mediate ADCCis maintained.

The results demonstrate that CD19 surprisingly exhibited lower levels ofinternalization than expected following administration of anti-CD19antibodies. In particular, the results demonstrate that CD19unexpectedly persists on the cell surface following binding of ananti-CD19 antibody, thus, the B cell remains accessible to the ADCCactivity. These results demonstrate, in part, why the anti-CD19antibodies and treatment regimens of the invention are efficacious intreating B cell malignancies.

FIGS. 12A-12C document the extent of B cell depletion and the ability ofanti-hCD19 antibodies to bind hCD19 and thus inhibit the binding ofother anti-hCD19 antibodies. The results in FIG. 12A demonstrate that asingle administration of FMC63 (250 μg) to TG-1^(+/−) mice results insignificant depletion of both blood and spleen B cells within 1 hour ofantibody administration. In this experiment, blood and spleen cells wereharvested and assessed for B cell frequencies prior to anti-CD19antibody administration or at various times thereafter (1, 4, or 24hours). Blood samples were stained with anti-Thy1.2 and anti-B220 toidentify B cells in the lower right quadrant. Spleen cells were stainedwith anti-IgM and anti-B220 antibodies to identify B cells within theindicated gate. Each time point represents results with one mouse.Unexpectedly, blood B cells were cleared more rapidly than splenic Bcells.

The B cell depletion described in FIG. 12A suggested that theadministered antibody rapidly saturated available antibody-binding siteson hCD19 within 1 hour of administration. To confirm this observation,mice were treated with either FMC63 (hCD19 binding antibody) orisotype-control antibody. At various time thereafter blood and spleen Bcells were stained with the fluorochrome-conjugated B4 antibody toidentify unoccupied antibody binding sites on the surface of mCD19⁺ ormCD20⁺ B cells. The frequencies of cells within the upper andlower-right quadrants are indicated. Each time point represents resultsobtained from one mouse. The results indicate FMC63 treatment resultedin a progressive depletion of hCD19 bearing cells over the course of theexperiment with blood B cells being depleted more rapidly than spleen.Those B cells remaining at each time point could be identified by theirexpression of mCD19 or mCD20, but were not stained by B4 suggesting thatthe administered FMC63 was bound to the remaining B cells. These findingconfirm the ability of FMC63 to bind and deplete B cells in vivo.Moreover, FMC63 prevents B4 binding suggesting that these antibodiesrecognize overlapping epitopes on hCD19. The results in FIG. 12C confirmthat HB12b antibody treatment (250 μg) also saturates antibody-bindingsites on hCD19 within 1 hour of administration and results in thedepleting of hCD19 positive B cells. Unexpectedly, the HB12b antibodydid not completely inhibit binding of the B4 antibody suggesting thatunlike FMC63, HB12b recognizes an epitope on hCD19 that is distinct fromthat recognized by B4. The results shown in FIGS. 12B-12C demonstratethat most anti-CD19 antibodies inhibit the binding of most otheranti-CD19 antibodies, indicating that most anti-CD19 antibodies bind tosimilar, the same, or overlapping regions or epitopes on the CD19protein. Alternatively, these observations may also result from therelatively small size of the CD19 extracellular domain compared with thesize of antibody molecules.

Example 5 Anti-CD19 Antibody Treatment Abrogates Humoral Immunity andAutoimmunity

The assays described in this example can be used to determine whether ananti-CD19 antibody is capable of eliminating or attenuating immuneresponses. Anti-CD19 antibodies identified in these assays can be usedto engineer chimeric, human or humanized anti-CD19 antibodies using thetechniques described above. Such antibodies can in turn be used in thecompositions and methods of the invention for the treatment of B cellmalignancies in humans.

The effect of anti-CD19 antibody-induced B cell depletion on serumantibody levels was assessed by giving hCD19TG^(+/−) mice a singleinjection of anti-CD19 antibody. FIG. 13A shows CD19 antibody treatmentreduces serum immunoglobulin levels in TG-1^(+/−) mice. Two-month-oldlittermates were treated with a single injection of FMC63 (closedcircles) or control (open circles) antibody (250 μg) on day 0. Antibodylevels were determined by ELISA, with mean values (±SEM) shown for eachgroup of ≧5 mice. Differences between CD19 or control mAb-treated micewere significant; *p<0.05, **p<0.01. The results show that after 1 to 2weeks, serum IgM, IgG2b, IgG3, and IgA antibody levels weresignificantly reduced, and remained reduced for at least 10 weeks (FIG.13A). IgG1 and IgG2a serum levels were significantly below normal at 6and 4 weeks post-treatment.

Since hCD19TG^(+/−) mice produce detectable autoantibodies after 2 mosof age (Sato et al., J. Immunol., 157:4371 (1996)), serum autoantibodybinding to ssDNA, dsDNA and histones was assessed. FIG. 13B showsanti-CD19 antibody treatment reduces autoantibody anti-dsDNA, anti-ssDNAand anti-histone autoantibody levels after anti-CD19 antibody treatment.The results show that anti-CD19 antibody treatment significantly reducedserum IgM autoantibody levels after 2 weeks and prevented the generationof isotype-switched IgG autoantibodies for up to 10 weeks (FIG. 13B).Thus, B cell depletion substantially reduced acute and long-termantibody responses and attenuated class-switching of normal andpathogenic immune responses.

The influence of B cell depletion on T cell-independent type 1 (TI-1)and type 2 (TI-2) antibody responses was assessed by immunizinghCD19TG^(+/−) mice with TNP-LPS or DNP-Ficoll (at day zero), 7 daysafter anti-CD19 antibody (FMC63) or control antibody treatment.Significant hapten-specific IgM, IgG, and IgA antibody responses werenot observed in anti-CD19 antibody-treated mice immunized with eitherantigen (FIGS. 14A and 14B). Antibody responses to the T cell-dependent(TD) Ag, DNP-KLH, were also assessed using mice treated with anti-CD19antibody 7 days before immunization (FIG. 14B). FIG. 14C shows thatDNP-KLH immunized mice treated with anti-CD19 antibody showed reducedhumoral immunity. Littermates were treated with FMC63 (closed circles)or control (open circles) antibody (250 μg) seven days before primaryimmunizations on day zero, with serum obtained on the indicated day. ForDNP-KLH immunizations, all mice were challenged with 100 μg of DNP-KLHon day 21. All values are mean (±SEM) ELISA OD units obtained using serafrom five mice of each group. Differences between anti-CD19 or controlantibody-treated mice were significant; *p<0.05, ** p<0.01. The resultsshow that control antibody-treated littermates generated primary IgMantibody responses 7 days after DNP-KLH immunization and secondaryresponses after antigen challenge on day 21 (FIG. 14C). However,significant hapten-specific IgM, IgG or IgA antibody responses were notdetected in CD19 mAb-treated mice immunized or re-challenged withantigen. To assess the effect of B cell depletion on secondary antibodyresponses, mice were also immunized with DNP-KLH and treated withanti-CD19 antibody 14 days later (arrows) (FIG. 14D). By day 21, serumIgM, IgG, and IgA anti-DNP antibody responses had decreased in CD19mAb-treated mice to levels below those of immunized mice treated withcontrol mAb. However, re-challenge of control mAb-treated mice withDNP-KLH on day 21 induced significant secondary antibody responses,while CD19 mAb-treated mice did not produce anti-DNP antibodies afterDNP-KLH rechallenge. Thus, CD19 mAb-induced B cell depletionsubstantially reduced both primary and secondary antibody responses andprevented class-switching during humoral immune responses.

Example 6 Anti-CD19 Antibody Treatment in Conjunction with Anti-CD20Antibody Treatment

The assay described herein can be used to determine whether othercombination or conjugate therapies, e.g., anti-CD19 antibodies incombination with chemotherapy, toxin therapy or radiotherapy, havebeneficial effects, such as an additive or more that additive depletionof B cells. The results of combination therapies tested in animal modelscan be correlated to humans by means well-known in the art.

Anti-CD20 antibodies are effective in depleting human and mouse B cellsin vivo. Therefore, the benefit of simultaneous treatment with anti-CD19(FMC63) and anti-CD20 (MB20-11) antibodies was assessed to determinewhether this enhanced B cell depletion. Mice were treated withsuboptimal 2 μg doses of each antibody individually, or a combination ofboth antibodies at 1 μg, or with combined 2 μg doses. FIG. 15 shows theresults of TG-1^(+/−) mice treated with control (250 μg), FMC63 (CD19, 2μg), MB20-11 (CD20, 2 μg), FMC63+MB20-11 (1 μg each), or FMC63+MB20-11(2 μg each) antibodies on day zero. Blood B cell numbers were measuredat time zero, one hour, and on days one, four and seven. Tissue B cellnumbers were determined on day seven. Values represent means (±SEM) fromgroups of three mice. The results shown in FIG. 15 demonstrate thatsimultaneous anti-CD19 and anti-CD20 antibody treatments are beneficial.B cell depletion in mice treated with a combination of both antibodiesat 1 μg was intermediate or similar to depletion observed followingtreatment of mice with 2 μg of each individual antibody (FIG. 15).However, the simultaneous treatment of mice with both antibodies at 2 μglead to significantly more B cell depletion than was observed witheither antibody alone. Thus, combined anti-CD19 and anti-CD20 antibodytherapies had beneficial effects that enhanced B cell depletion. Thislikely results from the accumulation of more therapeutically effectiveantibody molecules on the surface of individual B cells.

Example 7 Subcutaneous (S.C.) Anti-CD19 Antibody Administration isTherapeutically Effective

The assay described herein can be used to determine whether asubcutaneous route of administration of an anti-CD19 antibody caneffectively deplete B cells. The results of the efficacy of differentdelivery routes tested in animal models can be correlated to humans bymeans well-known in the art.

Since anti-CD19 antibody given i.v. effectively depletes circulating andtissue B cells, it was assessed whether anti-CD19 antibody given s.c. ori.p. depleted B cells to an equivalent extent. Wild-type mice weretreated with the FMC63 antibody at 250 μg either subcutaneous (s.c.),intraperitoneal (i.p.) or i.v. Values represent mean (±SEM) blood (perml), bone marrow, spleen, lymph node, and peritoneal cavity B220+ B cellnumbers on day seven (n>3) as assessed by flow cytometry. Significantdifferences between mean results for each group of mice are indicated;*p<0.05, **p<0.01 in comparison to the control. The results in FIG. 16demonstrate that subcutaneous (s.c.), intraperitoneal (i.p.) and i.v.administration of CD19 antibody effectively depletes circulating andtissue B cells in vivo. The vast majority of circulating and tissue Bcells were depleted in mice given anti-CD19 antibodies as 250 μg doseseither i.v., i.p., or s.c. (FIG. 16). Unexpectedly, giving anti-CD19antibody i.p. did not deplete peritoneal B cells significantly betterthan i.v. treatment. Accordingly, an anti-CD19 antibody can be used toeffectively deplete both circulating and tissue B cells when given as≦64 mg s.c. injections. Since anti-CD19 antibodies are effective down to10 μg doses i.v. (FIG. 10D) even lower s.c. antibody doses are likely tobe effective.

Example 8 Anti-CD19 Antibody Treatment Abrogates Tumor Growth In Vivo

Burkitt's lymphoma, a B cell malignancy in humans, is characterized bytranslocations of the c-myc proto-oncogene to Ig gene promoter regions,leading to aberrant c-Myc over-expression. Similarly, Eμ-cMyc transgenic(cMycTG) mice, in which the c-myc proto-oncogene is under the control ofthe Ig heavy chain enhancer, develop aggressive B cell-derived lymphomasat an early age, have about 90% mortality rate by 20 weeks of age, andhave a median age of survival at about 12 weeks (Harris et al., J. Exp.Med. 167:353 (1988) and Adams et al., Nature 318:533 (1985)). Tumorsfrom c-MycTG mice are not restricted to a specific B cell developmentalstage, but predominantly present with Ig gene rearrangements andphenotypes characteristic of pre-B or immature B cells (Adams et al.,Nature 318:533 (1985)). To assess the efficacy of CD19-directedimmunotherapy in vivo, hCD19TG-1^(+/+) and cMycTG mice were crossed togenerate hCD19TG-1^(+/−) cMycTG^(+/−) mice that developed aggressive Bcell-derived lymphomas at an early age. Tumor cells derived from onemouse were isolated, expanded in vitro, and characterized phenotypicallyto be hCD19⁺ and mouse CD19⁺ CD20⁻ CD43⁻ IgM⁺ IgD⁻ B220⁺ lymphoblasts,which are typical of the pre-B/immature B cell tumors that develop inc-mycTG^(+/−) mice (Harris et al., J. Exp. Med. 167:353 (1988) and Adamset al., Nature 318:533 (1985)). Tumor cells (10⁵) from hCD19TG-1^(+/−)mycTG mice were transplanted i.v. into 20 Rag^(−/−) mice on day 0. Equalnumbers of randomly selected mice were treated with FMC63 (filledcircles) or control (open circles) antibody (250 μg) on days 1 and 7.FIG. 17A shows the numbers of circulating tumor cells (±SEM) quantifiedby flow cytometry over a 6 week period and FIG. 17B shows mouse percentsurvival over a 7 week period. Each value indicates the percentage ofviable mice on each day they were examined. The results in FIG. 17demonstrate that anti-CD19 antibody treatment prevents hCD19⁺ lymphomagrowth in vivo. Transplantation of these tumor cells into twentyRag^(−/−) mice resulted in the appearance of circulating mouse CD19⁺ andB220⁺ lymphoblasts by 2 weeks in ten randomly selected recipients thatwere treated with a control mAb, with death by 3.5 weeks. By contrast,treating ten mice with anti-CD19 antibody (day 1 and 7) following tumortransplantation prevented the appearance of circulating tumor cells inall 10 recipients for up to 7 weeks. One anti-CD19 antibody-treatedmouse died during blood harvest, but never displayed circulating tumorcells. Thus, anti-CD19 antibody treatment may offer an effective therapyfor treating patients with B cell lineage malignancies, especially thosewith tumors that do not express CD20 or express CD20 at low levels.

The present invention is not to be limited in scope by the specificembodiments described herein. Indeed, various modifications of theinvention in addition to those described will become apparent to thoseskilled in the art from the foregoing description and accompanyingfigures. Such modifications are intended to fall within the scope of theappended claims.

Various publications are cited herein, the disclosures of which areincorporated by reference in their entireties.

The present invention is not to be limited in scope by the specificembodiments described herein. Indeed, various modifications of theinvention in addition to those described will become apparent to thoseskilled in the art from the foregoing description and accompanyingfigures. Such modifications are intended to fall within the scope of theappended claims.

Various publications are cited herein, the disclosures of which areincorporated by reference in their entireties.

What is claimed is:
 1. A pharmaceutical composition comprising amonoclonal chimerized, human or humanized anti CD19 antibody comprisingthe sequences as set out as amino acids 33 to 37, amino acids 51 to 68and amino acids 101 to 114 of SEQ ID NO:4 and the sequences as set outas amino acids 44 to 58, amino acids 74 to 80 and amino acids 113-121 ofSEQ ID NO:18; that (a) is of the IgG1 or IgG3 human isotype, or (b)mediates human antibody-dependent cellular cytotoxicity (ADCC), in apharmaceutically acceptable carrier, and wherein one amino acidsubstitution is introduced into one or more of the sequences selectedfrom the group consisting of amino acids 33 to 37 of SEQ ID NO:4, aminoacids 51 to 68 of SEQ ID NO:4, amino acids 101 to 114 of SEQ ID NO:4,amino acids 44 to 58 of SEQ ID NO:18, amino acids 74 to 80 of SEQ IDNO:18, and amino acids 113-121 of SEQ ID NO:18.
 2. The pharmaceuticalcomposition of claim 1, wherein a therapeutically effective amount ofthe monoclonal chimerized anti-CD19 antibody of the IgG1 or IgG3 humanisotype for treating B cell malignancy is less than about 1 mg/kg ofpatient body weight.
 3. The pharmaceutical composition of claim 1,wherein a therapeutically effective amount of the monoclonal chimerizedanti-CD19 antibody of the IgG1 or IgG3 human isotype for treating B cellmalignancy is greater than about 2 mg/kg of patient body weight.
 4. Thecomposition of claim 1, wherein the anti-CD 19 antibody that mediatesADCC is of the IgG1, IgG2, IgG3, or IgG4 human isotype.
 5. Thepharmaceutical composition of claim 1, wherein the anti-CD19 antibodyhas a half-life in a subject of at least 4 to 7 days.
 6. Thepharmaceutical composition of claim 1, wherein the anti-CD19 antibody isdetectably labeled, is a naked antibody, is conjugated to a therapeuticcompound, is conjugated to a cytotoxic agent, or is conjugated to adiagnostic agent.
 7. The pharmaceutical composition of claim 1, whereinthe anti-CD19 antibody is bispecific.
 8. The pharmaceutical compositionof claim 7, wherein the bispecific anti-CD19 antibody has specificityfor binding leukocyte effector cells.
 9. The pharmaceutical compositionof claim 1, wherein the ADCC function of the anti-CD 19 antibody isassessed by measuring the ability of the anti-CD 19 antibody to mediatetarget cell lysis by leukocyte effector cells in vitro.
 10. Thepharmaceutical composition of claim 1, wherein the anti-CD19 antibodycomprises a heavy chain consisting of a sequence having at least 90%identity to SEQ ID NO:4.
 11. The pharmaceutical composition of claim 1,wherein the anti-CD19 antibody comprises the light chain consisting of asequence having at least 95% amino acid sequence identity to SEQ IDNO:18.
 12. A method of treating a B cell malignancy in a human patientcomprising; administering a pharmaceutical composition according toclaim
 1. 13. The method accordingly to claim 12, wherein the anti-CD 19antibody comprises a heavy chain consisting of a sequence having atleast 90% identity to SEQ ID NO:4.
 14. The method accordingly to claim12, wherein the antibody comprises the light chain consisting of asequence having at least 95% identity to SEQ ID NO:18.
 15. The methodaccordingly to claim 12, wherein the antibody is able to depletecirculating B cells.
 16. The method accordingly to claim 12, wherein theantibody is able to deplete bone marrow B cells.
 17. The methodaccordingly to claim 12, wherein the B cell malignancy is acutelymphoblastic leukaemia, mantle cell lymphoma, pre-B cell acutelymphoblastic leukaemia, or precursor B cell lymphoblastic lymphoma. 18.The method accordingly to claim 12, wherein the anti-CD19 antibody thatmediates ADCC is of the IgG1, IgG2, IgG3, or IgG4 human isotype.
 19. Themethod accordingly to claim 12, wherein the B cell malignancy is treatedprior to the administration of the anti-CD19 antibody.
 20. The methodaccordingly to claim 12, wherein the B cell malignancy is treated with atherapy other than an anti-CD19 antibody therapy subsequent to theadministration of the anti-CD19 antibody.
 21. The method accordingly toclaim 12, wherein the treatment for the malignancy is chemotherapy,radioimmunotherapy, toxin therapy, prodrug-activating enzyme therapy,antibody therapy, monocyte or macrophage enhancing therapy,immunoregulatory therapy, tumor neovasculature (statin) therapy,calicheamicin therapy, surgical therapy, or any combination thereof.